0001104659-15-034272.txt : 20150505 0001104659-15-034272.hdr.sgml : 20150505 20150505160635 ACCESSION NUMBER: 0001104659-15-034272 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150331 FILED AS OF DATE: 20150505 DATE AS OF CHANGE: 20150505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AxoGen, Inc. CENTRAL INDEX KEY: 0000805928 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 411301878 STATE OF INCORPORATION: MN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36046 FILM NUMBER: 15832982 BUSINESS ADDRESS: STREET 1: 13859 PROGRESS BLVD. STREET 2: SUITE 100 CITY: ALACHUA STATE: FL ZIP: 32615 BUSINESS PHONE: (386) 462-6817 MAIL ADDRESS: STREET 1: 13859 PROGRESS BLVD. STREET 2: SUITE 100 CITY: ALACHUA STATE: FL ZIP: 32615 FORMER COMPANY: FORMER CONFORMED NAME: LECTEC CORP /MN/ DATE OF NAME CHANGE: 19920703 10-Q 1 a15-7805_110q.htm 10-Q

Table of Contents

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2015

 

or

 

o

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                to                

 

Commission file number:  001-36046

 

AxoGen, Inc.

(Exact name of registrant as specified in its charter)

 

Minnesota

 

41-1301878

(State or other jurisdiction of
incorporation or organization)

 

(I.R.S. Employer
Identification No.)

 

13631 Progress Blvd., Suite 400, Alachua, FL

 

32615

(Address of principal executive offices)

 

(Zip Code)

 

386-462-6800

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x  NO o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES x  NO o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer o

 

Accelerated filer o

 

 

 

Non-Accelerated filer o

 

Smaller reporting company x

(Do not check if a smaller reporting company)

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES o  NO x

 

As of May 4, 2015 the registrant had 24,926,014 shares of common stock outstanding.

 

 

 



Table of Contents

 

Forward-Looking Statements

 

From time to time, in reports filed with the Securities and Exchange Commission (including this Form 10-Q), in press releases, and in other communications to shareholders or the investment community, the Company may provide forward-looking statements concerning possible or anticipated future results of operations or business developments. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “may”, “should”, variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product development, product potential, regulatory environment, sales and marketing strategies, liquidity, capital resources or operating performance. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this Form 10-Q should be evaluated together with the many uncertainties that affect the Company’s business and its market, particularly those discussed in the risk factors and cautionary statements in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and the Company assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

 

3


Table of Contents

 

PART 1 — FINANCIAL INFORMATION

 

ITEM 1 — CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

AxoGen, Inc.

Condensed Consolidated Balance Sheets

 

 

 

March 31,
2015
(unaudited)

 

December 31,
2014

 

Assets

 

 

 

 

 

Current assets:

 

 

 

 

 

Cash and cash equivalents

 

$

19,255,725

 

$

8,215,791

 

Accounts receivable, net of allowance for doubtful accounts of approximately $101,000 and $94,000, respectively

 

3,161,588

 

2,872,308

 

Inventory

 

3,337,898

 

3,213,620

 

Prepaid expenses and other

 

259,948

 

109,369

 

Total current assets

 

26,015,159

 

14,411,088

 

Property and equipment, net

 

583,420

 

619,028

 

Intangible assets

 

597,453

 

577,174

 

Deferred financing costs

 

939,894

 

793,499

 

 

 

$

28,135,926

 

$

16,400,789

 

Liabilities and Shareholders’ Equity (Deficit)

 

 

 

 

 

Current liabilities:

 

 

 

 

 

Accounts payable and accrued expenses

 

$

3,423,272

 

$

2,431,194

 

Current Deferred Revenue

 

14,118

 

14,118

 

Total current liabilities

 

3,437,390

 

2,445,312

 

Note Payable — Revenue Interest Purchase Agreement

 

25,269,050

 

25,085,777

 

Long Term Deferred Revenue

 

109,984

 

115,380

 

Total liabilities

 

28,816,424

 

27,646,469

 

Commitments and contingencies

 

 

 

 

 

Shareholders’ equity (deficit):

 

 

 

 

 

Common stock, $.01 par value; 50,000,000 shares authorized; 24,926,014 and 19,488,814 shares issued and outstanding

 

249,260

 

194,888

 

Additional paid-in capital

 

92,761,697

 

78,675,686

 

Accumulated deficit

 

(93,691,455

)

(90,116,254

)

Total shareholders’ equity (deficit)

 

(680,498

)

(11,245,680

)

 

 

$

28,135,926

 

$

16,400,789

 

 

See notes to condensed consolidated financial statements.

 

4


Table of Contents

 

AxoGen, Inc.

Condensed Consolidated Statements of Operations

(unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,

 

March 31,

 

 

 

2015

 

2014

 

Revenues

 

$

4,951,316

 

$

3,138,256

 

Cost of goods sold

 

982,881

 

701,300

 

Gross profit

 

3,968,435

 

2,436,956

 

Costs and expenses:

 

 

 

 

 

Sales and marketing

 

3,932,522

 

2,720,707

 

Research and development

 

671,036

 

812,615

 

General and administrative

 

1,908,581

 

1,894,776

 

Total costs and expenses

 

6,512,139

 

5,428,098

 

Loss from operations

 

(2,543,704

)

(2,991,142

)

Other expense:

 

 

 

 

 

Interest expense

 

(994,748

)

(1,191,317

)

Interest expense — deferred financing costs

 

(33,746

)

(51,216

)

Other income (expense)

 

(3,003

)

(5,889

)

Total other expense

 

(1,031,497

)

(1,248,422

)

Net loss

 

$

(3,575,201

)

$

(4,239,564

)

Weighted Average Common Shares outstanding — basic and diluted

 

22,517,361

 

17,383,786

 

Loss Per Common share — basic and diluted

 

$

(0.16

)

$

(0.24

)

 

See notes to condensed consolidated financial statements.

 

5


Table of Contents

 

AxoGen, Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited)

 

 

 

Three Months Ended March 31,

 

 

 

2015

 

2014

 

Cash flows from operating activities:

 

 

 

 

 

Net loss

 

$

(3,575,201

)

$

(4,239,564

)

Adjustments to reconcile net loss to net cash used for operating activities:

 

 

 

 

 

Depreciation

 

41,898

 

33,944

 

Amortization of intangible assets

 

11,772

 

10,955

 

Amortization of deferred financing costs

 

33,746

 

51,216

 

Share-based compensation

 

368,249

 

257,542

 

Stock grants

 

—

 

60,125

 

Interest added to note

 

183,273

 

891,845

 

Change in assets and liabilities:

 

 

 

 

 

Accounts receivable

 

(289,280

)

(71,458

)

Inventory

 

(124,278

)

(67,661

)

Prepaid expenses and other

 

(150,579

)

101,230

 

Accounts payable and accrued expenses

 

992,078

 

(175,196

)

Deferred revenue

 

(5,396

)

(3,571

)

Net cash used for operating activities

 

(2,513,718

)

(3,150,593

)

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

Purchase of property and equipment

 

(6,288

)

(195,482

)

Acquisition of intangible assets

 

(32,051

)

(8,346

)

Net cash used for investing activities

 

(38,339

)

(203,828

)

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

Proceeds from exercise of stock options

 

—

 

92,424

 

Proceeds from issuance of common stock

 

13,772,133

 

—

 

Debt issuance costs

 

(180,142

)

—

 

Net cash provided by financing activities

 

13,591,991

 

92,424

 

 

 

 

 

 

 

Net increase/(decrease) in cash and cash equivalents

 

11,039,934

 

(3,261,997

)

Cash and cash equivalents, beginning of year

 

8,215,791

 

20,069,750

 

 

 

 

 

 

 

Cash and cash equivalents, end of period

 

$

19,255,725

 

$

16,807,753

 

 

 

 

 

 

 

Supplemental disclosures of cash flow activity:

 

 

 

 

 

Cash paid for interest

 

$

803,607

 

$

303,919

 

 

See notes to condensed consolidated financial statements.

 

6


Table of Contents

 

AxoGen, Inc.

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

1.        Basis of Presentation

 

The accompanying condensed consolidated financial statements include the accounts of AxoGen, Inc. (the “Company” or “AxoGen”) and its wholly owned subsidiary AxoGen Corporation (“AC”) as of March 31, 2015 and December 31, 2014 and for the three month periods ended March 31, 2015 and 2014.  The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2014, which are included in the Annual Report on Form 10-K as of and for the year ended December 31, 2014.  The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all adjustments necessary for a fair presentation of results for the periods presented.  Results for interim periods are not necessarily indicative of results for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

2.        Organization and Business

 

Business Summary

 

AxoGen, Inc. is a leading medical technology company dedicated to peripheral nerve repair. The company has created and licensed a unique combination of patented nerve repair technologies to change the standard of care for patients with peripheral nerve injuries. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance® Nerve Graft, an off-the-shelf commercially available processed human nerve allograft for bridging severed nerves without the comorbidities associated with an additional surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and the AxoTouch™ Two-Point Discriminator, a tool useful for measuring sensation after a nerve injury, following the progression of a repaired nerve, and during the evaluation of a person with a possible nerve injury, such as nerve division or nerve compression.

 

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen.  AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

 

3.        Summary of Significant Accounting Policies

 

Revenue Recognition

 

Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is delivered to the customer or distributor, at which time title passes to the customer or distributor, provided, however, that in the case of revenues from consigned sales delivery is determined when the product is utilized in a surgical procedure. Once a product is delivered, the Company has no further performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred.

 

7


Table of Contents

 

Cash and Cash Equivalents and Concentration

 

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

 

Accounts Receivable and Concentration of Credit Risk

 

Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.

 

In 2013, we established a reserve for doubtful accounts as we did have some accounts deemed uncollectible.  We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected.  The analysis excludes certain government related receivables due to our past successful experience in collectability.  Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance.  The remaining balances outstanding over 60 days have a percentage applied by aging category (5% for balances 61-90 days and 20% for balances over 90 days aged), based on a historical valuation that allows us to calculate the total reserve required.  The reserve balance was determined by applying a percentage to the cumulative balance between 60 and 90 days and a higher percentage to the balance over 90 days.  In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account.  The write off process involves approval by senior management based on the write off amount.  The allowance for doubtful accounts reserve balance was approximately $101,000 and $94,000 at March 31, 2015 and December 31, 2014, respectively.

 

Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures.

 

Inventories

 

Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:

 

 

 

March 31,
2015

 

December 31,
2014

 

 

 

(unaudited)

 

 

 

Finished goods

 

$

2,188,691

 

$

2,072,235

 

Work in process

 

272,470

 

331,891

 

Raw materials

 

876,737

 

809,494

 

 

 

$

3,337,898

 

$

3,213,620

 

 

Inventories were net of reserve of approximately $575,000 and $404,000 at March 31, 2015 and December 31, 2014, respectively.

 

8


Table of Contents

 

Income Taxes

 

The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.

 

The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2011 through 2014; there currently are no examinations in process.

 

Fair Value of Financial Instruments

 

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.

 

Share-Based Compensation

 

Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the October 2011 merger of LecTec, Inc. and AxoGen Corporation, and based on the Company’s common stock for periods subsequent to such merger. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the three months ended March 31:

 

Three months ended March 31,

 

2015

 

2014

 

Expected term (in years)

 

4.0

 

4.0

 

Expected volatility

 

76.32

%

81.26

%

Risk free rate

 

1.28

%

1.12

%

Expected dividends

 

0.0

%

0.0

%

 

The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the three months ended March 31, 2015 and 2014 as they were deemed insignificant.

 

9


Table of Contents

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements

 

In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”) which changes the presentation of debt issuance costs in financial statements to present such costs as a direct deduction from the related debt liability rather than as an asset. ASU 2015-03 will become effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. We do not expect the adoption of this standard will have a material impact on our consolidated financial statements.

 

In February 2015, the FASB issued Accounting Standards Update No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis” (“ASU 2015-02”) which updates the considerations on whether an entity should consolidate certain legal entities. The update removes the indefinite deferral of specialized guidance for certain investment funds and changes the way that entities evaluate limited partnerships and fees paid to service providers in the consolidation determination. ASU 2015-02 will become effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements.

 

In January 2015, the FASB issued guidance, which completely eliminates all references to and guidance concerning the concept of an extraordinary item from GAAP. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

 

In June 2014, the FASB issued updated guidance related to stock compensation. The amendment requires that a performance target that affects vesting and that could be achieved after the requisite period, be treated as a performance condition. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

 

In May 2014, the FASB issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016; however, in April 2015, the FASB voted to propose a one year deferral of the effective date. The proposed deferral may permit early adoption, but would not allow adoption any earlier than the original effective date of the standard. We are currently evaluating the impact this standard will have on our consolidated financial statements.

 

10


Table of Contents

 

The Company’s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures.

 

4.        Property and Equipment

 

Property and equipment consist of the following:

 

 

 

March 31,
2015

 

December 31,
2014

 

 

 

(unaudited)

 

 

 

Furniture and equipment

 

$

880,114

 

$

873,824

 

Leasehold improvements

 

285,697

 

285,697

 

Processing equipment

 

1,194,712

 

1,194,712

 

Less: accumulated depreciation and amortization

 

(1,777,103

)

(1,735,205

)

Property and equipment

 

$

583,420

 

$

619,028

 

 

5.        Intangible Assets

 

The Company’s intangible assets consist of the following:

 

 

 

March 31,
2015

 

December 31,
2014

 

 

 

(unaudited)

 

 

 

License agreements

 

$

851,603

 

$

850,859

 

Patents

 

111,303

 

79,996

 

Less: accumulated amortization

 

(365,453

)

(353,681

)

Intangible assets, net

 

$

597,453

 

$

577,174

 

 

License agreements are being amortized over periods ranging from 17-20 years. Patent costs were being amortized over three years. As of December 31, 2014, the patents were fully amortized, and the remaining patents of $79,996 were pending patent costs and were not amortizable. Amortization expense for the three months ended March 31, 2015 and 2014 was approximately $12,000 and $11,000, respectively. As of March 31, 2015, future amortization of license agreements is expected to be $36,000 for the remainder of 2015 and $48,000 for 2016 through 2020.

 

License Agreements

 

The Company has entered into multiple license agreements (the “License Agreements”) with the University of Florida Research Foundation (“UFRF”) and University of Texas at Austin (“UTA”). Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with 60 days

 

11


Table of Contents

 

prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below:

 

·                       AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products. One of the agreements also contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees. Also, when AxoGen pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%;

 

·                       If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from the third party to the licensor. Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sublicensee fees for its own use of the technologies;

 

·                       AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and

 

·                       Currently, under one of the License Agreements, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee. Other milestone fees are due if AxoGen develops certain pharmaceutical or medical device products under the License Agreements. No such products are currently under development.

 

Royalty fees were approximately $96,000 and $61,000 during the three months ended March 31, 2015 and 2014, respectively, and are included in sales and marketing expense on the accompanying condensed consolidated statements of operations.

 

6.        Accounts Payable and Accrued Expenses

 

Accounts payable and accrued expenses consists of the following:

 

 

 

March 31,
2015

 

December 31,
2014

 

Accounts payable

 

$

1,966,422

 

$

1,160,859

 

Miscellaneous accruals

 

194,985

 

105,315

 

Accrued compensation

 

1,261,865

 

1,165,020

 

Accounts Payable and Accrued Expenses

 

$

3,423,272

 

$

2,431,194

 

 

7.        Notes Payable

 

Notes Payable consists of the following:

 

 

 

March 31,
2015
(unaudited)

 

December 31,
2014

 

 

 

 

 

 

 

Term Loan and Revenue Interest Agreement with Three Peaks Capital S.a.r.l. (“Three Peaks”) for a total term loan amount of $25,000,000 which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of March 31, 2015 and December 31, 2014 resulted in a 10% rate. The Revenue Interest Agreement is for a period of ten years. Royalty payments are base on a royalty rate of 3.75% of revenues up to a maximum of $30 million in revenues in any 12 month period.

 

$

25,269,050

 

$

25,085,777

 

Long-term Notes Payable

 

$

25,269,050

 

$

25,085,777

 

 

12


Table of Contents

 

Note Payable

 

On October 5, 2012, AxoGen entered into a Revenue Interests Purchase Agreement (the “Royalty Contract”) with PDL BioPharma, Inc. (“PDL”), pursuant to which the Company sold to PDL the right to receive royalties equal to 9.95% of the Company’s Net Revenues (as defined in the Royalty Contract) generated by the sale, distribution or other use of AxoGen’s products Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector.  The Royalty Contract had a term of eight years. Under the Royalty Contract, PDL received royalty payments based on a royalty rate of 9.95% of the Company’s Net Revenues, subject to certain agreed upon minimum payment requirements, which were anticipated to be approximately $1.3 to $2.5 million per quarter tobegin in the fourth quarter of 2014 through the third quarter of 2020 as provided in the Royalty Contract. The Company recorded interest using its best estimate of the effective interest rate accruing interest using the specified internal rate of return of the Put Option of 20%.  The total consideration PDL paid to the Company was $20,800,000 (the “Funded Amount”), which included $19,050,000 PDL paid to the Company on October 5, 2012, and $1,750,000 PDL paid to the Company on August 14, 2012 pursuant to an Interim Revenue Interest Purchase Agreement between the Company and PDL, dated August 14, 2012 (the “Interim Royalty Contract”). Upon the closing (the “Closing”) of PDL’s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty Contract, the Interim Royalty Contract was terminated. On November 12, 2014, the Company paid PDL $30.3 million to fully extinguish the Royalty Contract.  The Company has no further obligations under the Royalty Contract.

 

On November 12, 2014, the Company sold 643,382 shares of common stock for a total of $1.75 million to PDL (“PDL Equity Sale”) at a price of $2.72 per share pursuant to a Securities Purchase Agreement by and between the Company and PDL.  The Company intends to use the proceeds from the PDL Equity Sale for general corporate purposes.

 

Term Loan Agreement and Revenue Interest Agreement

 

On November 12, 2014, (the “Signing Date”), AxoGen, as borrower, and AC, as guarantor, entered into a term loan agreement (the “Term Loan Agreement”) with the lenders party thereto and Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP (“Oberland”), as administrative and collateral agent for the lenders. Under the Term Loan Agreement, Three Peaks has agreed to lend to AxoGen a term loan of $25 million (the “Initial Term Loan”) which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 (“the Initial Closing Date”) resulted in a 10% rate. Under certain conditions, AxoGen has the option to draw an additional $7 million (“Subsequent Borrowing” and, together with the Initial Term Loan, the “Term Loan”) during the period of April 1, 2016 through June 29, 2016 (the closing date of each such Subsequent Borrowing, a “Subsequent Closing Date” and, together with the Initial Closing Date, the “Closing Dates”) under similar terms and conditions. AxoGen has to maintain certain covenants including limiting new indebtedness, restriction of the payment of dividends and maintain certain levels of revenue. Three Peaks has a first perfected security interest in the assets of AxoGen.

 

13


Table of Contents

 

In addition, AxoGen entered into a 10 year Revenue Interest Agreement (“Revenue Interest Agreement”) with Three Peaks. Royalty payments are based on a royalty rate of 3.75% of AxoGen’s revenues up to a maximum of $30 million in revenues in any 12 month period. In the event the Subsequent Borrowing is drawn, the royalty rate increases proportionally up to a maximum of 4.80%. AxoGen has to maintain certain covenants including those covenants under the Term Loan.

 

Under the Term Loan Agreement, AxoGen has the option at any time to prepay the Term Loan, in whole or in part, and the Royalty Interest Agreement, defined below, by making the following payment, and Three Peaks has the right to demand the following payment upon a change of control of AxoGen, sale of the majority of AxoGen’s assets or a material adverse change to AxoGen: (i) on or prior to the first anniversary of the applicable Closing Date, 120% of the outstanding principal amount of the Term Loan or any portion being prepaid; (ii) after the first anniversary but no later than the second anniversary of the applicable Closing Date, 135% of the outstanding principal amount of the Term Loan or any portion being prepaid ; (iii) after the second anniversary but no later than the third anniversary of the applicable Closing Date, 150% of the outstanding principal amount of the Term Loan or any portion being prepaid; or (iv) after the third anniversary of the applicable Closing Date, an amount generating an Internal Rate of Return of 16.25% of the outstanding principal amount of the Term Loan or any portion being prepaid. In all cases, the amount due is reduced by the sum of interest and principal previously paid and all amounts received under the Revenue Interest Agreement. In each such case AxoGen will also owe an additional 3% of the originally advanced Term Loan amount. Upon payment to Three Peaks, AxoGen would have no further obligations to Three Peaks under the Term Loan or the Revenue Interest Agreement.

 

In connection with the Term Loan Agreement, on the Signing Date, the Company and its wholly owned subsidiary, AC entered into a Security Agreement (the “Security Agreement”) with Three Peaks, pursuant to which each of the Company and AC grants to Three Peaks a security interest in certain collateral as specified in the Security Agreement to guarantee the payment in full when due of the Secured Obligations.

 

Also in connection with the above transaction, the Company sold 1,375,969 shares of common stock to Three Peaks for a total of $3.55 million (“Three Peaks Equity Sale”) at a price of $2.58 per share.  Pursuant to the equity purchase provisions in the Three Peaks Term Loan Agreement, in the event that we sell prior to November 12, 2016 our securities at a lower price per share than the $2.58 per share paid by Three Peaks, or where the terms of such subsequent sale are otherwise more favorable, then in such case we have agreed to match the more favorable terms of such subsequent sale with respect to the shares purchased by Three Peaks. A subsequent sale does not include the issuance of securities or options to our employees, officers, directors or consultants pursuant to our approved employee option pool or any other employee stock purchase or option plan existing as of November 12, 2014.

 

The Company records interest using its best estimate of the effective interest rate.  This estimate takes into account both the rate on the Term Loan Agreement and the rate associated with the 10 year Revenue Interest Agreement with Three Peaks.  The effective interest rate is based on actual payments to date, projected future revenues and the projected royalty payments and the quarterly interest payments due on the Term Loan Agreement.  From time to time, AxoGen will reevaluate the expected cash flows and may adjust the effective interest rate.  Determining the effective interest rate requires judgment and is based on significant assumptions related to estimates of the amounts and timing of future revenue streams.  Determination of these assumptions is highly subjective and different assumptions could lead to materially different outcomes.

 

14


Table of Contents

 

8.        Stock Options

 

The Company granted stock options to purchase 269,500 shares of common stock pursuant to its 2010 Stock Incentive Plan for the three months ended March 31, 2015.  Stock-based compensation expense was $368,249 and $257,542 for the three months ended March 31, 2015 and 2014, respectively. Total future stock compensation expense related to nonvested awards is expected to be approximately $2,275,000 at March 31, 2015.

 

9.        Public Offering of Common Stock

 

On February 5, 2015, AxoGen entered into the Underwriting Agreement with the Underwriter, in connection with the offering, issuance and sale (the “Offering”) of 4,728,000 shares of the Company’s common shares, par value $0.01 per share (the “Common Shares”), at a price to the public of $2.75 per share.  The Company also granted to the Underwriter a 30-day option to purchase up to an aggregate of 709,200 additional Common Shares to cover over-allotments, if any.

 

The Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the Securities and Exchange Commission, and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the Offering, dated February 5, 2015.

 

As of February 13, 2015, the Offering was completed with the sale of 5,437,200 Common Shares, which included the exercise of the over-allotment option, at $2.75 per share resulting in gross proceeds to AxoGen from the Offering of approximately $15.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen estimated at approximately $1.4 million. The Common Shares were listed on the NASDAQ Capital Market.

 

10.      Subsequent Events

 

Commercial Lease

 

On April 21, 2015, AxoGen Corporation, a wholly owned subsidiary of AxoGen, Inc.  (“AxoGen” or the “Company”), entered into a Commercial Lease with Ja-Cole, L.P. (the “New Lease”) for property located in Burleson, Texas. The New Lease supersedes and replaces a current lease with Ja-Cole. Under the terms of the New Lease, AxoGen leased an additional 2,100 square feet of warehouse space that will be combined with its current 5,400 square feet of warehouse/office space in Burleson, Texas.   The New Lease is for a three year term expiring April 21, 2018, renewable thereafter by agreement of the parties, at an annual cost of $60,000 per year.  The expanded Burleson facility will house raw material storage and product distribution and allow expansion space as required for AxoGen operations.

 

Processing Agreement

 

Under an Amended and Restated Nerve Tissue Processing Agreement (the “Agreement”) with LifeNet Health, AxoGen processes and packages Avance® Nerve Graft using its employees and equipment located at LifeNet Health, Virginia Beach, Virginia.  As a result of business requirements of LifeNet Health and their need for additional space on April 16, 2015 they notified AxoGen that it will need to transition out of the Virginia Beach facility on or before February 27, 2016 and therefore is terminating the Agreement effective February 27, 2016.   AxoGen’s planning has included the establishment of manufacturing space under its full control to meet its needs as it continues to expand its revenues. AxoGen is formalizing its plans and has sufficient time to establish new manufacturing space under its control that will meet its future needs.

 

15


Table of Contents

 

ITEM 2 — MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Unless the context otherwise requires, all references in this report to “AxoGen,” “the Company,” “we,” “us” and “our” refer to AxoGen, Inc. and its wholly owned subsidiary AxoGen Corporation (“AC”).

 

OVERVIEW

 

AxoGen, Inc. (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. The company has created and licensed a unique combination of patented nerve repair technologies to change the standard of care for patients with peripheral nerve injuries. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with an additional surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and the AxoTouch™ Two-Point Discriminator, a tool useful for measuring sensation after a nerve injury, following the progression of a repaired nerve, and during the evaluation of a person with a possible nerve injury, such as nerve division or nerve compression.

 

Revenue from the distribution of these products is the main contributor to AxoGen’s total reported sales and has been the key component of its growth to date. AxoGen revenues increased in the first quarter of 2015 compared to 2014 primarily as a result of sales to new accounts, increased product usage by existing accounts and a price increase effective March 1, 2015. AxoGen has continued to broaden and strengthen its sales and marketing activity with a focus on the execution of its sales operations.  This is expected to have a continued positive contribution to its revenue growth in the long term.

 

Results of Operations

 

Comparison of the Three Months Ended March 31, 2015 and 2014

 

Revenues

 

Revenues for the three months ended March 31, 2015 increased 57.8% to approximately $4,951,000 as compared to approximately $3,138,000 for the three months ended March 31, 2014.  This increase was primarily a result of increased product usage by existing accounts and sales to new accounts.  In addition, AxoGen recognized approximately $142,000 of grant revenue in the first quarter of 2015 as compared to approximately $62,000 in grant revenue in first quarter 2014.

 

Gross Profit

 

Gross profit for the three months ended March 31, 2015 increased 62.8% to approximately $3,968,000 as compared to approximately $2,437,000 for the three months ended March 31, 2014.  Such increase in aggregate dollars was primarily attributable to the increased revenues in the first quarter of 2015. Gross margin improved to 80.1% for the three months ended March 31, 2015 as compared to 77.7% for the same period in 2014 as a result of manufacturing efficiencies, a price increase in March 2015 and favorable product mix.

 

Costs and Expenses

 

Total cost and expenses increased 20.0% to approximately $6,512,000 for the three months ended March 31, 2015 as compared to approximately $5,428,000 for the three months ended March 31, 2014. These increases were primarily due to increased sales and marketing activities.

 

Sales and marketing expenses increased 44.5% to approximately $3,933,000 for the three months ended March 31, 2015  as compared to approximately $2,721,000 for the three months ended March 31, 2014. This increase was primarily due to an expansion of our direct sales force, and increased support for both our direct sales force

 

16


Table of Contents

 

and independent distributors, sales training and surgeon education. As a percentage of revenues, sales and marketing expenses were 79.4% for the three months ended March 31, 2015 compared to 86.7% for the three months ended March 31, 2014. Such lower sales and marketing expenses as a percentage of revenue were a result of the revenue increase outpacing increases in costs and expenses.

 

General and administrative expenses  of approximately $1,909,000 for the three months ended March 31, 2015 were flat as compared to approximately $1,895,000 for the three months ended March 31, 2014. As a percentage of revenues, general and administrative expenses were 38.6% for the three months ended March 31, 2015 as compared to 60.3% for the three months ended March 31, 2014. Such lower general and administrative expenses as a percentage of revenue were a result of the revenue increase outpacing increases in costs and expenses.

 

Research and development expenses decreased approximately 17.5% to approximately $671,000 in the three months ended March 31, 2015 as compared to approximately $813,000 for the three months ended March 31, 2014.  Research and development includes AxoGen’s product development, clinical efforts substantially focused on its biological license application (“BLA”) for the Avance® Nerve Graft and surgeon education. This activity varies from quarter to quarter due to the timing of certain projects.  A substantial portion of the research and development expenses in 2014 and thus far in 2015, relate to expenditures for such clinical activity including preparation for the start of the BLA study during 2015. Although AxoGen’s products are developed for sale in their current use, it does conduct limited research and product development efforts focused on new products and new applications to existing products.  AxoGen has become more active in pursuing research grants to support this research.  This AxoGen product pipeline development also contributed to a portion of the research and development expenses in 2015, with grant revenue offsetting a portion of this activity.

 

Other Income and Expenses

 

Interest expense decreased 16.5% to approximately $995,000 for the three months ended March 31, 2015 as compared to approximately $1,191,000 for the three months ended March 31, 2014. This decrease was due to the difference in the interest related to the Revenue Interest Agreement with Three Peaks as compared to the interest related to the Royalty Contract and the interest accrued related to PDL.  As a result of the accounting treatment for the Three Peaks and the PDL transaction, interest expense included approximately $183,000 and $892,000 for the three months ended March 31, 2015 and 2014, respectively, of non-cash expense that is based upon the terms of the Three Peaks and PDL transactions and increases in AxoGen revenues. Other than the $183,000 and $892,000 non-cash expense, the remaining $812,000 and $299,000 in interest expense for the three months ended March 31, 2015 and 2014, respectively, is related to cash paid for interest on the Term Loan Agreement and note payable.

 

Interest expense—deferred financing costs decreased 33.3% to approximately $34,000 for the three months ended March 31, 2015 as compared to approximately $51,000 for the three months ended March 31, 2014. This decrease is primarily due to lower deferred financing cost amortization associated with the Three Peaks agreement from applying the effective interest rate method as compared to the PDL agreement from applying the effective interest rate method.  Additionally, the deferred financing fees associated with the Three Peaks agreement are spread out over 10 years compared to 8 years for the PDL agreement.

 

Income Taxes

 

The Company had no income tax expenses or income tax benefit for each of the three months ended March 31, 2015 and 2014 due to incurrence of net operating loss in each of these periods.

 

Effect of Inflation

 

Inflation has not had a significant impact on the Company’s operations or cash flow.

 

17


Table of Contents

 

Liquidity and Capital Resources

 

Note Payable

 

On October 5, 2012, AxoGen entered into a Revenue Interests Purchase Agreement (the “Royalty Contract”) with PDL BioPharma, Inc. (“PDL”), pursuant to which the Company sold to PDL the right to receive royalties equal to 9.95% of the Company’s Net Revenues (as defined in the Royalty Contract) generated by the sale, distribution or other use of AxoGen’s products Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector.  The Royalty Contract had a term of eight years. Under the Royalty Contract, PDL received royalty payments based on a royalty rate of 9.95% of the Company’s Net Revenues, subject to certain agreed upon minimum payment requirements, which were anticipated to be approximately $1.3 to $2.5 million per quarter to begin in the fourth quarter of 2014 through the third quarter of 2020 as provided in the Royalty Contract. The Company recorded interest using its best estimate of the effective interest rate accruing interest using the specified internal rate of return of the Put Option of 20%.  The total consideration PDL paid to the Company was $20,800,000 (the “Funded Amount”), which included $19,050,000 PDL paid to the Company on October 5, 2012, and $1,750,000 PDL paid to the Company on August 14, 2012 pursuant to an Interim Revenue Interest Purchase Agreement between the Company and PDL, dated August 14, 2012 (the “Interim Royalty Contract”). Upon the closing (the “Closing”) of PDL’s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty Contract, the Interim Royalty Contract was terminated. On November 12, 2014, the Company paid PDL $30.3 million to fully extinguish the Royalty Contract.  The Company has no further obligations under the Royalty Contract.

 

As a result of the accounting treatment for the PDL transaction, interest expense for the three months ended March 31, 2014 included approximately $892,000 of non-cash expense that was to be paid in the future based upon the terms of the PDL transaction and increases in AxoGen revenues. The $892,000 of non-cash expense was derived from taking the effective interest on the put in 2014 on the PDL agreement less the actual cash payment made to PDL for the quarter.  Other than the $892,000 non-cash expense, the remaining $299,000 in interest expense for the three months ended March 31, 2014 is related to cash paid for interest on the note payable with PDL.

 

On November 12, 2014, the Company sold 643,382 shares of common stock for a total of $1.75 million to PDL (“PDL Equity Sale”) at a price of $2.72 per share pursuant to a Securities Purchase Agreement by and between the Company and PDL.  The Company intends to use the proceeds from the PDL Equity Sale for general corporate purposes.

 

Term Loan Agreement and Revenue Interest Agreement

 

On November 12, 2014, (the “Signing Date”), AxoGen, as borrower, and AC, as guarantor, entered into a term loan agreement (the “Term Loan Agreement”) with the lenders party thereto and Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP (“Oberland”), as administrative and collateral agent for the lenders. Under the Term Loan Agreement, Three Peaks has agreed to lend to AxoGen a term loan of $25 million (the “Initial Term Loan”) which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 (“the Initial Closing Date”) resulted in a 10% rate. Under certain conditions, AxoGen has the option to draw an additional $7 million (“Subsequent Borrowing” and, together with the Initial Term Loan, the “Term Loan”) during the period of April 1, 2016 through June 29, 2016 (the closing date of each such Subsequent Borrowing, a “Subsequent Closing Date” and, together with the Initial Closing Date, the “Closing Dates”) under similar terms and conditions. AxoGen has to maintain certain covenants including limiting new indebtedness, restriction of the payment of dividends and maintain certain levels of revenue. Three Peaks has a first perfected security interest in the assets of AxoGen.

 

In addition, AxoGen entered into a 10 year Revenue Interest Agreement (“Revenue Interest Agreement”) with Three Peaks. Royalty payments are based on a royalty rate of 3.75% of AxoGen’s revenues up to a maximum of $30 million in revenues in any 12 month period. In the event the Subsequent Borrowing is drawn, the royalty rate increases proportionally up to a maximum of 4.80%. AxoGen has to maintain certain covenants including those covenants under the Term Loan.

 

Under the Term Loan Agreement, AxoGen has the option at any time to prepay the Term Loan, in whole or in part, and the Royalty Interest Agreement, defined below, by making the following payment, and Three Peaks has the right to demand the following payment upon a change of control of AxoGen, sale of the majority of AxoGen’s assets or a material adverse change to AxoGen: (i) on or prior to the first anniversary of the

 

18


Table of Contents

 

applicable Closing Date, 120% of the outstanding principal amount of the Term Loan or any portion being prepaid; (ii) after the first anniversary but no later than the second anniversary of the applicable Closing Date, 135% of the outstanding principal amount of the Term Loan or any portion being prepaid ; (iii) after the second anniversary but no later than the third anniversary of the applicable Closing Date, 150% of the outstanding principal amount of the Term Loan or any portion being prepaid; or (iv) after the third anniversary of the applicable Closing Date, an amount generating an Internal Rate of Return of 16.25% of the outstanding principal amount of the Term Loan or any portion being prepaid. In all cases, the amount due is reduced by the sum of interest and principal previously paid and all amounts received under the Revenue Interest Agreement. In each such case AxoGen will also owe an additional 3% of the originally advanced Term Loan amount. Upon payment to Three Peaks, AxoGen would have no further obligations to Three Peaks under the Term Loan or the Revenue Interest Agreement.

 

In connection with the Term Loan Agreement, on the Signing Date, the Company and its wholly owned subsidiary, AC entered into a Security Agreement (the “Security Agreement”) with Three Peaks, pursuant to which each of the Company and AC grants to Three Peaks a security interest in certain collateral as specified in the Security Agreement to guarantee the payment in full when due of the Secured Obligations.

 

Also in connection with the above transaction, the Company sold 1,375,969 shares of common stock to Three Peaks for a total of $3.55 million (“Three Peaks Equity Sale”) at a price of $2.58 per share.  Pursuant to the equity purchase provisions in the Three Peaks Term Loan Agreement, in the event that we sell prior to November 12, 2016 our securities at a lower price per share than the $2.58 per share paid by Three Peaks, or where the terms of such subsequent sale are otherwise more favorable, then in such case we have agreed to match the more favorable terms of such subsequent sale with respect to the shares purchased by Three Peaks. A subsequent sale does not include the issuance of securities or options to our employees, officers, directors or consultants pursuant to our approved employee option pool or any other employee stock purchase or option plan existing as of November 12, 2014.

 

As a result of the accounting treatment for the Three Peaks transaction, interest expense for the three months ended March 31, 2015 included approximately $183,000 of non-cash expense that is expected to be paid in the future based upon the terms of the Three Peaks transaction and increases in AxoGen revenues. The $183,000 of non-cash expense was derived from taking the imputed interest on the Three Peaks agreement less the actual cash payment made to Three Peaks for the quarter.  Other than the $183,000 non-cash expense, the remaining $812,000 in interest expense for the three months ended March 31, 2015 is related to cash paid for interest on the Term Loan with Three Peaks.

 

The Company records interest using its best estimate of the effective interest rate.  This estimate takes into account both the rate on the Term Loan Agreement and the rate associated with the 10 year Revenue Interest Agreement with Three Peaks.  The effective interest rate is based on actual payments to date, projected future revenues and the projected royalty payments and the quarterly interest payments due on the Term Loan Agreement.  From time to time, AxoGen will reevaluate the expected cash flows and may adjust the effective interest rate.  Determining the effective interest rate requires judgment and is based on significant assumptions related to estimates of the amounts and timing of future revenue streams.  Determination of these assumptions is highly subjective and different assumptions could lead to materially different outcomes.

 

The Company had no material commitments for capital expenditures at March 31, 2015.

 

Public Offering of Common Stock

 

On February 5, 2015, AxoGen entered into the Underwriting Agreement with the Underwriter, in connection with the offering, issuance and sale (the “Offering”) of 4,728,000 shares of the Company’s common shares, par value $0.01 per share (the “Common Shares”), at a price to the public of $2.75 per share.  The Company also granted to the Underwriter a 30-day option to purchase up to an aggregate of 709,200 additional Common Shares to cover over-allotments, if any.

 

The Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the Securities and Exchange Commission, and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the Offering, dated February 5, 2015.

 

19


Table of Contents

 

As of February 13, 2015, the Offering was completed with the sale of 5,437,200 Common Shares, which included the exercise of the over-allotment option, at $2.75 per share resulting in gross proceeds to AxoGen from the Offering of approximately $15.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen estimated at approximately $1.4 million. The Common Shares were listed on the NASDAQ Capital Market.

 

Cash Flow Information

 

AxoGen had working capital of approximately $22.58 million and a current ratio of 7.57 at March 31, 2015, compared to working capital of $11.97 million and a current ratio of 5.89 at December 31, 2014. The increase in working capital and the current ratio at March 31, 2015 as compared to December 31, 2014 was primarily due to the public offering in February.  In February 2015 AxoGen completed a public offering of 5,437,200 shares of Common Stock at $2.75 per share resulting in gross proceeds to AxoGen from the offering of approximately $15.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen estimated at approximately $1.4 million. The Company believes it has sufficient cash resources to meet its liquidity requirements for at least the next 12 months.

 

AxoGen’s future capital requirements depend on a number of factors, including, without limitation, continued adoption of our products by surgeons and growth of our revenues, continued expansion and development of our direct sales force, expenses associated with our professional education programs, maintaining our gross margins, expenses related to our facilities for production and distribution of products and general market conditions.   AxoGen could face increasing capital needs which could be substantial depending on the extent to which AxoGen is unable to increase revenues.

 

If AxoGen needs additional capital in the future, it may raise additional funds through public or private equity offerings, debt financings or from other sources.  The sale of additional equity would result in dilution to AxoGen’s shareholders. There is no assurance that AxoGen will be able to secure funding on terms acceptable to it, or at all. The increasing need for capital could also make it more difficult to obtain funding through either equity or debt.  Should additional capital not become available to AxoGen as needed, AxoGen may be required to take certain action, such as, slowing sales and marketing expansion, delaying regulatory approvals or reducing headcount.

 

During the three months ended March 31, 2015, the Company had a net increase in cash and cash equivalents of approximately $11,040,000 as compared to a net decrease of cash and cash equivalents of approximately $3,262,000 in the three months ended March 31, 2014. The Company’s principal sources and uses of funds are explained below:

 

Cash used in operating activities

 

The Company used approximately $2,514,000 of cash for operating activities in the three months ended March 31, 2015, as compared to using approximately $3,151,000 of cash for operating activities in the three months ended March 31, 2014. This decrease in cash used in operating activities is primarily attributable to the increase in accounts payable and accrued expenses offset by the net loss generated in the three months ended March 31, 2015, along with an increase in our accounts receivable and inventory.

 

Cash used for investing activities

 

Investing activities for the three months ended March 31, 2015 used approximately $38,000 of cash as compared to using approximately $204,000 of cash in the three months ended March 31, 2014. This decrease in use is principally attributable to the non recurrence of purchases of certain fixed assets for the expansion of the headquarters office and the opening of the worldwide distribution facility in Burleson, Texas that occurred in the period in 2014.

 

Cash provided by financing activities

 

Financing activities in the three months ended March 31, 2015 provided approximately $13,592,000 of cash as compared to providing approximately $92,000 of cash in the three months ended March 31, 2014. The increase

 

20


Table of Contents

 

was due to proceeds received from the public offering consummated in February 2015 compared to the exercise of stock options in the same period of 2014.

 

Off-Balance Sheet Arrangements

 

AxoGen does not have any off-balance sheet arrangements.

 

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not Applicable.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

The Company maintains “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, (the “Exchange Act”), that are designed to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, and Board of Directors, as appropriate, to allow timely decisions regarding required disclosure.  In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable assurance of achieving the desired objectives, and we necessarily are required to apply our judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

 

Our management, including our principal executive officer and principal financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2015 and concluded that our disclosure controls and procedures were effective.

 

Changes in Internal Controls Over Financial Reporting

 

During the quarter ended March 31, 2015, there were no changes in the Company’s internal control over financial reporting (as defined in Rule 13a-15(f) and 15d—15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

21


Table of Contents

 

UNITED STATES

PART II —OTHER INFORMATION

 

ITEM 1 — Legal Proceedings

 

The Company is not a party to any material litigation as of March 31, 2015.

 

ITEM 1A  — RISK FACTORS

 

The Company faces a number of risks and uncertainties.  In addition to the other information in this report and the Company’s other filings with the Securities and Exchange Commission, readers should consider carefully the risk factors discussed in Part I “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2014.  There have been no material changes to these risk factors.  If any of these  risks actually occur, the Company’s business, results of operations or financial condition could be materially adversely affected.

 

ITEM 2   —  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3   —  DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4   MINE SAFETY DISCLOSURES

 

Not Applicable.

 

ITEM 5  — OTHER INFORMATION

 

None.

 

22


Table of Contents

 

ITEM 6  — EXHIBITS

 

Exhibit
Number

 

Description

 

 

 

10.1*

 

Term Loan Agreement dated as of November 12, 2014 among AxoGen, Inc. as Borrower, AxoGen Corporation, as Guarantor, the Lenders party hereto and Three Peaks Capital S.a.r.l., as Administrative Agent and Collateral Agent (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K/A filed on February 4, 2015).

 

 

 

10.2

 

Revenue Interest Agreement dated as of November 12, 2014 among AxoGen, Inc., AxoGen Corporation and Three Peaks Capital S.a.r.l. (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K/A filed on February 4, 2015).

 

 

 

10.3

 

Security Agreement dated as of November 12, 2014 among AxoGen, Inc., AxoGen Corporation and Three Peaks Capital S.a.r.l. (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K/A filed on February 4, 2015).

 

 

 

10.4

 

Securities Purchase Agreement dated as of November 12, 2014, between AxoGen, Inc., and PDL BioPharma, Inc. (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K/A filed on February 4, 2015).

 

 

 

31.1†

 

Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

31.2†

 

Certification of Principle Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

32††

 

Certification Pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS

 

XBRL Instance Document.

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document.

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document.

 

 

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document.

 

 

 

101.LAB

 

XBRL Extension Labels Linkbase.

 

 

 

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document.

 

*     Confidential treatment has been granted for portions of this Exhibit pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 as amended.  The confidential portions have been deleted and filed separately with the United States Securities and Exchange Commission.

 

†  Filed herewith.

 

††  Furnished herewith.

 

23


Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

AXOGEN, INC.

 

 

 

 

Dated May 5, 2015

/s/ Karen Zaderej

 

Karen Zaderej

 

Chief Executive Officer

 

(Principal Executive Officer)

 

 

 

 

 

/s/ Lee Robert Johnston, Jr.

 

Lee Robert Johnston, Jr.

 

Chief Financial Officer

 

(Principal Financial and Accounting Officer)

 

24


Table of Contents

 

EXHIBIT INDEX

 

Exhibit
Number

 

Description

 

 

 

10.1*

 

Term Loan Agreement dated as of November 12, 2014 among AxoGen, Inc. as Borrower, AxoGen Corporation, as Guarantor, the Lenders party hereto and Three Peaks Capital S.a.r.l., as Administrative Agent and Collateral Agent (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K/A filed on February 4, 2015).

 

 

 

10.2

 

Revenue Interest Agreement dated as of November 12, 2014 among AxoGen, Inc., AxoGen Corporation and Three Peaks Capital S.a.r.l. (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K/A filed on February 4, 2015).

 

 

 

10.3

 

Security Agreement dated as of November 12, 2014 among AxoGen, Inc., AxoGen Corporation and Three Peaks Capital S.a.r.l. (incorporated by reference to Exhibit 10.3 to the Current Report on Form 8-K/A filed on February 4, 2015).

 

 

 

10.4

 

Securities Purchase Agreement dated as of November 12, 2014, between AxoGen, Inc., and PDL BioPharma, Inc. (incorporated by reference to Exhibit 10.4 to the Current Report on Form 8-K/A filed on February 4, 2015).

 

 

 

31.1†

 

Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

31.2†

 

Certification of Principle Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

32††

 

Certification Pursuant to 18 U.S.C. §1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS

 

XBRL Instance Document.

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document.

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document.

 

 

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document.

 

 

 

101.LAB

 

XBRL Extension Labels Linkbase.

 

 

 

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document.

 

*                 Confidential treatment has been granted for portions of this Exhibit pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 as amended.  The confidential portions have been deleted and filed separately with the United States Securities and Exchange Commission.

 

†  Filed herewith.

 

††  Furnished herewith.

 

25

 EX-31.1 2 a15-7805_1ex31d1.htm EX-31.1

EXHIBIT 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Karen Zaderej, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of AxoGen, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)             Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)             Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)              Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)             Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)             All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)             Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 5, 2015

 

 

/s/ Karen Zaderej

 

Karen Zaderej

 

Chief Executive Officer

 

1

 EX-31.2 3 a15-7805_1ex31d2.htm EX-31.2

EXHIBIT 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Lee Robert Johnston, Jr., certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of AxoGen, Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a)             Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)             Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)              Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)             Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)             All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)             Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 5, 2015

 

 

/s/ Lee Robert Johnston, Jr.

 

Lee Robert Johnston, Jr.

 

Chief Financial Officer

 

1

 EX-32 4 a15-7805_1ex32.htm EX-32

EXHIBIT 32

 

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (SUBSECTIONS (A) AND (B) OF SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE)

 

In connection with the Quarterly Report on Form 10-Q (the “Report”) of AxoGen, Inc.  (the “Company”), Karen Zaderej, Chief Executive Officer of the Company and  Lee Robert Johnston, Jr., Chief Financial Officer of the Company, each certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of her/his knowledge that:

 

1.     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2.     The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: May 5, 2015

/s/ Karen Zaderej

 

Karen Zaderej

 

Chief Executive Officer

 

(Principal Executive Officer)

 

 

 

/s/ Lee Robert Johnston, Jr.

 

Lee Robert Johnston, Jr.

 

Chief Financial Officer

 

(Principal Financial Officer)

 

1

 EX-101.PRE 5 axgn-20150331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.INS 6 axgn-20150331.xml XBRL INSTANCE DOCUMENT 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:MaximumMember 2015-01-01 2015-03-31 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:MaximumMember 2014-12-30 2014-12-31 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:MaximumMember 2014-11-12 2014-11-12 0000805928 us-gaap:SellingAndMarketingExpenseMember 2015-01-01 2015-03-31 0000805928 us-gaap:SellingAndMarketingExpenseMember 2014-01-01 2014-03-31 0000805928 us-gaap:LeaseholdImprovementsMember 2015-03-31 0000805928 us-gaap:EquipmentMember 2015-03-31 0000805928 axgn:FurnitureAndOfficeEquipmentMember 2015-03-31 0000805928 us-gaap:LeaseholdImprovementsMember 2014-12-31 0000805928 us-gaap:EquipmentMember 2014-12-31 0000805928 axgn:FurnitureAndOfficeEquipmentMember 2014-12-31 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember 2012-08-13 2012-10-05 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember 2012-08-13 2012-08-14 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanAndRevenueInterestPurchaseAgreementMember 2015-03-31 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanAndRevenueInterestPurchaseAgreementMember 2014-12-31 0000805928 us-gaap:PatentsMember 2015-01-01 2015-03-31 0000805928 us-gaap:PatentsMember 2015-03-31 0000805928 us-gaap:LicensingAgreementsMember 2015-03-31 0000805928 us-gaap:PatentsMember 2014-12-31 0000805928 us-gaap:LicensingAgreementsMember 2014-12-31 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember 2014-11-12 2014-11-12 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember 2012-10-04 2012-10-05 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2015-03-31 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2014-12-31 0000805928 2015-02-13 0000805928 axgn:ThreePeaksCapitalMember 2014-11-12 0000805928 axgn:PDLEquitySaleMember 2014-11-12 0000805928 2014-03-31 0000805928 2014-01-01 2014-03-31 0000805928 2015-05-04 0000805928 2015-01-01 2015-03-31 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2014-11-12 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember 2015-03-31 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember 2014-12-31 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:MaximumMember 2014-11-12 0000805928 axgn:ThreePeaksCapitalMember axgn:RevenueInterestPurchaseAgreementMember 2014-11-12 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember 2012-10-05 0000805928 us-gaap:LicensingAgreementsMember us-gaap:MinimumMember 2015-01-01 2015-03-31 0000805928 2013-12-31 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember 2014-12-31 0000805928 2015-02-13 2015-02-13 0000805928 us-gaap:LicensingAgreementsMember us-gaap:MaximumMember 2015-01-01 2015-03-31 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember 2014-11-12 2014-11-12 0000805928 2015-02-05 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember 2015-03-31 0000805928 us-gaap:PatentsMember 2014-01-01 2014-12-31 0000805928 us-gaap:LicensingAgreementsMember 2015-01-01 2015-03-31 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:MinimumMember 2014-10-01 2014-12-31 0000805928 axgn:PDLEquitySaleMember axgn:RevenueInterestPurchaseAgreementMember us-gaap:MaximumMember 2014-10-01 2014-12-31 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2015-01-01 2015-03-31 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2014-12-01 2014-12-31 0000805928 axgn:ThreePeaksCapitalMember axgn:TermLoanMember 2014-11-12 2014-11-12 0000805928 axgn:JaColeMember us-gaap:SubsequentEventMember 2015-04-21 0000805928 axgn:JaColeMember us-gaap:SubsequentEventMember 2015-04-21 2015-04-21 0000805928 axgn:AgeOver90DaysMember 2013-12-31 0000805928 axgn:Age61To90DaysMember 2013-12-31 0000805928 axgn:AgeOver90DaysMember us-gaap:MinimumMember 2013-01-01 2013-12-31 0000805928 axgn:Age61To90DaysMember us-gaap:MinimumMember 2013-01-01 2013-12-31 0000805928 axgn:Age61To90DaysMember us-gaap:MaximumMember 2013-01-01 2013-12-31 0000805928 us-gaap:MinimumMember 2013-01-01 2013-12-31 0000805928 2015-02-05 2015-02-05 0000805928 2015-03-31 0000805928 2014-12-31 iso4217:USD xbrli:shares axgn:product utr:sqft xbrli:pure xbrli:shares iso4217:USD 1165020 1261865 709200 P60D P90D P61D P90D 0.05 0.20 60000 2100 0.01 0.01 0.01 7000000 2500000 1300000 15000 12500 105315 194985 79996 P60D P30D 0 0 4728000 30300000 0.0375 15000000 0.20 1 0.03 0.01 0.0995 0.0375 0.048 0.0375 0.0375 P3Y 0.03 0.1625 1.35 1.5 1.2 false --12-31 Q1 2015 2015-03-31 10-Q 0000805928 24926014 Yes Smaller Reporting Company AxoGen, Inc. 2431194 3423272 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="text-indent:0pt;margin-left:0pt; padding-right:17.2pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">6.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;font-size:10pt;">Accounts Payable and Accrued Expenses</font></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:14.4pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Accounts payable and accrued expenses consists of the following:</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:59.38%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.08%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Accounts payable </font></p> </td> <td valign="bottom" style="width:01.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:16.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,966,422&nbsp; </td> <td valign="bottom" style="width:01.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:16.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,160,859&nbsp; </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Miscellaneous accruals </font></p> </td> <td valign="bottom" style="width:01.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.04%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>194,985&nbsp; </td> <td valign="bottom" style="width:01.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.06%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>105,315&nbsp; </td> <td valign="bottom" style="width:01.08%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Accrued compensation </font></p> </td> <td valign="bottom" style="width:01.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,261,865&nbsp; </td> <td valign="bottom" style="width:01.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,165,020&nbsp; </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">Accounts Payable and Accrued Expenses</font><font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:16.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,423,272&nbsp; </td> <td valign="bottom" style="width:01.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:16.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,431,194&nbsp; </td> <td valign="bottom" style="width:01.08%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 1160859 1966422 2872308 3161588 1735205 1777103 78675686 92761697 94000 101000 51216 33746 51216 33746 10955 11772 5400 16400789 28135926 14411088 26015159 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="text-indent:0pt;margin-left:0pt; padding-right:17.2pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">1.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Basis of Presentation </font></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The accompanying condensed consolidated financial statements include the accounts of AxoGen,&nbsp;Inc. (the &#x201C;Company&#x201D; or &#x201C;AxoGen&#x201D;) and its wholly owned subsidiary AxoGen Corporation (&#x201C;AC&#x201D;) as of March&nbsp;31, 2015 and December&nbsp;31, 2014 and for the three month periods ended March&nbsp;31, 2015 and 2014.&nbsp;&nbsp;The Company&#x2019;s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and should be read in conjunction with the audited financial statements of the Company for the year ended December&nbsp;31, 2014, which are included in the Annual Report on Form&nbsp;10-K as of and for the year ended December&nbsp;31, 2014.&nbsp;&nbsp;The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all adjustments necessary for a fair presentation of results for the periods presented.&nbsp;&nbsp;Results for interim periods are not necessarily indicative of results for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 20069750 16807753 8215791 19255725 -3261997 11039934 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Cash and Cash Equivalents and Concentration</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 0.01 0.01 0.01 50000000 50000000 643382 1375969 19488814 5437200 24926014 19488814 24926014 1750000 3550000 194888 249260 701300 982881 5428098 6512139 25000000 25000000 25000000 LIBOR LIBOR LIBOR 0.10 0.10 0.09 0.09 0.09 P8Y P10Y P6Y 793499 939894 14118 14118 115380 109984 33944 41898 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="text-indent:0pt;margin-left:0pt; padding-right:17.2pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">8.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Stock Options </font></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company granted stock options to purchase 269,500 shares of common stock pursuant to its 2010 Stock Incentive Plan for the three months ended March&nbsp;31, 2015.&nbsp;&nbsp;Stock-based compensation expense was $368,249 and $257,542 for the three months ended March&nbsp;31, 2015 and 2014, respectively. Total future stock compensation expense related to nonvested awards is expected to be approximately $2,275,000 at March&nbsp;31, 2015.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> -0.24 -0.16 2275000 1400000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Fair Value of Financial Instruments</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company&#x2019;s long-term debt approximates its carrying value based upon current rates available to the Company.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 353681 365453 48000 36000 48000 48000 48000 48000 850859 79996 851603 111303 577174 597453 P3Y P20Y P17Y 1894776 1908581 2436956 3968435 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Income Taxes</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section&nbsp;382 as a result of changes in ownership.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company&#x2019;s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December&nbsp;31,&nbsp;2011 through 2014; there currently are no examinations in process.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> -175196 992078 71458 289280 -3571 -5396 67661 124278 -101230 150579 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="text-indent:0pt;margin-left:0pt; padding-right:17.2pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">5.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Intangible Assets </font></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company&#x2019;s intangible assets consist of the following:</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:57.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">(unaudited)</font></p> </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">License agreements</font></p> </td> <td valign="bottom" style="width:01.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.44%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>851,603 </td> <td valign="bottom" style="width:01.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.44%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>850,859 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.70%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Patents</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>111,303 </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79,996 </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Less: accumulated amortization</font></p> </td> <td valign="bottom" style="width:01.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(365,453 </td> <td valign="bottom" style="width:01.82%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(353,681 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:57.70%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">Intangible assets, net</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>597,453 </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>577,174 </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">License agreements are being amortized over periods ranging from 17-20 years. Patent costs were being amortized over three years. As of December&nbsp;31, 2014, the patents were fully amortized, and the remaining patents of $79,996 were pending patent costs and were not amortizable. Amortization expense for the three months ended March&nbsp;31, 2015 and 2014 was approximately $12,000 and $11,000, respectively. As of March&nbsp;31, 2015, future amortization of license agreements is expected to be $36,000 for the remainder of 2015 and $48,000 for 2016 through 2020.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">License Agreements</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company has entered into multiple license agreements (the &#x201C;License Agreements&#x201D;) with the University of Florida Research Foundation (&#x201C;UFRF&#x201D;) and University of Texas at Austin (&#x201C;UTA&#x201D;). Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below:</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 00.00pt; display: inline;"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font> </p> </td><td style="width:21pt;"><p style="width:21pt;width:21pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="display: inline;font-size:10pt;color:#000000;">AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products. One of the agreements also contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees.&nbsp;Also, when AxoGen pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%; </font></p></td></tr></table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;color:#000000;">&nbsp;</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 00.00pt; display: inline;"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font> </p> </td><td style="width:21pt;"><p style="width:21pt;width:21pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="display: inline;font-size:10pt;color:#000000;">If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from the third party to the licensor.&nbsp;Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sublicensee fees for its own use of the technologies; </font></p></td></tr></table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;color:#000000;">&nbsp;</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 00.00pt; display: inline;"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font> </p> </td><td style="width:21pt;"><p style="width:21pt;width:21pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="display: inline;font-size:10pt;color:#000000;">AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and </font></p></td></tr></table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;color:#000000;">&nbsp;</font> </p> <div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 00.00pt; display: inline;"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="margin:0pt;font-family:Symbol;font-size:10pt;;"> &#xB7;</font> </p> </td><td style="width:21pt;"><p style="width:21pt;width:21pt;font-size:0pt;"></p></td><td align="left" valign="top"> <p style="font-family:Times New Roman;font-size: 10pt;margin:0pt;"> <font style="display: inline;font-size:10pt;color:#000000;">Currently, under one of the License Agreements, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee.&nbsp;Other milestone fees are due if AxoGen develops certain pharmaceutical or medical device products under the License Agreements. No such products are currently under development.</font></p></td></tr></table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;color:#000000;">Royalty fees were approximately $96,000 and $61,000 during the three months ended March&nbsp;31, 2015 and 2014, respectively, and are included in sales and marketing expense on the accompanying condensed consolidated statements of operations.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;color:#000000;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;color:#000000;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 1191317 994748 303919 803607 2072235 2188691 3213620 3337898 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Inventories</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Inventories are comprised of implantable tissue, nerve grafts, Avance</font><font style="display: inline;font-size:6.5pt;">&#xAE;</font><font style="display: inline;font-size:10pt;"> Nerve Graft, AxoGuard</font><font style="display: inline;font-size:6.5pt;">&#xAE;</font><font style="display: inline;font-size:10pt;"> Nerve Connector, AxoGuard</font><font style="display: inline;font-size:6.5pt;">&#xAE;</font><font style="display: inline;font-size:10pt;"> Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:57.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.66%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;">(unaudited)</font></p> </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Finished goods</font></p> </td> <td valign="bottom" style="width:01.76%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.46%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,188,691&nbsp; </td> <td valign="bottom" style="width:01.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.48%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,072,235&nbsp; </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Work in process</font></p> </td> <td valign="bottom" style="width:01.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>272,470&nbsp; </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>331,891&nbsp; </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Raw materials</font></p> </td> <td valign="bottom" style="width:01.76%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>876,737&nbsp; </td> <td valign="bottom" style="width:01.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>809,494&nbsp; </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.66%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,337,898&nbsp; </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,213,620&nbsp; </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Inventories were net of reserve of approximately $575,000 and $404,000 at March&nbsp;31, 2015 and December&nbsp;31, 2014, respectively.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 809494 876737 404000 575000 331891 272470 60125 27646469 28816424 16400789 28135926 2445312 3437390 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="text-indent:0pt;margin-left:0pt; padding-right:17.2pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">7.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Notes Payable</font></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Notes Payable consists of the following:</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:63.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2015</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(unaudited)</font></p> </td> <td valign="bottom" style="width:01.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.74%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:63.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Term Loan and Revenue Interest Agreement with Three Peaks Capital S.a.r.l. (&#x201C;Three Peaks&#x201D;) for a total term loan amount of $25,000,000</font><font style="display: inline;font-size:10pt;"> which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of March&nbsp;31, 2015 and December&nbsp;31, 2014 resulted in a 10% rate. The Revenue Interest Agreement is for a period of ten years. Royalty payments are base on a royalty rate of 3.75% of revenues up to a maximum of $30 million in revenues in any 12 month period.</font></p> </td> <td valign="bottom" style="width:01.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:14.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,269,050&nbsp; </td> <td valign="bottom" style="width:01.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:14.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,085,777&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.74%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">Long-term Notes Payable</font></p> </td> <td valign="bottom" style="width:01.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:14.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,269,050&nbsp; </td> <td valign="bottom" style="width:01.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:14.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,085,777&nbsp; </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Note Payable</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">On October&nbsp;5, 2012, AxoGen entered into a Revenue Interests Purchase Agreement (the &#x201C;Royalty Contract&#x201D;) with PDL BioPharma, Inc. (&#x201C;PDL&#x201D;), pursuant to which the Company sold to PDL the right to receive royalties equal to 9.95% of the Company&#x2019;s Net Revenues (as defined in the Royalty Contract) generated by the sale, distribution or other use of AxoGen&#x2019;s products Avance</font><font style="display: inline;font-size:6.5pt;">&#xAE;</font><font style="display: inline;font-size:10pt;"> Nerve Graft, AxoGuard</font><font style="display: inline;font-size:6.5pt;">&#xAE;</font><font style="display: inline;font-size:10pt;"> Nerve Connector and AxoGuard</font><font style="display: inline;font-size:6.5pt;">&#xAE;</font><font style="display: inline;font-size:10pt;"> Nerve Protector.&nbsp;&nbsp;The Royalty Contract had a term of eight years. Under the Royalty Contract, PDL received royalty payments based on a royalty rate of 9.95% of the Company&#x2019;s Net Revenues, subject to certain agreed upon minimum payment requirements, which were anticipated to be approximately $1.3 to $2.5 million per quarter tobegin in the fourth quarter of 2014 through the third quarter of 2020 as provided in the Royalty Contract. The Company recorded interest using its best estimate of the effective interest rate accruing interest using the specified internal rate of return of the Put Option of 20%.&nbsp;&nbsp;The total consideration PDL paid to the Company was $20,800,000 (the &#x201C;Funded Amount&#x201D;), which included $19,050,000 PDL paid to the Company on October&nbsp;5, 2012, and $1,750,000 PDL paid to the Company on August&nbsp;14, 2012 pursuant to an Interim Revenue Interest Purchase Agreement between the Company and PDL, dated August&nbsp;14, 2012 (the &#x201C;Interim Royalty Contract&#x201D;). Upon the closing (the &#x201C;Closing&#x201D;) of PDL&#x2019;s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty Contract, the Interim Royalty Contract was terminated. On November&nbsp;12, 2014, the Company paid PDL $30.3 million to fully extinguish the Royalty Contract.&nbsp;&nbsp;The Company has no further obligations under the Royalty Contract.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">On November&nbsp;12, 2014, the Company sold 643,382 shares of common stock for a total of $1.75 million to PDL (&#x201C;PDL Equity Sale&#x201D;) at a price of $2.72 per share pursuant to a Securities Purchase Agreement by and between the Company and PDL.&nbsp;&nbsp;The Company intends to use the proceeds from the PDL Equity Sale for general corporate purposes.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">Term Loan Agreement and Revenue Interest Agreement</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">On November&nbsp;12, 2014, (the &#x201C;Signing Date&#x201D;), AxoGen, as borrower, and AC, as guarantor, entered into a term loan agreement (the &#x201C;Term Loan Agreement&#x201D;) with the lenders party thereto and Three Peaks Capital S.a.r.l. (&#x201C;Three Peaks&#x201D;), an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP (&#x201C;Oberland&#x201D;), as administrative and collateral agent for the lenders. Under the Term Loan Agreement, Three Peaks has agreed to lend to AxoGen a term loan of $25 million (the &#x201C;Initial Term Loan&#x201D;) which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of November&nbsp;13, 2014 (&#x201C;the Initial Closing Date&#x201D;) resulted in a 10% rate. Under certain conditions, AxoGen has the option to draw an additional $7 million (&#x201C;Subsequent Borrowing&#x201D; and, together with the Initial Term Loan, the &#x201C;Term Loan&#x201D;) during the period of April&nbsp;1, 2016 through June&nbsp;29, 2016 (the closing date of each such Subsequent Borrowing, a &#x201C;Subsequent Closing Date&#x201D; and, together with the Initial Closing Date, the &#x201C;Closing Dates&#x201D;) under similar terms and conditions. AxoGen has to maintain certain covenants including limiting new indebtedness, restriction of the payment of dividends and maintain certain levels of revenue. Three Peaks has a first perfected security interest in the assets of AxoGen.</font> </p> <p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In addition, AxoGen entered into a 10 year Revenue Interest Agreement (&#x201C;Revenue Interest Agreement&#x201D;) with Three Peaks. Royalty payments are based on a royalty rate of 3.75% of AxoGen&#x2019;s revenues up to a maximum of $30 million in revenues in any 12 month period. In the event the Subsequent Borrowing is drawn, the royalty rate increases proportionally up to a maximum of 4.80%. AxoGen has to maintain certain covenants including those covenants under the Term Loan.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Under the Term Loan Agreement, AxoGen has the option at any time to prepay the Term Loan, in whole or in part, and the Royalty Interest Agreement, defined below, by making the following payment, and Three Peaks has the right to demand the following payment upon a change of control of AxoGen, sale of the majority of AxoGen&#x2019;s assets or a material adverse change to AxoGen: (i)&nbsp;on or prior to the first anniversary of the applicable Closing Date, 120% of the outstanding principal amount of the Term Loan or any portion being prepaid; (ii)&nbsp;after the first anniversary but no later than the second anniversary of the applicable Closing Date, 135% of the outstanding principal amount of the Term Loan or any portion being prepaid ; (iii)&nbsp;after the second anniversary but no later than the third anniversary of the applicable Closing Date, 150% of the outstanding principal amount of the Term Loan or any portion being prepaid; or (iv)&nbsp;after the third anniversary of the applicable Closing Date, an amount generating an Internal Rate of Return of 16.25% of the outstanding principal amount of the Term Loan or any portion being prepaid. In all cases, the amount due is reduced by the sum of interest and principal previously paid and all amounts received under the Revenue Interest Agreement. In each such case AxoGen will also owe an additional 3% of the originally advanced Term Loan amount. Upon payment to Three Peaks, AxoGen would have no further obligations to Three Peaks under the Term Loan or the Revenue Interest Agreement.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In connection with the Term Loan Agreement, on the Signing Date, the Company and its wholly owned subsidiary, AC entered into a Security Agreement (the &#x201C;Security Agreement&#x201D;) with Three Peaks, pursuant to which each of the Company and AC grants to Three Peaks a security interest in certain collateral as specified in the Security Agreement to guarantee the payment in full when due of the Secured Obligations.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Also in connection with the above transaction, the Company sold 1,375,969 shares of common stock to Three Peaks for a total of $3.55 million (&#x201C;Three Peaks Equity Sale&#x201D;) at a price of $2.58 per share.&nbsp;&nbsp;Pursuant to the equity purchase provisions in the Three Peaks Term Loan Agreement, in the event that we sell prior to November&nbsp;12, 2016 our securities at a lower price per share than the $2.58 per share paid by Three Peaks, or where the terms of such subsequent sale are otherwise more favorable, then in such case we have agreed to match the more favorable terms of such subsequent sale with respect to the shares purchased by Three Peaks. A subsequent sale does not include the issuance of securities or options to our employees, officers, directors or consultants pursuant to our approved employee option pool or any other employee stock purchase or option plan existing as of November&nbsp;12, 2014.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company records interest using its best estimate of the effective interest rate.&nbsp;&nbsp;This estimate takes into account both the rate on the Term Loan Agreement and the rate associated with the 10 year Revenue Interest Agreement with Three Peaks.&nbsp;&nbsp;The effective interest rate is based on actual payments to date, projected future revenues and the projected royalty payments and the quarterly interest payments due on the Term Loan Agreement.&nbsp;&nbsp;From time to time, AxoGen will reevaluate the expected cash flows and may adjust the effective interest rate.&nbsp;&nbsp;Determining the effective interest rate requires judgment and is based on significant assumptions related to estimates of the amounts and timing of future revenue streams.&nbsp;&nbsp;Determination of these assumptions is highly subjective and different assumptions could lead to materially different outcomes.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 25085777 25085777 25269050 25269050 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="text-indent:0pt;margin-left:0pt; padding-right:17.2pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">2.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Organization and Business</font></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Business Summary</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">AxoGen,&nbsp;Inc. is a leading medical technology company dedicated to peripheral nerve repair. The company has created and licensed a unique combination of patented nerve repair technologies to change the standard of care for patients with peripheral nerve injuries. AxoGen&#x2019;s portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance</font><font style="display: inline;font-size:6.5pt;">&#xAE;</font><font style="display: inline;font-size:10pt;"> Nerve Graft, an off-the-shelf commercially available processed human nerve allograft for bridging severed nerves without the comorbidities associated with an additional surgical site, AxoGuard</font><font style="display: inline;font-size:6.5pt;">&#xAE;</font><font style="display: inline;font-size:10pt;"> Nerve Connector, a porcine submucosa extracellular matrix (&#x201C;ECM&#x201D;) coaptation aid for tensionless repair of severed nerves, AxoGuard</font><font style="display: inline;font-size:6.5pt;">&#xAE;</font><font style="display: inline;font-size:10pt;"> Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and the AxoTouch</font><font style="display: inline;font-size:6.5pt;">&#x2122;</font><font style="display: inline;font-size:10pt;"> Two-Point Discriminator, a tool useful for measuring sensation after a nerve injury, following the progression of a repaired nerve, and during the evaluation of a person with a possible nerve injury, such as nerve division or nerve compression.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Avance</font><font style="display: inline;font-size:6.5pt;">&#xAE;</font><font style="display: inline;font-size:10pt;"> Nerve Graft is processed in the United States by AxoGen. AxoGuard</font><font style="display: inline;font-size:6.5pt;">&#xAE;</font><font style="display: inline;font-size:10pt;"> Nerve Connector and AxoGuard</font><font style="display: inline;font-size:6.5pt;">&#xAE;</font><font style="display: inline;font-size:10pt;"> Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen.&nbsp;&nbsp;AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 92424 13591991 -203828 -38339 -3150593 -2513718 -4239564 -3575201 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Recent Accounting Pronouncements</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In April&nbsp;2015, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued Accounting Standards Update No.&nbsp;2015-03, &#x201C;Simplifying the Presentation of Debt Issuance Costs&#x201D; (&#x201C;ASU 2015-03&#x201D;) which changes the presentation of debt issuance costs in financial statements to present such costs as a direct deduction from the related debt liability rather than as an asset. ASU 2015-03 will become effective for public companies during interim and annual reporting periods beginning after December&nbsp;15, 2015. Early adoption is permitted. We do not expect the adoption of this standard will have a material impact on our consolidated financial statements.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In February&nbsp;2015, the FASB issued Accounting Standards Update No.&nbsp;2015-02, &#x201C;Consolidation (Topic 810): Amendments to the Consolidation Analysis&#x201D; (&#x201C;ASU 2015-02&#x201D;) which updates the considerations on whether an entity should consolidate certain legal entities. The update removes the indefinite deferral of specialized guidance for certain investment funds and changes the way that entities evaluate limited partnerships and fees paid to service providers in the consolidation determination. ASU 2015-02 will become effective for public companies during interim and annual reporting periods beginning after December&nbsp;15, 2015. Early adoption is permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In January&nbsp;2015, the FASB issued guidance, which completely eliminates all references to and guidance concerning the concept of an extraordinary item from GAAP. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December&nbsp;15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In June&nbsp;2014, the FASB issued updated guidance related to stock compensation. The amendment requires that a performance target that affects vesting and that could be achieved after the requisite period, be treated as a performance condition. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December&nbsp;15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In May&nbsp;2014, the FASB issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance is effective for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2016; however, in April&nbsp;2015, the FASB voted to propose a one year deferral of the effective date. The proposed deferral may permit early adoption, but would not allow adoption any earlier than the original effective date of the standard. We are currently evaluating the impact this standard will have on our consolidated financial statements.</font> </p> <p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company&#x2019;s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company&#x2019;s consolidated financial condition, results of operations, or disclosures.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> -1248422 -1031497 -2991142 -2543704 -5889 -3003 891845 183273 180142 8346 32051 195482 6288 109369 259948 13772133 1750000 20800000 19050000 92424 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="text-indent:0pt;margin-left:0pt; padding-right:17.2pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">4.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Property and Equipment </font></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Property and equipment consist of the following:</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:57.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">(unaudited)</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Furniture and equipment</font></p> </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>880,114 </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>873,824 </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Leasehold improvements</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>285,697 </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>285,697 </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Processing equipment</font></p> </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,194,712 </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,194,712 </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Less: accumulated depreciation and amortization</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,777,103 </td> <td valign="bottom" style="width:01.86%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:18.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,735,205 </td> <td valign="bottom" style="width:01.24%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:57.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Property and equipment</font></p> </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>583,420 </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>619,028 </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 873824 1194712 285697 880114 1194712 285697 619028 583420 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:57.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">(unaudited)</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Furniture and equipment</font></p> </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>880,114 </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.34%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>873,824 </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Leasehold improvements</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>285,697 </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>285,697 </td> <td valign="bottom" style="width:01.24%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Processing equipment</font></p> </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,194,712 </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,194,712 </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Less: accumulated depreciation and amortization</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,777,103 </td> <td valign="bottom" style="width:01.86%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:18.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1,735,205 </td> <td valign="bottom" style="width:01.24%;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:57.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Property and equipment</font></p> </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>583,420 </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.36%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>619,028 </td> <td valign="bottom" style="width:01.24%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 812615 671036 -90116254 -93691455 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Revenue Recognition</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is delivered to the customer or distributor, at which time title passes to the customer or distributor, provided, however, that in the case of revenues from consigned sales delivery is determined when the product is utilized in a surgical procedure. Once a product is delivered, the Company has no further performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred.</font> </p> <p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 3138256 4951316 61000 96000 30000000 30000000 30000000 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:59.38%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.08%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Accounts payable </font></p> </td> <td valign="bottom" style="width:01.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:16.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,966,422&nbsp; </td> <td valign="bottom" style="width:01.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:16.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,160,859&nbsp; </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Miscellaneous accruals </font></p> </td> <td valign="bottom" style="width:01.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.04%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>194,985&nbsp; </td> <td valign="bottom" style="width:01.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.06%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>105,315&nbsp; </td> <td valign="bottom" style="width:01.08%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.38%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Accrued compensation </font></p> </td> <td valign="bottom" style="width:01.68%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,261,865&nbsp; </td> <td valign="bottom" style="width:01.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,165,020&nbsp; </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:59.38%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">Accounts Payable and Accrued Expenses</font><font style="display: inline;font-size:10pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.68%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:16.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,423,272&nbsp; </td> <td valign="bottom" style="width:01.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:16.76%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,431,194&nbsp; </td> <td valign="bottom" style="width:01.08%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:63.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2015</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">(unaudited)</font></p> </td> <td valign="bottom" style="width:01.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.74%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:16.02%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:63.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10.1pt;line-height:106.67%;text-indent: -10.1pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Term Loan and Revenue Interest Agreement with Three Peaks Capital S.a.r.l. (&#x201C;Three Peaks&#x201D;) for a total term loan amount of $25,000,000</font><font style="display: inline;font-size:10pt;"> which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of March&nbsp;31, 2015 and December&nbsp;31, 2014 resulted in a 10% rate. The Revenue Interest Agreement is for a period of ten years. Royalty payments are base on a royalty rate of 3.75% of revenues up to a maximum of $30 million in revenues in any 12 month period.</font></p> </td> <td valign="bottom" style="width:01.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:14.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,269,050&nbsp; </td> <td valign="bottom" style="width:01.60%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:14.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,085,777&nbsp; </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:63.74%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">Long-term Notes Payable</font></p> </td> <td valign="bottom" style="width:01.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:14.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,269,050&nbsp; </td> <td valign="bottom" style="width:01.60%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.38%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:14.64%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25,085,777&nbsp; </td> <td valign="bottom" style="width:01.04%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:57.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.70%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">(unaudited)</font></p> </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">License agreements</font></p> </td> <td valign="bottom" style="width:01.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.44%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>851,603 </td> <td valign="bottom" style="width:01.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.44%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>850,859 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.70%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Patents</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>111,303 </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79,996 </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.70%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Less: accumulated amortization</font></p> </td> <td valign="bottom" style="width:01.80%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(365,453 </td> <td valign="bottom" style="width:01.82%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(353,681 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">)</font></p> </td> </tr> <tr> <td valign="top" style="width:57.70%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 20pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;">Intangible assets, net</font></p> </td> <td valign="bottom" style="width:01.80%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>597,453 </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>577,174 </td> <td valign="bottom" style="width:01.10%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:57.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.66%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;">(unaudited)</font></p> </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Finished goods</font></p> </td> <td valign="bottom" style="width:01.76%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.46%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,188,691&nbsp; </td> <td valign="bottom" style="width:01.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.48%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,072,235&nbsp; </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Work in process</font></p> </td> <td valign="bottom" style="width:01.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>272,470&nbsp; </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>331,891&nbsp; </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Raw materials</font></p> </td> <td valign="bottom" style="width:01.76%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>876,737&nbsp; </td> <td valign="bottom" style="width:01.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>809,494&nbsp; </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.66%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,337,898&nbsp; </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,213,620&nbsp; </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:55.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:02.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:55.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected term (in years)</font></p> </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.0&nbsp; </td> <td valign="bottom" style="width:02.76%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.0&nbsp; </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:55.28%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected volatility</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76.32&nbsp; </td> <td valign="bottom" style="width:02.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> <td valign="bottom" style="width:18.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81.26&nbsp; </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:55.28%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Risk free rate</font></p> </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.28&nbsp; </td> <td valign="bottom" style="width:02.76%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> <td valign="bottom" style="width:18.68%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.12&nbsp; </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:55.28%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected dividends</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0&nbsp; </td> <td valign="bottom" style="width:02.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> <td valign="bottom" style="width:18.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0&nbsp; </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 2720707 3932522 257542 368249 0.000 0.000 P4Y P4Y 0.8126 0.7632 0.0112 0.0128 269500 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Share-Based Compensation</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee&#x2019;s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the October&nbsp;2011 merger of LecTec,&nbsp;Inc. and AxoGen Corporation, and based on the Company&#x2019;s common stock for periods subsequent to such merger. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the three months ended March&nbsp;31:</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:55.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:02.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:55.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected term (in years)</font></p> </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.0&nbsp; </td> <td valign="bottom" style="width:02.76%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.0&nbsp; </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:55.28%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected volatility</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76.32&nbsp; </td> <td valign="bottom" style="width:02.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> <td valign="bottom" style="width:18.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81.26&nbsp; </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:55.28%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Risk free rate</font></p> </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.28&nbsp; </td> <td valign="bottom" style="width:02.76%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> <td valign="bottom" style="width:18.68%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.12&nbsp; </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:55.28%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected dividends</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0&nbsp; </td> <td valign="bottom" style="width:02.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> <td valign="bottom" style="width:18.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0&nbsp; </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the three months ended March&nbsp;31, 2015 and 2014 as they were deemed insignificant.</font> </p> <p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 2.72 2.58 2.75 2.75 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="text-indent:0pt;margin-left:0pt; padding-right:17.2pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">3.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-size:10pt;"></font><font style="display: inline;font-weight:bold;font-size:10pt;">Summary of Significant Accounting Policies </font></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Revenue Recognition</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is delivered to the customer or distributor, at which time title passes to the customer or distributor, provided, however, that in the case of revenues from consigned sales delivery is determined when the product is utilized in a surgical procedure. Once a product is delivered, the Company has no further performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred.</font> </p> <p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Cash and Cash Equivalents and Concentration</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Accounts Receivable and Concentration of Credit Risk</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#x2019;s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In 2013, we established a reserve for doubtful accounts as we did have some accounts deemed uncollectible.&nbsp;&nbsp;We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected.&nbsp;&nbsp;The analysis excludes certain government related receivables due to our past successful experience in collectability.&nbsp;&nbsp;Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance.&nbsp;&nbsp;The remaining balances outstanding over 60 days have a percentage applied by aging category (5% for balances 61-90 days and 20% for balances over 90 days aged), based on a historical valuation that allows us to calculate the total reserve required.&nbsp;&nbsp;The reserve balance was determined by applying a percentage to the cumulative balance between 60 and 90 days and a higher percentage to the balance over 90 days.&nbsp;&nbsp;In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account.&nbsp;&nbsp;The write off process involves approval by senior management based on the write off amount.&nbsp;&nbsp;The allowance for doubtful accounts reserve balance was approximately $101,000 and $94,000 at March&nbsp;31, 2015 and December&nbsp;31, 2014, respectively.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company&#x2019;s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Inventories</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Inventories are comprised of implantable tissue, nerve grafts, Avance</font><font style="display: inline;font-size:6.5pt;">&#xAE;</font><font style="display: inline;font-size:10pt;"> Nerve Graft, AxoGuard</font><font style="display: inline;font-size:6.5pt;">&#xAE;</font><font style="display: inline;font-size:10pt;"> Nerve Connector, AxoGuard</font><font style="display: inline;font-size:6.5pt;">&#xAE;</font><font style="display: inline;font-size:10pt;"> Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:57.66%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">March&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">December&nbsp;31,</font><br /><font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.66%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;"></font><font style="display: inline;font-weight:bold;font-size:8pt;">(unaudited)</font></p> </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:right;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Finished goods</font></p> </td> <td valign="bottom" style="width:01.76%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.46%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,188,691&nbsp; </td> <td valign="bottom" style="width:01.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.48%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,072,235&nbsp; </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Work in process</font></p> </td> <td valign="bottom" style="width:01.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>272,470&nbsp; </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.84%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>331,891&nbsp; </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:57.66%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Raw materials</font></p> </td> <td valign="bottom" style="width:01.76%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>876,737&nbsp; </td> <td valign="bottom" style="width:01.82%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:18.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>809,494&nbsp; </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:57.66%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,337,898&nbsp; </td> <td valign="bottom" style="width:01.82%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:01.34%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">$</font></p> </td> <td valign="bottom" style="width:17.48%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,213,620&nbsp; </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Inventories were net of reserve of approximately $575,000 and $404,000 at March&nbsp;31, 2015 and December&nbsp;31, 2014, respectively.</font> </p> <p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Income Taxes</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section&nbsp;382 as a result of changes in ownership.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company&#x2019;s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December&nbsp;31,&nbsp;2011 through 2014; there currently are no examinations in process.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Fair Value of Financial Instruments</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company&#x2019;s long-term debt approximates its carrying value based upon current rates available to the Company.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Share-Based Compensation</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee&#x2019;s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the October&nbsp;2011 merger of LecTec,&nbsp;Inc. and AxoGen Corporation, and based on the Company&#x2019;s common stock for periods subsequent to such merger. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the three months ended March&nbsp;31:</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:55.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">Three&nbsp;months&nbsp;ended&nbsp;March&nbsp;31,</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2015</font></p> </td> <td valign="bottom" style="width:02.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 8pt"> <font style="display: inline;font-weight:bold;font-size:8pt;">2014</font></p> </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;text-align:center;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:55.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected term (in years)</font></p> </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.0&nbsp; </td> <td valign="bottom" style="width:02.76%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.0&nbsp; </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> </tr> <tr> <td valign="top" style="width:55.28%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected volatility</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76.32&nbsp; </td> <td valign="bottom" style="width:02.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> <td valign="bottom" style="width:18.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>81.26&nbsp; </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:55.28%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Risk free rate</font></p> </td> <td valign="bottom" style="width:01.86%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.28&nbsp; </td> <td valign="bottom" style="width:02.76%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> <td valign="bottom" style="width:18.68%;background-color: #CCEEFF;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1.12&nbsp; </td> <td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> <tr> <td valign="top" style="width:55.28%;padding:0pt;"> <p style="margin:0pt 0pt 0pt 10pt;line-height:106.67%;text-indent: -10pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Expected dividends</font></p> </td> <td valign="bottom" style="width:01.86%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 12pt"> &nbsp;</p> </td> <td valign="bottom" style="width:18.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0&nbsp; </td> <td valign="bottom" style="width:02.76%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> <td valign="bottom" style="width:18.68%;;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0&nbsp; </td> <td valign="bottom" style="width:02.74%;padding:0pt;"> <p style="margin:0pt;line-height:106.67%;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">%</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the three months ended March&nbsp;31, 2015 and 2014 as they were deemed insignificant.</font> </p> <p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Use of Estimates</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Recent Accounting Pronouncements</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In April&nbsp;2015, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued Accounting Standards Update No.&nbsp;2015-03, &#x201C;Simplifying the Presentation of Debt Issuance Costs&#x201D; (&#x201C;ASU 2015-03&#x201D;) which changes the presentation of debt issuance costs in financial statements to present such costs as a direct deduction from the related debt liability rather than as an asset. ASU 2015-03 will become effective for public companies during interim and annual reporting periods beginning after December&nbsp;15, 2015. Early adoption is permitted. We do not expect the adoption of this standard will have a material impact on our consolidated financial statements.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In February&nbsp;2015, the FASB issued Accounting Standards Update No.&nbsp;2015-02, &#x201C;Consolidation (Topic 810): Amendments to the Consolidation Analysis&#x201D; (&#x201C;ASU 2015-02&#x201D;) which updates the considerations on whether an entity should consolidate certain legal entities. The update removes the indefinite deferral of specialized guidance for certain investment funds and changes the way that entities evaluate limited partnerships and fees paid to service providers in the consolidation determination. ASU 2015-02 will become effective for public companies during interim and annual reporting periods beginning after December&nbsp;15, 2015. Early adoption is permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In January&nbsp;2015, the FASB issued guidance, which completely eliminates all references to and guidance concerning the concept of an extraordinary item from GAAP. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December&nbsp;15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In June&nbsp;2014, the FASB issued updated guidance related to stock compensation. The amendment requires that a performance target that affects vesting and that could be achieved after the requisite period, be treated as a performance condition. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December&nbsp;15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In May&nbsp;2014, the FASB issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance is effective for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2016; however, in April&nbsp;2015, the FASB voted to propose a one year deferral of the effective date. The proposed deferral may permit early adoption, but would not allow adoption any earlier than the original effective date of the standard. We are currently evaluating the impact this standard will have on our consolidated financial statements.</font> </p> <p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Company&#x2019;s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company&#x2019;s consolidated financial condition, results of operations, or disclosures.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> -11245680 -680498 <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="text-indent:0pt;margin-left:0pt; padding-right:14.2pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">9. </font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;font-size:10pt;">Public Offering of Common Stock</font></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">On February&nbsp;5, 2015, AxoGen entered into the Underwriting Agreement with the Underwriter, in connection with the offering, issuance and sale (the &#x201C;Offering&#x201D;) of 4,728,000 shares of the Company&#x2019;s common shares, par value $0.01 per share (the &#x201C;Common Shares&#x201D;), at a price to the public of $2.75 per share.&nbsp; The Company also granted to the Underwriter a 30-day option to purchase up to an aggregate of 709,200 additional Common Shares to cover over-allotments, if any.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The Offering was made pursuant to the Company&#x2019;s effective shelf registration statement on Form&nbsp;S-3 (Registration No.&nbsp;333-195588) previously filed with the Securities and Exchange Commission, and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the Offering, dated February&nbsp;5, 2015.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">As of February&nbsp;13, 2015, the Offering was completed with the sale of 5,437,200 Common Shares, which included the exercise of the over-allotment option, at $2.75 per share resulting in gross proceeds to AxoGen from the Offering of approximately $15.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen estimated at approximately $1.4 million. The Common Shares were listed on the NASDAQ Capital Market.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="text-indent:0pt;margin-left:0pt; padding-right:12.2pt;"><font style="display: inline;font-weight:bold;font-size:10pt;">10.</font></font><font style="text-indent:0pt;margin-left:0pt; padding-right:4pt;text-align:left"><font style="display: inline;font-weight:bold;font-size:10pt;">Subsequent Events</font></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Commercial Lease</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">On April&nbsp;21, 2015, AxoGen Corporation, a wholly owned subsidiary of AxoGen,&nbsp;Inc.&nbsp;&nbsp;(&#x201C;AxoGen&#x201D; or the &#x201C;Company&#x201D;), entered into a Commercial Lease with Ja-Cole, L.P. (the &#x201C;New Lease&#x201D;) for property located in Burleson, Texas. The New Lease supersedes and replaces a current lease with Ja-Cole. Under the terms of the New Lease, AxoGen leased an additional 2,100 square feet of warehouse space that will be combined with its current 5,400 square feet of warehouse/office space in Burleson, Texas.&nbsp;&nbsp;&nbsp;The New Lease is for a three year term expiring April&nbsp;21, 2018, renewable thereafter by agreement of the parties, at an annual cost of $60,000 per year.&nbsp;&nbsp;The expanded Burleson facility will house raw material storage and product distribution and allow expansion space as required for AxoGen operations.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Processing Agreement</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Under an Amended and Restated Nerve Tissue Processing Agreement (the &#x201C;Agreement&#x201D;) with LifeNet Health, AxoGen processes and packages Avance&#xAE; Nerve Graft using its employees and equipment located at LifeNet Health, Virginia Beach, Virginia.&nbsp;&nbsp;As a result of business requirements of LifeNet Health and their need for additional space on April&nbsp;16, 2015 they notified AxoGen that it will need to transition out of the Virginia Beach facility on or before February&nbsp;27, 2016 and therefore is terminating the Agreement effective February&nbsp;27, 2016.&nbsp;&nbsp;&nbsp;AxoGen&#x2019;s planning has included the establishment of manufacturing space under its full control to meet its needs as it continues to expand its revenues. AxoGen is formalizing its plans and has sufficient time to establish new manufacturing space under its control that will meet its future needs.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Accounts Receivable and Concentration of Credit Risk</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer&#x2019;s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">In 2013, we established a reserve for doubtful accounts as we did have some accounts deemed uncollectible.&nbsp;&nbsp;We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected.&nbsp;&nbsp;The analysis excludes certain government related receivables due to our past successful experience in collectability.&nbsp;&nbsp;Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance.&nbsp;&nbsp;The remaining balances outstanding over 60 days have a percentage applied by aging category (5% for balances 61-90 days and 20% for balances over 90 days aged), based on a historical valuation that allows us to calculate the total reserve required.&nbsp;&nbsp;The reserve balance was determined by applying a percentage to the cumulative balance between 60 and 90 days and a higher percentage to the balance over 90 days.&nbsp;&nbsp;In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account.&nbsp;&nbsp;The write off process involves approval by senior management based on the write off amount.&nbsp;&nbsp;The allowance for doubtful accounts reserve balance was approximately $101,000 and $94,000 at March&nbsp;31, 2015 and December&nbsp;31, 2014, respectively.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company&#x2019;s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> <div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-size:10pt;text-decoration:underline;">Use of Estimates</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 12pt"> <font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div> 17383786 22517361 EX-101.SCH 7 axgn-20150331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Summary of Significant Accounting Policies (Details 2) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accounts Payable and Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accounts Payable and Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Notes Payable link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Stock Options link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Public Offering of Common Stock link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Accounts Payable and Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Summary of Significant Accounting Policies (Details 3) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Intangible Assets (Details 2) link:presentationLink link:calculationLink link:definitionLink 40503 - Disclosure - Intangible Assets (Details 3) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Notes Payable (Details 2) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Notes Payable (Details 3) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Public Offering of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 axgn-20150331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 axgn-20150331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 axgn-20150331_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!J:8UQ[@$``#H7```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F-%.VS`4AN\G\0Z1;U'C MV@$&J"D7,"X'TN`!//NTB>K8EFU8^_8[2:%"J&M5K1+GIE$;^_Q?K>B3\D]N MEITM7B&FUKN:B7+,"G#:F];-:_;\=#^Z9$7*RAEEO8.:K2"QF^G)M\G3*D`J M<+=+-6MR#M><)]U`IU+I`SB\,_.Q4QF_QCD/2B_4'+@ MOW1X`F4*$91)#4#N;#ENB^Y$9%,+]RQ`[UZ``? M9^_AT,KJVP;+Q",?PF;NKGQL.!^C#PF[W@B'`[R7N?WN4^/#`3[TL]$VT`;,EFP_-]_0O````__\#`%!+`P04``8`"````"$`M54P M(_4```!,`@``"P`(`E]R96QS+RYR96QS(*($`BB@``(````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M`````(R2ST[#,`S&[TB\0^3[ZFY("*&ENTQ(NR%4'L`D[A^UC:,D0/?VA`." M2F/;T?;GSS];WN[F:50?'&(O3L.Z*$&Q,V)[UVIXK9]6#Z!B(F=I%,<:CAQA M5]W>;%]XI)2;8M?[J+*+BQJZE/PC8C0=3Q0+\>QRI9$P4P>J/OH\^;*W-$UO>"_F?6*73HQ`GA,[RW;E0V8+J<_; MJ)I"RTF#%?.&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;',@H@0!**```0`` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````"\F,UNVS`0A.\%\@X"[S'- MW<1)BL@YM"B0:YL^`"'1EA"9$DCVQV]?PHBI&F@G%V$O`KB"J<'L>CY1CT^_ M#T/UTX78C[Y69K56E?/-V/9^7ZOO+U^N[U45D_6M'4;O:G5T43UMKSX\?G6# M3?E'L>NG6.5=?*Q5E]+T4>O8=.Y@XVJ6\.J>CE.^='O;S[N=GWC/H_-CX/SZ1_/T+_&\!H[YU+> MU(:]2[4JI:A/=PROLF:E_R,G^R$KYQ[)H8VP'-H@.?RPI)S&#LVGSO9^;E8I M(15DEE11YF-644IO(T,&R>$;83E\@^3<":NY0V(,":LQ!.5(FV.@.W0K[`[= M(G=8.HH91C$O&L6QL\&UWU+(Y(O9]CD#0C"3*2 M%F5D2;DY;4KI''SP?,G2F<,PRG MWTDHZ22F$7L!)F$>;YY_-KFZ?L\SYXTIS:48N\&9[SI,Q#+A8CUV_SS^^G'N M.MI0D=!,"C9V=TR[UY/OWZZV4KVLI'QQ0$#HL;LQIKCT/!UO6$[UF2R8@#NI M5#DU4*JUIPO%:*(WC)D\\T+?'WDYY<+=*URJ4S1DFO*8WQ'%,FK` MOM[P0KN3JY1G[&D_D4.+XI[FX/L]L=4&5Q;3D&=R] MB/S(]2;-D`OE)"RE968>8;R#.N05#L)P5'VSBN*)LZW^;*I*Y_V9BT1NJZ]" MM+NFBL#`MK[US!.S@?N^[S?7?C.^WIC#19#WD'Z=(/Q._>Z(>KQ#(@16BLR$ MX69'YF*?/I>PA%7J&#FB=!91RKW$J1,*%90N"3EAE/*(1%IC2C M(F9()40JX?^I@('&3(1DZKQ/,+,TX"G'9@9(97"BF0\5;`;";Y(9=F6F5'-- M9$H6BFD@KP8.3S)"W340>)0'M::"_ZV;ZA6:EIH+IC56^(D4?G9_?UGF.56[ MRL&2KP6'74"%(3=Q+$MAL`SLUV:,\Z[,0L&^5,!&CC8Z!<"PCZ%0+79;*&%;;\0\/8IA+D-+6Z_6.H[9BC/\%J'&&(H M.I/9:WU$`N.[_U.M;7[\PWTI03"Z(487BE-]D-8R87!#"]Q^[%IN,+^AQ6\; M.SN1"%,+16>8H^VM-"(,+A0G">`D(@PL%!V!UJE*C@R`,8TL3/M/5[Q_(XPI M%%T?W>/UB)=A:Y2:4*_F"YZD8IK%\(A7O=7/2(/A:+_-O<-3[N0?````__\# M`%!+`P04``8`"````"$`E0OW\W@$``!Q#P``&````'AL+W=O@&VN49*CAJHS1YHCC49S>:;$25`! M1T";]N]GF^V`;:95,B]M,(OEM:_V7G][KROGC;==*9J-2Y:^Z_"F$/NR.6[< MO_Y\6B2NT_5YL\\KT?"-^\$[]]OVYY_6%]&^="?.>P<8FF[CGOK^O/*\KCCQ M.N^6XLP;>',0;9WW\-@>O>[<\GP_?%17'O7]R*OSLG&18=7>PB$.A[+@CZ)X MK7G3(TG+J[P'_=VI/'=7MKJXA:[.VY?7\Z(0]1DHGLNJ[#\&4M>IB]7W8R/: M_+D"N]])D!=7[N%A1E^712LZ<>B70.>AT+G-J9=ZP+1=[TNP0+K=:?EAXSZ0 M549]U]NN!P?]7?)+I_UVNI.X_-*6^]_*AH.W(4XR`L]"O$CH][U<@H^]V==/ M0P1^;YT]/^2O5?^'N/S*R^.IAW"'8)$T;+7_>.1=`1X%FB4-)5,A*A``?YVZ ME*D!'LG?A_^7.UZ4?^#(**HD(0J$@;J MU7MZ*XF'@@;['O,^WZY;<7$@:6#+[IS+%"0K(+X:AC)&4S^S%$R4)`^29>-" MMH,1'83G;1NRM?<&'BT49#>'$!.171$R$*!NE`AVZQ+_V^=7)1(LE<@82&D[ M7`#N41JU]ITCPF"$&$K`0;H2Z2P&N?2U(OG1Q@TT`6$XTJ-&A&#B2-&9MF`( M`!9=P-<;2S`(U#>.K(T1D@X1"]*0,&(A,AW!"$MH."$,:9#'MTN38$M:;$E# M2#Q(2Q.:)':ZZ(#8)\SW1P9#6'2/,`FVA"4C+08+(2B,I5$2,"N:!%O2K#39(02E13'QV92_@_9,!R2$1F0*IR&,0*7?[K0! M;4FS?+)3&-1&4C\)9TEN0I(TB.-)ORE/ML^;8TJPV>K-(9IU;,0HUX6$$F8E M7*9H$!(&-/'3J5Q,>7=U<8(]V9`W]63,.87!O1'GG&JZIS"O$JIQ<*S./J.%D]4'F; MMM9W,'$-XXDWOH"!YYP?^8^\/99-YU3\`)3^,H8*;W%DPH=>G(>YXUGT,.H, M/T\PVG*X^/I+`!^$Z*\/&ULE%7;;N(P M%'Q?:?_!\GOC)#10$*%J0>Q6VDJKU5Z>C>,0JW$;2O]]CF]($JI:^D#B, MY\S,.7&FMWM9HRW71J@FQTD48\0;I@K1K'/\Y_?RZ@8C8VE3T%HU/,?/W.#; MV=V$"B>4TMZ#>5:,T+FV27T$FJGS;M%5.R M!8J5J(5]]J08239Y6#=*TU4-OO?)-64OW'YQ1B\%T\JHTD9`1X+0<\]C,B;` M-)L6`ARXV)'F98[ODLE\B,ELZO/Y*_C.=.Z1J=3NFQ;%#]%P"!O:Y!JP4NK) M01\*]P@VD[/=2]^`GQH5O*2;VOY2N^]=*&R5X\$PRD;Q(`$X6G%CE\)18L0VQBKY+X"2`U4@ M20\D<#V0).FG208'$KB^DJ0W69(-/Y9"@BV?TH):.IMJM4,P>2#6`&?O0TBP= MCN/LU;07-^]#XIML-'K5WU,')KOJW$P/X,UXOWENTZG*P8G*@.GDTWG04P"S MWU7P?F4'_J@S`=.IW'G0JSS\3&4'/O5\VIF`>;%.^".WYW9 M?P```/__`P!02P,$%``&``@````A`)UC!D:L`@``"@<``!D```!X;"]W;W)K M&ULE)5=;YLP%(;O)^T_6+XO8+X2HI"J3=6MTBI- MTSZN'3#!*F!D.TW[[W=L4Q*2:DMO`B:O'[_G/<8LKU_:!CTSJ;CH7\TQ4IIV)6U$QW+\RA2^7GW^M-P+^:1JQC0"0J=R7&O=+WQ? M%35KJ?)$SSKXIQ*RI1J&J.UQ26XELJG77]5B+8'Q(8W7+]:*$9ML7C8=D+230-U MOY"8%F]L.SC#M[R00HE*>X#SG='SFC,_\X&T6I8<*C"Q(\FJ'-^0Q3K%_FII M\_G-V5X=W2-5B_T7RL=4P4$"A@O3`RI$`T8@%_4H"$\X0D MZ?^M^*XLF](=U72UE&*/8.>!<=53LX_)`L@FG@A"?C\>R,7,N3&3[%10*VCI M\RH*TJ7_#'TH!LWMN2:<*M;O*()1XH._T23D]G&39E*.8XR.3,Y&OBWDUFE< MWTUEZZ,'$P<0S;&#?\=CQ!#C9.7YR9"-CX@U* MO-R;$9]Z.W!=*DXS&[S%V3P9%[:"]400)!$Y"";.X`VYW)D1GS@CA_W@G#G- MX"Q,R3P]K.RL310D38+PP)AX2Z?>+MOX9M+4(\E.'-PZC>ML%(=1.#OM[+$B MC"-"LG@,V'ETQYE[47NZ98]4;GFG4,,JV,V!-X,RI3O,W$"+WKZ0&Z'A$+*W M-7QS&.SIP`-Q)81^&YCC&PO=V]R:W-H965THRIMT0`GD@N/OT MJ5.7+A>+KV]5:;VR5A2\CFW?\6R+U1G/BWH;V[]^/C_,;$O(M,[3DMP8DQ8PU"*V=U(V<]<5V8Y5J7!XPVK8V?"V2B4\MEM7-"U+ MP@M.^6V/'#7VV1 M_U/4#*(-><(,K#E_0>BW')?@L'MV^EEEX'MKY6R3[DOY@Q_^9L5V)R'=8_`( M'9OG[T],9!!1H'&",3)EO`0!\&E5!98&1"1]4_\/12YWL1U.G/'4"WV`6VLF MY'.!E+:5[87DU?\$\CLJ(@DZDA#4=_O!K20N"5+^/:4R72Y:?K"@:,"D:%(L M07\.Q$?'2$;OZD>>@HM(\H@LL0W5#DX(2,_K,HBF"_<50IIUF-4YQA\BDB," M,P'R>HW@N*[Q,1SUDH`0B=+L2!$.B=;EC.X1@V!3 MC-$%5H29JKJ`]FB*36A?A6D0%1^J4@_+;96J3IF2`J,D.A#5J@^2S.!T@`NB ML*=IN;I1%'5"O76$7FB*(M!8!>I,T''33)=_5S-5Z&%T@ME98Z?^J15N=^Q" M.+"]:>&X7KH^-<.K?:S#Z,8_:J$^MCC-^(VYH,8XS,7I]4!M7%'']B2D9#B> M4=1)![@0$6QSFJA/(D)-41<31$;N5SB8P"W30Z*M#._,7=W3ITYX/1]:MU2Q M2;I3%UPW&NB-^:"NJ(<@],[R0:!3/HS+D_@?]5:8(@?Y0%$C"-\G>;G49J+EQS26, MJNKK#GZ:,!A?/`?`&\[E\0$-]#]VEK\!``#__P,`4$L#!!0`!@`(````(0!V MP&N8>0(``,D&```9````>&PO=V]R:W-H965TKI%22RRE`3S,O]\/4*<>5IT;6^3E M?;X#T/'S3I9HP[41JDIQ$L48\8JI3%3+%/_^-7\:8&0LK3):JHJG^(T;_#SY M_&F\57IE"LXM`H?*I+BPMAX18EC!)361JGD%,[G2DEH8ZB4QM>8T\XMD25IQ MW".2B@H'AY%^Q$/EN6!\IMA:\LH&$\U+:B%^4XC:'-PD>\1.4KU:UT],R1HL M%J(4]LV;8B39Z'59*4T7)>2]2SJ4';S]X,)>"J:54;F-P(Z$0"]S'I(A`:?) M.!.0@2L[TCQ/\4LRF@XPF8Q]??X(OC6-=V0*M?VB1?9-5!R*#6UR#5@HM7+2 MU\S]!8O)Q>JY;\`/C3*>TW5I?ZKM5RZ6A85N=R$AE]YMQPZ"@8!.UNLZ) MJ1("@%\DA=L94!"Z\\^MR&R1XG8OZO;C=@)RM.#&SH6SQ(BMC57R;Q`E>ZM@ MTMJ;P'-ODK0>-2$A()_?C%HZ&6NU1;!G`&EJZG9@,@+CZPE!)D[[XL1^"<1J MH`F;26O8&9,-5([M-=,KFJ."`/1(!EJ3[$K:AL;IOKQ([KBQLGY\@P MW??3G<%_D;"I'D03MQ`#L^0 M8?HNTMWG#Q\7)WY'MMZW1RALF`[;YUHOPVT43FM-E_P[U4M1&53R''9_'/6A M,SK<16%@5>U/YT)9N$/\:P&?#`Y'-XY`G"ME#P-WVQT_0I-_````__\#`%!+ M`P04``8`"````"$`U_!:XGL$```R$```&0```'AL+W=O>*7$25,`1 MIDW[[_=>+A^VF6GH2SXNQ\?']UX?X\V7M[*P7GDMO+>DME5FZZ^G2M3I M4P'K?F/W:=9SMW\F]&6>U4**8[,`.H>$3M<<.9$#3+O-(8<58-JMFA^W]@-; M)YYK.[M-FZ#O.;]*Y;>N&P>Q%-J+\02#641&)UY$L07WW MW/LTR7U'`M\]R6IQ[_E!.$.*0\MJLY2D3;K;U.)J0>N!<'E)L9'9&IC[]-!B MAH3]*E^0*"1Y0):M#7L&4B&AR*\[+_0VSBL4)NLP^RF&Z8BX1V`5D#:A`'R. MM/[],,B!)0SK@!2KZ_AY>7NY"$:Y_41["F@3#=.T4N(I0E%":J<0SQU8-+'0 M!_/%(GAK0VW&)(3+@;>=>D\8ZE_,7&P&$B6@20'>^5(0#!M`D<(F929,U#;! MW7+EW_N&V)@0H]A$'^(O5^'8&9I8V''SQ2+8%.L;>2-,T(KUHV"JE0"*5FU$ M$+#@%_VX^HQ4!.M2O7#DI1(3AJ0R%@3&]HJUYV[D&TM-Z'F[$BVGP6>$(M@4 M:DRT)\R8LM@,)$I`DX)GKN)%'^]A!-_:%H11I)B!1`EH4J+/2$&PF965T6F$ MH?*%/ENYYJX@P*@UT4>XH1\-E)I4!F?B_+2U:%-L,#!3KW6@44P\B21J1-># MKCV[C(P\'BS@`WOK0*H>&C9&$A6CZT%?5O3@$;>$G'W<7HS<7/4Z+PS-/!$( M/$$1/Y:I36;<,:E2^V'XXJ(>8@Q=6I%Z0R)YNB8Q&D^/VTFV]AA) MU(BN!YUYOA[R\1NE)-`X>\S,2*)&=#WHOHJ>F:4DS];R-"TE@;121N,QU)6R M!_4O#@F^2L+>;Y>C2T6_5:3>*"6YLRJ1*8=@5TK%PCL]9B1A2D37@Z8[7P]9 M](U2*C[>Z3$C"5,BNAYTWOEZR*?5_'BA:;&,0/T1R983C^T08_,EVI@@BJ*1 M5)>+;JS(G=EYY.&Z[(F)],ZOF$ADGNZL!XV=IT0TJ7";TJ1^W'DMVC@/(N-L MVG>@,6_Q)(*7.-P)].+WLTS2%8TN'R6O3SSF12&M3+S@][:&JP)ZY_``;FR7],2_I?4IKZ15\"-0NHL`=F=-=S[ZTXA+>^5Y$@W< MU=J?9[B;&PO=V]R:W-H965T;:B]O7IG9>2,\I:S,737S7(6W."MIN,_?WKX>;Q'6XP&V!:]:2S'TC MW+U=?OZTV+'^B5>$"`<86IZYE1#=W/-X7I$&\PGK2`O_E*QOL(!AO_5XUQ-< MJ$5-[06^/_,:3%M7,\S[2SA86=*;&O)^15.<5:*"=!Y M6NAQSJF7>L"T7!04,I"V.STI,_<.S=XKH=M*0+DCR$@F-B_> M[@G/P5&@F0219,I9#0+@UVFHW!K@"'Y5SQTM1)6YX6P2Q7Z(`.YL"!*!O+Q)\,T6>%R?!F3MUG;TX%,_VO"J!E<;H>LN,UL:$%1DL,2-? M9H]]T>"Q^K&_FA, MK-1%23@-#H51!JY-P`RE?G`HOZ4,OI'+E4FPK2R(TWW&NG(:8U3.F+`BSZZ) M+,$?[1F-,2(;$U;D^)K($CS*.1F9O=(878TD\1&:VJ:L+4`<)L$!8"F3AYKQ ML9_?)Q(\5H;LP"N-,3PQ)JS(Z361)?BC:FB,$=F8L"(CZ&:7)ZW0XZS']1A` MNB#0@6=I;/NR/H>PU8WZ[_F2(-TR[W5832:8Q&C5=>-N3N.@W1[NC+A#XF.[PEWW&_ MI2UW:E+"F>)/8N@YO;Y*Z(%@G3H.-TS`%4"]5G#E(W"R^!,`EXR)]X&\K.PO MDIWO2%NP8J(FEF&GIG#(HA`9 M?Y'9M>*UL22*E\R`?GT1C>[9JFP*7<74V[699;)J@.(D2F$^6U(25-GNZ[F6 MBIU*6/<'7;*LYVY?[N@KD2FI96'F0!=:H?=KWH;;$)@.^US`"M#V0/$B(<]T ME](E"0_[UJ"_!;_IT7.@+_+VDQ+Y+Z+FX#;DR;#3'[SDF>$Y9(X$F)&3E&_X MZ5<8BB"(;@$81/_;AWF.,4HXA!D_]R%?V[3]IH*<%^Q:FM_E[67A"S6\]4F6E"`!R>N MS:M`2A)D5VUD]8\%T8[*DL0="?S?['R\GM-EM'Z`8]%QP'_'0:.)'*%=4VO7 M"S/LL%?R%D"Q@FK=,"Q]N@/>[WL"9B#V&<$)@W`.&[LQ;6(N%6]C&G\-,P[,L"# MZ3(0G)#E:+6^'Q9AJPJ%IJ,!)RZ03(^+8*C"4=S%L!KKAT5`>0YY6+J(M$?X M>8!OI@M!L"MDY88Y6L2JM?TI6FU'OK=*TQ[@ZU@_H@/!KHZUI\,B(-A@R,9% MI#W"%[)Y1`B"72'?ZLQFQB+671U&6S\O=KZM&*=`\`B;O%$1[,K8NJL]6H3U MX_2]K9SV"-^/[2-"$.P*H?X6L1"LD.(PF]%XMH"646!SF5%/==IC?4T43I+I M[K1H3Y77IHX=9EPPU&\I`^9.#C:YR3XE3-@[N1XO14/ MP`4X]C_-WG9,1Y:_NZG%C/I;-[)I2RI>;N-U1+\)=2J:8B^<[A*BO:3YF[QE M3(CM-G%$/;GI,'_GT$/M%VXX=U*\;G+L,$["O%:`-R7D&>UU>Y^Q!W3%U9FG MO"QUD,DKWD\HF#J,#A>N[B8T3,#5I6%G_BM39U'KH.0%?!K--R!%V&PO=V]R:W-H965T7I_D')_8;R!W7W[L=X/O^:G<%H?[832:#`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`?=A8.8HVF&<0I$!;HW][)W811)&K(R2E4)-&\C3+6Y6QKJCO. MK^GY;F]*9\2F=,WY+RWP3S=N#U.7)47%C!0[0TD2?0[#L'.:1:CA9S3Q)-2( M,YJ(Q)&HH6'414E0W^2:^AKQ_5!?_.WLQ]Z\U05=6HU=@4SCI11D%#`*.`6" M`DF!\D"0GS[9_OUCQ'I=]/*[("/+4^X&?Y^7\C/BC/K8:+S\*,@H8!9P"08&D0'D@R$_O6/WS,V(Z M?V3A6UK-36)WF-%\N@A^V"-H-,V.S2D0%$@*E`>"E".]SODY]UO[ZE$T>;H+.)&7/9`, M"`/"@0@@$HCR29BQ,5:]NSBR-DSO'!>V*9#,$;=J3D>?)\%/!*LF@Q@K1,\NMWXIK$AGP:V5BZS(KP@E&6@8$`Y$`)%`E$_"C(W7\3*^O%9'UAE] MT.56Y&=*2>8"=1H&A`,10"00Y9,P4^-V^F=JO5$XI]#EGH&R=T#F0P2]VG=Y M94"8(Z[O%Z/%+.C[&?0]AQCBZA@28BB?A)4ROJE_I:S+"BM%C/PR\JR8JQ0E MF=/,K8F:)'550B/`(`X'(H!((,HG8>[&\_3/W3JD,'=RB[F,K&A6YT7N4=/V MS6;3SH`P(!R(`"*!*)^$21NCTS]I:XO\10`=6^1Y)S?AE&2@84`X$`%$`E$^ M"3,U_J9_IM8-A=-+O5OD62:7*249:%A+.K^0)*0Y>"MJFD,`D4"43X+DX__E MX>I1Q,,E]`;6B;IU+P62`6%`.!`!1#KBUD_]"6VX1JCWWP^K<96_BZU1"UHA M(4=>.I%?!?!WH&&.V'4O6DSJ[2#,B8>:^1F)""3QQ+JI,(R$@RN?A.4AIK"? M%8K/F,.$WLTYD5\F:AM^+G=T[D9VJ' M=20##0/"@0@@$HCR29BI\6.]5\'8NK>P]>DJZ$1=7BF0#`@#PH$((-(1=\&< M\PG*'Q2F3EQ@S[8^XP83+77#NNG/@#`@'(@`(H$HGX297N7=XC/>+8&V;KQ;LP.G;IB?*=4P MT'`@`HATQ+9U;&\*PO5;^8/"U*]R<+&U8N$533^6<:(NT11(!H0!X4`$$`E$ M^23,]"H'%ULK]D$[4[^6NF%=[AD0!H0#$4`D$.63(%/SU4+_5;I64YM&/X1P M(ON-BVLQ8CI3I_%R=R1H3#**P2@.1`"1CEPZ'W59$U;L*DN7G+-T],;5B5JS M.2%W=ZD3^.6R<=\=PF`(!R*`2$?>#:LN",(J$6=W^2.?Y)RC(T58.I'>`-M/ M/Y,I:9&T%35K:=:2"\-8*VJ&<2`"B`2B6G+^8&&)C$OK;9`2Z^F"Y71*[Y"< MJ)L^(DB=P&\D&_?=(0R&<"`"B`2B'#EWH+`L5_G&Y(QOG-);)B=J#PU5L4'\ MJE#"7(Q.PX$((/*#(ZOWWP]K0@SE!U>3]8@ZA>Y"@6^[$C"20#(@#`@'(H!( M(,HG8:97&4G]^-;'WWLY43=S*9"L)5[)IN26DK6B;I&@'E6`1@(Q#YVU'MXF M;Y\ALX\F[?/3OYODP\XUO2]MGU[[&YJD9PI?1;5H_`$9X%MWJ M1X.T?MR^H1\U.ZZ>\]]7I^?MH1SL\B=]J,EHKOOB9!]6LR^JXE@_*/585/HA ML_K?%_U08:Z?%)F,M/BI**KFA3F`>4BN?M+JX3\```#__P,`4$L#!!0`!@`( M````(0#8&HW+F@@``.TK```9````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`,.`8"`PD!@H`SXZ^M_%SP8CU MYN/904.?60VP8\&R65/A.EFM5B%:6`Q*HF0=+0(LX;A;`=OT=RNA)$WBI3[V MKF/:+!D%>O6JHK>W\54Q8EP5-$\SJP%5L6`-JN+?&H,"6Q-?P'&7`K:P%?%; M2-Q"`>#9UQLUM&^VU%B?>K_?^Z97OJF;YLU8FP6;>*9U0"S&#`,.`8"`XF!`L"SHP\/.(:W[1CQT#YE M-<`.!@P#CH'`0&*@`/#LK.^Q8\1H=!*\3UF-W98621RO(G^UY%;0^648<`P$ M!A(#!8!G3\_>.X:K46.#>,MQ(K?Q+M-`_T,6G01X)(03(@B1A"A(?*,FE*"X M-KRWA#;*>"]$>`1=0)HU_;;$4XT@A!)B(+$MVN2!;![>QF& M-H?X-I&+S(FZ>\X)881P0@0ADA`%B>_+Y(GQOHQZ:'\)K0CZPH01#2=$$"() M49#XODPB&._+Y@=]FR#?X8TFA#$DC)?I>H&6:NXDG75&""=$$"()49#X1LW9 M/]ZH30J^4>0B,X^T>I3MAA.GO1L.2!Q-`F.N46>=$R((D80H2'RCYO@'1L>% MF="&!L\PW7!0LDC1T.>NE\X<(X03(@B1A"A(?+LF#P"[`QN.30^>S;A[\&F& M*`M!Q&A(3@@CA!,B")&$*$A\7R88C/=E8X1>>6!AX@>O$&0-YPL31C2<$$&( M)$1!XOLRB6"\+YL?O/&*T--4%K8A`YJ/\='?BMKG>G9MUA).B"!$$J(@\:Q& M=V6<1HTR3HI<9$ZTB)LC/Y@%:$_*AP1L2,"=H%O#8JB))$T4)'Y-4!RZO5RC MOAB$A]^)[#8<-;LP"7XC-&R$ACL-+(Z]Q5M7EZ25@L2OSUWY*>K)3S&:$ID3 MZ9,([`TX&8\1L3$B?A6URTH0(@E1D/@%T6M__'X1&35:1`E^3G6B;A$A03XD M8$,"[@1PGM@[ZX@D&@6)7X2[4EK4E])PJG:B[GYR1ZYE055A`Y]STJ,8:"%) M"P6)7P$3I$8?&^:WZW@:I.C7))D3V96[-$^+=-L@\E..]$5G2U&Z,9D#L!](NC'R<:08@D1$'B^T6Q;JQ?&]2\'(33=Q99 MT=4OL4O2GFO1%8`3(@B1A"A(?+LH[35V1\SFGMB7DG/-BKK]2O]1S:YB^Q7M M7WE$$B`AG!!!B"1$0>+9-[_H@;N6L9\,KN6F%3K$%NC`SISHZCY`43%W@FYL M&2&<$$&()$1!XMM%X<[8->+;:SGN"7D17LM.U+G)"6&$<$($(9(0!8GO[ZYP M%MMP=ON9S(F@+]NL(XQH."&"$$F(@L3W=5?&BGLR%GDFWU;!O5]HW_X[%Y:W(B\.AFFS+#_/F9*1_`7REU[Q^?7#_3+EN?-6_''YO*V/U630_&JNPSTFR33R<6^KFE_J,MS M\[[A2UGKURR;;]_U:[6%?FLKF&GQ:UG6[0_F`N8UT>:%Q>?_`P``__\#`%!+ M`P04``8`"````"$`LD7`I[@"``#A!@``&0```'AL+W=O.,6`58V0[ M3?OO=XP3"F2KOHD8O3&DNFPR'7H`1:ZC,>5-F^-?/AYM; MC+0A34YJV;`,OS&-[]:?/ZV.4CWKBC&#P*'1&:Z,:9>^KVG%!-&>;%D#=PJI M!#&P5*6O6\5(WAT2M1\%0>H+PAOL');J&@]9%)RR>TD/@C7&F2A6$P/\NN*M M/KL)>HV=(.KYT-Y0*5JPV/.:F[?.%"-!EX]E(Q79UQ#W:S@C].S=+2[L!:=* M:ED8#^Q\!WH9\\)?^."T7N4<(K!I1XH5&=Z$RUV*_?6JR\]OSHYZ<(UT)8]? M%,^_\89!LJ%,M@![*9^M]#&W6W#8OSC]T!7@NT(Y*\BA-C_D\2OC966@V@D$ M9.-:YF_W3%-(*-AX46*=J*P!`'Z1X+8S("'DM?L_\MQ4&8Y3+YD'<0ARM&?: M/'!KB1$]:"/%'R<*3U;.)#J9Q$!_NA]=:^([H"Z^>V+(>J7D$4'/P"-U2VP' MADLP/@?F,/I0_QM)K#C#L^&# MHWGOZ^"9=T:)TD03! M6+!S@@YQ1`2-.R3ZF,2*IR3O.7:Y<)K%J7UNH]EB0C(41,D\F;T7R?[6YAPW3SP^QLP85I2LB>B2MYH5+,"+`-O#GE2;D:YA9%M]Z+OI8'9 MTEU6\"EAT&^!!^)"2G->V'>O_SBM_P(``/__`P!02P,$%``&``@````A`*WU M+W?T!```H1(``!@```!X;"]W;W)K9(`(Z.WO9QN[\84F#:J4!+J\ MO;SV]EZ&U;>WYNB]5%U?\W;MHT7H>U5;\FW=[M?^/W\_W*6^UP]%NRV.O*W6 M_GO5^]\VO_ZR>N7=4W^HJL&#"&V_]@_#<%H&05\>JJ;H%_Q4M?"?'>^:8H#+ M;A_TIZXJMN.@YAC@,(R#IJA;7T98=K?$X+M=75;WO'QNJG:00;KJ6`S`OS_4 MI_XC6E/>$JXINJ?GTUW)FQ.$>*R/]?`^!O6]IES^V+>\*QZ/L.XW1(OR(_9X M,0G?U&7'>[X;%A`ND$2G:V8!"R#29K6M805"=J^K=FO_.UKF./*#S6H4Z-^Z M>NV-WUY_X*^_=?7VC[JM0&W(D\C`(^=/`OIC*V[!X&`R^F',P)^=MZUVQ?-Q M^(N__E[5^\,`Z8Y@16)AR^W[?=67H"B$64@:)3\"`?CTFEJ4!BA2O(W?K_5V M.*Q]$B^B)"0(X-YCU0\/M0CI>^5S/_#F/PE"@M0Y"%9!X%L%07AV$**"P+<. M@M,(1?'75`*YK%&E^V(H-JN.OWI0>D"\/Q6BD-$2(@MY"(C\N3RP)#'FNQ@T M#@5T#SE]V2"V"EX@#:6"9%,(MA'Y)XCP#`F`WIDCR&9RO,Y-@-<^];TS-XS. M84?ZF82,13?>R(T;UL0@R.T3"S"(9T[L+#F3$*84PU&4X,CFEIN0%*,H89J] MQ0U6:'(3B:,7Z_HC<6*0PY'8!#()24:.!,4H2E,;D9L(G":8A!IA400Z)L7K M>1-@AQJU)\XD1%$C)$F9GE@FTD)@1&)\H:3B.=0$V*'FI"V3$$D-1XQ1EYD) M0"$CL=XPEF;)'&("[!"+'BJ#1ZI5: MQAU[X,2!Y!8$4X*0D6:;IF,$7R1QZ@#$ MJ>T,F0T>03]P=D=^!6!3FV4`XE3F[$OBE':F,!_*D80PIP1S"X(I;%VDQ;7I M.29P8X*G;D!<-T!FM\<1CED837C:F#"-DD3W1YOH+%-`4U<@SA[,%$;J"';$ M4D?IW$:@B*1Z`3:Y6::`IJY`]*K5'C6[/DY3Z!%X0L_")#&%OTM-9)8YH*D[ M$*?^,X6!>CV?,8F>7+45&><"QE(0S_*($6T?<*E.C5108)8/C&C;1:EN`4HAV?4E M.8:3&,7,J<-A/&4X^@;A-6&#GYG3@O(AHY?29W M0"%"\"BHMXI-<99/X*E/4!U8:6CZQ%V@CDR9PLCG+OSYJ<3"7#B5R)<,\O'Y5.RKGT6WK]O>.U8[V#7A(@$N MG7S%("\&?AH?DQ_Y`*\&QI\'>!54P3-TN`#PCO/AXT*\Q#B_7-K\#P``__\# M`%!+`P04``8`"````"$`/S3LIZL"``"@!P``&````'AL+W=OV`"58! M(]MIVG^_8SM)@;1=DXN`\7M>/>ZD>=,FY0>#0Z!27QK3S,-19R6NF`]GR M!F8*J6IF8*BVH6X59[DKJJLP(F02UDPTV#O,U4<\9%&(C-_*;%?SQG@3Q2MF M@%^7HM5'MSK[B%W-U,.NOP89GL`FRD?+#2^]P^@N+PK/K.+<`/A7)>L%UE?LK]5RZV MI8'5'D-#MJ]Y_GS+=0:!@DT0C:U3)BL`@']4"_MF0"#LR5WW(C=EBD>38#PE M(PIRM.':W`EKB5&VTT;6?[V('JR\270P@>O!A$87FXP.)G!],8EF8SJ>_!\E M]&VYE&Z98K)W;:R\Q*^Z[6O= M>=`#@&`N![!%$&878#8`\)+$)4@))>0E`$>X[@J2N#O?XX,NNWSO+YX5#[B2 M`9>74.+`2$!H?W[]]GP/"S;(Q[&LN(\U'J2Q\I*IHQI#&/8W('M7TH.;7`)G MQ0.X028K+_%P49Q$$T+C`5Q70I-X-IMU)#VXZ25P5CR`&^RUE9>\"]>5O`'G M#UE_?+1LR[\SM16-1A4O8).18`KI*W_$^H&1K3LF-M+`T>AN2_@2&POP"QC[`W.Z]'Z6?9'__ M[XN(3&8F956A>K"8&J`.%!D9\<5W/D7D=__P<3+./A2+RT_/[! M]7(Y_^;KK\O!=3')R_YL7DSYY7*VF.1+_EQ'NP8-L-1W]ZZHX]F_V#O<>//^N'#W_;OG\Q6RPFA33 M9088V1CQDR M+#YF_UC<-L>E/9W?SEL+[&QO_7'C`Z?%8C03'H;9BWS9>O8(3`T-6R?C_*HY MR_%JL0"T[&14#@#O7XI\L7&FN)7PR-MB/ELLX8OL;)DO5V5SZG\I6E^%&4Y& MXV*1'0/LU6S1PL39)!_K]VK^X]EDGD];`R,\L\ED-@6(V>!]+SN[SA=%F;U9 M+8U+`:\)5\)T?<\GL%0+W.;(@.G.L7_<::YS/(/6T[(89GPJ9^/1D`T/LQ_R M<3X=%``*\Y?9HW=G+[*'CYL/OR@&B2N?-'^,1,O+DBF^:?V8N9P7@^7H`T.:<+Z:?@"J M#@XX713S?#3,BH]HCA)J2LYGR^MBT9SB?+:$:P>!(QT?S3&G"Q30`A6A682- MN:3!-MH<^FJ*9KL:@8>L>ZX7Q66!P`RSR]$4Y(CY![.RC5F'Z\CHTUPD4F\\ MRB]&X]%R5+1)F"@SSV]%%H,=W"]6K!W1LFGB803R;0&"5RV-L(ZT&AC-"7^> M+8OL-$"PA4#:=.BP90%=E]GI:C&XSLLB.[I:%(6PVISA]0P,G1>+298P=R=0 M=P"#$IB,EEK$^6&`3@?_&"<0V%SW\Z?/GYK?F6:XGHV'&+?_9HP`3SP"6:/! M:/FX+46N5DI7*P_[VSO9'.6(**V*;[/];>-O\7OI&B=?+:]GB]&?B^&WV>Z3 MWK/=@][VSA,CW,ZSWI/#P]XA?X;!H[(4)8VO-VNJH^$0]IA-87')P]9HF@WR M^0B6;^X-?EE-5F-3,&%'S2%.=5M_(Q*ZGWE=,:I!W(7(YI/W5'ZG*&M,<[$< M87T>;U*&]YJL"4$2H;IR^X)6:\XAGL.T!!X`6"?_W<-:_'"OX+F:33";+:=0< M\T9V,-J`UB:3;@YH:#[=_'TK&8LO6#1?=D0H,"FR1V'VEMOB&S53'4%L0O`S M_H7VV?S^GXO1U;4\51S-L,D M_EJPG6L?RM$_RFC8)E(RYM1)W,&,E< M3E*W,R",C3LP=C3\TZH,%G$YDQ,WPQCB+,B%TP,9W^JS^8$K>:+RY0)KW;WF MBV+.?"-CP29NCR;R^_]LOTEB1U_RFIH/W)?GS-!L06L@A^_D#'8"9*Y_=J7X MK,56B>'S(<&?802OIKFEXVO\OH*=!+_/6*OFC+3DK,.Z-.=\$=VP1;<;)K)^ MF3+-69L<-,*)+BT*NX.#DJ,&M="?L'G3'6XNBPN-+Z0 M7;$/=X1PAL&N@;WL@J3%=*H0A3W>8M>:Z]_Q+"D#/06CD%IH/G>VFL_'YDY@ M_(8D#M`U*P7=PJ54H!1<5&BW+=&Q92V^DS9">5@PT5SD!S2\S4@P6.(C=@F^ M\DW?E/-\0!X*=546BP_%@^<[_$582SEEOP2"X&["C2*F`/3,E> MR2A$-PJZC5?#(L,8VR0KA27L/Z2"/G]2+BA[I)__]I?_A2F;D\#XVU_^=\:6 M^<*'\?=CTS0C'K[!*R>,GMU,X:!R=5&.AJ-\<1MFQ(XM2+>XSGVD&8[]:5L5 M?VUP_?E3S&+9G&00BLE%L4A?>RPBG`NJY34A6P;?+Z\#F4L2?>+>KLG(C3WI M*Z@2TM)N_EHB._?'V77^H8`KBRDZB`!?8;04+B18#$T6;T8`H[_!I@@R7X#F M$;Q69L1Y\K5`$+\7R@#CA,3HYT_D^/X1ZR,FDCQ'.MVY3"*)2=%H\HO((=A6T[AU MK1DP.IOCR@(7D$SR*:Z8YTL6Q>685(XR0[B[E>LQA='*4JPJF//L,A\M1.$D MM9J(/U=CN#QNRS6+O'D;5PQM*V]KH^*6XDB!.YTM<6A\N1&\,)H.H;0\[JXU MR%>-C4S][(A/Y>AJ.B+85Q;7)@^B'SG.8P-E>4OI;(5'%<<6XQ$.OL774L]) M/S"LE?)]L[C*I]$_$EY_6)6C*3AJ:J#=_KV'QBFRL]6$\*612ULH*[ZN>E"> M>3:&Z25(DT)X&F?+8G`]G8UG5[G-44H;$"X4P/\ZB<#TGO&`HX@96+1%' M?OP5*[E0NED!I M"0##29#YDF!&FLT)#Y7TSRG_*?^L3,+W#P[Z^P^^?O[=`)J86IY@R7;TS>($ MS>QCSD<39OVYN,G>SI!'_7J93\3^-H4-_]IF73[__&\;E]K9_BU7ZC:]0"FN M^7&17Y)@!2NSR\LM*+I%I6?LCI:\-=?C"=F00"(-@UROV&!@$P;-<.DOET;] MB\5HB#MSE95"?.0E9P9"0]/0L-UL<8'95$I5COQ,`0QCW:Y@:JI\&@[+E8D$ M/BY);_',"H[;B+W_F(0ZGDU1IZ3@(9:$A80VTK>ZF*SP=',B>+3AH!B/R2PN ML`7P]\=,SL?+XY_,^QC,\KE[9IGR]:;B&_0&O51MI(\H!9O%OG<5`I2HFL/PF&8*Z8D, MI44B*0_H-X+=]ABMDII&"JF0DZ))*5F1@.1!6*)FD_8<9D.?6>,+%1Z2245: MJ6*(F.8R([O,I#J14SPN64(U^93^[9`$DZ^W"-_(I`<@@A>#;4J5QS?%L]C[[ M8225?JV^D1#=%T,7?#F]9%8PN!?*;F$-R"9M,-%E:/;W&?@K-G1,Q MT^@M_L6CQ:M-$\L5PU'GVRG1$#I^E?>4J\:O]Q-+H/512*RE1)8ZK M](2;X11.?U0*QHRK:/\51[ZCE=GN:>_W[3]C*_(025/:6 MC#DQH:RBVYNJ9R@.`2O*JS.*PBZF4\D+-.^*[!2.;J%\GYHYI,'Q+Q<$CQXN M0R?(5_:"K@?S4B>7HX_,8IJ]P$0HHK2>BR'A)6[M+0$G"0!JN=9CH'&0!%;@ M41F('(WOW0!D+UG*%R9X4%P>#(EH6%JERW07>=(^^[3"O4??:^S)&(]^M%;Z M0\4W^1XYG17D5,FG*&VU(M,CJY;X4BOFL?)OK-]$E3&4+Z$]A&V"`B;7;_7I MT[1F9YVDBO1O;&JUI(E#S,$".K!6L0\18+/`SH)3I?C$=79OZAYXO(+@8=22M6Y]$$ M]#KIQC.E2.1F4-PJH)?/(R0DD&C#$;6).7'XI7`2-?1@G`$KMV2':"R11;`# M0)R#O,J4],P%[!?9A_2"EP(CG?O920'*"?475RS"HO$7Y\WR>C2?RT.2_JLQ M$YM+]'(93'S+0'O*IZMS1J_:!#OG'R6U\=Q(9U0"H5JK4E!6]?4*4G/QP#CR MMVFSTPJUT-(J`O8$(;^);=!^E2I):7;[\+)JQS)%<$S-#H7KF=VF%CH!ZOF* MQ*\8'WII\92$UA0DXV?$%;U!YNN:RBKI@C'ME$1I0RMI6$#@?CXK M0!'%&\&;)-+#\:1$9$NF/#$@+$@I>5T1.MOBM=I$GP1)Z;7SYD^&H6B96`AY MK'*MV"HD'#E2R@U%A`E<&H>QJ0OOEBLQ:[>R?11^LLN"G5D.@2?-RBHY1V>I MI:DB"DR8)/\\)MI)3TOW@@><9?"Y*+Q?QG416B&M90IZQA!GZ/&(:3"'4F', M!3&,=355/:=(3HS40[88E>^5U344:*8F+EH,$FQ@*7L4VO#:K"%:'/L*;UFA MR2EI#J0FS8%LD#YCZX9P,0_FGBP*>2NJ.$;#K,H``_+D""K]E)+*\&+0K>Y\*.=S M5],A_C;J2]D(9HL1$>I">6"4OM+J4:$P,"+"(^,H$J9>TC!+$U:LR""ECV;3 MGE*<(B& M&Q=`*FDP@UF5N1(ZW2TRYR.2XAKQ$H%"?.&0KGCF]5F#0W M?`BQ!M32\;9I6X)Z4P,I*I8Z!PY7N#&DH5=*9-/HA!4=`*&R")5Z8M-Q36\- MO;6JR!D=M"I<-#`GPG>IC+2@7Y_:#Q*5 M=&%]N+:814H9*U@>0O9+#3OT`Z,JK?R=6ZY6=05U>&>/]K\RUDJS'NQL/0L4 M%VUW`5#*)OUN*Z41^`J/90JD>$VAN%!:_K9*BQCY3(.4F'ES+O+QP)HBC57+]4#W:WZVK#PQ*W+6;#YC0^B\5%<09+HKE MC:J=8$R;3-OA]BPJ3N*G5@$FH^BZ2E&$!!I"?# MK"%%TY6`D;Q>%2J`S"DD@Q`J=0H1&1@MG'RB]Y1PY\86P>TQ>Q9'&+KEIB,. M?N)&W"O4XV]BWVM@K_M.^;C$-5>CO1<8JEV+?F5;B#Q&F0SD2!% M6>@"7&[7-XIELT>7HT6YY*@!!0O[A`/P6($?70HUA.7S2N6NBS?'^.J*M_GCH]2:TNK%/5&GM?Q6:Q5O/OBP^<5N;X?#%P?/ M=MI'0G9[VT]W>[M[^^V?_GFV>"]_+!BXUJ0\]^3I=ONY/9JP#KO6>IO?@$/\ M"[K#;LS9OZS2RI$M_$$N?YQZ;R7SX_A[." M4;.TZ)3D$B:47C$H'UU^DBZ:8)E_-#>:PV+4S,S3%F/&?@\<(C9F6\5Q(QF& M1?(D@')IEWZBJYI*7@RH"8:;U>2:JH7';6?T.F!!R8/013H]Y"N#6YFRQIYX MN\0)"\L(5(4OP3FK]1C;,@);`8$EX2Y7*B+($+MC1L1@?GPQ(911P]5P=,FT MRFR4^!'N;9I$$N/3.8<71@E>40^@6_!MXJL1`L._$Z6KSIF1%Z+]`EH_@T5M!=RJF0#5'C>L74$K>A$\;1O2*P&+SEU MM+19S1(QMS#2C?J:E,RZ$+9(6\%?GEE_I4Y8Y69"=A+NQT<[\]0^79R'N]J4 MQ>JTTHD1O&7*2CIJ&UTH$=KRK\[!3Y0C52N6A)+B<"*#D$'A+Y(1(8X5-DAQ M61($!RJ&RAHNZ;-"B"=K\+[(%0N.#4\;0WL?)$2".^`<]:0I@2@&$66VG&-H M$LJG6^(8I.DB!+_&ZT`?P0%E8N05'6K4)T*J0PDH4$BT(48@]&93BH_RCQH; M#N4M;_LTSB&D<2J7\!`]XZ1#C-4T[6_HXN$\X:A2PY+4V4IE3!?K$*3 M3F6N8=OK`H`N!97-1TVHLH;T0B^66TIH9.!UQ4Z!F2>@8FU"HQ9?=:^&D;2V M=^6T\2[;6J`"-HAX4E7$)]TM<.;A6L:CY)5+MA*7KJ//TT`H! MC?3,,/72=$DMAU1-6*1%S3.=--OZP=),&G/G<:..8TFH"$2J)DIDC@?4`N9> MV;#J4M+V(#X[.B;SM;WK5Q=P+-.!SND6!P4G)W5))`$@P/N MT%I:TO,(%YSYO+EK*^2YL/J'8E!E:>L$\QHYUB<8J/:[L!3& MO"`.L[^GLM#5"8+YBDS]0'Z5TC803@ZI0';$JP:K/%M@[S6:B>E#(@(0)4[%!16(O:%US'9 M*/NP)P92@6_K4E719`VE M:)29%DV4E%(6_'8D+Z5F6I(:8N"[_AFSJZ-CA1MOW!\:VR5^J42,:,:$O.GM MF@Z$&QBGK?ENUW'IFMW1M+Z-JBQJ1[!4Q+0"I170,)M6LFMS-=PRC!51_"O$ M:ZX]H^/-S6K/$H0*=&)@"N-O]YS7P0&K9K;@IM@=>1,.`F]Q7,@.`M&S=EH MY2>>]#LB[_1P)?Y-U^#I07]OMQW.?]4<=[C3WSUHCU-9F&X6^%+LV'R(9SI2 M!3O]G8X5$ZR)*9JS;7=M\1SN#]JBIOYK`A5]=@\C7'`K,YO,CE23M9;@H7HU M&G:N3Z,XP@X@P3O)1EGDK6[^AEFJ](H8A)9V*Y_06.T'M.C30XCJLWM03740 M-8.3E`0+08L_6<^0:;D((LKBV`ZPF+\8O[74050G-EO-UD9/5%U6J79$R6QP MO45.OSIA%<^2K5OJ(%^N@,UOM.5=@5O^/L1GVG6H\H-&LFJ$79S>!G4R-='' M2>]P;T'%R\!=K62<^'BN MLPM*%]7_3PXLICU0KGH%$J_A$[G+K5=>.GFXA M)T1<+KI[]@=\IW:,3PR=-7^$LKS$4]A,9E;AT)XB:OHY6[$24"W0W.#0& MZ(XBWXMDS2Y\JO%"E<%R_E.GA+NCH4-1M0553V[V:9D>X6&,+(?<]M#Y)'%&;YBP<7"NS'V;*\^BL MS,G1V0]V6";XN)W#W\W-8?QY1@T4KM[?VM[KZ9SPF7D3EV9DA=Y36=-P&%HT M>J%>KE=XM-8D>*P+1EC+UCTZ>T=T85/9\J[O8LI(D\'C:Y-Y8UBAQ?#X^[M^6C+3PTIJ\-_.*HK8ESDQ[2EL^,8RZ2*-%!7&0_$3.V.EA/R M`,3X#4)76_#,W`5JB70OU>T0/B-\-,C).ZXYSH%YS#OC3*RXC]Y$J?DF+RFC M2*>"=3SXH8TJ9;`#H86_?O;2VHWR88A8T,-P(C+/5OH972Y#;ME``[JA,+E+ M8R&163(PYR<:K;TDM$[$:H!<1LNDH6I6B@"^#XP>T:B\)Y M,;*Z)]?M&M<=)PA$OD?G'`@>9(<[VX^_R=)M@FA==SS7!Q^%!IDV%^[6N'!E M[.[QF+9+7M)UK7F?9/:,(>0*HX+0K>$8=PTSJ>]F3#LK/30:1]#DMLFGA]H3 MO`-?A0XQ$KPZ*AZ2Q3P$<92'(4UNYO"*YD@3(S%53(?2UX`>L;:>2Z)35U-U M(;HAE6MJ-X*0LJIPN*=W,23+D)WUYR_5!&ON-SA,0;3W+9,%0^8D+=5N1848 M.IE)JHO&[O_/HB$'J@J!:AU[VF!D^Y`]C_+5DAF9X%\K%W_@,,8=8A%I'GTL MN41C>A(578E\.O$-S6@)X_0[#H956B":=$I\5H2"74R)!+KIA@*QESA89R@I M6C&5(CWNCW!]^./1T6F=6VOSH6#6-=Q&[24PHIH+WIGY(<9!LH'AR?C;?;7= M"'6<=%A=WV4<1[%>0%=YM4B0Q#O:GC",1*XPYAKR\&'WKSZGWPEX3/# M^W?FJY]RM[@=;*7CGS>UJPRF4--<7?YOP97Y1NZ5$0:-U;$*055FIIU)++5YRIC%2?.24U)!..1%C2/;C:PR"3VA+D%HB=$O61J M8)TH:1UT=)JI#F)$(<5`R_YK!Q3+Y%_R@*YO<6J( MG1T!OAWTBDM&T\R'Q?](+[A.D8Q6UEQSLR\9BM-D*:]0.E`5 M$0<[6A?Q6;(\8=P7+<[!M]4Y+1YNQUG2U!\L3P^F(+?.7R`G7#YNL*RY$R1!WRS8!NJP`,W#EK#8*%B9>(LIK2\AM*2R9S!1'@&6#A92-C( M/;5TJJ(RVS'_+X@BV@>4UB)F\*).5M!"<8H](_W:Z%14JEFY.73$ M4V=>'75D*&=#Q/+J5(G>H*.T#FWE"`-3)0K)W%F[KJ4"4`BA_LPF+(-79_!F M6']:OPGO)4EWN^NS,:K[^.F3?O?#K:.F:\.4V+LK-!)(=.;P[M1EIS%.T`\;+N M(VM@:@SHIMQ^O_51UZ&WB3:F_#">`@DI:" MCT9`)Z"3#[+S=&MWVTU&GXO$+?7NF2++UG9.1%J<$H:9#\)<:WBKDC+AAKO@ M;JD$93="2=^H<8RX(V:WW41)_58UM#@>J7OX]%GOV;,#SQK/<>8%L_^.<))& M,TXW**?*;ONT*F,!5/C#'+B0L@S&7]I.X'M-"3>!+%CGH0.%(EG7N05:4N,= M^CMVG[YIM]`N,J:/R5%25:DL297:TB*@!AO[)#/6X#^S[*F29=G^AWO<5!&>FP&I(%(2LDI]O.O@+4E/.^U[0L(7 M,VTI+E*M[T[>GMCS4K3KCY[3#P1#D#'&Z<5)45KWW?F11O<9*D1I/<"?>(,F M?[2!\\@ST+!I81M9.DIF77UWR$#;MAZ*!LB"D%H,NN2TBW-^&^V?>I^H4 M(ZM_"FX.W-E%B1:)VU&(X->%&8DYXQ3R%6,[CXF)KE\V_S8DJJ.T:-[X.4J* MN7G-NQ,!A,HY$J*BZ6OC22D3!$>.N?-7Q&U\),;G$2BM MJS'I+@(Y.-9@J84LAY,:!"/Z+2:*1]F\?2(>JD3>$1H$+=T6-N:L8-BQ(A@S MVWB2.3S:"Q(VPQ?7HFE%1*8"2&V4@C"N3CL,YVKD^9MESR[P_&F)\<"_"<=Y M)S?)A;"#AYKW/?4OK5P"3:D,NW6QM`K>G__OO4QD:`NAMH]K.+NEMX^N1*4L MUW7[5]K`WE<4]89!`#IHF9HZU!+K=RM46JFZPI,EW=GO[*"\,4$9#Q`(\Q&R>"!)9G"JK'V."D*&>&4:GA&M)5H=F M"%Z5PN6#'EQ$C8A:74%WX;H)@A]@%;>B.&O8HI)SQ#$JP4*/8QNGDC\I.D7* M%DG(5W8Q5<2G2-:N\6"+FMJ`F_NU!]BVM!3!!3UFO!;"*K!,RDDL:K&F+?S` MH\%DD>$RV^L_W?_JVZ;#T^TIT6L:H*:[)^@/0*[K#SNR+'93#KQ+YVF'1#.4 MPI0$-^C"G!YAP6/L!=(IO-`94G9;K1:XCM@#18[KK\L:M$XU(^MZ%2(B#JP? MZQH&'6),=].DSI7:U`KD-NVES<<>1D;Q)7R74V!.(+P/:+KXXX)>9C.VZB6^ M0R2DKA)$G+U!4U#A2"C&DY&LB0%4,J>QV[(^@0WJ(-^3C@'AW`PWN5B1]'%6 MC0CSEI'C8<+XYE*+PMVOMU07#_[.;0` MIN'K20]_N/9ZC9;S^+:F1T.K^YS)JE-)S]QA%4(>'OAKIVHM`[_`!U_WKD/W M#)@*9L-<+-?#6LO/P(F:T>V'GZ21E)"U](I^0R\,)1*>2TDO_D)3Q]O#X>4J M3]':?:C5ENG52UJ:+ZU3_V60S:;,'/1_U6/IH;NZM5W3*2@*0IB:]9HN1KW<[#=.]Q_UFIXZU[K)]*4W%B:3PNNRA!=*(OC M:[56Y`5ESPX[SOWM;._W]G;:/W2OQLZ,*J(^)'>-T5JKMPN/'AZT)WVNW:&H MVD?U_.[%V%]_6GL+6%QRG1$8KW_J=PO_MC=E/H_X7S_=N0?5]GJ[3SLHQP%) MPO6=KL.+/Y,'3.S=1-?3_IT_K_UX?\Y\?JZ@X_5,;CGB]#:4(DB$8*'(Y*0X MU9ZYU9VUL_[B_Z8:_V)_VH#+&J4O<[Q1C20*2<<,-12 M[CEZU7O\\(L_)-!2EMYB*<'&=;IDJ_/;<.*#,?39$=?P M6C`OL>B3_VPJGDA52JE@8!!80<3IH;A9')@H[\$)5NIDF3WKZZH0>=(J')/9 MYZI!FRJ6)ICN]:L?WKR5;>#=H%_%+DK3#(V^+;0CGGB> M[3")^E7=#MY!%F!V''NFR7:&8QT21=%B5%A"B2OX4%MVY2UK)3UI?K`^A)(4 MK8E MGF#X\8[-+8/!M.4FTI',<"-832IBTB4B^CATUU\UJ*>;S-2H!G/6ZVO1]8FWQFD:<2\W55W;T.`+91Y<*9`A#2XIF\&OS_:_ M,DZH?"@KT^3-73R.9X49$H(96?W:%7)B`IC>RR$J MP\(@CDY;,+DZ_WGCQ._W%G73>&(*TA"_MZOD3^/5YL0?GS^==\A8=LT;6#"1 M,HX(CYWRB.K[70J8FY+9RZ004CSD2J!F#5."J:WD[Z4=>@J]XZ'3&`A9!HIS MV0H78[XG&MA@GLT6QT23U0FJ9BCB.\NKKQ_7>;C3W],/#W?[^\FNR-8&$\QO M5BV7K9&.NJ3IC4QV_!646=%@+2MJJ96U$=1;4'>H(S^@'^9J8G4]Z@2[?JU" M\CC\D)WR#Q=R0/@W'<00:%4J-SUAEM7<;85`Z>OJVH30*6(Z&!Z0]Q*M\:*@ MPFE]]IK\E/K[&S\+:7O^*G&4>U+.MK@CME+JZ6A.5%MYN$ODP%N(5=N( M]NM$T2?AE#EF;I?<'4L1WT->UXK1MJ'%#6__.S1ZFI5+GGG M#X4LB+J[9AIQ&U_)0--9T;3,78:Y?N]#W+P@`73,%_X.FVTN%Y&1U@GQ=MVH M4]D0^PNG.A0@JL;'COUO,_V0B)7_T6$5QEUJ9;MI>N$__`J#R"Y)# M28"@%G2U;!,.@F7G-05O=PNIIC!GDY&]J+)I'U9AD\+Q(H"RS"0GJ([;^4@2 MQR92/D?$G3&3Z([[A\!&!Q#!]0HCU0EPP:]T#>'.B#IYP.0RW190ZSVR>^:!Y;C-&*F`5M?2TTD=L4WM7 MA*/_OZ1(1?;_#%_(J*U&1@4=Y(+TZ&[_*;R+"K.EUKDXX^:*%??$B>H=_B1> MEKCT#NYM85)*Q>I"W@\6^@A:-'\Y]^'OLMEKOL8-?WB!V9&:&:=;_7E!@_T+2(7 M)LV`:P;9ZQ`T!<_%PGKC_4IH(FU?Z2YY($D+.<;MH.%_N&B_ID?W7(\:T83[ MB(=@)Q*O;PS]WYG[%[TO#('W,9E(VEKZ MZRS=9\EI+,D58@=!Q#9H_!F=V'-J& M(),B6^"[0B2=%D.F5;;"(*DFS`;EUP;O.#1U,9MOL97*>57Q66+)AB[FD@ZE MHNXP%"8>F^V(ZPKUKM1VPKW0P35K);;([=V9V?*MF&,6-Y M'W;%DI@5A%W`)&EN4=FUT-J8*@&6Z-Y01?*(5$JV]U38H4@HM;Z0-8_(+"+O M>N&MF5P93P/[X\R=X&=S@6TG?Q9=$M'5Q MZ?146%9'S2E0ZM;7NB+KD9$EF1P&U4^6,ZT.(LA'2/GX=3*SJJ@8V!%T"\=S MZZT:?@N$`K$ZEM.&3#WCW!MEK@BHP2YI?A0.IHR9?\$6]JJ$YF^WAC#VND^.7`R6=P+JBURO&EB9^R$F^#87Z;LA([ M!_W=OP=95)&Q)GMN8%'CCG@FP&:5>G7F4V^7_+M*X>8B\7>R7Q+EBKGAU_B" M``MB]:M:^'U*318::2IEN-D<&6S6E6:^B2",#H"=8;;.+.]>J?M@](-%`0RO MFE!E:6@OD1M6NC?`%'(,T>XC^#7EE32N]W78>8':VW'J@?3Z@[6X.BE[:1>A M]XX--P,Y:(/XZBYAY?Z3GUA-6=/3#-#L]>#.R1FS`**%TFD;WO+-7H^;T5V( MGWG%7"NX:__4Z3UTE5S\[BW7WW7@6-^:3,RWJU$!'8ZF:/M-E;->!6"Z9=Q> M50#'8N8,(_'9:A,0*X2T!%X:$\G/(W;[IS7,20`")]ENF?(-76CQ'4A-8JG5 M3FMV49TTEC/9Z>UQT>VS@V>;LB8-%JN7>P'SX5Y_OQ8/KM>' MOYQ%V3^LLBB6]B!ADDIE0I$.?F!G25M@/Y%$R^_J78ZI>;%.LDX6#02)CAM^ M"ZUG):T2E=6MA72>&CNP@]>!_DKD6/['+XQ&[Y`%JI(_R>HIOUW;#^3EBA@4 M6`U".YH#F8G[M;NEA1N@T50-^?CP'@)W-I0=L++;#0?]O%_R,O_`!;@X`$9) MJ\Y66HIM^=FB%,GCA!!C:27KMDQ/?V%A$WGB!#7?1Z?$$EVXKH$0S8WAJZJ> ML`9_ZO4+&68#1#W6=MF`=ETERM!2\6H<&$ZGWN/5>Y@'?X/?@D^>:E'/,0_` M\BJH6^0%7(EO]+15(-0[&:>)$?1&5BR;L0;%YR M6-XV0S8M'`3P.H,KI`[92)ZXC<-[77MOM-CF'L&=,4N-Q5/VS%3;0H"AI[E%,I%+[X:$:.L-$L<$NI#&.*$]C3&U.Q&S-@F M3JSM-L0WBG,JPZQWY1!UZZY1.4U"E1KC#&"[5>X27>&)!/5B^YU6/BR=TDPP M"?NVX(OP4J@8YVS"8&J4^=-J>&57=)B5K>&U=@N4[C!*]S[&$P3@.3*0<;,V M$+TEPYZN@+@2GZ^CGR.=Q+"3<@U;QD3N\HL' MJHP*MH>N2UECIZ85!/<.#GN[3YX9[NG(>MK;?[*;4L9?7LF>4Q5VO6V4Y)/U M?04F<>2P[:HE,`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`QI6H-.":RL^-#>N0NK#^(=\Z M)@_>RU[WN?TJZM.?*0[9=DQKR_##54261+QV@R@,#[_]L%IPS$6B;.=QG3CI M40FP$LP(IPDPN5LN"-'5X3XS1MLFCV,+8:55M5''FU MD%P=.=AVP(A6;5[RR1_7'#Y0`PP0P"**M>4J8](1X0O+Z!L8\H!BSPL2?,=< M7\/6,BX^90T++FH@DX5D9# M0]!(3=Y6,/"+;OQJ1$.<:KO1[97CZ-=`H]GA"ZD('&$5#\E7RYI(Y M0'=NAZBSKND2VZ<%C.V-(5YS$;IZE[TQ(C$?VX:553/34G#5>YH=RO!VN\__ M%M;\<0&Y:A%UC.C]*:60_/*1*%.P97.]?QKQ^O+IB-OUE2?L9?%OHQ^6JO[V MF0O%[GJ92[TC4L1?G]1`AIEX)\74WMXLCJQ$R!D:BL42^H&;/VG66QVSU.MJ M:&'SVK/)4GI/3VC4L,P>UI])"(L$`<\FT'TK%9MI%&\:=8M3F=W=IZ%(+PSS M/-=#R20A0I(8]8]%>Y_(5FN#;,]C&/O\*:K-OV*&2)]8ZX\JB.L&&=8AMUE> M6Q`+_-3H5L@%79%:U%%D)M%RR)8D)>MCI3G,[D1O!Y$J$7ZA$;/;X50@UL6Z MC'"ILS$Q@4"FRE'J2F*B2S#-L#./('6F$:CE2JJ']V>3!`M9`/&Z`6QU_;NA M38`F-9C@#?&2@=UA+R<K^T]R M+K57MJ<([PH07^DV4'5BL6A3*?`B"GNE@(;]TAOLFW.A-=SZB1?5@N=R^^@> M$*X]FD2^N<"KZD*;(W_WUWWF)E.S?@U.;7L/DN%%%[ENPD3 M?&F'[:)CUUS^Y_JILGLMXT\$_[`YW2_A'5)6NM+A\T?L2QF4LR41PQWOOCY$=*:3M.W8#B2B4P7W+;? MZXYS;^N$MPXUP?@)N\#!J.;71U<61[2F:XX+=VTTO];C!SO24;P>^04W3C0' MU'??6L2.]MRQX^;DV?_(-FP#&/3^\>;J+?`T@Y\0:PX-KW=N?JT9WA!@;=I? M\_?-(/X*?LQV-W)D?!/D;0_O8=F$.OU:>P-@X(\6CGX-7'LM[GR94E^8VR8X M3_R<2//K]`QG[+'/]DZ>NV5@_1T97V"?-'W5C';W[&O*MZ:WOZ0=UB]Y(VJ6 MIY^>;^YZ;96DXGO9CXK'FX,MK+*+X5[=<3%=OO3`AL,,%L]5]C:V@D*::D7"*J^U;)-O!NH$Q__C[MK M:8TCAL%_98X]E$WS(.VID#X"A;"$ONZ!32&7I M$M:6;=DCZ_%)#@C/?W*3>>-*1IJGJ@&=B_#T97Q@M7C%=%GS$B653O/,.8^) MK_%B'((7?-Q###AXGS<<2LJ9>1K5#@S/;,<;,N-:G[Y,@ZC&7=08$]N$)=E& M<[':M8_RHM$&`A'G@'ZN`V9V/BO-F*"@&JMZ7[AN?KZHPN#I)[B=5%G):C@L M:KK2E`;T3GAP2.,^IJ'["`]ALHKINF=R`DZB'A,_JET[0PK28?%CY[HQ9G*4 MHB6>\CH_+O]]6LJCJ,;A^TP8QA)097T;:.!D#9'R8FCIQ6VM^;39%\B$%1"A M8M5?^'DB>6\UH-(')="9_Q'I`+5=N#US)_5RTCA>0L/S>8BK(< M\5)0YDIF71*3XCR`(\3W&J%@!O;K=7@5WYFX!N-45$+11)SCLMMOJ_$MBS3^ M<3$OR,[8JDI<.<(`L;4R?NG-PZJ"8Q,(#N$<;BE-XC7?9UL]?G,'_1#>++B5 MH4:!PP\_<5\2]@%LDR;\5H5JI=J(W_T%A*J/^GT,..F8`)?QL5F'XG>8UT_@ M'X1(L7X[\:,*H4H?>`@(,=U[VDA<%K3V=3W&^)_&-ONG7]&8QXA$,;BED M(6IIJ(`<5=,8-Q\_W##UC@F$T.4DN%[9=,'GWA",^43-W)[7#*;$'X3"71`4 M,X]BX5_6E$K(%<\"R6Y.*%9!12*80</@/TM*I9S M+^QH0\#AY&-MR2%N*8K2#GYUEZ&!AB(7J2RIRQJWD7YLKGXH&D/"SAXK]@2[!J9G(4?#DT2V(Q6Q[F[D]#%ORE MCV<\,G]LY86(F0H,GL/T($0K]P&5/6M'<#*63!7,\5._(8+ALBH9B'_T]']M MGN!Z"6M$!>>Q@<"CD%?45"79A6"`MO/S/`(NSI/LP-3ZS/BPA=8E5;T@\%F] M%V]UR=5)S"T*5^VWL+X!RL%&/@KD/"K7LO*[2_D>0*V MY$BB)WR;(6@%&0([?##,,!L+7X5P#^Q5F=S,E30[VST`D^1FMQ MMQ58&-`/862>KG@F&;LO:C5D"%]GA1.&9200BAQG:)?Z;+HP(#^I"FM3GIR, M4ZE:/1_B"`_"UZOAS$`W?JS=CV^5"6%#P`:HQO#=K\8-,!B*1X,4$!3?63S` M=%M.\2.-'F(;8%NR@\J3O%*PA\RE=I&=['9/KW\!``#__P,`4$L#!!0`!@`( M````(0"?8.RT\0L```)J```-````>&POKI-U4J]JC)@$E_\A1JSF]RI_WO?&W][@[$] MAH'9'WKH-F"8]S[O^\SSV+[Y_M7WM,].M''#8*+W+KNZY@2+<.D&3Q/];X_6 MQ4C7-K$=+&TO#)R)_N9L].]O?_N;FTW\YCF?GATGUH!$L)GHSW&\ONYT-HMG MQ[";51CY=@P?HZ?.9ATY]G*#@WRO8W2[5QW?=@,]H7#M+T2(^';T MLEU?+$)_;^X!U->>:2\RVNQ#B;SO+J)P$Z[B M2R#7"5*(;^2$M^>;#UW__S16?[KIV_*W_WTK=[)V!":8(-ZFI?= M6K+P=4*YDTIP>[,*`R+($-2$VKI^"<(O@87?@3.`>/BSVYO-+]IGVX,C/82W M"+TPTF*P,LC'C@2V[R2_F-F>.X]<_-G*]EWO+3ELX`'F&.GO?!?,A`<["8?S M\IDCFDRF$<+@9.KC$2J3#R+9>+!>)OOG/3)QO`;-O([1'\>+25$OES1>9;\H MZ?`87KFM")_H:3[1+0MR2*_;1;52@YV(V7C6!7YG8W8U.)MD?:MO#:5*QOEB MV6[(L&_)5&4#0^O]\.YLZI3/K$JZ-`V?*P(PX.1JT870K8GOH86O<_C)F0O: M:2S&"BV7]%GH%;GQT?6=C?;@?-%^#'T[0,72HL9^O;\F,\!227,^+9]\YE7# MRW+9W='*<=,6E&-+W?ATLEPUR]+:PM0,YW-`*B]]/Q M3#[2V7@LFZAAP4LRT?<#?$DF:L%_,VDZ36NA*0MD3D^+75PY=R^'X_%XU+L: MC49CL]\S3:;D>>K1;K!T7AU<3$M34QG!`!",^Z/QE0%`NN:(L3HK@CX`&`X& MHT%O;)CP/TNUIT<@6Z<#7;55"0)%5B4(%%F5+=XZ$C)_&BG0QU( M*[S3:.*:MK)!?2K$Q-?#%9JQ[)&T849:S8<`>*1M&B,K(^TUF78YXWD[` M]+P'R8Z^N9\?!@,8)0,S/#M),,U/V%%-3M`(I[O]XC:2)U(#A7;E2E@&PB0; MLZ/:=G*GI10J\\+QO$]8*_^QRLLS=*%N;UY79.<%;(?!K0FXL0/?0JLW?9N4 MXN0#B%\UR*@7BTY3-(8K/[SWW*?`=UD?3 M$S(_1&'L+&*VAX?UV:OP]"OP]%)"(GB.X6]6\`<]">OC&/[0I]EK1-"+4O[@ M7,+\9?H#[E9*G1I,0)VZ#H],!+`:SQ"`$50@P-U5J0[`/54@@%5.A@`M5Y7QE"B%)%S`4&H$T4*<1 M>5Y)X>;8JM8C&"A;_N_:ZG75V$CM52V:@%8V/%D])2M'L`5; M2Y&E-%[/9F>]4^TYC-Q?8)&)U[4MH)GJ1#I>!QF["WKD2V2O'YU76(HFIX1> M5SL"LM5EVB$6Q\BW63.LYT6.]FAL;>_HME*;A>:@8Z]KC6HCS,6U)JB?([`@ MK+05"&^YU,X[6:4B&B6G#B/,;K^_'`X"VU)M;2\;PRE=0%)P8\Y1K28H[\HQ M4%,A'J$0$8S6QH`AS'$=I(QY#R8YRIC#WG!US(6U7IF0CDC)N.A3IG;L/TAE MOB\QM8J`JNX^=E'Y$L7'WS1MWF9SC4I3'8OPI"K#;27\[$+#:T7P5$'%_(QD M#QK`_=UU?)WN+-9Y;Z6Y!&B-V[?!39SP%+C;^-^I=?@U8:&1P'8GL9U-I15` MA8?!X9KY(Q^<0L$HU:5DU[+C=,5[=5,JX\/QH,1VI#GQ7$U=PA#&=*B[<\XE M#^%UA`'AQXU M:HMS`U7`RDH3SIL4R=ZPV(M=N\E=NYGN3 M-+S?)=R?N_M[[4)[O\`Y4QZ*&*[SK>O!#5-P"H3[QA;;#=P78)H<3,\DU='* MZY8!98[2@OY?6UI`(5&4@7L)"2Z85;:E!>P36GV0EM""RUI;TX)BD]+"G9X% M+A/R?%M<,"2EQ>M^(*A[5V-'G=#P1U?[77CKROX@9&$5R45F%' MWE?[@KY*:15VY'T516Z+J[`C4*6ZAR_:TBKLR.<)4S!/4!D+._*Z'PCJ?C>C M\AYO"'I\0J6P';PC.L+EH(B.$BJ%U7@O[PMZ>4*EL!?OWZ:@?R=4"DL!/2*1 M"5^(2Y3;J,]KUQ34[M1>9EF7=QBL,R(PX);(BZT'3]@(\?D<;(,N-C2(0-AM M%*+T["Q>M!G<;R$GQ,<#EE$10O>O:\\.[#B,WC3`5>FW(P.@$#>]_>"*K#1D8 MG9#ADRK.GT3(?`C6V]Q"?"[%TBU"XJ,;O#A+WG-X#>-9'1%*#\XVCNS<__B0 M,@05\X!WZZ.CU9(5%QV`+/_ MY6MQQQ:F]QB?]\/NY9*O!T!12V=E;[WX,?]RHA?O_\+N(`;.E/[J!_=S&#,2 M$[UX_Q%OS091#,L@2#>/"(HB@5-@7_ MJ3@VT:9F66%.B0-))?1O:XX`!P[IAEP&[[3!L M*]`"NW2?)EN'K0/Z%?9(2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B).5Q MVZM=KGJ(Q#X?TSAH>W>&_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6 MF[CMA4HEFY6*]&$8R\L\(3',3;B(L()7$53&`A\!W8A5UJK59B7"-/90C",@ M>WLRH3Y!0TW2V\J(]QB\QDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^8WXT M)`^4AQB6"B;:7M7\O,K6U0K>3!`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX`OWU M)9E;G4ZGT4IEL40-R#[6E_`;U69]>\W!&Y#%-Y;P] M?O/R\1?E>%G$__K#)[_\_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%'1?B0 M1D2B6^0('?`(=#.&<24G(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW5T#Q M*`->G]UW9!V$8J9H"><;8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\6,:[ MBV/'M;U9`E4S"TK']MV0.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^4>@> M11U,2TTRI",GD!:+=FD$?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM`?H6G'X#0[TJ M=?L>FT1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W0_0[ M^`''*]U]EQ+'W:<7@CLT<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC&O]= MV684ZK;E\*YLM[UMV,3*DF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#>6U^A M5^7RQ=?E12F&*JT;$MMKF\X[6MEX3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+:6L\]/[* MGC8;^AQB*X?$:H^/[?"Z'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6TT*= MF5O-B&:*HL,M5UF;V)S+P>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[]5'F M%N.%BW21#/&8I#[2>B_[J&:+T5';:S76&A[R<=+V)G!4ALZ%8JNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V6&"D M,Z7M<:%"#E4H":G?%]`XF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D-9PDU0$- MD*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-=`YMZ;_=0"*%N MJDE:!@SN9/RY[VD&C0+=Y!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$O#U8 M[*IVO5F>[;U%1?3$HLVJ9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+&L-@ MWA`E<)&$]!_8_ZCPF?W@H3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+&R0[: M8-*DK&G3UDE;+=NL+[C3S?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[MM+4 MX-F3*0I#D^P@8QQCOI05/V;QT7UP]`Y\-I@Q)4TPP:&PO=V]R M:W-H965TINI:VT M6NWEV0$3K`)&MM.T?[\S.*$QV7;3/(0P/IPYJJ3C!;]0TWMA;X_]QK*6V(88GD)ARA+GK-; MD>\:UFI#(EE-->A7%>_4D:W)+Z%KJ'S<=5>Y:#J@V/":ZY>>E#A-'M]O6R'I MIH:ZGX,IS8_<_?.,M`[.A3=B`C1"/"+TO,`0/>V=/W_4-^"Z= M@I5T5^L?8O^5\6VEH=LS*`CKBHN76Z9R,!1HW'"&3+FH00!\.PW'R0!#Z'-_ MW?-"5PF9S-U9Y$\"@#L;IO0=1TKBY#NE1?/'@((#E2$)#R1P/9`$,W<:SJ+% M1U@F!Q:X'EE"-YCZ\_\K\4Q5O4FW5-/U2HJ]`X,'NE5'<8R#&'C_[0K8@=@; M!"<$-@84K*"33^M)-%MY3V!_?L"D!@/?KYA@A,F.&.P;Z!C$@#V7BT$PBL&6 MH;KT&#C)',UM=9G!6.I.,)88<.-R,0BVQ(P#F0G8F:-!G95Y^I',"(:9//4[ M6@R\QAF#,=.-5F4G`2LS3/3E-2,X(4`U=#JCV@TFZJ7+;41;:Z]U4A>*1J,4J;&HQ1-9N>J7IS MV5*%)]3%>Q?!8U6!;49J,-"BUXXN0QN3'3'CO;O\B!@$C\6,$J4&L^P;-_?A M,Q)BUOO1,JZ8(\"\W1HFMRQC=:V<7.SP]1X"T1`=3IZ;";X_1O$TC-,^[@T+ M<")T=,L>J-SR5CDU*X'2=R/P2IHSQ=QHT?7OU(W0__[:]L?:1 M7R@5!BC4?&=>A&@VMLVS"ZT(MUA#:U@YL;8B`A[;L\V;EI*\"ZI*VW.=>U[;:QN4 M]MN\``T]]LN0?\6],:U_PU^8;>T+?(_BYI"MJ%.L@)' MQAXE]6LN(0BV9]%)5X&_6R.G)W(MQ3_L]@049"Q MO(54RE@)!X"_1E7(UH",D.?N\U;DXK(S_:6U"!W?!;IQI%PDA90TC>S*!:O^ M4Z3.T2CB]2(^G+Y?]RQOM7`7RP^H!+T*?-Y5/GH4.'3G)]1%WGL46R6GRW5$ M!-EO6W8SH('!/F^(?!W<#2@/258I&=/^HZQ#NJ7(%ZG2:4%".;3*T]Y?+K?V M$Y0WZSD'Q8&W\\YQ%U/.P\"1U93"T2`\`#$&$@RD&F"#R=$IE!([]:$I7V^G MP9@,PL;"Z:$/KW`";.PU#DI0-.=XTYWB.-6DZ1!W^M) M^WFR)'EG0I./%?;\NVY7T(/BJ/=55O@!`Q$&8@PD&$@U8')Z.(I^>MG<;Y=< M!@%/<^$O5V-VE`O%T5Q@(,)`C(%$`6'WM@2AMW(,':6SIN@-SJE$7@AS`93!D)5DWU$'<=K%8K375B&6YAO;KO:UH9A*PO MT)D.BJ-9QT"$@5@!?=D]*T376O+&>JH)3CS*&0U]Z[S]8LH@Y#'$'A5'\S@` M]SO)#U'S1@-G_)+!0(*!5`,FQM:_8DP&86/HZC\HCF9,`:I-0V<]:\$(1\08 M2#"0:L#$%33`+]2KB\*^_.F+;<=]?P[$L^09(:D.C)U M)J>%#WRYJ;I3T!*$. MW`"FT:I97#T(UG3ST9$)F*&[?R_PFXG"5[MC`?G$F!@>Y`;CK[#]_P```/__ M`P!02P,$%``&``@````A`/^LO+S#`@``F@<``!D```!X;"]W;W)K&ULE)5=;YLP%(;O)^T_6+XOWY]12-50=9NT2=.TCVL'3+`* M&-E.T_[['>.4`*VVY"9@\OKE.>^QS?KVN6W0$Q62\2[#KN5@1+N"EZS;9_C7 MSX>;!".I2%>2AG/LJ94(7#H9(9KI?J5;%X>6=LJ8"-H0 M!?RR9KU\=6N+2^Q:(AX/_4W!VQXL=JQAZF4PQ:@M5E_V'1=DUT#=SVY`BE?O M8?#&OF6%X))7R@([VX"^K3FU4QN<-NN2004Z=B1HE>$[=Y7'V-ZLAWQ^,WJ4 MDWLD:W[\)%CYE744PH8VZ0;L.'_4TB^E?@23[3>S'X8&?!>HI!4Y-.H'/WZF M;%\KZ'8(!>FZ5N7+/94%!`HVEA=JIX(W``"_J&5Z94`@Y'FX'EFIZ@S[D17& MCN^"'.VH5`],6V)4'*3B[1\C*+)9"WY$L/(`7/9$KV-W!R$7/N=.3AJF@EM#2IXT7 MI6O["?I0G#3;=S1S1?Z.PADE-O"-D)#;]9!Z4H8#C$9(UUE"&HWINZXLGSR8 M$4`T4X)_QZ/%$./TS5XP5C9$N#6:U(3G)DF4NG-%/E,XL>?YX:B8L4&)E[-I M\9(M&7T-F]'$ABWV@OC8O,MD:C2%+XBCV MXSEZ/A,X:9">0:?&:PNGT1%7IF2G-9ISCT`HQ8367&ZR+%OWX^ M7-U@I`VI,U+)FJ7XE6E\N_[X8760ZDF7C!D$#K5.<6E,L_1]34LFB/9DPVJ8 MR:42Q,"C*GS=*$:R=I&H_"@(YKX@O,;.8:DN\9!YSBF[EW0O6&V M<*JDEKGQP,YWH.XKMPN4VPOUZU^?G-V4$/[I$N MY>&SXME77C-(-I3)%F`GY9.5/F9V"!;[9ZL?V@)\5RAC.=E7YH<\?&&\*`U4 M>P8!V;B6V>L]TQ02"C9>-+-.5%8``+](<'LR("'DI?T_\,R4*8[GWBP)XA#D M:,>T>>#6$B.ZUT:*/TX4'JV<270TB8'^.!]=:N([H#:^>V+(>J7D`<&9@2UU M0^P)#)=@W`7F,/I0_QSPB!#QG_G?0.Q8HMBBV"9=NX`?`^L4WV/5?,KGO)B`0R-"2QV8KA M,+U-9!>E^'H`$`:+WM]!.HT[.I9Z.Q@8$8#-D.#MG:T8"`<[1TD\V=EIX!2> MTI.AXOA-99O)_(;>,&&ZE/> M1]3S]U!;\91Z/L;8.,V1.O2BFV!XA9^N)F_'=K(@C(:2$6OR'E8KGK(F$U:G MZ3(\GH2F:@W.)AV1ZY>NGPBF"K9E5:41E7O;"R,H63_:M^F[R+Z:D_$-M.^V MV?G]!+3/AA3L&U$%KS6J6`Z64'\HL'(-V#T8V;1=;"<--,[VMH3O)(.7*/!` MG$MIN@?;6/HO[_HO````__\#`%!+`P04``8`"````"$`/M(H-^@$``#5$0`` M&0```'AL+W=O]@JE?:F*0_C-WYG_)GU M]X^JM-YITQ:LWMCN;&Y;M,[9H:A/&_NO']&W1]MJNZP^9"6KZ<;^25O[^_;7 M7]97UKRV9TH["Q3J=F.?N^Y"'*?-S[3*VAF[T!K>'%E391T\-B>GO30T._2- MJM+QYO.54V5%;0L%TMRCP8['(JQ%;:O*27JJ69.]E.#[PUUFN=3N'Y!\5>0-:]FQFX&< M(SJ*/3\Y3PXH;=>'`ASPM%L-/6[L9Y>DKF<[VW6?H+\+>FV5_ZWVS*YQ4QQ^ M*VH*V88Z\0J\,/;*0],#1]#80:VCO@)_--:!'K.WLON371-:G,X=E-L'1]P8 M.?P,:9M#1D%FYOE<*6U8]8]XZ0X2HK$W-(;/H?%B-?,?Y@OW"R++000^!Q%W]NC[R]7CP_T]>1A$ MX//+(HY(29_A,.NR[;IA5PN&+9AO+QF?!"YYLBV96I&0,=G_E6M(,A=YYBH; M&^8;I+.%`?*^]7QW[;Q#4?,A9H=CC(A`1O`*Z[>DY)>O, M@S(!(BLDO[<*`_NC\\6/S'(.DD M0D*Q(*O^+-%W*$$D55MI_OEQ#VUE=\QPWD[W/!!E.@]$'`WZO4F0Y6VEWR,2 MH5:Q((OEN%`DB*1J*\T@[,_(X!-/^MWEY0JZ54$\.).-I?-ZK^2RU]"3.:"5 MNAIZ[DI/2R`;*NDTP5SJ>,@@$R1GGFBA%A^5@V_%0^D5&ZO)E335Y/ M*C]9F1/PEM0?[`+9FEQ_X"0M%R"7BQA9%4A9<((A2D$A1GN,(HQBC!*,4@WI MMOG)2K$]L;ZJ_L0Y#,X3%H4`HQ"C/4811C%&"4;\_G;KA/`G M[F/BME#1YD0#6I:ME;,W?M>")6.['O%X$7SNUVZ#[_@%D1LVN4?@7#K!%P0. M?*K7?CN2:W8)W#.P%KQBL!N/,$?".Q2F*<^ M@;T*\_"1P%:!>?Q(8#/`?.>3W91.X)-@BH<^@0,7U@E7!$XD$_R!P-Z,>>03 MV*&!.V/5X%)]R4[T]ZPY%75KE?0(`V'>;[&-N):+AVZ8ZB^L@VMU/^O/\/,) MA3O=G"^R1\8Z^<"_8/Q!9OLO````__\#`%!+`P04``8`"````"$`B9BI[90$ M``#M$0``&0```'AL+W=O M?3QCO\:[^OJ>I=:;*,I$YFN;35S;$GDL]TE^7-O__/WRY+V=U+:R>/GMF,LBVJ4P[WUL5G6!?B3B6I+/ M5GF2U]^*9/]'D@NH-O1)=6`GY:N2?MNK$`QV!J-?Z@[\65A[<8@N:?67O/XN MDN.I@G;[,",UL>7^@XLRAHI"FHGGJTRQ3`$`7JTL44L#*A*]U^_79%^=UO8T MF/AS=\I`;NU$6;TD*J5MQ9>RDMF_*&)-*DSB-4G@O4G"@LG,\^=/CV29-EG@ MOY_$>_*9']R?D(/%J6O-HRK:K`IYM6`!P_3+3:+30=TJKBCR% M_7";6@U:V]"3KEZ,&9!;U.#J5_4*S0`G`0T)\CZ.I`8!.D'R_*";:`PM7,<;G%LHZO]ZV`SK(YQ&=![EOX1G9-G4J+OM1%%/ M$3(SPFE$YU+&2[CNU`EM&M+WN\TW=R1KO9R(@L$!WXJZ/=D-@XB.J(QW/"+: MM(88&`MIJWX^0EUIR$R(YR1B,;E_2_SKT>9)Y)ILHVH,UGC>=@\ M[[<&IQ&=TC@*;B\X[[,CP/RMTXCZOQX.(IQ&=![#\\=UTT-;O]W-1D2YS-.` M4XW.!2N8KK([=5)JHXN#C0GW;32P6QNS$W4;DT80$6_=>!/,1'$4H4C3THKE M1=VH&?P:[J+=;?_9J^_KW0.X;)^CH_@>%<PN2_/?SKE[OWZO*E?BW+9D`63O7]\+5I MSLOQN-Z^EL=-/:K.Y8E:GJO+<=/0GY>7<7V^E)M=JW0\C/W)9#8^;O:GH;2P MO-QBHWI^WF_+N-J^'8.VXN7][.OVZKXYE, M/.T/^^9[:W0X.&Z7Q#N3W-V^ZV6K;[1]@_KC?7JJZ>FY&9&XL.XH^ M1^-H3)8>[G9[\D"$?7`IG^^'C]ZR"*;#\<-=&Z"_]^5[;?Q_4+]6[]EEO_OW M_E12M"E/(@-/5?5%B!8[@4AY#-IIFX'?+X-=^;QY.S1_5.]YN7]Y;2C=(7DD M'%ONOL=EO:6(DIF1'PI+V^I`':!_!\>]&!H4DCIS>Z.U-&Z/ESO9XK17K^5*]I MMK:]IJ?NM3_RII,V1U?"&RD]>M[4T;$<'>U@BS?-YN'N4KT/:`93^NOS1JP' MWI*,Z5$F?[H;=S\:=C3>A)%'8>5^2$[0@*IIKGQ]\.;SN_%7&M];);-RR'") MM980@UF8C6V0V""U06:#W`:%`<84A"X2-,3_#Y$05D0DM`\K#?K0^);;6D*K MQ#9(;)#:(+-!;H/"`,QMFJ"FV^[E1>=9"-\/:6I>R;.2:5>W-HUK(#&0!$@* M)`.2`RE,PORD3IM^RH$^$HO*=9>%'DT.DKOBLQ3RHR[M:R`QD`1("B0#D@,I M3,)\IDZ;/E]W5`BWCNIQN))D2A/&<'UAC=Y.2*O%0!(@*9`,2`ZD,`ESE-9K MT]&;DROTN,^2F)D$$@-)@*1`,B`YD,(DS$':5TP'KV=2"'.O))G2Y#`R&5F9 M[(2Z3`))@*1`,B`YD,(DS%%1OL)^=,,T%7K<9TG,3`*)@21`4B`9D!Q(81+F M(&VRIH/7,RF$N5>2F%Y)$O3K;:P(F[>^Q[.==$(ZVRD8RCH98]CXUO:5=T+: M4&$:8KY[5`6;SAOSM'G=;[^L*AJ>U&U'4`*J*E2M(8SPH+1V[X=F5!0RPZ*1 MWQ8H_L0+K9#T`MJ55*,^NIE&G9DI-Y/W`MI,H9$L^27DH[D:*M3*%I7^_DB`JFR`>$J$H^Y;TL9VA; MUMU;>1+Y-#SZ16XQX7ZMM50?HU@CTN\5?1@SUBA M:22+?\\+[.@DO8A.68J&LEY*O$7,HRB:\0SFO82V4S`[/#BB-K*#0V^PY-_M M"XZLKUB<5,G%QYJU,JX])67&2:*`-GHCP-9`2I0B26D74VV+#:2YM?1DO:)I MWI+*>REMOOC(/`^JJ,/^UZ#*6HX%5:*0N;BPYN&:-*Q%+E;(IZ*B#RI.8&5> M["1?'\)H/@VMN*=H.[O)=JZD0F5[/O?LU!3,-@^GJ/I^',X_J_./-D4Z@^EV M15DZTJ_HG*X\LYJ4;V*(8D0)HA11ABA'5##$W18UH.5VL!"'6>I#A$Q6B%PPMOJ'P]66HR[\WJ M4V4>4*P4C:HI090BRA#EB`J&N*NB0#1<=91[YLB6Y23S3Z(I7RFL`Z>UUTGU MV064H%2**$.4(RH88BZ+JL1TV:A\KWO?*O(R3R$C;VM$,:($48HH0Y0C*ACB MKCHJVEG0#N2?/%7T53UKK&D*\3?9A7TFT4MUF4>4($H198AR1`5#/!PT2#^7 M>:%H95XBEGE`L0\H090BRA#EB`J&N*NN2G3:?I]PO=(9<]S'4E2A/O=K3:B$ MZK?YA54HQUJJVP<336ACZ?6B_L6`^R`*-&-MNGVBRLK.7*9$&4T9#/LR;HTH M1I0@2A%EB')$!4/<55$0V:[>EBY92C%?)3+3I<@'Z;+U$E$`B*C1PTA7_P[" M?7#53K?LFC[62PJQ=$DI`\4HE2!*$66(I?@WC_/UO@^%C@*&3D98TH1I0@2A%EB')$!4/<55%F MV#-K=M.PE`4*FUD2F>E2Y(-TV7H)[1N.F=6_!#$?Z.0,?;C%A5:1[UL*F>E" M%"-*$*6(,D0YHH(A[JJC8O%#<4CPDP5+@`6+0B'-'6,UL][(U[U45[`@2A"E MB#)$.:*"(1X-43[8@_>FQ,NZPQR[@40L\8!BE$H0I8@R1#FB@B'NJJM@N:JUV2.*$26(4D09HAQ1P1!W5=0B1E:O[QITL44XPU(IT;2]\J*^ZP** ME:(AE2!*$66(2G7Y>%0#[;5F[@<$X@#R0[+ MFSNKP*>K.[[8_J`EH);`V3+5UWUL'9^L44WLL.:3#I5?KI89M;1E(5A;4$M[ MG&ZW!!/J0?L!`5K$5:3VD-%N\>AWZ`3&T0-O3BWM5P'0H1[0N[M+)Z*6]ANW MK>-3W^B-T*'C4]_HY0A;Z/[4HS-JI."27XDP.^RL1,H<_'&Z?*3A@C^\HJPX M>;BD#\P.>8JA,X0406<`*7ZN\!4B>JX8T1>9I?C>@C]-WU>6XH,*MM"!.^FX M_*83=-)QM<3>E'1FX6E;1+O#TG M_VC4<>I3U="E-UKCZ-(3W7(LZ;[11&SYSU75Z#_HI\?=O,9C,SCKKS_*B_8]KYNBNFYT,IOK6G[-JD-Q M/6WTO[Z%7U:ZUK3I]9!>JFN^T7_FC?YU^^LOZ[>J?FG.>=YJH'!M-OJY;6^> M8339.2_39E;=\BO<.59UF;;P9WTRFEN=IX?.J;P8YGR^-,JTN.I,P:L?T:B. MQR++_2I[+?-KRT3J_)*V,/[F7-P:KE9FC\B5:?WR>ON25>4-))Z+2]'^[$1U MKWN#R1?%EE=-=6QG8&83<#?]3:(3^FKY?VS^HMSHO3N87IMB$B&IAW^.GG3089!9F9:5.E MK+K``.!?K2QH:4!&TA_=]:TXM.>-;BYT[3EOVK"@4KJ6O39M5?[#;I)>@CF; MO3-<>^?%WIE9INVLNH?>&>VR=X1K M[T@^/%BGUX`K'^S,7-G$7M*([SP`P[#L;4F$K8W(*[^"H(5!"J(%)!K()$`%+8L,3%L*(!0M&"-U1JG'*IGQPS(^),(N(C$B`2(A(A$B.2B$0*$%XR M8H#W9Y(:RU$Q8L'B$&9RI1P\L4^HG MQ\R(.).(^(@$B(2(1(C$B"0BD0*$EZP8X/V9I,9R5(R(43&R&/=;OR?2NC6) M/-O!8,1G.T1"T6`CE(VIO+[BP8@+):*0%#N!GE8,7EBG[;G(7G85E"<,>R(I M"^@J^EZ#BLA)Z72A717VWQZ):>'([!H4CC!D0GD(FYPKQ[7G5F..?([` M?W0T47$P>UFA.B3'S(A4;MB*.[VG%OQ;6=Q\JLQ*+]']KS+#B&N MY1!E&PU&&QY5B)6BT:K[R)I2BD<;KI1(2G)^:$^EY,=/)0=R^^1+;V]'+0],4>PXC&&7`LJ4:A=91U%T_+*8H]'*RZ?_)>\ MG%7:R"E9)7`>\J&DLF80GLO'L"-]?R@7H/*AO>=68V[\'EG@/^8&;W%,WG*Z M,K57"\M4EGZ(M:.'M&-NQ;27Q)V;2O^92-IR.FF[^'XZOU6W]]H&J..A;V`] MIY1/AJ2^`2&?(!1@%&(4811CE$A(#ILVD6K8]@/-,&'=IQ2JV)"R3]3>2HC> MQRC`*,0HPBC&*)&0'"KM&850)SI`<2I9ARG%QY!E#:ME#V>M=',1D(]1@%&( M4811C!$]W1V?R.)CI[7LR*W,ZU.^SR^71LNJ5WH2"[G?K@?,CHEWC@>?1[#F M5;[RX*MB@A-P@"*:N@,ND/.I.RX_BU:>`ONO%[#$*G=@Z_3HQHC5X&#[R9S@ M.WK@/<5-#XZCL,YNX<'Y#>9/EO<$J<4W=I8'AQ\3W/;@K&""+SWXQ,8\H=GH M>G,E9FB6(1M3,4#K"]F8N@.]$/A,Q0'-#?A,W8$.`7RF0H$W/OA,W=FYWFYR MT'O7VT_>\%T//OMP^#Z9P].GX@]=CWX"89?(]>##;X*#%/T`@CO&D$OXD>&6 MGO+?T_I47!OMDA^A].?=/E:SGRG8'VV_CS]7+?S,T&WI9_@Y*8#4:75X.+U>MR^[!^?;H;_.LW_#7SW_]RZ>?V]VW_?-J=;B@'E[W=X/GP^'M=CC<+Y]7F\7^J66Q^UNLSC0/W=/P_W;;K5X:)TV+\/QU=5LN%FL7P>AA]O=.7UL'Q_7RU6S M77[?K%X/H9/=ZF5QH./?/Z_?]JFWS?*<[C:+W;?O;[\LMYLWZN+K^F5]^*/M M='"Q6=ZZI]?M;O'UA>+^?31=+%/?[3^@^\UZN=ONMX^'2^IN&`X48[X9W@RI MI\^?'M84@4_[Q6[U>#?X,KIU\^O!\/.G-D'_7J]^[K/_O]@_;W^:W?KA;^O7 M%66;ZN0K\'6[_>9-W8-'Y#P$;]U6X!^[BX?5X^+[R^&?VY]VM7YZ/E"Y*XK( M!W;[\$>SVB\IH]3-Y;CR/2VW+W0`]-^+S=H/#'[>8_P6@4NPJ=C&,G]+?0R0G'272DO]%Q/+^\ MKJKI['I./W_"CO>3\T MCP[T-SK,+^>CJYO).Q'1C&Q_B/Y^Z`!OHA_]37ZG4'3E(J\?UOX23^ZI=[24`K).0ZN/QM;-*A\)U]\+W<#BH*&S9XFQ(_/%/RG MX0\:Q,MH+Y-)(H"30$A@)K`0N`RQLFH8R[`FM2.6U)-7;.]T-:!Z>J'>T M:9>RMIPUD`:(`J*!&"`6B,L)BY<.6L8[JB[]/#T=LO>C24)V)V(.1N.;8_EK M(`T0!40#,4`L$)<3%C,==![SZ4"]<1MH&H_W@4QIXG2ACZ[$*#X:);<&B`*B M@1@@%HC+"0N4%NP\T+":G5%<[\=C#B2O))`&B`*B@1@@%HC+"0N03C!Y@*25Q)( M`T0!T4`,$`O$Y80%2"=;&>!LT@;XP7.O[XA'',B4EL"LRO*LMQJTCCSHB.GFEB&I$#2*%2",RB"PBQQ`/U>N.;$2? MGKJCH%+H=)."N8](3-Z)F+R=57)L$"E$&I%!9!$YAGC(7G-D(9^]'(^"6&'1 M!Y1/XVB5H0:10J01&406D6.(A^KUA@AU7%W2B>J#LWD4A`L+/6H9/I^GLO!' MJZ[P@%3LGM:&9*41&406D6.(9\,K$9&-\Z9UD#`L^ES5!!TY`M0@4H@T(H/( M(G(,\5"]%LE"?6=:!^7"XHMBAI^3*UG=HU6J6T.=^(6?UH.$%"*-R""RB!Q# M/&2O3K*0SY_60=90S^F([_T%/`61S>$:48-((=*(#"*+R#'$0_7Z1(0ZN?:[ M*A^>UT'IL-BC^.'S>B8K?[1*26M&@!0BC<@@LH@<0SP=7LV(=)PWKX,,8M'G MRBC.:T#-")!"I!$91!:18XB'ZC6+"'5.NV0?+WP0/RSTHQ[*!=I<%OYHU14> MD!H!TH@,(HO(,<2R,>ZKTUI'KM,BRJ<\H@:10J01&406D6.(ARITFE_=>IW) MQRCA(A+*_%H4OK,Z%AZ10J01&406D6.(9Z.OA!NCA(N(%1Y478-6"I%&9!!9 M1(XA'JI72]F,/WTF'P=ME4_KB(1`%]N@=6?553?JM.Q,CE8:D4%D$3F&>,A] M==H8=5I$K+JHT]!*(=*(#"*+R#'$0_5J*:MN_VD=9!.543DDA"S27CFD( MDHNE(:)LXY_&2[LO%^Z:MK>S(IHPP3\6.SBJLTIUU=B725;3X[641>28(YL6 M_AY/K^A;1Z[H(O*:*AO[HCAULLH2DA"[]AW+P9&L>-K$=9).5EWW)J&3W=MD MQ;L7:MPEJ[9[GDFO\_J,HXEW%)D,R)_&LDQ*@9@S5U_NI#JP>D*R`^\"9BT:VC(XG< M=*1-1!,Z3W7IFH@55G56R5%C7Z:SROL2L]IV5JDOQ_KBZ?*"\']-E^]#C*Z( MLE7*KT7>*L]-0/YQ/1Z>YMLN+=BY7!L>YY!DO* MMAMPOVW?*.CBZ2Y;Z">H00.8K4O*QBK:VC8RYE$2E$&I%!9!$YAGC(?:6LG_PR^H!HK>^J"ZB)CIF5 M0J01&406D6.(A^HUYOG5#8HTERF3@/@5ZD2\F7A9SIUG?&=M"*+/J`V-P%U$P`*40:D4%D$3F&>*@%/5K1&O7!&T@35*<1 M\>O3":B*X,@F-2#5]94&AT9D$%E$CB&6BVE?==HZ\K->1'G9$36(%"*-R""R MB!Q#/%0O^<0([U%V_W2.6,TB$F47FK#NK%)!&T0*D49D$%E$CB&>BY),/.OA M+-2&?I&CA+"R`VK02B'2B`PBB\@QQ$/U^BDK^^G5S-=05C<@_PN=`)L*E5Y' M1[+JJGMT3$BAE49D$%E$CB$>08XJ$* M'=9[MW&*$BTBG^>L\/*BI[-*56X0*40:D4%D$3F&>#;Z2K0I2K2(6.Ɍ: MM%*(-"*#R")R#/%0/R31IBC1(A+36ER9UIU55]VCMDM(H95&9!!91(XA'K(7 M3-E*=K9$FP:EE4NTB+)2UH@:1`J11F00642.(1YJ0:)=W_1Y'&"**BTB,:_% M/D+=6:4R-X@4(HW((+*('$,L'55?E=8ZU8F3>$3^^B=;R\4N2IT'[Y53GSE>!EGTXB).)4?RSZR$YM?%OBJA'HX(J M/.OQJ0I58$1\'%5B1M?),<]1Z(N/HTI,/Y4<62:GD*-S^C+O]<5SU%JE=MF4X\/:UGWEH,[(#$M!9GW3HZYM,:D4*D$1E$%I%C MB(?<5_;-4/9%E)6R1M0@4H@T(H/((G(,\5`+ZJW?Z7J&08XKGHJ])FJ-(B8F4/5AEJT$HA MTH@,(HO(,<1#%2JMOSZ?H8*+2%1>7*K6G557^2CJ\@D/2*.C0601.898.N9] M%5SKR$]T$65EKA$UB!0BC<@@LH@<0SS4@H+KM]3/4<)%)"HO-A;JSNI8>40* MD49D$%E$CB&>CKX2;HX2+B)6>91P:*40:40&D47D&.*A"@GGYWR_U_+G*.\B M$I67>S:=55?YJ`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`&;M6>ZDIQEMB@(J>A[R]HP41)',)*C<&0:2IB?BOC0\%+XT`4 MSYF!_'4F*GU"*^(Q<`53]X?J(I9%!1`[D0OS9$&)5\2KK_M2*K;+0?=C,&/Q M"=O>].`+$2NI96HF`$==HGW-5_2*`M)FG0A0@&7W%$\CL@U6-\&(;`UH"+LT5Z/(C%91,+9 M9+[TIP&X>SNNS9U`2.+%!VUD\=\H=/1#5UN-: M9+)\L4M.1<4XJ#[X/5>L1UH[V8;HL$)8F_7U\T-G2]64L;9`-5OD\^%*+KI4 MHP5B7)>UMO35++L4KZM!YRYN;0'XEIK%L!H(GS[W]3I!X1;E#: MM]F"`7-7W^4+^LXFQ^BC"^JAT2:N30/Z\#T_US>Y]F)YP#T8PG9HK,V. MWH88?VZ?K;9N=]/F">S.BNWY=Z;VHM1>SE/`]&WQE=N^[L;("KH&-J@TL#7M MWPR^DCAL"'\".:=2FM,-,-/FNVOS#P``__\#`%!+`P04``8`"````"$`'MK" MS+L"``"C!P``&````'AL+W=O#.PENVC9:-,H;:16JJI>GKW&@!6,D>W-)G_?,68)E#39]@7P,'/. MG)EAV%P]R@H]<&V$JE,<6`4)M4EQ:VR2$&%9R24V@&E[#FUQI22T<=4%,HSG-VB!9D3@, MET1246./D.AS,%2>"\9O%#M(7EL/HGE%+>1O2M&8$YIDY\!)JN\/S053L@&( MO:B$?6I!,9(LN2MJI>F^`MV/T9RR$W9[F,!+P;0R*KN M=YDS03"91-^V'?BJ4<9S>JCL-W7\Q$516FCW`A0Y84GV=,,-@XH"3!`O'!)3 M%20`5R2%&PVH"'UL[T>1V1*>UL%JL9@O5Y<`L^?&W@J'B1$[&*ODK\ZKP_(H M<8<"]PYEM@P6E^$L`M(W0(C/J!5X0RW=;K0Z(I@:H#0-=3,8)0#\LB*0XGQW MSCG%,-60JX$V/&RC,-J0!R@=ZWRNO0]#Y.?"/0^;9M'>B!JJ,?/2.#Z^WI171Q4'_R>*S8A[9RB M=DR'582P(>OK5,ZYI>K+V%F@F@/ROU1R.:8Z6Z"+&[-VEJF:RRG%;!:[C^J- M(KK`,4=G@6X-E,U>GA&WIP%49Q-3!K;L8=D!O[5?Q+G;Q?]KGRL/UC50**PXI2%W=@^EO`SY+`'P@!&(U?* MG@[`3/K?Z_8W````__\#`%!+`P04``8`"````"$`I#')5K@%``!4%@``&``` M`'AL+W=O@&UN;B4] MFM#JW9%VI-5J+\\T(0F:$"*@IV?^?LN4$[M,7\A+=S"'\JG;,=3JTX_FZ'VO MNKYN3VN?+4/?JTYENZU/^[7_S]^/B\SW^J$X;8MC>ZK6_L^J]S_=__K+ZJ7M MOO6'JAH\L'#JU_YA&,YW0="7AZHI^F5[KDYP9]=V33'`9;88 M\#!,@J:H3SY:N.OFV&AWN[JL'MKRN:E.`QKIJF,Q`/_^4)_[B[6FG&.N*;IO MS^=%V39G,/%4'^OAYVC4]YKR[LO^U';%TQ'\_L&BHKS8'B\FYINZ[-J^W0U+ M,!<@T:G/,I`!6+I?;6OP0(7=ZZK=VO_,[G+!_>!^-0;HW[IZZ:W?7G]H7W[K MZNT?]:F":$.>5`:>VO:;@G[9JB5X.)@\_3AFX,_.VU:[XODX_-6^_%[5^\,` MZ8[!(^78W?;G0]67$%$PL^2QLE2V1R``?[VF5J4!$2E^C/]?ZNUP6/LB6<9I M*!C`O:>J'QYK9=+WRN=^:)O_$,2T*33"M1$![/5]/M=(@(1&_QZ*H;A?=>V+ M!T4#6_;G0I4@NP/#%\>0QM75MSP%%Y61S\K*VH=J!R=Z2,_W^U2L@N\0T5)# M-E,(HXC\@E")`'97BN"W3?'UF%^8*+!BHG*@J&UP`6Q?J7%GWRDBCJX0P@0" M-)^)`J_]R-HX-6:1&T*P8!39W%H@&X.5^1LK,!28O7%\]0>I%'9(`3I"9%&3CIS^W[,.#/W"3U)Z;V?3`6FM++0H840 M32O)>.3PSFT`AU:(3%P),08U;0?N?68CVJ'FM-A&8ZP*URO(-@GA=+AZ0[DH MK;22^`$75%9;$3+C)"H"0XRNKDQP5\!S@L@DRZ*WR-TDV`SE%^3F*M#9Y.Q` MC!TH:X5&1DGH_,B@X)+(F&[6D4$,1F;!,\G=&LL9@:0LBDWO4G9*5>>S0PVV MV?$).\1H=HQ'/#5[CP[DC$"2-$E,(5)VCI)_4%4HQX2=J0@=.\1S&I?5O0I>3A-(0V8L'2F,DWY(O=I/HC MVE&)20QM75_$PMI9YY<`X#1_*[V.\G^0WJGD9\9GG5Y;TQ<\9B)ED^HC&,&@ M!J3I;YKAF[2?H7!#<1OA<$]RC;&%`Y\:5\CF_"9Y']%.XAS/-QJCBS_AF0/( M*8#).+)DF9*[2>_Y*WKOM-U&8S0YP;Y)ZC<-NJ(4W# M8UEIS(5;!N]8UV-04*35]+I1.7C<98-66OT,V5 M\EJ;SY,LCGI-0N1*EL;8)&R5EW`.F)."(0\TK[.>K^OCCQJ:I+XZ^F0S4["YGU9J?9(.05-HZ*SPP2"C%)G*OFW!9K M)F+)I%MA.<&\ETI'T&>RG`J[>Z1LN"W:C(5"2N'$-R>8A>`)>&+TE]:<(^PS MB:)4DW":#722$8-"D'$&[Q=.O^;!^,FXT M!GDRR>,XM=[ML1HI)LG"-(U-_U"BSGDP+Z`"SP7[Q)2.LFXTQA(6>X62N$GX M83SG?JNQT.0!TZE!.)C(0I&$3L+5E$^9082`PF3&`V2'0SP<\=J!R;# M90JJUN%4$"^&]CR.UI[:`:9YX\\#3&\KF/&$2P#OVG:X7*AQUW4>?/\_```` M__\#`%!+`P04``8`"````"$`.4\DQ@4)```O+```&0```'AL+W=O3B6#\.WJGI?CD;EYBT_K,N;XCT_4LM+<3JL*_KS]#HJWT_Y>EMW M.NQ'\7@\'QW6N^/0>EB>+O%1O+SL-GE:;#X.^;&R3D[Y?EW1^,NWW7O9>#ML M+G%W6)^^?;S_MBD.[^3B>;??53]KI\/!8;/4K\?BM'[>D^X?T72]:7S7?X#[ MPVYS*LKBI;HA=R,[4-2\&"U&Y.GQ?KLC!2;L@U/^\C!\BI9Z,A^.'N_K`/UG MEW^6WO\'Y5OQ*4^[[1^[8T[1ICR9##P7Q3=CJK<&4><1]!9U!OYY&FSSE_7' MOOI7\:GRW>M;1>F>D2(C;+G]F>;EAB)*;F[BF?&T*?8T`/IW<-B9J4$16?^H M?S]WV^J-_C>YN9O-IO.[6W+SG)>5V!F?P\'FHZR*PW^=E?-EO<3."_TZ+Y/Y MS>QV/(GHHI].MZ3F^F\>SVKK[\F8XTN%K]O.UX MZ25O74_Z_=HE:>'5EURT'?_BDB.;L7H"I.MJ_7A_*CX'M*HH)>7[VJS1:$G> MFLQ;N>U<^-54H#E@G#P9+P]#&A4EN:3Y^_TQCL;WH^\TYS;.9H4V$;=(&@LS MP8S;-`19"$0(9`A4"+0'1A2$-A(T[?X/D3!>3"0:#:L&>*$)9#<6398;%HHONS^)=_DV1@_#&F%G,FSLZEWG#J-"9`42`9$`)%`%!#M M$Z:3!NWKM!/]QFQ/YR6;?K0XR.Z,9FL4+]JT)T!2(!D0`40"44"T3YAF&K2O M^;Q08UP+;>;ARI(I+1A/>KAH6Z.F6PHD`R*`2"`*B/8)$TI;KR_TXN2:?ERS M)7XF@:1`,B`"B`2B@&B?,(%TA_`%GL^D,>:J+)G2XO`R&0?[4&O49A)(!D0` MD4`4$.T3)M24E'`_NF"9FGY=0;-F$6#NC#*!K5NIMR-Z@P:-[I!MM[V MRXO(U!W],[MZVVV^K0I:FF33,R$FI,/56<9)$!*+6$@L8B%QB*J`=@>(X@D7 ME-5C?!A.XO8^)AKDQ\7ZFG=6REEY2+..?!:84J0_$CWBJ?9OU=L:AN[%3;Q7 MD4/>G;=!46N5.C3MRK(,D<".TJ')M/6E$&G6D4LUY4@H=6&2<'G*;47#1%L4 MTVIJDQE'03*3R%GY<;!H[G>DTTTX"UQ'NAEY[H/)+]"]=.B\>]5TY.Z#0>C& MJAX]CZDI=\*8TD'Q2T&U)1,+JD5SFMR>ZCF/31*YCGY0+8KIEM9V[`FJLZ+[ M0FL51Q!4<"_=%<^[5XT5=P]!]=WSH)K2ZM=!_;-X_]7FY*]/6Y^QJ%KD;44) M-9L]S$,IH@R10"01*42:(2[;%%R>[+_8?VQY1NZZ_<>BJ5G2W='W-IPUK573 M,8T`98@$(HE((=(,<0*GKZ%EEB`0BB4@AT@QQ MJ:8("Z7&MV:K^.KS#5O.,>T6!37U79CYUJK+/*`L`B00240*D6:(A\/496$X M9A?4UI$MZ)AZB[R<)L[*0RFB#)%`)!$I1)HA)M7<&D.I\>R*Q->.>,'E4)#X M19#XSJI-/*(,D4`D$2E$FB$>#5.P79/XV%9Z?N(=\K*<($H198@$(HE((=(, M<:FF'O2DGM_08U<]>ANZ0_RA1QP\RTPZJRZ[UA=U;%"&5@*11*00:8:X9%.N M>9(OWM!C6^>Q[+K2SRNGG967\!11AD@@DH@4(LT0EVKJEU#JF`+_Q>T\=G60 MGW>+^*H.#\V)ZTA639)31!DB@4@B4H@T0SP8IHX*@W')=F[>I@2'2(>\FBQ! ME"+*$`E$$I%"I!GB4DVQ%$B=W)EW45_.O"V[V)QWE1A-_:Z$"Y]R)'%KU64> M4(96`I%$I!!IAG@XKBWAS"$BS#S4:XFS8BL>K#*T$H@D(H5(,\2EFLHHR'QT MS8JW%1;+>UMT^7D/3]%Q:]7E'5"&5@*11*00:89X,*XMX"B5D'HP9SGJ' M@LP'CTF2SJJ)4(HH0R00240*D6:(A^/:ZFZ"U9U#+/-0\*5HE2$2B"0BA4@S MQ*7V5'=79A[K.WJ$:R9#D/GP\5YGU66^[=B@#*T$(HE((=(,\7!<6]]-L+YS MB&7>6GDH1:L,D4`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`JS)K MX&MUM.IK1;)]ZU2>+6S)(7L[-W_0 M6T**XZF!80#PUR@+-C4@(]E'^WDK]LUI M;;J+R?QIZMI@;KR0NHD*)FD:^5O=T/)O;F1W4ES$Z43@4X@\[CSKG.&S<[8G MR_E\ME@^/2X"EFT8\-F)+"?.)%:&L:9$VV657T9L!"@337UXPM.]OW3$,4DROTY?VLNE!6)O+,5-8F#`8* M5\.4?-_8WGQEO<,TRCN;[8B-:K$3%FS.,-E`!Z$.(AW$.DATD$K`@B3TF8"I M]#]D@JFP3(@8M@(,J7&TL(6%<`ET$.H@TD&L@T0'J024L%TG�N\X0M_/LA,S]8)&!W M)V9NY'A]^7>(!(B$B$2(Q(@DB*0R46*&0!BOFXY60&"T<*?:'- MXMY(N`6(A(A$B,2()(BD,E$"7:B!\MWL@>(R/S5F3N1*(A(@$B(2(1(CDB"2 MRD0)$`Z*QRO)C-6H.)G!XI`J^:15LC?J*XE(B$B$2(Q(@D@J$R50UBVB<^F! M2C(_-69.Y$HB$B`2(A(A$B.2()+*1`D0#ELYP/MKDAFK47$B1\4)[-U]V3JB MK%O'5JL=]D;"+4)"<6\C31M'.\:2WD@(I;*0$KL-!XP?H\,::]UO<<0Z3 M=G!T4'JXE0OE':P\3Y6/L'SER,,KGBJ?*O+JY&*=SD]EDK=(<,2+ M>FUMCAPX6?M08<*H8]EU5C`DX1ATR(632G+4EDPX6`G'"&O%@Y6LY:J#2`8K MH94J6FJ.6'NDYPC>PF"TCZ\_WF(IZ>)(F7C.5%L7.[NSDM/%D0OGGI0N-/%Z M*Q%BA+7B#FE:6KN2#%9"*U6TU'2QSNJ_IHMW9TJZ.)K+"\F9ZL>QW3G*Z>+( M@=.S3Q>\/:LS(NP<'7DU.U-M&XBP?"P<[\HGPDJ5U[:!5)%7D\JZN,^3^IU> M/SL#X`6[/P1X*ZADE2/E$$`H`(]VCQQ:]1"C"*,8HP2C5$%JV*RWD\(>.>/D M^'@G"')BFF[A;H>-?#;KT0ZC`*,0HPBC&*,$(W;!-`R"Q\LQOJB`4<56E/YGY\#8#(>M\[D/S/\)!J+WRTNV??&@Q M1^R7/G1F(]R&'^#)UI12#QZTQ[;V`+9ZGVWD6`PV;I]MR_A)8+O@XXX\@=T+ M?,:>P+7>\YC6EEWWC2AM'1_>^?%O;UT?7HXQ?Y[YSU!5_&#K^=O1R'>>OQM] M$'@^M)58*;"G$/98$B//9RT6=HD]'QK+$0Y2K,&")U9?$+AEO&9'\EM6'8M+ M;9S)`2;>M'UIJ/@])?_2=%O+"VW@?K'=94YPGTS@RFG*SL`#I8WXPGZ@OZ'> M_`,``/__`P!02P,$%``&``@````A`.YI%U/S`@``_0@``!D```!X;"]W;W)K M&ULG%;;;IPP$'VOU']`?@\&]I($+1MM&J6-U$A5 MU4J3.B.5J&F"7JE"-]N/'S9'(9]42:GV`*%6"2JU;F*, M55I23I0O&EK#DUQ(3C3X2@(UI@35B.'$,LY&"+/64KO1'K@ MM-8.1-**:#B_*EFC.C2>SH'C1#X=FHM4\`8@]JQB^M6"(H^G\4-1"TGV%>A^ M"9LU0*)7+M`QQV!YUJOL;7&)"VFXR!`I-V3](\0;LPO@T7"&\W M-D&_&#VJP7]/E>+X6;+L*ZLI9!OJ9"JP%^+)N#YDQ@3!>!)];ROP37H9SL=52ED%&#\:&604E'!`>#7X\RT!F2$O-CKD66Z M3-`B\*]6J^7ZZA)@]E3I>V8PD9<>E!;\M_,*6RR'$K4H<.U0UO[J,EB$0/H7 M$.Q.9`7>$4VV&RF.'G0-4*J&F!X,8P`^KPBD&-^=<4X0=#6<54$9GK?1(MC@ M9TA=VOK<.A_X[7W"W@,#:<\,;/.9C;-A-KDU1[EUAB%-=)YF\2\TQCE!R\'A MIP*=CRWS2`]$#?6X'O%-?=]/JHF#[(-?G[$I:>MD&V+$"F%#UO>IC+.EZM/8 M6B";`_(W"K8>4\T6:.+&K*UEJN;R',5B1A)-X)BCM4"U!LK>Z!$SIP[/X19]U_2;."8MS--Q87FI9\D<$[= M;.0)33M!QOJ6;^@[F2*S2Q>V`\2-:SM2.M,9?>:='^A[_RV#371:LLZTM&O& M3D&W;-PLYE06]!.M*N6EXF`62033M;?V2VX7F?A3^S+>N>6'^R>P?!I2T$&4I!0``NA(``!D```!X;"]W;W)K M&ULK%A=;Z,X%'U?:?\#XGW"1T*:H"2C)H0/:59: MK69GGREQ$M2`(Z!-^^_W&F/7]F6J[,=+:0[W'GS.]34VJZ]OU<5Z)4U;TGIM M>Q/7MDA=T$-9G];VG]_C+PO;:KN\/N076I.U_4Y:^^OFUU]6-]H\MV=".@L8 MZG9MG[ON&CI.6YQ)E;<3>B4UW#G2ILH[^-FCV5!(EJ\5*3N.$E#+GD'XV_/Y;45;%5Q#UV5-\\OUR\%K:Y`\51> MRNZ])[6MJ@BS4TV;_.D"NM^\65X([OX'HJ_*HJ$M/783H'/X0+'FI;-T@&FS M.I2@@-EN->2XMA^],/-\V]FL>H-^E.36*O];[9G>DJ8\?"MK`FY#G5@%GBA] M9J'9@4&0[*#LN*_`[XUU(,?\Y=+]06\I*4_G#LH=@"(F+#R\1Z0MP%&@F?@! M8RKH!08`?ZVJ9%,#',G?^NNM/'3GM3V=3X('=^I!N/5$VBXN&:5M%2]M1ZN_ M>)`W4'$2?R"!JR"Y/WDV),-U2/8FBR"8S1Y9M50V\6-`K8W%YSUG9>N+0M M44S.(,O[L^I"61G)(V-9VS`8*%P+4_)UX\^6*^<5IE$QQ&QQC*='[$0$FS., M-C*!O0G$)I"80&H"F0(X8()T`J;2_^`$8V%."`U;`2C6&+)%A$B)3&!O`K$) M)":0FD"F`)KL*98]A35AO)M%O5G2VH;^D?7VEH$N:SO$](M)7\X=0B*$[!$2 M(R1!2(J03$4TO3!H7.8):_S/);,\:!*(DYK]P#4T\R!_*/+&^/0+>&( M:@E'5$L&Q.?KH>L9#;*7]X6(&'$D,J9?4UUO9A@A[PN.3.70C(!WC#H)%"-& MM,,[3(AG>;IXCOBP2GS4>KG01[8;@OAKNU_-.1*H;PEXY>MI>QXTA5>1PFV\ M2F+$G=S#G8YPP]Y1'T"F/(SZTJ]3HNT:O[(8TQ3^.3&&F M*VE&9^QED)@0,2)*9(Q*--5]2&60(,I4(LT9*!9R!K9T,,Z[.XQ1Z"9Q1)MD MOFM,_]T0I)C$D2ET@6*2.CB(+:RRC?-7H]QO2)2/R4/A51.KW1 M[IE&KYO*-G/F]O5CZGVG5W!K='%7%CB/D1BNT"&%=Q7BR"&&9Q'BT#/?]%M#@3Y9A.H;#B?VQ/[`;\5LF881_ M"P)&XZ!YGX2.8C6]L@W`[)G@7A+LQ/`I"V,-AGF@>PFX&XW$0PIX& MXTD0PA9N!)^':1_O2"?@R\$U/Y'?\N94UJUU(4>8"&Z_?VOXMP?^HQM:_8EV M\,V@[_HS?",B<(QTV:OH2&DG?L"#'?G5:?,W````__\#`%!+`P04``8`"``` M`"$`RIF7:=P%``!S%@``&0```'AL+W=O_??=XQML#W< M-G?MR[+YF/F8;SP>#VQ^^5)=C;>B: MW.#.J6ZJK(.?S=EJ[TV1'7NGZFK9\_G2JK+R9C(&OWF$HSZ=RKP(ZORU*FX= M(VF*:]9!_.VEO+>"K6^E_H[W4[W%3'G\M;P5D&]:)KL!S7;]0T_1((7"VD'?4K\#O MC7$L3MGKM?NC?D^*\GSI8+E=4$2%^<>O0='FD%&@F=E]&'E]A0#@KU&5M#0@ M(]F7_OI>'KO+UK2]F;URB;L$>^.Y:+NHI)RFD;^V75W]S:P(C6I@L3D+7`7+ M-O9CK>QWJ!LOL[$!(@)$1( MA)`8(0E"4AE1=$+0>'EGWC<;I9!,_6!S@-V@V796ZA+NF9&]'I;]@)``(2%" M(H3$"$D0DLJ(HAF"_B'-U*_7+$IRSQ!9($("A(0(B1`2(R1!2"HCBD#HW[+` MCXN7&JNJ&"*K8LAB+-Z`(]`UAO4GMM:YPL%()"Q"1/%@(Q/9:B$E@Y$@2F4B M13N<.[)VUKG[@NXN9?ZRKR%>B'HB)POHT*QO4PXU)0R14\(0.24`S<:$Q-P!$Z5TD$@'*7L< MK>@^\M;K]5)-1#):")Y4X5&30X'24Z36K9+02].F_T:M)I:/7 M?TTJ&]^4I#+(522NM"UX(-Q13BJ#;&BH8U+1WN6.+CTLWG;NVG-<+>\1YHXY M]#%WHG%['M&7)E6XU732$>_;Z?Q]?U=%P]`]3>+#TX9UAXMF>#],SQJ.E#S,TQN.E#Z\,$[CGPP0-N#74#7SRNV?G MXK>L.9>WUK@6)RBY>=\_&O;1D/WH>/]\KCOXUM>WT@M\W"U@&I[30>!4UYWX M01\P?"[>_0,``/__`P!02P,$%``&``@````A`,3]%C8K!@``R1<``!D```!X M;"]W;W)K&ULK%A=;Z,X%'U?:?\#XGU"3`@DJ.FH MA$]I5UJM9G>?*2$-:@@1T';FW^\UML'V9;IIM2_#]'#OB<^Q?7WQW=?O]=EX M+=NN:BX[DRR6IE%>BN9079YVYE_?XB\;T^CZ_'+(S\VEW)D_RL[\>O_K+W=O M3?O'-LVCKOX<_VR>JN;9D?AJ3Z M;-G+I6O5>74Q&8/?WL+1'(]5489-\5*7EYZ1M.4Y[V'\W:FZ=H*M+FZAJ_/V M^>7ZI6CJ*U`\5N>J_S&0FD9=^-G3I6GSQS/H_DZ6EL+F.[O#A4HH+8;;7G8L\!0L[F+M+5W MC7K+$^'YT5%;;-*'-13F?7Y_US9O!FQ,F-7NFM-M3GS@%8N'#7]<3C];3;", M*,D#9=F9(`C620=;X/7>=M9WUBLLVX+'!#B&J!%[$4'7**4-=2#2@5@'$AU( M=2"3``M,&)V`I?8_.$%9J!-"0R``R1I-MH@0*:$.1#H0ZT"B`ZD.9!*@R%ZI MLN>KAIAG&KPS87N.\TQ<5Y43\)BA:`W3N$=(B)`((3%"$H2D",ED1-$)@\;3 MN_!@J[XOF>;!YH"X4;/MZ)I9D+T=IWV/D!`A$4)BA"0(21&2R8BB&0;]*K*!"L[I-.51+&");PA#9$H[8K-`OB5;IH_&]$!$CCF2,&0Z+)7$T M(\;W@B.3.10C:".+CK`;=C;-4\5SA'4V]`3:<\0;-W;(D!74&6D]K-311V.0 M&'V,B!*&.--1D2(DD[,4S7!4?THSS5,U,\2&MG/2XVY5/7L>-!D3<@1.E2G- MUA<""W+6PT+9;)9$G^88$2>W$*L$0KE!%/@QCQ>S%F2J8H M:L\L4SK%"*9,85+]H6V4YH_MT@\KX_:J2U@OIGC%(&TE::+W(E'VBB6NP3)I M">KUB"="E-`8"RZED'G:-DJF1)E>V^?I%"7HL_^B5UVE79OF*H'/QP^9RCH_ MQ50&:0M0Z]WVA$=-WH0<<,R76]6CJUM_1AS)R+K7>Y41#%N MEVR7]D8M$)G"K=I)&\*?V_FMN4(9F^T,8!V+UH"PKE+Q4VXT66O/HZ1^(<10 MA*$80PF&4@QE"J3*IFVB+GM]0R,`&O53D4.2KCV&0@Q%&(HQE&`HQ5"F0*I4 MVA5*4F>:/'DJ60\)=&)[!G`A124[S@CM,11B*,)0C*$$0RF&Z*W8-`BFC]UR ML1N*NFR?RGUY/G=&T;S0&RS;A>4YPNQZ+2!KN%\;I*$WKKAYT]Z$Q/8CJ%!@ MA_8&"IY/RQE^`]=X#W-X0*_W9N(#VX=O;LP3K'SX2,7X@^,_@"'X1>#X\(4W M@X/N>=F0`+L$9V3@Q]#):J+#C0\=*XY/-C[TI!@/R1+L&TY>C0GZ$;!O[DU( M".3,&06'-.3,O0E__!0``__\#`%!+`P04``8`"````"$`@19- M!JL"```X!P``&0```'AL+W=O; M]^_6)Z4/IN#<(D"H3((+:^N8$,,*+JD)5,TK^)(I+:F%5YT34VM.4Q\D2Q)- M)@LBJ:AP@Q#K:S!4E@G&[Q4[2E[9!D3SDEK(WQ2B-F>&04$!)HCF#HFI M$A*`*Y+"3084A+[X^TFDMH"G:1#=SL/Y`OS1GAO[(!PF1NQHK)(_6Z\6JT&) M6A2XMRC313!?3J;AOT%(DY$7>$\MW:RU.B$8&J`T-74C&,8`?%D12'&^6^>< M8!AJR-5`%YXW4;1C>";A:EHL;LK:6L:S5D.)M-E04P=W1:*X&AVUFY!;B,7_Z=]%F_]XB3=!UA<-0:0 M$S_(NEE]S8M5-:0)VTM9V%C^L8`_%(?3.0E@KC*E[/D%B$GWS]O\`@``__\# M`%!+`P04``8`"````"$`O43::1`#``##"0``&0```'AL+W=O-X2%X25R"*$8@H&3Q(6T5L>G0I:*@LB:$X4 MG%]FK)(-6A%-@2N(>#A55Q$O*H`XLIRI9P.*G"(*[].2"W+,0?>3/R=1@VT> M!O`%BP27/%$NP&%[T*'F#=Y@0-IO8P8*=-H=09,=.OCAC;]`>+\U"?K-Z%EV M[AV9\?-GP>*OK*20;:B3KL"1\P?M>A]K$P3C0?2=J#G+Y2E MF8)R+T"1%A;&S[=41I!1@'$#J.:43D1">I>/&G]M%G:C&"&@-^:XS9TEVLO)G_?Q!LSV/DW1)%]EO! MSP[T#%#*BN@.]$,`'M<#A]"^!^V\0]#3<%8)17CPM--IYA^:=PP\%6A]3Y)X>B.KJ ML1WBKEYLDB:I.@ZR#WYMQH:DM9-OFK2;10CKLKY>/^ULJ-HTUA;(9H=\.9[) M99]JLD`=UV>M+4,UJS[%ZVJTS)W&GZQ&Q_59:\M0S69( M$2P6$UI"!_8Y:@OT7D?9>ER9#]/M7=),8)^W,0W%^?I#[R3P]5H9[POH>E+T MJ[5Y0=/%M)A<+K\>%'8HF]'1F$8T70P+S3*M8KZ="G8%V0G5F'HUFWLOZ'OO M]/#;\=%^TXUI1-^;IH4>21=MV)CF_^:079EVIQ14I/03S7/I1/RDUV$`6Z*U MMJOZ$.CX2_L\/-C\X?8-K-"*I/0;$2DKI9/3!#`]\P4)NX3M@^(5-!=L4JY@ M>YK;#/XL4=@4G@LR$LY5\P#,N/W[M?\+``#__P,`4$L#!!0`!@`(````(0`$ M26[0<0<``.X@```9````>&PO=V]R:W-H965T"SE$A1M$FN/<:`-8"1[=G9??M4N[M-5Y=GAB&Y M"9G/53_]5Q]]ROSKV_1EX5I-&UV MWF;'ZERLS)]%8WY=__K+\K6JGYM#4;0&*)R;E7EHVXLW'C?YH3AES:BZ%&>X MLJOJ4];"G_5^W%SJ(MMV2:?CV)Y,9N-35IY-KN#5MVA4NUV9%T&5OYR*<\M% MZN*8M3#^YE!>&JEVRF^1.V7U\\OE2UZ=+B#Q5![+]F*@LR(#R.OCC``^*]Q*MG2 M@(ID/[K/UW+;'E:F,QM-YQ/'@G#CJ6C:J&22II&_-&UU^H<'66Q0O8@M1.!3 MB-CNR%Y,K>GL$RJN4(%/H3+]O`@,NO,#GT)D\7F1F1"!S_M',AMKP'TY`KAL]OOX;>6D(P M[4SDD:FL3!@8K(X&UOWWM>W:R_%W6*NYB-G0&`M'^#*"K28F&^@@U$&D@U@' MB0Y2!8RA"'TE8+W^#Y5@*JP2TL-&`J4TFFT9(5,"'80ZB'00ZR#10:H`9-NA MMATX>(:/##G?+&EEPM[LY]N:/&!;&Q'3G5C==/J$!(2$A$2$Q(0DA*0J07YA MT'2:1_,W3TEIF>7!)H&XWK/M.IIG'F0_]-/O$Q(0$A(2$1(3DA"2J@1YAD'? MY9GE=9[ETMQPHAHD)"`D)"0B)"8D(215"3((9[-J\/W%RX*Q*TY45YS`1I#. M`T'@].CGW[*U$RSL@V1:1(3B/D85T@[+I`^20JDJA+S#+47USD_P;D&WAS)_ MWE0P7ACU0$T<.*GY^- MB>5BC:2_+C5250,5@G6QY%9VP\YF>=B\(,HV%H1W.MV]B1,'SAEE/6CG0=@' MR=%'1"@6,6Z_U!)"4C4+>89;]EV>61[VS(D-1[_B1YL-7P0I91`$[BY*FKX0 M1!"NU0S/=$2TXUNTDT'M.=9.56U4/PO\WE7`+A%74"`;CF&E%@L\%%\F*C44 MR('C34G4[J?A-:I?3%0KOD8I6LX$#R*Y1DFM%&GA&K&.2=]8\+L`1GOS`6/Q MK@MNG_(+-P+A%>=H)ZHOH]1R<2T'3L1KN1SM!`U%(D3);XRH5GR-4K6T;9Q< MHZ16BK1PN5BG]5_+Q;LU5"Z!E$/)$DBM#4<`.S>..'K*J](.^^112R2J)"&A51%%.4 M4)0BA*VR3DZQ.M"M?TX3*[IRDHH"BD**(HIBBA*$4(^V/= MFN)/:L=;G+?9>(FT>!,M*\2F':-`[/NO M$SW5.T89I=:(:]G(_53O&&4BM%!7>5JC02VM8XP_TL(U8DW;/;O(%@V@:(O3[2_7&D-'V^B%)00%%(44113%%"$7NEQ\;%OY'[XZ_H^)N6 M4U'O"[\X'ALCKU[8ZS=XB+9>]EB^&YQYCZ`$G8]V!=H]CW5;0U?F<*6[+>LY MM@.O&IVA'-N%*UW?3'*F\O6D=@7>6S[:0UKP/K,[0K3XC0U"0_$PJ*$Q/;K> M(V\%="$8Z^!08:3#I8)O@%]80Z4"*?A!,G0%Q`:_/86Z#Q4W6'CP9(\JQ0L/ MGMU1'E@3CSV^H5?@<8W''L;0*X%E0&9!>0,7=G,O,W0>/V9YP_Q8.;! M$^N![YY[\.R6\FCFP1-WP,?]M,+;YDNV+W[/ZGUY;HQC ML8/M,.E^X];\?37_HQ6_\9^J%MXS=S_W#_#O"@IX*SAA3YYV5=7*/]@7]/]2 M8?TO````__\#`%!+`P04``8`"````"$`5H.-5A03``!$<0``&0```'AL+W=O M'J\ M^GW[>MCMGS]>#V[NKJ^VS_?[A]WSUX_7__[5_#*_OCH<-\\/F\?]\_;C]9_; MP_7?/OWU+Q]^[%]_.WS;;H]75,/SX>/UM^/Q97E[>[C_MGW:'&[V+]MG*OFR M?WW:'.F?KU]O#R^OV\U#F_3T>#N\NYO>/FUVS]>QAN7K)77LOWS9W6_5_O[[ MT_;Y&"MYW3YNCG3\AV^[ET.N[>G^DNJ>-J^_?7_YY7[_]$)5?-X][HY_MI5> M7SW=+_W7Y_WKYO,CZ?YC,-[MU^^7B]&BS]X.[N^O;3A[:%_K/;_C@4_W]U^+;_85]W#W_? M/6^IN:FC0A=\WN]_"Z'^(2!*OH5LTW;!/U^O'K9?-M\?C__:_W#;W==O1^KO M"4D*RI8/?ZKMX9Z:E*JY&4Y"3??[1SH`^N_5TRZ,#6J2S1_MWQ^[A^.WC]>C MZSP=UB](8B.B7;#Z*_[SK`1QB'0CBBU.6X^ M?7C=_[BB\Y0Z^?"R"6?]8$FUY:$4&^>2W-\AZ>,U MG8>G_J;!SF6M4TP[E;7=V0!10#00`\0"<4!\29A>.FBI=S"Y">?I>@X>+4_0T0!40#,4`L$`?$EX1IIH,N-9\7&H);H7D\KB,9TPCZ MN?3F%)33%!`-Q`"Q0!P07Q(FE";L4FB'O*3NCD%G7H9B`9B@%@@#H@O"6N$ M8&1AS;J@ET,>UQP)S7=93@-$`=%`#!`+Q`'Q)6$":2'N)3#D<8&1E,,8B`*B M@1@@%H@#XDO"!`YHA2D5GI^1VFBN*Z'QN.LY1`J11F00640.$9G\MKWC07!] MP63T&:*#Z$[$,C/B9^$Z197C%I%"I!$91!:10^09XNJ#URC4O]&[T9F0Y'P2 MK@<1B15'M$+31>5$A4@C,H@L(H?(,\0E![]12+YXY1E$H\+41U2>M"FJ0`J1 M1F00640.D6>(2PTV0T@=3FYH37[G$C2(?H5)CT@L0F,^_)N42%%=QY\2,](8 M91!91`Z19XBW1O`BHC4N\I/A%!>3=4)%+S>(%"*-R""RB!PBSQ"7&EQ)+ZG1 MSE#-N7/6X<*=U#.I@!1&:40&D47D$'F&N-3@/7I)C::%28V(206D!H`T(H/( M(G*(/$-<:G`AA=0W)NOH69B^B-A2#$@-`&E$!I%%Y!!YAKB^8$(*?9?/S-&] MA/.A,,03/A>M!Z7'B9>YB!0BC<@@LH@<(L\04S]\E]%JH[G12D@LQ:(5FBXJ MG^$*D49D$%E$#I%GB$ONZ[V&)^^51:P3*L]=1`J11F00640.D6>(2Q5&*XSM MT3S<]'WO6CQ$$Y:06(NG?/PW751N-(5((S*(+"*'R#/$FZ.O"1NB"4N(]3SX M,H51&I%!9!$Y1)XA+K5BPF9T$__]'8\F;'CR4N7$-Y,=?XKJ.AZ0[NK*40:1 M1>00>89X:P0OU6>.#V>*,&$)L8Z/4052&*41&406D4/D&>)2*R:LE_L>HBE+ M2)SQ<]GQ,;%TWUUB[F6-R""RB!PBSQ!OC>":>G5\M%NECQF"`VL0*40:D4%D M$3E$GB$N-1BH7E*C\V)2(RH&=#,$I!!I1`:11>00>8:X5&'9SEM24@'G<$2E M)4U1!5*(-"*#R")RB#Q#3%]XOM*K*]O$UI^5,S,\>(FWI>CS\]G8I,0"*40: MD4%D$3E$GB&N7OBS\[T[0E.6D+"DHA6:+BJW@D*D$1E$%I%#Y!GBDBL^[:*; M!".T90D57=D@4H@T(H/((G*(/$-<:L6#]5J?1NC)$N+KT_!.K$]=5-?QL:YB MR=(891!91`Z19XBW1G!$?2;M4;12Y:2=$.OX&%4@A5$:D4%D$3E$GB$N57BP M-TYK-%XC<%E-0C27=%T9H\*YUEV5#\5S6)T3XRLKX5T"DU%7E\V(UR4>>;DN M*A^$SZBMB[="Q9ZE,_WX;7?_VWI/1TV?5VF=$;TW$=^F&*$U2ZCHZ28AUC@Q MD<[.]A6,NX&X3M418/(*YV5 MZ_()T0,X0JR-QC5GV=X6N'SV:>O@-P$3X@-O)";=)D=U$E5"87+HFFLD9EC= M166)!NNR7519ESBK71>5Z_*L+MY(2X[&,IBX%26\U)?B!9#)")N94=B MKFU",246OE4ATH@,(HO((?(,<(ZPO^KM!W\4HZCL:0I):3 MD5C"URFJ,*8-(H5((S*(+"*'R#/$U0?#6*A_X]Q-]K)X=CV.*,P.Q90L6J'I MHO(84(@T(H/((G*(/$-<3+.SQ:0C:V(RI.U&8,2"'2B`PBB\@A\@QQ MJ167.*&5]IWOIHS1,R849LBBVZ5G[**Z;H]U46)&&J,,(HO((?(,L;:8U-S@ M)>\ZMXE\P4JH['9$"I%&9!!91`Z19XA+#69*C/`>W1Y2Q$J=D.AVX?B;+BKW ML4*D$1E$%I%#Y!GB;5'S9!=U._JP"?HP1`J11F00640.D6>(2PT&J>CV\W/Y M)-JIBT)A&53@210J01&406D4/D M&>+ZA-.Z>&&:G$Q7,1F/Q;7S.D6Q22LF%DAAE$9D$%E$#I%GB*L7/NR-WCV9 MKSS%K"<1<2*2A?FZO,/1ATTB*KJR0:00:40& MD47D$'F&N-2*Z>KU)&2")BPAOBC);]PU7537\;&N8K[3&&40640.D6>(MT;% MEUWT"&R"3BPAUO$QJD`*HS0B@\@BP*;JKA,KU"9%"I!$91!:10^09XOKZ6JGIR4J5ZY.X\;E. M4:QWP7`IC-*(#"*+R"'R#''U[W)74W17"8GU2;1"TT6=IBE$&I%!9!$Y1)XA M+ED8KHO7IREZKX18[\:H`BF,TH@,(HO((?(,<:D5[S5?]'EY='HR8[D#UPF) M!4K<^C+YM&5'1S@T@ATH@,(HO((?(, M<:DU$];=M+_H&?44_5A"X5EH=X-D+!Y5-#EQ=KH;HC*:_^RQ=0[HYNG,>ZPJ.\(E$\`-"8:/(G MGDVT+)&K#TZIN&2^?)Q'BU5>/4\CXH]1Q_).:(J*CROCQ@XYD2:.0KVXEZ9S M(BTL192X]6*J=4W$I:!]JR[61K.^#JY-Y`XN(?[L="*?G>:H8H1DQ-1/Q.*I M%D9@ MG:+80(Z)!5(8I1$91!:10^09XNJ%+WRC=]$,SB+BE[L3T0I-%W4R@X@T(H/( M(G*(/$-<)2^YJP M.9JPA)C4&%4@A5$:D4%D$3E$GB$N59BP\S/8'(U60N7ZA$@ATH@,(HO((?(, M<7U]7=7\Y*K*]4E<`:Q35-&5#2*%2",RB"PBA\@SQ-4'VU,8K3=Z-YJD\A)B M'I%8GT0K-%U4-TV=$C/2&&40640.D6>(2Q:&Z^*+S#EZKX18[\:H`BF,TH@, M(HO((?(,<:D5[]7O`FI^,F.YM]8)\05J*NZ1-%U43E2(-"*#R")RB#Q#O#F$ M&;N\Y]&7S2,JNKE!I!!I1`:11>00>8:XU(H)"V_WO/.5M3E:LH1$M\M[3UU4 MU^VQKN)26F.40601.42>(=86BXI+N^C>;)O(75E"9;-EW4J><1:40&D47D$'F&>'/TM6D+M&D)L9Y'FX91 M&I%!9!$Y1)XA+E78M#"W]>QYM'"+B$3/BUN]31?5]?PI,2.-40:11>00>89X M<_1U=8N3J\M'O$Z(]7R,*I#"*(W((+*('"+/$)E[> M1>^B(=XW=`NU=0L6=I`:10J01&406D4/D&>)2*_:N MU^V'!;J[A$3'BZ<@31?5=7RLBQ(STAAE$%E$#I%GB+=&7W>W0'>74'%^-X@4 M(HW((+*('"+/$)=:<7>7.1KTZ^P-K?\.@^(RJ-O\D1 M?T'A:?OZ==ML'Q\/5_?[[^'W-@:T0>RG#R<>?PYDO5@L0Z/1*29+Z%-//Q4B MRQ8CRFI/3"@94TFK&THF5-)^4PE*IE0RK1W#8D8E[4L2D#.GDO:7#$3):CY> MKD*+52114;B%42NA@Z,K_5H)'1Q=&-=*Z.#H&K%60@='EU2U$FINNL"HE"RH MMPA)Z- M4$Y5Z8R4TAW\6@XII1O>E9(Y*:6;O[424DKW2FLEI)1N+=9*:"C6CWI*M='; MDYBSF@Z7JVH;T$N/E%/]G"E]#KV:A[6MIS2JZ$VV6@GU`KW452NA7J!WH"HE M,SH">I)=*Z$CH(>ZM1(Z`GH&6BF94&WT#95:"=5&W^VHE5!M]*T(+%E-)LM5 MM47IRPR44U4Z(:7TRCW6MI[0J*(WU&LE-*KH;>U:"8TJ>KFY4C*E447O`E=* MQJ0TN@AYEHQ):9RDH83TT'=4L;;5>+I<55N'OEI*.56E8U)*7X#$VM9C4DK? M%ZR5D%+Z]ERE9$)*ZZ6JVKKK*DD[*Y5J6U$QT8;X]1*:(S2KC"U$NHYVBBE5D(]1]O]5$K&5!O= M1*Z4#$@I;<6+):O!8KFJ*J4=="FGV@M#4DKO36%MM"\KE525#NG8:(?06@XI MI0TU:R6DE-X]JI70&*67BVHE-!)I7\)*"!M:T'I)-V;Z^5D$[:R;Q60CKCDP(Q#FFC;BJIZAS0>*=MI;$V M^OVS5?W(**$2OPY=5N-A:%;XJG4?E8)UF&MJ/,R<-4[:JM)(64W8FD9WK9MH M/R@ZTEI-M!71,FPTA(U$&PLMPTY"6$)[S%!.;0C1CC&44RNAC5:681L5K(VV M35F&35&P9$U'O:X>->V[M0S;2V&.HI*PN5:M9$HEM1S:>6L9=IG"'-J`B_34 M:K.C*96T.;>G$4D_8?>R^;K]Q^;UZ^[Y?O/>5````J0```!````!X;"]C86QC0VAA:6XN>&UL M/(Y!"@(Q$`3O@G\8YNYF]2`J2184?($^(&1'$T@F2R:(_MYX\=)0-%2WGMXY MP8NJQ,(&M\.(0.S+'/EI\'Z[;@X(TAS/+A4F@Q\2G.QZI;U+_A)<9.@&%H.A MM>6DE/A`V/$K-KG6L3R5+)3=+(&HYJ=TX[E7N`K3:0S5X/B+$_@$A M_5)9K?XC]@L``/__`P!02P,$%``&``@````A``NJ5+W)`@``50D``!``"`%D M;V-0&UL(*($`2B@``$````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M````````````G%913]LP$'Z?M/]0Y1U2*$P32H.@=`)I6RNEL$?+=2ZM16(' MGU/1_?J=D[8D8*+!2^38G^^^N^_.=G3Y7.2##1B46HV#D^-A,``E="K5:AS< M+WX:X5C(,M8'`9?_T2S8TNP5@)."`3"L?!VMKR(@Q1K*'@>$S+ MBE8R;0INZ=>L0IUE4L"-%E4!RH:GP^&W$)XMJ!32H_)@,&@L7FSL9XVF6CA^ M^+#8ED0XCJ[*,I>"6XHR_B6%T:@S.Y@^"\BCL+T8$;L$1&6DW<;#*&S_1HG@ M.4S(<)SQ'"$*7R:B6^`N:7,N#<;1QEYL0%AM!BC_4MI.@\&2(S@ZXV##C>3* M$BT':W[J<5ZB-?$?;1YQ#6`Q"@G03-;#-K8]EF?QZ+Q&T*B+=!8:)K30Y;B0 M-@><97-NK(?RZ+S-N6;1,&X([55D5!MLJBSEB]VI1FVIV\P/,4PT":T04D8C MU+E,N:6?:YYS)2B;!Z#+2^.E?\O)1_8DEKP5'W*SV^)W<\U1(M,9FQM`*N>Z MN+R$9F;%E?Q;`^IT75@W_UA8. M>"\BL5H\LEGIFM`?^KQ:4I>R69:!H5YR*9CHHM"*N;U^H]42X:FB<-ET0U^_ MX?Z<^O7MWW/J9>,7@BU<#OW,WNC1!^Z7Q1]&1Y<^X_WQCKSQ]N\Y^\2>YAC; MG7F'>GPGKS=@NEMT)J+PEV)TGLH_@<``/__ M`P!02P,$%``&``@````A`*?IF5DR`0``0`(``!$`"`%D;V-0-JOT&B4^<"-YVQFHT!X\6K+S MLU)8*CH'#ZZSX(("GT22\538"C4A6(JQ%PUH[K/H,%'<=D[S$*^NQI:+=UX# M+@BYQ!H"ESQP/`!3.Q/1A)1B1MH/UXX`*3"TH,$$C_,LQ]_>`$[[/P=&Y<2I M5=C;N-,4]Y0MQ4&027R/'M(=E>?%[=UFA5A!\HN4#&=3 M$)H3NKAZ+?'1-7!E&UL4$L!`BT`%``&``@````A`+55,"/U````3`(```L````````` M````````)P0``%]R96QS+RYR96QS4$L!`BT`%``&``@````A`"LP7-0#`@`` M,18``!H`````````````````30<``'AL+U]R96QS+W=O`0``'$/ M```8`````````````````!$.``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`!M5^-G7`P``,0T``!D````````````` M````71@``'AL+W=O&PO=V]R:W-H965T MP0``#(0```9```` M`````````````!L?``!X;"]W;W)K&UL4$L!`BT` M%``&``@````A`/"O\),Y`P``B0H``!D`````````````````S2,``'AL+W=O M&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`!R["=$,"```ZR@``!D`````````````````""L` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`*WU+W?T!```H1(``!@`````````````````"S\``'AL+W=O&PO&PO0``!X;"]T:&5M92]T:&5M93$N M>&UL4$L!`BT`%``&``@````A`.R[Z$WZ`@``D0@``!D````````````````` MO)<``'AL+W=O&PO=V]R:W-H965T?``!X;"]W;W)K&UL4$L!`BT`%``& M``@````A`*!J8NW:`@``O@<``!D`````````````````$:(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`'7C.OB.#P``RED``!@`````````````````)+\``'AL+W=O&PO=V]R:W-H M965T&UL4$L!`BT`%``&``@````A`*0QR5:X!0``5!8``!@` M````````````````'-4``'AL+W=O&UL4$L!`BT`%``&``@````A`&9`+=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`,J9EVG&PO=V]R:W-H M965T&UL4$L! M`BT`%``&``@````A`+U$VFD0`P``PPD``!D`````````````````.@(!`'AL M+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A M`*>?O/>5````J0```!``````````````````="`!`'AL+V-A;&-#:&%I;BYX M;6Q02P$"+0`4``8`"````"$`"ZI4O XML 12 R33.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock Options (Details) (USD $)
 3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Stock Options    
Stock options granted under 2010 Stock Incentive Plan (in shares) 269,500us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross  
Stock-based compensation $ 368,249us-gaap_ShareBasedCompensation $ 257,542us-gaap_ShareBasedCompensation
Total future stock compensation expense related to nonvested awards $ 2,275,000us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized  
XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v2.4.1.9
Property and Equipment (Details) (USD $)
Mar. 31, 2015
Dec. 31, 2014
Property and equipment    
Less: accumulated depreciation and amortization $ (1,777,103)us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment $ (1,735,205)us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
Property and equipment 583,420us-gaap_PropertyPlantAndEquipmentNet 619,028us-gaap_PropertyPlantAndEquipmentNet
Furniture and Office Equipment    
Property and equipment    
Property and equipment, Gross 880,114us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= axgn_FurnitureAndOfficeEquipmentMember		 873,824us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= axgn_FurnitureAndOfficeEquipmentMember
Leasehold Improvements    
Property and equipment    
Property and equipment, Gross 285,697us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_LeaseholdImprovementsMember		 285,697us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_LeaseholdImprovementsMember
Processing equipment    
Property and equipment    
Property and equipment, Gross $ 1,194,712us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentMember		 $ 1,194,712us-gaap_PropertyPlantAndEquipmentGross
/ us-gaap_PropertyPlantAndEquipmentByTypeAxis
= us-gaap_EquipmentMember
XML 15 R9.htm IDEA: XBRL DOCUMENT v2.4.1.9
Property and Equipment
 3 Months Ended
Mar. 31, 2015
Property and Equipment  
Property and Equipment

 

4.Property and Equipment

 

Property and equipment consist of the following:

 

 

 

March 31,
2015

 

December 31,
2014

 

 

 

(unaudited)

 

 

 

Furniture and equipment

 

$
880,114

 

$
873,824

 

Leasehold improvements

 
285,697

 
285,697

 

Processing equipment

 
1,194,712

 
1,194,712

 

Less: accumulated depreciation and amortization

 
(1,777,103

)
(1,735,205

)

Property and equipment

 

$
583,420

 

$
619,028

 

 

 

EXCEL 16 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]D8S0P960W,%\R,C=D7S0R,V)?.#1E9E\Q86,T M861C83DP9&8B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I%>&-E;%=O5]O9E]3:6=N M:69I8V%N=%]!8V-O=6YT/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U M#I%>&-E;%=O#I%>&-E M;%=O#I.86UE/DEN=&%N9VEB;&5?07-S971S/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-T;V-K7T]P=&EO;G,\+W@Z3F%M93X- M"B`@("`\>#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-U;6UA#I7;W)K#I%>&-E;%=O#I7 M;W)K#I%>&-E;%=O M#I7;W)K#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT-#PO>#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-U;6UA#I7;W)K5]A;F1?17%U:7!M96YT7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/DYO=&5S7U!A>6%B;&5?1&5T86EL#I. M86UE/@T*("`@(#QX.E=O#I% M>&-E;%=O#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@ M(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7V1C-#!E9#'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^07AO1V5N+"!);F,N/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^36%R(#,Q M+`T*"0DR,#$U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^9F%L2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\ M=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6%B;&4@+2!2979E;G5E($EN=&5R97-T(%!U M2`H9&5F:6-I="DZ/"]S=')O;F<^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\2`H9&5F:6-I="D\+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'!E M;G-E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAAF%T:6]N(&]F(&1E9F5R6%B M;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!F:6YA M;F-I;F<@86-T:79I=&EE65A3H\+W-T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D8S0P960W,%\R M,C=D7S0R,V)?.#1E9E\Q86,T861C83DP9&8-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO9&,T,&5D-S!?,C(W9%\T,C-B7S@T969?,6%C-&%D8V$Y M,&1F+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$6QE M/3-$)VUA3I4:6UE6QE/3-$)W1E>'0M:6YD96YT.C!P M=#MM87)G:6XM;&5F=#HP<'0[('!A9&1I;F3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.C$P<'0[)SXQ+CPO9F]N=#X\+V9O;G0^/&9O;G0@F4Z(#$R<'0G/@T*"0D)/&9O M;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA#(P,40[*2!A;F0@:71S('=H;VQL>2!O=VYE9"!S=6)S M:61I87)Y($%X;T=E;B!#;W)P;W)A=&EO;B`H)B-X,C`Q0SM!0R8C>#(P,40[ M*2!A28C>#(P,3D[2!A M8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E65A65AF4Z M(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^ M)FYB6QE/3-$)VUA7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAAF%T:6]N(&%N M9"!"=7-I;F5S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`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`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`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!O9B!3:6=N:69I8V%N="!!8V-O M=6YT:6YG(%!O;&EC:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\9&EV/B`\9&EV('-T>6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUAF4Z(#$R<'0G/@T*"0D)/&9O M;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6QE/3-$)V1I6QE/3-$)W1E>'0M:6YD96YT.C!P=#MM87)G M:6XM;&5F=#HP<'0[('!A9&1I;F'0M86QI9VXZ;&5F M="<^/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)V1I2!O9B!3 M:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(#PO9F]N=#X\+V9O;G0^ M#0H)"3PO<#X-"@D)/'`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`H-24@9F]R(&)A;&%N8V5S(#8Q+3DP(&1A>7,@86YD(#(P)2!F;W(@8F%L M86YC97,@;W9E7,@86YD(&$@:&EG:&5R('!E2!W2`D,3`Q+#`P,"!A;F0@)#DT M+#`P,"!A="!-87)C:"9N8G-P.S,Q+"`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`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`Q+C@R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.CAP=#LG/D1E8V5M8F5R)FYB6QE/3-$)V1I6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D) M"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)W=I9'1H.C$X+C@P)3MB;W)D97(M M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`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`Q M+C6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$W+C0V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR+#$X."PV.3$F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$X M+C@P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS,S$L M.#DQ)FYB6QE/3-$=VED=&@Z,#$N,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)W=I9'1H.C$X+C@T M)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX,#DL-#DT)FYB M6QE M/3-$)W=I9'1H.C`Q+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-36QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$ M)W=I9'1H.C$W+C0V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P M="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y M1#D@.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#,S-RPX.3@F;F)S<#L-"@D)"0D\ M+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I M9'1H.C`Q+C,T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D M;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@ M.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HQ-RXT."4[8F]R9&5R+71O<#HQ<'0@6QE/3-$=VED=&@Z,#$N M,3(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.R<^)FYB6QE/3-$ M)VUA&EM871E;'D@)#4W-2PP,#`@86YD("0T,#0L,#`P M(&%T($UA2X\+V9O;G0^#0H)"3PO<#X-"@D)/'`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`Q M.3MS(&QO;F&EM871E2X\+V9O;G0^#0H)"3PO<#X-"@D)/'`@3I4:6UE6QE/3-$)V1IF4Z(#$P M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[=&5X="UD96-OF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA'!E;G-E(&]V M97(@=&AE(&5M<&QO>65E)B-X,C`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`Q-3PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-S8E.W!A9&1I M;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I M;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H) M"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG M:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^,C`Q-#PO9F]N=#X\+W`^#0H)"0D) M/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z M,#(N-S0E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)W=I9'1H.C$X+C8X)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXT+C`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB M'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`R+C6QE/3-$ M)VUA3I4 M:6UE6QE/3-$=VED=&@Z-34N,C@E.W!A9&1I;F6QE/3-$)W=I9'1H M.C$X+C8X)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX,2XR-B9N8G-P M.PT*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C`R+C6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B4\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D) M"3QT9"!V86QI9VX],T1T;W`@6QE/3-$)W=I9'1H.C`Q+C@V)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UEF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$P<'0G/@T* M"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$X+C8X)3MB86-K9W)O=6YD M+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+C$R)FYB6QE/3-$ M)W=I9'1H.C`R+C6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B4\+V9O;G0^/"]P/@T*"0D)"3PO M=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`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`Q.3MS(&UA;F%G96UE;G0@:&%S(')E=FEE=V5D(&%N M9"!C;VYS:61E6QE/3-$)VUA3I4:6UE6QE/3-$)V1I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]D8S0P960W,%\R,C=D7S0R,V)?.#1E9E\Q86,T861C83DP9&8- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9&,T,&5D-S!?,C(W9%\T M,C-B7S@T969?,6%C-&%D8V$Y,&1F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!A;F0@17%U:7!M96YT/"]S=')O M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\6QE/3-$)VUA3I4 M:6UE6QE/3-$)W1E>'0M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[('!A9&1I M;F3H@:6YL M:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P<'0[)SXT+CPO9F]N M=#X\+V9O;G0^/&9O;G0@2!A;F0@ M17%U:7!M96YT(#PO9F]N=#X\+V9O;G0^#0H)"3PO<#X-"@D)/'`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`Q+C@V)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$W M+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXX.#`L,3$T#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C@V)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$W M+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXX-S,L.#(T#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T M=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C(T)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-36QE M/3-$)W=I9'1H.C$X+C'0M86QI9VXZ6QE/3-$)VUA M3I4:6UE M3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXR.#4L-CDW#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$=VED=&@Z,#$N,C0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)W=I9'1H.C`Q+C@V)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)W=I9'1H.C$X+C3I4:6UEF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)V1IF4Z,3!P=#LG/DQEF%T:6]N/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I M9'1H.C$X+C6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ M."XW,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M;&5F M=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(MF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C4W M+C8V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q M+C@V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ M6QE M/3-$)W=I9'1H.C`Q+C,V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$ M.40Y1#D@.V)A8VMGF4Z M(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE M.V9O;G0M6QE/3-$)W=I9'1H.C$W+C,T)3MB M;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P M,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.V)A8VMGF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB M6QE/3-$)VUA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T* M"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/BAU M;F%U9&ET960I/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H.C$X+C@P)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$=VED=&@Z,#$N,3`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`Q+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-RXT M-"4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)W=I M9'1H.C`Q+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-RXT M-"4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$=VED=&@Z,#$N.#`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z,3!P=#MT M97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I M9'1H.C$X+C@P)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M M'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N M,3`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$X+C@P)3MB;W)D97(M=&]P.C%P M="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXH,S8U+#0U,PT*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T:#HP,2XX,B4[8F%C M:V=R;W5N9"UC;VQOF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C$P)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D) M"3QT9"!V86QI9VX],T1T;W`@6QE/3-$)V1I6QE/3-$=VED=&@Z,#$N.#`E.W!A9&1I;FF4Z(#$R<'0G M/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)W=I9'1H.C`Q+C,T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N M;VYE("-$.40Y1#D@.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HQ-RXT-"4[8F]R9&5R+71O<#HQ<'0@6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$)V1IF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0MF5D M(&]V97(@=&AR964@>65AF5D+"!A;F0@=&AE M(')E;6%I;FEN9R!P871E;G1S(&]F("0W.2PY.38@=V5R92!P96YD:6YG('!A M=&5N="!C;W-TF%B;&4N($%M;W)T:7IA M=&EO;B!E>'!E;G-E(&9O&EM871E;'D@)#$R M+#`P,"!A;F0@)#$Q+#`P,"P@F%T:6]N(&]F(&QI8V5N'!E8W1E9"!T;R!B92`D,S8L,#`P(&9OF4Z(#$R M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB M6QE/3-$)VUA6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E1H92!#;VUP86YY(&AA6EN M9R!T96-H;F]L;V=Y('5S960@:6X@2!T:&4@0V]M<&%N>2!W:71H(#8P(&1A>7,@<')I;W(@=W)I='1E;B!N M;W1I8V4N($%D9&ET:6]N86QL>2P@:6X@=&AE(&5V96YT(&]F(&1E9F%U;'0L M(&QI8V5N2!F86EL2!T97)M6QE/3-$)VUA6QE/3-$=VED=&@Z,3`P)3L@8V5L M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,#X\='(^/'1D('-T>6QE/3-$ M=VED=&@Z,3AP=#L^/'`@6QE/3-$)W=I9'1H.B`P,"XP,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX-"@D) M"3QP('-T>6QE/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT M+7-I>F4Z(#$P<'0[;6%R9VEN.C!P=#LG/@T*"0D)"3QF;VYT('-T>6QE/3-$ M)VUAF4Z(#$P<'0[)SX@)B-X0C<[/"]F;VYT M/@T*"0D)/"]P/@T*"0D\+W1D/CQT9"!S='EL93TS1'=I9'1H.C(Q<'0[/CQP M('-T>6QE/3-$=VED=&@Z,C%P=#MW:61T:#HR,7!T.V9O;G0M2!I;F-L=61E(&$@8W)E9&ET(&EN M(&9U='5R92!Q=6%R=&5R6%L='D@97AC965D2!F965S+B9N8G-P.T%L7,@2!S=&%C:R!C87`@87!P;&EE M6QE/3-$)VUA M6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@6QE/3-$=VED=&@Z,C%P M=#L^/'`@6QE M/3-$)V1IF4Z,3!P=#MC;VQO2!A('!E2!T96-H;F]L;V=I97,@8V]V97)E9"!B>2!,:6-E;G-E($%G M3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,3AP=#MF;VYT+7-I>F4Z,'!T.SX\+W`^ M/"]T9#X\=&0@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F="!S='EL93TS1"=W M:61T:#H@,#`N,#!P=#L@9&ES<&QA>3H@:6YL:6YE.R<^#0H)"0D\<"!S='EL M93TS1"=F;VYT+69A;6EL>3I4:6UE$(W.SPO9F]N=#X-"@D)"3PO M<#X-"@D)/"]T9#X\=&0@F4Z,'!T.SX\+W`^/"]T M9#X\=&0@86QI9VX],T1L969T('9A;&EG;CTS1'1O<#X-"@D)"3QP('-T>6QE M/3-$)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P M<'0[;6%R9VEN.C!P=#LG/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M&]'96X@ MF4Z(#$R<'0G/@T*"0D)/&9O M;G0@3H@:6YL:6YE.V-O;&]R.B,P,#`P,#`[)SXF M;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D)/&1I=B!S='EL93TS1'=I9'1H.C$P M,"4^/'1A8FQE('-T>6QE/3-$=VED=&@Z,3`P)3L@8V5L;'!A9&1I;F<],T0P M(&-E;&QS<&%C:6YG/3-$,#X\='(^/'1D('-T>6QE/3-$=VED=&@Z,3AP=#L^ M/'`@6QE/3-$)W=I9'1H M.B`P,"XP,'!T.R!D:7-P;&%Y.B!I;FQI;F4[)SX-"@D)"3QP('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$P<'0[ M;6%R9VEN.C!P=#LG/@T*"0D)"3QF;VYT('-T>6QE/3-$)VUAF4Z(#$P<'0[)SX@)B-X0C<[/"]F;VYT/@T*"0D)/"]P/@T* M"0D\+W1D/CQT9"!S='EL93TS1'=I9'1H.C(Q<'0[/CQP('-T>6QE/3-$=VED M=&@Z,C%P=#MW:61T:#HR,7!T.V9O;G0M2!H87,@;F]T(')E8V5I=F5D(&5I=&AE6QE/3-$ M)VUAF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0MF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL M:6YE.V-O;&]R.B,P,#`P,#`[)SXF;F)S<#L\+V9O;G0^#0H)"3PO<#X-"@D) M/'`@3I4:6UE6QE/3-$)V1I MF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO M9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E;G-E6%B M;&4@86YD($%C8W)U960@17AP96YS97,\+W-T'0^ M/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1IF4Z(#$P<'0G/@T*"0D)/&9O;G0@6QE/3-$)V1I3I4:6UE6QE/3-$)V1I'0M:6YD96YT.C$T+C1P=#MF;VYT+69A;6EL>3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/D%C8V]U M;G1S('!A>6%B;&4@86YD(&%C8W)U960@97AP96YS97,@8V]N3I4:6UE6QE/3-$)V1I6QE/3-$=VED M=&@Z,3`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`Q+C6QE/3-$ M)VUA3I4:6UE6QE/3-$)VUA3I4:6UE M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/D1E8V5M8F5R)FYB6QE/3-$)V1I'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/D%C8V]U;G1S('!A M>6%B;&4@/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX] M,T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C,P M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y M1#D@.V)O6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HQ-BXW-B4[8F]R9&5R+71O<#HQ<'0@6QE/3-$)W=I9'1H.C`Q+C`X)3MB M86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-3DN,S@E M.W!A9&1I;F6QE/3-$=VED=&@Z,#$N-C@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H M.C$X+C`V)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE6QE/3-$)W=I9'1H.C4Y+C,X)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA MF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0MF4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C`Q+C6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE M/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P M<'0[)SY!8V-O=6YT6QE/3-$)V1IF4Z M,3!P=#LG/B9N8G-P.SPO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@ M=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#$N-C@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]W6QE/3-$)VUA3I4:6UEF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H.C$V+C3I4 M:6UE6QE/3-$9FQO870Z;&5F=#X\ M+V1I=CXR+#0S,2PQ.30F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI M9VX],T1B;W1T;VT@6QE/3-$)VUA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$ M;6%R9VEN+6QE9G0Z,'!T.VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.R<^)FYB6QE/3-$ M)VUA6QE/3-$)V1I6QE M/3-$)W1E>'0M:6YD96YT.C!P=#MM87)G:6XM;&5F=#HP<'0[('!A9&1I;F'0M86QI9VXZ;&5F="<^/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)V1I3I4:6UE M6QE M/3-$)V1IF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0MF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)V)O6QE/3-$=VED=&@Z-C,N M-S0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)W=I9'1H.C$V+C`R)3MB;W)D97(M M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1IF4Z.'!T.R<^*'5N875D:71E M9"D\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1'=I9'1H.C`Q+C8P)3MP861D:6YG.C!P=#L^#0H)"0D) M"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT M.F)O;&0[9F]N="US:7IE.CAP=#LG/D1E8V5M8F5R)FYB6QE/3-$)V1I6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL M:6YE.R<^)FYB6QE/3-$)W=I9'1H M.C$V+C`R)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE M("-$.40Y1#D@.V)O6QE/3-$=VED=&@Z,#$N-C`E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB'0M86QI9VXZ6QE/3-$=VED=&@Z,#$N,#0E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYB3H@ M:6YL:6YE.V9O;G0M#(P,4,[5&AR964@4&5A:W,F(W@R,#%$.RD@9F]R(&$@ M=&]T86P@=&5R;2!L;V%N(&%M;W5N="!O9B`D,C4L,#`P+#`P,#PO9F]N=#X\ M9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="US:7IE.C$P<'0[ M)SX@=VAI8V@@:&%S(&$@2!P87EM96YT6QE/3-$)W=I M9'1H.C`Q+C8P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@ M3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$T+C8T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z M;&5F=#X\+V1I=CXR-2PR-CDL,#4P)FYB6QE/3-$)W=I9'1H.C`Q+C8P)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H M.C$T+C8T)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-2PP M.#4L-S6QE/3-$)W=I9'1H.C`Q+C`T)3MB86-K9W)O=6YD+6-O;&]R.B`C M0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C,N-S0E.W!A9&1I;F6QE/3-$)W=I9'1H.C`Q+C,X)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P M="!N;VYE("-$.40Y1#D@.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG M/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O M='1O;2!S='EL93TS1"=W:61T:#HQ-"XV-"4[8F]R9&5R+71O<#HQ<'0@6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$T+C8T)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P M="!N;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-2PP.#4L-S6QE/3-$=VED=&@Z,#$N,#0E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D) M)FYB'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB M6QE/3-$)VUA6QE M/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D]N($]C=&]B97(F;F)S<#LU+"`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`F(W@R,#%#.T-L;W-I;F2!P86ED(%!$3"`D,S`N,R!M:6QL M:6]N('1O(&9U;&QY(&5X=&EN9W5I6%L='D@0V]N=')A8W0N M)FYB6%L='D@0V]N=')A8W0N/"]F;VYT/@T*"0D\ M+W`^#0H)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/D]N($YO=F5M8F5R M)FYB#(P,40[*2!A M="!A('!R:6-E(&]F("0R+C6QE/3-$)VUA3I4:6UE M6QE M/3-$)V1I3I4:6UE6QE/3-$)V1IF4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M#(P,40[*2P@07AO1V5N+"!A2!T:&5R M971O(&%N9"!4:')E92!096%K#(P,4,[3V)E&]'96X@82!T97)M(&QO M86X@;V8@)#(U(&UI;&QI;VX@*'1H92`F(W@R,#%#.TEN:71I86P@5&5R;2!, M;V%N)B-X,C`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`H:2DF;F)S<#MO;B!O2!B=70@ M;F\@;&%T97(@=&AA;B!T:&4@2!P;W)T:6]N(&)E:6YG('!R97!A:60[(&]R M("AI=BDF;F)S<#MA9G1E&]'96X@=VEL;"!A;'-O(&]W M92!A;B!A9&1I=&EO;F%L(#,E(&]F('1H92!O3I4:6UE6QE/3-$)V1IF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M2!A;F0@:71S('=H;VQL>2!O=VYE9"!S=6)S:61I87)Y+"!! M0R!E;G1E2!!9W)E96UE;G0@*'1H92`F(W@R M,#%#.U-E8W5R:71Y($%G#(P,40[*2!W:71H(%1H2!!9W)E96UE;G0@=&\@9W5A6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D%L M2!386QE)B-X,C`Q1#LI M(&%T(&$@<')I8V4@;V8@)#(N-3@@<&5R('-H87)E+B9N8G-P.R9N8G-P.U!U M2!4:')E92!096%K65E(&]P=&EO;B!P;V]L(&]R(&%N>2!O=&AE&ES=&EN M9R!AF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6UE;G1S('1O(&1A M=&4L('!R;VIE8W1E9"!F=71U2!P87EM96YT2!I;G1EF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\ M+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1IF4Z(#$P<'0G/@T* M"0D)/&9O;G0@6QE/3-$)V1IF4Z,3!P=#LG/CPO9F]N=#X\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z,3!P=#LG/E-T M;V-K($]P=&EO;G,@/"]F;VYT/CPO9F]N=#X-"@D)/"]P/@T*"0D\<"!S='EL M93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF M;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.R<^)FYB6QE/3-$ M)VUA2`D,BPR-S4L,#`P(&%T($UA6QE/3-$)VUA M7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@ M3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA6QE/3-$)V1I6QE/3-$)V1I3I4:6UE6QE/3-$)V1IF4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M&]' M96X@96YT97)E9"!I;G1O('1H92!5;F1E#(P,4,[3V9F97)I M;F28C>#(P,3D[6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/E1H92!/9F9E28C>#(P,3D[2!F:6QE9"!W:71H('1H92!396-U&-H86YG M92!#;VUM:7-S:6]N+"!A;F0@<'5RF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@ M:6YL:6YE.R<^)FYB6QE/3-$ M)VUA&]'96X@9G)O;2!T:&4@3V9F97)I;F<@;V8@87!P2`D M,34N,"!M:6QL:6]N+"!B969O&EM871E;'D@)#$N-"!M:6QL:6]N+B!4:&4@0V]M;6]N(%-H M87)EF4Z(#$R<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYBF4],T0Q/B`\+V9O;G0^/"]P M/@T*"3PO9&EV/B`\+V1I=CX\'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`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`Q1#LI(&9O2!L;V-A=&5D M(&EN($)U'!I2!A9W)E M96UE;G0@;V8@=&AE('!AF4Z(#$R<'0G/@T*"0D)/&9O M;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z M(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M2!N M;W1I9FEE9"!!>&]'96X@=&AA="!I="!W:6QL(&YE960@=&\@=')A;G-I=&EO M;B!O=70@;V8@=&AE(%9I29N8G-P.S(W+"`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`@86YD("0Y-"PP,#`@870@ M36%R8V@F;F)S<#LS,2P@,C`Q-2!A;F0@1&5C96UB97(F;F)S<#LS,2P@,C`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`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`Q+C@R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP M=#LG/D1E8V5M8F5R)FYB6QE M/3-$)V1I6QE/3-$)VUAF4Z(#$R<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)W=I9'1H.C$X+C@P)3MB;W)D97(M=&]P M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`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`Q+C6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$W+C0V)3MB86-K9W)O=6YD+6-O;&]R.B`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`Q+C$R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-36QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I M9'1H.C$W+C0V)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D M;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@ M.SMF;VYT+69A;6EL>3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXS+#,S-RPX.3@F;F)S<#L-"@D)"0D\+W1D M/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@6QE/3-$)W=I9'1H M.C`Q+C,T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B M;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.W!A M9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#HQ-RXT."4[8F]R9&5R+71O<#HQ<'0@6QE/3-$=VED=&@Z,#$N,3(E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL M:6YE.R<^)FYB6QE/3-$)VUA M&EM871E;'D@)#4W-2PP,#`@86YD("0T,#0L,#`P(&%T M($UA2X\+V9O;G0^#0H)"3PO<#X-"@D)/'`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`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/&1I=CX@ M/&1I=B!S='EL93TS1&UA3I4:6UE M6QE M/3-$)V1IF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.C$P M<'0[=&5X="UD96-O6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E1H92!R97-P96-T:79E(&-A6%B;&4@86YD(&%C M8W)U960@97AP96YS97,N(%1H92!F86ER('9A;'5E(&]F('1H92!#;VUP86YY M)B-X,C`Q.3MS(&QO;F&EM871E2X\+V9O;G0^#0H)"3PO<#X-"@D)/'`@3I4:6UE6QE/3-$)V1IF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE M.R<^)FYBF4],T0Q M/B`\+V9O;G0^/"]P/@T*"3PO9&EV/B`\+V1I=CX\'0^/&1I M=CX@/&1I=B!S='EL93TS1&UA3I4 M:6UE6QE/3-$)V1IF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.C$P<'0[=&5X="UD96-OF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE M.R<^)FYB6QE/3-$)VUA'!E;G-E(&]V97(@=&AE(&5M<&QO>65E)B-X,C`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`Q-3PO9F]N M=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T M>6QE/3-$=VED=&@Z,#(N-S8E.W!A9&1I;F'0M86QI M9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I M>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T M.R<^,C`Q-#PO9F]N=#X\+W`^#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$=VED=&@Z,#(N-S0E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I9'1H.C$X+C8X M)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ M<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y M1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXT+C`F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)W=I M9'1H.C`R+C6QE/3-$)VUA3I4:6UE6QE/3-$ M=VED=&@Z-34N,C@E.W!A9&1I;F6QE/3-$)W=I9'1H.C$X+C8X)3L[9F]N="UF86UI;'DZ M5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXX,2XR-B9N8G-P.PT*"0D)"3PO=&0^#0H)"0D)/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`R+C6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B4\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@6QE/3-$)W=I M9'1H.C`Q+C@V)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W MF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$ M)W=I9'1H.C$X+C8X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT M+69A;6EL>3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXQ+C$R)FYB6QE/3-$)W=I9'1H.C`R+C6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B4\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D)/'1R M/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@6QE/3-$)V1IF4Z,3!P=#LG/D5X<&5C=&5D(&1I=FED96YD6QE/3-$ M=VED=&@Z,#$N.#8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B4\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HQ."XV."4[.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W M6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B4\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D\+W1R/@T*"0D\+W1A M8FQE/CPO9&EV/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.V9O;G0M9F%M M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)/&9O M;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUAF5D M(&EN('1H92!P97)I;V0@;V8@8VAA;F=E+"!A;F0@86QS;R!I;7!A8W0@=&AE M(&%M;W5N="!O9B!U;F%M;W)T:7IE9"!C;VUP96YS871I;VX@97AP96YS92!T M;R!B92!R96-O9VYI>F5D(&EN(&9U='5R92!P97)I;V1S+B!4:&4@0V]M<&%N M>2!D:60@;F]T(&%P<&QY(&$@9F]R9F5I='5R92!A;&QO8V%T:6]N('1O(&ET M2!W97)E(&1E96UE9"!I;G-I9VYI9FEC86YT+CPO9F]N=#X-"@D) M/"]P/@T*"0D\<"!S='EL93TS1"=M87)G:6XZ,'!T.W1E>'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB M6QE/3-$)VUA'0^/&1I=CX@/&1I=B!S='EL93TS1&UA M3I4 M:6UE6QE/3-$)V1IF4Z(#$P<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.C$P<'0[=&5X="UD96-O3I4:6UE6QE/3-$)V1IF4Z(#$P<'0G/@T* M"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE6QE/3-$)V1I'0^/&1I=CX@/&1I=B!S='EL93TS1&UA3I4:6UE6QE/3-$)V1IF4Z(#$P<'0G/@T*"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O M;&0[9F]N="US:7IE.C$P<'0[=&5X="UD96-O6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/DEN($%P6EN9R!T:&4@4')E2!A9&]P=&EO;B!I'!E M8W0@=&AE(&%D;W!T:6]N(&]F('1H:7,@6QE/3-$)VUA M3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/DEN($9E8G)U87)Y)FYB#(P,40[*2!W:&EC:"!U<&1A=&5S M('1H92!C;VYS:61E2!S:&]U M;&0@8V]NF5D(&=U:61A;F-E(&9O2!T:&%T(&5N=&ET:65S(&5V86QU871E(&QI M;6ET960@<&%R=&YE3I4:6UE6QE/3-$)V1IF4Z(#$P M<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M29N8G-P.S(P,34L('1H92!&05-"(&ES M2!E;&EM:6YA=&5S(&%L M;"!R969E'!E8W0@=&AE(&%D;W!T:6]N(&]F('1H:7,@9W5I M9&%N8V4@=&\@:&%V92!A(&UA=&5R:6%L(&EM<&%C="!O;B!O=7(@8V]NF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)VUA2!A9&]P=&EO;BX@5V4@9&\@;F]T(&5X<&5C="!T:&4@861O<'1I;VX@;V8@ M=&AI6QE/3-$)VUA3I4:6UE M6QE M/3-$)V1IF4Z,3!P=#LG/DEN($UA>29N M8G-P.S(P,30L('1H92!&05-"(&ES&-H86YG92!F;W(@=&AO65A6QE/3-$)VUA M3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/E1H92!#;VUP86YY)B-X M,C`Q.3MS(&UA;F%G96UE;G0@:&%S(')E=FEE=V5D(&%N9"!C;VYS:61E6QE/3-$)VUA3I4:6UE6QE/3-$ M)V1I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D8S0P M960W,%\R,C=D7S0R,V)?.#1E9E\Q86,T861C83DP9&8-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO9&,T,&5D-S!?,C(W9%\T,C-B7S@T969?,6%C M-&%D8V$Y,&1F+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`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`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`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@ M;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@ M.V)O3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/D9I;FES:&5D(&=O;V1S/"]F M;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ MF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@ M;F]W6QE M/3-$)W=I9'1H.C`Q+C,T)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A M9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W:61T M:#HQ-RXT."4[8F%C:V=R;W5N9"UC;VQO'0M86QI9VXZ M6QE/3-$)W=I9'1H.C`Q+C$R)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-36QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXR-S(L M-#6QE/3-$=VED=&@Z,#$N.#(E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W'0M:6YD96YT.B`M,3!P M=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/E)A=R!M871E6QE/3-$)W=I9'1H.C$X M+C@P)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX-S8L-S,W M)FYB6QE/3-$)W=I9'1H.C`Q+C@R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149& M.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N.G)I M9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYB M6QE/3-$)V1I6QE/3-$=VED=&@Z,#$N-S8E.W!A9&1I;FF4Z(#$R<'0G/@T* M"0D)"0D))FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C$W+C0X)3MB;W)D97(M=&]P.C%P="!S M;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB M;W)D97(M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT M.C%P="!N;VYE("-$.40Y1#D@.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXS+#(Q,RPV M,C`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@ M6QE/3-$)VUA3I4:6UE M6QE M/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,3`P)3X\=&%B;&4@8V5L M;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$,"!S='EL93TS1"=B;W)D97(M M8V]L;&%PF4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z M.'!T.R<^5&AR964F;F)S<#MM;VYT:',F;F)S<#ME;F1E9"9N8G-P.TUA6QE/3-$)W=I M9'1H.C$X+C8X)3MB;W)D97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)V1I6QE/3-$)W=I9'1H.C$X+C8X)3MB;W)D97(M=&]P.C%P="!N;VYE("-$ M.40Y1#D@.V)O6QE/3-$)V1I6QE M/3-$)V1IF4Z,3!P=#LG/D5X<&5C=&5D M('1E6QE/3-$)W=I9'1H.C`Q+C@V)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C$X+C8X)3MB;W)D97(M=&]P.C%P="!S;VQI M9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D M97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO M870Z;&5F=#X\+V1I=CXT+C`F;F)S<#L-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)V1IF4Z,3!P=#LG/D5X<&5C=&5D('9O;&%T:6QI='D\+V9O;G0^/"]P/@T*"0D) M"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H M.C`Q+C@V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXW-BXS,B9N8G-P.PT* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I M9'1H.C`R+C6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1IF4Z,3!P=#LG/B4\+V9O M;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S M='EL93TS1"=W:61T:#HQ."XV."4[.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$=VED=&@Z,#(N-S0E.W!A9&1I;FF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M'0M:6YD96YT.B`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`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\6QE/3-$)VUA3I4:6UE M6QE M/3-$)V1I6QE/3-$=VED=&@Z,3`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`Q+C@V)3MP861D:6YG.C!P=#L^ M#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA M3I4:6UE3H@:6YL:6YE.V9O;G0M M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/D1E8V5M8F5R)FYB6QE/3-$)V1I6QE/3-$)VUA M3I4:6UE M6QE/3-$)V1I6QE/3-$=VED M=&@Z,#$N.#8E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R M.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G M/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS M1"=D:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z M.'!T.R<^*'5N875D:71E9"D\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D) M/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C@V)3MP861D M:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4 M:6UE6QE/3-$)VUA3I4:6UE'0M:6YD96YT.B`M,3!P=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$ M)V1IF4Z,3!P=#LG/D9UF4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z,3!P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z,3!P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D) M)FYB6QE/3-$)V1IF4Z,3!P=#LG/DQE87-E:&]L9"!I;7!R;W9E;65N=',\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I M9'1H.C`Q+C@V)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I4:6UE M3I4:6UE M6QE/3-$9FQO870Z;&5F=#X\+V1I M=CXR.#4L-CDW#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$=VED=&@Z,#$N.#8E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYBF4Z,3!P=#MT97AT+6%L M:6=N.G)I9VAT.R<@;F]W'0M:6YD96YT.B`M,3!P=#MF;VYT M+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z M,3!P=#LG/E!R;V-EF4Z M(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C@V)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE MF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXH,2PW-S6QE/3-$=VED=&@Z M,#$N.#8E.SX-"@D)"0D)/'`@F4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@ M:6YL:6YE.V9O;G0M6QE M/3-$)W=I9'1H.C$X+C6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H) M"0D\+W1R/@T*"0D)/'1R/@T*"0D)"3QT9"!V86QI9VX],T1T;W`@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P M=#LG/B0\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS M1&)O='1O;2!S='EL93TS1"=W:61T:#HQ-RXS-"4[8F]R9&5R+71O<#HQ<'0@ M3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXU.#,L-#(P#0H)"0D)/"]T9#X-"@D)"0D\ M=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)W=I9'1H.C`Q+C@V)3MB86-K M9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA3I4:6UE'0M86QI9VXZ6QE M/3-$)VUA3I4:6UE6QE/3-$)V1I3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D8S0P960W,%\R,C=D7S0R,V)? M.#1E9E\Q86,T861C83DP9&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO9&,T,&5D-S!?,C(W9%\T,C-B7S@T969?,6%C-&%D8V$Y,&1F+U=O'0O:'1M;#L@ M8VAA6QE M/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED M=&@Z,3`P)3X\=&%B;&4@8V5L;'!A9&1I;F<],T0P(&-E;&QS<&%C:6YG/3-$ M,"!S='EL93TS1"=B;W)D97(M8V]L;&%P6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#$N.#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE M=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ8V5N M=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#AP M="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[9F]N M="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^36%R8V@F;F)S<#LS,2P\ M+V9O;G0^/&)R("\^/&9O;G0@3H@:6YL:6YE.V9O M;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/C(P,34\+V9O;G0^/"]P M/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS M1'=I9'1H.C`Q+C@R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$ M)VUA3I4:6UE6QE/3-$)VUA3I4:6UE M3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US M:7IE.CAP=#LG/D1E8V5M8F5R)FYB6QE/3-$)V1I6QE/3-$)VUA3I4:6UE6QE/3-$)V1I6QE/3-$=VED=&@Z,#$N.#`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S M($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ M8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z M(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T.R<^*'5N875D:71E9"D\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1'=I9'1H.C`Q+C@R)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP M('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/DQI8V5N6QE/3-$ M)W=I9'1H.C`Q+C@P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE/3-$)W=I9'1H.C$W+C0T)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX-3$L-C`S M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.C`Q+C@R)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G M/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M M6QE/3-$)W=I9'1H.C$W+C0T)3MB86-K9W)O M=6YD+6-O;&]R.B`C0T-%149&.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXX-3`L.#4Y M#0H)"0D)/"]T9#X-"@D)"0D\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$ M)W=I9'1H.C`Q+C$P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I M;F6QE/3-$)VUA3I4:6UE6QE M/3-$=VED=&@Z-36QE/3-$)W=I9'1H.C$X+C@P)3L[9F]N="UF86UI M;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ M6QE/3-$)VUA3I4:6UE3I4:6UE6QE M/3-$9FQO870Z;&5F=#X\+V1I=CXW.2PY.38-"@D)"0D\+W1D/@T*"0D)"3QT M9"!V86QI9VX],T1B;W1T;VT@'0M:6YD96YT.B`M,3!P M=#MF;VYT+69A;6EL>3I4:6UE6QE/3-$)V1IF4Z,3!P=#LG/DQE6QE/3-$)W=I9'1H.C`Q+C@P)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-% M149&.W!A9&1I;F6QE/3-$)VUA3I4:6UEF4Z,3!P=#MT97AT+6%L:6=N M.G)I9VAT.R<@;F]W6QE/3-$)W=I9'1H.C`Q+C@R)3MB86-K9W)O=6YD+6-O M;&]R.B`C0T-%149&.R<^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/BD\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HQ."XX,"4[8F]R9&5R+71O<#HQ<'0@;F]N92`C M1#E$.40Y(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M'0M86QI M9VXZF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D)/&9O M;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[ M9F]N="US:7IE.C$P<'0[)SY);G1A;F=I8FQE(&%S6QE/3-$)W=I9'1H.C`Q+C,T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C M,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M M8F]T=&]M.C)P="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N M;VYE("-$.40Y1#D@.W!A9&1I;F6QE/3-$ M)VUA3I4 M:6UE6QE/3-$)V1IF4Z,3!P=#LG/B0\ M+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1"=W:61T:#HQ-RXT-"4[8F]R9&5R+71O<#HQ<'0@6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$ M)W=I9'1H.C$W+C0T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB M;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P M="!D;W5B;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y M1#D@.SMF;VYT+69A;6EL>3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXU-S6QE/3-$=VED=&@Z,#$N,3`E.W!A M9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE M.R<^)FYB6QE/3-$)VUA7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'!E;G-E M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$6QE/3-$;6%R9VEN+6QE9G0Z,'!T.VUAF4Z(#$R<'0G/@T*"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)V)O6QE/3-$=VED=&@Z-3DN M,S@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.R<^)FYB6QE/3-$)W=I9'1H.C$X+C`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`Q+C`X)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA M3I4:6UE6QE/3-$)W=I9'1H.C4Y M+C,X)3MB86-K9W)O=6YD+6-O;&]R.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUAF4Z(#$P<'0G/@T*"0D)"0D) M/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H.C`Q+C(X)3MB;W)D97(M=&]P.C%P M="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y M(#MB;W)D97(M8F]T=&]M.C%P="!N;VYE("-$.40Y1#D@.V)O6QE/3-$)VUA3I4:6UE6QE/3-$)V1I MF4Z,3!P=#LG/B0\+V9O;G0^/"]P/@T* M"0D)"3PO=&0^#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1"=W M:61T:#HQ-BXW-B4[8F]R9&5R+71O<#HQ<'0@'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C6QE/3-$)VUA M3I4:6UE MF4Z(#$P M<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O M;G0M6QE/3-$)W=I9'1H.C$V+C3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#$V,"PX-3DF;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I MF4Z,3!P=#LG/DUI6QE/3-$)W=I9'1H.C$X M+C`T)3L[9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.V9O;G0M'0M86QI9VXZ6QE/3-$)VUA3I4:6UE3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ,#4L M,S$U)FYB6QE/3-$=VED=&@Z,#$N,#@E.W!A9&1I;FF4Z(#$R<'0G/@T*"0D) M"0D))FYB6QE/3-$)W=I9'1H.C$X+C`T)3MB;W)D M97(M=&]P.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE6QE/3-$9FQO870Z;&5F=#X\+V1I=CXQ+#(V,2PX-C4F;F)S<#L- M"@D)"0D\+W1D/@T*"0D)"3QT9"!V86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D))FYB'0M86QI9VXZ6QE/3-$)W=I9'1H.C`Q+C`X)3MB86-K9W)O=6YD+6-O;&]R M.B`C0T-%149&.W!A9&1I;F6QE/3-$)VUA M3I4:6UE M6QE/3-$=VED=&@Z-3DN,S@E.W!A9&1I;F6QE/3-$)W=I M9'1H.C`Q+C(X)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D M97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D M;W5B;&4@(S`P,#`P,"`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`@("`@("`\ M=&0@8VQA6QE/3-$)VUA6QE/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE3H@:6YL:6YE.V9O;G0M=V5I M9VAT.F)O;&0[9F]N="US:7IE.CAP=#LG/DUA6QE/3-$)V1I6QE/3-$)V1I6QE/3-$=VED=&@Z M,#$N-C`E.W!A9&1I;F'0M86QI9VXZ8V5N=&5R.V9O M;G0M9F%M:6QY.E1I;65S($YE=R!2;VUA;CMF;VYT+7-I>F4Z(#$R<'0G/@T* M"0D)"0D))FYB'0M86QI9VXZ8V5N=&5R.V9O;G0M9F%M:6QY.E1I;65S($YE=R!2 M;VUA;CMF;VYT+7-I>F4Z(#AP="<^#0H)"0D)"0D\9F]N="!S='EL93TS1"=D M:7-P;&%Y.B!I;FQI;F4[9F]N="UW96EG:'0Z8F]L9#MF;VYT+7-I>F4Z.'!T M.R<^1&5C96UB97(F;F)S<#LS,2P\+V9O;G0^/&)R("\^/&9O;G0@3H@:6YL:6YE.V9O;G0M=V5I9VAT.F)O;&0[9F]N="US:7IE M.CAP=#LG/C(P,30\+V9O;G0^/"]P/@T*"0D)"3PO=&0^#0H)"0D)/'1D('9A M;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C`T)3MP861D:6YG.C!P M=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UE6QE/3-$=VED=&@Z-C,N-S0E.W!A9&1I;F6QE M/3-$)VUA3I4:6UE6QE/3-$)VUA3I4:6UE6QE M/3-$)W=I9'1H.C$V+C`R)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P M(#MB;W)D97(M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M M.C%P="!N;VYE("-$.40Y1#D@.V)O3I4:6UE#(P,40[*2!F;W(@82!T;W1A;"!T97)M(&QO86X@86UO M=6YT(&]F("0R-2PP,#`L,#`P/"]F;VYT/CQF;VYT('-T>6QE/3-$)V1IF4Z,3!P=#LG/B!W:&EC:"!H87,@82!S:7@@ M>65A6UE;G1S M(&%N9"!A(&9I;F%L('!R:6YC:7!A;"!P87EM96YT(&1U92!A="!T:&4@96YD M(&]F('1H92!T97)M+B!);G1E2!A M="`Y+C`P)2!P97(@86YN=6T@<&QU65A6%L='D@<&%Y;65N=',@87)E(&)A2`Q,B!M M;VYT:"!P97)I;V0N/"]F;VYT/CPO<#X-"@D)"0D\+W1D/@T*"0D)"3QT9"!V M86QI9VX],T1B;W1T;VT@F4Z(#$R<'0G/@T*"0D)"0D) M)FYBF4Z,3!P=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P M=#MT97AT+6%L:6=N.G)I9VAT.R<@;F]WF4Z M(#$R<'0G/@T*"0D)"0D))FYB6QE/3-$)V1I6%B;&4\+V9O;G0^/"]P/@T*"0D)"3PO=&0^ M#0H)"0D)/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1'=I9'1H.C`Q+C8P M)3MP861D:6YG.C!P=#L^#0H)"0D)"3QP('-T>6QE/3-$)VUA3I4:6UEF4Z(#$P<'0G/@T*"0D)"0D)/&9O;G0@3H@:6YL:6YE.V9O;G0M6QE/3-$)W=I9'1H M.C$T+C8T)3MB;W)D97(M=&]P.C%P="!S;VQI9"`C,#`P,#`P(#MB;W)D97(M M;&5F=#HQ<'0@;F]N92`C1#E$.40Y(#MB;W)D97(M8F]T=&]M.C)P="!D;W5B M;&4@(S`P,#`P,"`[8F]R9&5R+7)I9VAT.C%P="!N;VYE("-$.40Y1#D@.SMF M;VYT+69A;6EL>3I4:6UE6QE/3-$=VED=&@Z,#$N-C`E M.W!A9&1I;FF4Z(#$R<'0G/@T*"0D)"0D))FYBF4Z,3!P=#MT97AT M+6%L:6=N.G)I9VAT.R<@;F]W6QE/3-$ M)VUA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7,\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA'0^.3`@9&%Y'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^.3`@9&%Y7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D8S0P960W,%\R,C=D7S0R,V)?.#1E M9E\Q86,T861C83DP9&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M9&,T,&5D-S!?,C(W9%\T,C-B7S@T969?,6%C-&%D8V$Y,&1F+U=O'0O:'1M;#L@8VAA M'0^-"!Y96%R65A7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA2!A;F0@97%U:7!M M96YT/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%T:6]N('!E M'0^,C`@>65A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F%B;&4@<&5N9&EN9R!C;W-T'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\2!F965S(&EN8VQU M9&5D(&EN('-A;&5S(&%N9"!M87)K971I;F<@97AP96YS93PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6%L='D@;V8@86=R965M96YT'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!F965S(')A;F=E('5N9&5R('1H92!L:6-E;G-E(&%G'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%L='D@7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA6%B;&4@86YD($%C8W)U960@17AP96YS97,@*$1E M=&%I;',I("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB6%B;&4@ M86YD($%C8W)U960@3&EA8FEL:71I97,\+W-T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]D8S0P960W,%\R,C=D7S0R,V)?.#1E9E\Q86,T861C83DP9&8- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9&,T,&5D-S!?,C(W9%\T M,C-B7S@T969?,6%C-&%D8V$Y,&1F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA6%B;&4@*$1E=&%I;',@,BD@*%531"`D*3QB M6%B;&4\+W-T6%B;&4\+W-T2!P97)C96YT86=E(&]N(&YE="!R979E M;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+C'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,3`@>65A M6%L='D@<&5R8V5N=&%G92!O M;B!N970@'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6%L='D@<&5R8V5N=&%G92!O;B!N970@'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S2!C;VYT'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^."!Y96%R M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G0@86UO=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^3$E"3U(\&5D(')A=&4L(&]P M=&EO;B`R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C`P)3QS M<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^3$E"3U(\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!H87,@=&AE(&]P=&EO;B!T;R!P6UE;G0@9F]R(&]N(&]R M('!R:6]R('1O('1H92!F:7)S="!A;FYI=F5R2!O9B!T:&4@87!P;&EC M86)L92!#;&]S:6YG($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA2!H87,@=&AE(&]P=&EO;B!T;R!P6UE;G0@ M9F]R(&%F=&5R('1H92!F:7)S="!A;FYI=F5R2!B=70@8F5F;W)E('1H M92!S96-O;F0@86YN:79E'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^."!Y96%R2!P97)C96YT86=E(&]N(&YE="!R979E;G5E M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!P97)C96YT86=E(&]N(&YE M="!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+C&EM=6T\+W1D/@T*("`@("`@ M("`\=&0@8VQA2!P97)C96YT86=E(&]N(&YE="!R979E;G5E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+C@P)3QS<&%N/CPO2!R M979E;G5E('!E'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E(')E;&%T960@=&\@;F]N=F5S=&5D(&%W87)D M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M,S`@9&%Y'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]D8S0P960W,%\R,C=D7S0R,V)?.#1E9E\Q86,T M861C83DP9&8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9&,T,&5D M-S!?,C(W9%\T,C-B7S@T969?,6%C-&%D8V$Y,&1F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$&UL/@T*+2TM+2TM/5].97AT4&%R=%]D8S0P960W,%\R >,C=D7S0R,V)?.#1E9E\Q86,T861C83DP9&8M+0T* ` end XML 17 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9
Accounts Payable and Accrued Expenses (Details) (USD $)
Mar. 31, 2015
Dec. 31, 2014
Accounts Payable and Accrued Liabilities    
Accounts payable $ 1,966,422us-gaap_AccountsPayableCurrent $ 1,160,859us-gaap_AccountsPayableCurrent
Miscellaneous accruals 194,985axgn_MiscellaneousAccrualsCurrent 105,315axgn_MiscellaneousAccrualsCurrent
Accrued compensation 1,261,865axgn_AccruedCompensationCurrent 1,165,020axgn_AccruedCompensationCurrent
Accounts Payable and Accrued Expenses $ 3,423,272us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent $ 2,431,194us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent
XML 18 R28.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangible Assets (Details 3) (USD $)
 3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Sales and Marketing Expense    
Intangible assets    
Royalty fees included in sales and marketing expense $ 96,000us-gaap_RoyaltyExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_SellingAndMarketingExpenseMember		 $ 61,000us-gaap_RoyaltyExpense
/ us-gaap_IncomeStatementLocationAxis
= us-gaap_SellingAndMarketingExpenseMember
Licensing Agreements    
Intangible assets    
License agreements extended period 60 days  
Minimum royalty of agreements 12,500axgn_MinimumRoyaltyOfLicenseAgreement
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember		  
Milestone fee upon receiving a Phase II Small Business Innovation Research $ 15,000axgn_MilestonePaymentContingentUponReceiptOfGrant
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember		  
Number of products under development 0axgn_NumberOfProductsUnderDevelopment
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember		  
Licensing Agreements | Minimum    
Intangible assets    
Royalty fees range under the license agreements 1.00%axgn_RoyaltyFeesPercentageUnderLicenseAgreements
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember		  
Licensing Agreements | Maximum    
Intangible assets    
Royalty fees range under the license agreements 3.00%axgn_RoyaltyFeesPercentageUnderLicenseAgreements
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		  
Royalty stack cap for royalties paid to more than one licensor for sales of the same product 3.75%axgn_PercentageOfCappingRoyaltiesForMultipleRoyaltyPaymentsToLicensors
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		  
XML 19 R30.htm IDEA: XBRL DOCUMENT v2.4.1.9
Notes Payable (Details) (USD $)
Mar. 31, 2015
Dec. 31, 2014
Note Payable    
Total Debt $ 25,269,050us-gaap_LongTermNotesPayable $ 25,085,777us-gaap_LongTermNotesPayable
Three Peaks | Term Loan And Revenue Interest Purchase Agreement    
Note Payable    
Total Debt $ 25,269,050us-gaap_LongTermNotesPayable
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanAndRevenueInterestPurchaseAgreementMember		 $ 25,085,777us-gaap_LongTermNotesPayable
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanAndRevenueInterestPurchaseAgreementMember
XML 20 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9
Notes Payable (Details 2) (USD $)
 3 Months Ended 0 Months Ended 2 Months Ended 3 Months Ended 1 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Nov. 12, 2014
Oct. 05, 2012
Aug. 14, 2012
Oct. 05, 2012
Dec. 31, 2014
Dec. 31, 2014
Note Payable                
Interest expense $ 994,748us-gaap_InterestExpense $ 1,191,317us-gaap_InterestExpense            
Revenue Interest Purchase Agreement | Three Peaks                
Note Payable                
Royalty percentage on net revenue 3.75%axgn_RoyaltyPercentageOfNetRevenue
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		   3.75%axgn_RoyaltyPercentageOfNetRevenue
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		       3.75%axgn_RoyaltyPercentageOfNetRevenue
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		 3.75%axgn_RoyaltyPercentageOfNetRevenue
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember
Minimum annual payment amounts                
Term     10 years          
Revenue Interest Purchase Agreement | Three Peaks | Maximum                
Note Payable                
Royalty percentage on net revenue     4.80%axgn_RoyaltyPercentageOfNetRevenue
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		          
Revenue Interest Purchase Agreement | PDL                
Note Payable                
Royalty percentage on net revenue       9.95%axgn_RoyaltyPercentageOfNetRevenue
/ dei_LegalEntityAxis
= axgn_PDLEquitySaleMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		   9.95%axgn_RoyaltyPercentageOfNetRevenue
/ dei_LegalEntityAxis
= axgn_PDLEquitySaleMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		    
Payment to extinguish royalty contract     30,300,000axgn_PaymentToExtinguishRoyaltyContract
/ dei_LegalEntityAxis
= axgn_PDLEquitySaleMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		          
Obligation under royalty contract 0axgn_ObligationUnderRoyaltyContract
/ dei_LegalEntityAxis
= axgn_PDLEquitySaleMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		              
Minimum annual payment amounts                
Term       8 years        
Internal rate of return on funded amount             20.00%axgn_PutOptionRequiredInternalRateOfReturnPercentage
/ dei_LegalEntityAxis
= axgn_PDLEquitySaleMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		 20.00%axgn_PutOptionRequiredInternalRateOfReturnPercentage
/ dei_LegalEntityAxis
= axgn_PDLEquitySaleMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember
Funded amount       19,050,000us-gaap_ProceedsFromIssuanceOfLongTermDebt
/ dei_LegalEntityAxis
= axgn_PDLEquitySaleMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		 1,750,000us-gaap_ProceedsFromIssuanceOfLongTermDebt
/ dei_LegalEntityAxis
= axgn_PDLEquitySaleMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		 20,800,000us-gaap_ProceedsFromIssuanceOfLongTermDebt
/ dei_LegalEntityAxis
= axgn_PDLEquitySaleMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		    
Revenue Interest Purchase Agreement | PDL | Minimum                
Note Payable                
Payment amount             1,300,000axgn_DebtInstrumentPeriodicPaymentPrincipalAndInterest
/ dei_LegalEntityAxis
= axgn_PDLEquitySaleMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember
/ us-gaap_RangeAxis
= us-gaap_MinimumMember		  
Revenue Interest Purchase Agreement | PDL | Maximum                
Note Payable                
Payment amount             2,500,000axgn_DebtInstrumentPeriodicPaymentPrincipalAndInterest
/ dei_LegalEntityAxis
= axgn_PDLEquitySaleMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		  
Term Loan | Three Peaks                
Note Payable                
Total debt $ 25,000,000us-gaap_DebtInstrumentFaceAmount
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		   25,000,000us-gaap_DebtInstrumentFaceAmount
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		       $ 25,000,000us-gaap_DebtInstrumentFaceAmount
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		 $ 25,000,000us-gaap_DebtInstrumentFaceAmount
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember
Interest rate stated (as a percent) 9.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		   9.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		       9.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		 9.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember
Basis spread on fixed rate, option 1 LIBOR   LIBOR         LIBOR
Basis spread on fixed rate, option 2 1.00%axgn_DebtInstrumentBasisSpreadOnFixedRateOption2
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		   1.00%axgn_DebtInstrumentBasisSpreadOnFixedRateOption2
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		         1.00%axgn_DebtInstrumentBasisSpreadOnFixedRateOption2
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember
Effective interest rate (as a percent) 10.00%us-gaap_DebtInstrumentInterestRateEffectivePercentage
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		           10.00%us-gaap_DebtInstrumentInterestRateEffectivePercentage
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		 10.00%us-gaap_DebtInstrumentInterestRateEffectivePercentage
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember
Minimum annual payment amounts                
Term     6 years          
XML 21 R8.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2015
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

 

3.Summary of Significant Accounting Policies

 

Revenue Recognition

 

Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is delivered to the customer or distributor, at which time title passes to the customer or distributor, provided, however, that in the case of revenues from consigned sales delivery is determined when the product is utilized in a surgical procedure. Once a product is delivered, the Company has no further performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred.

 

Cash and Cash Equivalents and Concentration

 

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

 

Accounts Receivable and Concentration of Credit Risk

 

Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.

 

In 2013, we established a reserve for doubtful accounts as we did have some accounts deemed uncollectible.  We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected.  The analysis excludes certain government related receivables due to our past successful experience in collectability.  Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance.  The remaining balances outstanding over 60 days have a percentage applied by aging category (5% for balances 61-90 days and 20% for balances over 90 days aged), based on a historical valuation that allows us to calculate the total reserve required.  The reserve balance was determined by applying a percentage to the cumulative balance between 60 and 90 days and a higher percentage to the balance over 90 days.  In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account.  The write off process involves approval by senior management based on the write off amount.  The allowance for doubtful accounts reserve balance was approximately $101,000 and $94,000 at March 31, 2015 and December 31, 2014, respectively.

 

Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures.

 

Inventories

 

Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:

 

 

 

March 31,
2015

 

December 31,
2014

 

 

 

(unaudited)

 

 

 

Finished goods

 

$
2,188,691 

 

$
2,072,235 

 

Work in process

 
272,470 

 
331,891 

 

Raw materials

 
876,737 

 
809,494 

 

 

 

$
3,337,898 

 

$
3,213,620 

 

 

Inventories were net of reserve of approximately $575,000 and $404,000 at March 31, 2015 and December 31, 2014, respectively.

 

Income Taxes

 

The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.

 

The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2011 through 2014; there currently are no examinations in process.

 

Fair Value of Financial Instruments

 

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.

 

Share-Based Compensation

 

Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the October 2011 merger of LecTec, Inc. and AxoGen Corporation, and based on the Company’s common stock for periods subsequent to such merger. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the three months ended March 31:

 

Three months ended March 31,

 

2015

 

2014

 

Expected term (in years)

 
4.0 

 
4.0 

 

Expected volatility

 
76.32 

%
81.26 

%

Risk free rate

 
1.28 

%
1.12 

%

Expected dividends

 
0.0 

%
0.0 

%

 

The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the three months ended March 31, 2015 and 2014 as they were deemed insignificant.

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements

 

In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”) which changes the presentation of debt issuance costs in financial statements to present such costs as a direct deduction from the related debt liability rather than as an asset. ASU 2015-03 will become effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. We do not expect the adoption of this standard will have a material impact on our consolidated financial statements.

 

In February 2015, the FASB issued Accounting Standards Update No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis” (“ASU 2015-02”) which updates the considerations on whether an entity should consolidate certain legal entities. The update removes the indefinite deferral of specialized guidance for certain investment funds and changes the way that entities evaluate limited partnerships and fees paid to service providers in the consolidation determination. ASU 2015-02 will become effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements.

 

In January 2015, the FASB issued guidance, which completely eliminates all references to and guidance concerning the concept of an extraordinary item from GAAP. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

 

In June 2014, the FASB issued updated guidance related to stock compensation. The amendment requires that a performance target that affects vesting and that could be achieved after the requisite period, be treated as a performance condition. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

 

In May 2014, the FASB issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016; however, in April 2015, the FASB voted to propose a one year deferral of the effective date. The proposed deferral may permit early adoption, but would not allow adoption any earlier than the original effective date of the standard. We are currently evaluating the impact this standard will have on our consolidated financial statements.

 

The Company’s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures.

 

 

XML 22 R32.htm IDEA: XBRL DOCUMENT v2.4.1.9
Notes Payable (Details 3) (USD $)
 0 Months Ended 1 Months Ended 3 Months Ended 0 Months Ended
Nov. 12, 2014
Dec. 31, 2014
Mar. 31, 2015
Oct. 05, 2012
Dec. 31, 2014
Feb. 13, 2015
Feb. 05, 2015
Credit facility disclosures              
Shares of common stock sold   19,488,814us-gaap_CommonStockSharesIssued 24,926,014us-gaap_CommonStockSharesIssued   19,488,814us-gaap_CommonStockSharesIssued 5,437,200us-gaap_CommonStockSharesIssued  
Value of common stock sold   $ 194,888us-gaap_CommonStockValue $ 249,260us-gaap_CommonStockValue   $ 194,888us-gaap_CommonStockValue    
Public offering price (in dollars per share)           $ 2.75us-gaap_SharePrice $ 2.75us-gaap_SharePrice
PDL              
Credit facility disclosures              
Shares of common stock sold 643,382us-gaap_CommonStockSharesIssued
/ dei_LegalEntityAxis
= axgn_PDLEquitySaleMember		            
Value of common stock sold 1,750,000us-gaap_CommonStockValue
/ dei_LegalEntityAxis
= axgn_PDLEquitySaleMember		            
Public offering price (in dollars per share) $ 2.72us-gaap_SharePrice
/ dei_LegalEntityAxis
= axgn_PDLEquitySaleMember		            
Three Peaks              
Credit facility disclosures              
Shares of common stock sold 1,375,969us-gaap_CommonStockSharesIssued
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember		            
Value of common stock sold 3,550,000us-gaap_CommonStockValue
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember		            
Public offering price (in dollars per share) $ 2.58us-gaap_SharePrice
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember		            
Term Loan | Three Peaks              
Credit facility disclosures              
Term 6 years            
Interest payable 9.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		 9.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		 9.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		   9.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		    
Face amount 25,000,000us-gaap_DebtInstrumentFaceAmount
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		 25,000,000us-gaap_DebtInstrumentFaceAmount
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		 25,000,000us-gaap_DebtInstrumentFaceAmount
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		   25,000,000us-gaap_DebtInstrumentFaceAmount
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		    
Basis spread on fixed rate, option 1 LIBOR LIBOR LIBOR        
Basis spread on fixed rate, option 2 1.00%axgn_DebtInstrumentBasisSpreadOnFixedRateOption2
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		 1.00%axgn_DebtInstrumentBasisSpreadOnFixedRateOption2
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		 1.00%axgn_DebtInstrumentBasisSpreadOnFixedRateOption2
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		        
Effective interest rate (as a percent)   10.00%us-gaap_DebtInstrumentInterestRateEffectivePercentage
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		 10.00%us-gaap_DebtInstrumentInterestRateEffectivePercentage
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		   10.00%us-gaap_DebtInstrumentInterestRateEffectivePercentage
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		    
Optional future additional borrowing 7,000,000axgn_DebtInstrumentOptionalAdditionalBorrowings
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		            
Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for on or prior to the first anniversary of the applicable Closing Date 120.00%axgn_UponCertainEventsMultipleOfOutstandingTermLoanLenderHasRightToDemandOnOrPriorToFirstAnniversaryOfApplicableClosingDate
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		            
Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the first anniversary but before the second anniversary of the applicable Closing Date 135.00%axgn_UponCertainEventsMultipleOfOutstandingTermLoanLenderHasRightToDemandAfterFirstAnniversaryButBeforeSecondAnniversaryOfApplicableClosingDate
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		            
Upon certain events, the percentage of outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand payment for after the second anniversary but before the third anniversary of the applicable Closing Date 150.00%axgn_UponCertainEventsMultipleOfOutstandingTermLoanLenderHasRightToDemandAfterSecondAnniversaryButBeforeThirdAnniversaryOfApplicableClosingDate
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		            
Upon certain events, the internal rate of return of the outstanding principal amount of the Term Loan the Company has the option to prepay and the lender has a right to demand after the third anniversary of the applicable Closing Date 16.25%axgn_UponCertainEventsInternalRateOfReturnOfOutstandingTermLoanLenderHasRightToDemandAfterThirdAnniversaryOfApplicableClosingDate
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		            
Upon certain events, the additional percentage of the originally advanced Term Loan amount owed 3.00%axgn_UponCertainEventsAdditionalPercentageOfOriginallyAdvancedTermLoanOwed
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_TermLoanMember		            
Revenue Interest Purchase Agreement | PDL              
Credit facility disclosures              
Term       8 years      
Royalty percentage on net revenue       9.95%axgn_RoyaltyPercentageOfNetRevenue
/ dei_LegalEntityAxis
= axgn_PDLEquitySaleMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		      
Revenue Interest Purchase Agreement | Three Peaks              
Credit facility disclosures              
Term 10 years            
Royalty percentage on net revenue 3.75%axgn_RoyaltyPercentageOfNetRevenue
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		 3.75%axgn_RoyaltyPercentageOfNetRevenue
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		 3.75%axgn_RoyaltyPercentageOfNetRevenue
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		   3.75%axgn_RoyaltyPercentageOfNetRevenue
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember		    
Revenue Interest Purchase Agreement | Three Peaks | Maximum              
Credit facility disclosures              
Royalty percentage on net revenue 4.80%axgn_RoyaltyPercentageOfNetRevenue
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		            
Royalty revenue per year $ 30,000,000us-gaap_RoyaltyRevenue
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		   $ 30,000,000us-gaap_RoyaltyRevenue
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		   $ 30,000,000us-gaap_RoyaltyRevenue
/ dei_LegalEntityAxis
= axgn_ThreePeaksCapitalMember
/ us-gaap_LongtermDebtTypeAxis
= axgn_RevenueInterestPurchaseAgreementMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember		    
XML 23 R2.htm IDEA: XBRL DOCUMENT v2.4.1.9
Condensed Consolidated Balance Sheets (USD $)
Mar. 31, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 19,255,725us-gaap_CashAndCashEquivalentsAtCarryingValue $ 8,215,791us-gaap_CashAndCashEquivalentsAtCarryingValue
Accounts receivable, net of allowance for doubtful accounts of approximately $101,000 and $94,000, respectively 3,161,588us-gaap_AccountsReceivableNetCurrent 2,872,308us-gaap_AccountsReceivableNetCurrent
Inventory 3,337,898us-gaap_InventoryNet 3,213,620us-gaap_InventoryNet
Prepaid expenses and other 259,948us-gaap_PrepaidExpenseAndOtherAssetsCurrent 109,369us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Total current assets 26,015,159us-gaap_AssetsCurrent 14,411,088us-gaap_AssetsCurrent
Property and equipment, net 583,420us-gaap_PropertyPlantAndEquipmentNet 619,028us-gaap_PropertyPlantAndEquipmentNet
Intangible assets 597,453us-gaap_FiniteLivedIntangibleAssetsNet 577,174us-gaap_FiniteLivedIntangibleAssetsNet
Deferred financing costs 939,894us-gaap_DeferredFinanceCostsNoncurrentNet 793,499us-gaap_DeferredFinanceCostsNoncurrentNet
Total Assets 28,135,926us-gaap_Assets 16,400,789us-gaap_Assets
Current liabilities:    
Accounts payable and accrued expenses 3,423,272us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent 2,431,194us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent
Current deferred Revenue 14,118us-gaap_DeferredRevenueCurrent 14,118us-gaap_DeferredRevenueCurrent
Total current liabilities 3,437,390us-gaap_LiabilitiesCurrent 2,445,312us-gaap_LiabilitiesCurrent
Note Payable - Revenue Interest Purchase Agreement 25,269,050us-gaap_LongTermNotesPayable 25,085,777us-gaap_LongTermNotesPayable
Long Term Deferred Revenue 109,984us-gaap_DeferredRevenueNoncurrent 115,380us-gaap_DeferredRevenueNoncurrent
Total liabilities 28,816,424us-gaap_Liabilities 27,646,469us-gaap_Liabilities
Commitments and contingencies      
Shareholders' equity (deficit):    
Common stock, $.01 par value; 50,000,000 shares authorized; 24,926,014 and 19,488,814 shares issued and outstanding 249,260us-gaap_CommonStockValue 194,888us-gaap_CommonStockValue
Additional paid-in capital 92,761,697us-gaap_AdditionalPaidInCapitalCommonStock 78,675,686us-gaap_AdditionalPaidInCapitalCommonStock
Accumulated deficit (93,691,455)us-gaap_RetainedEarningsAccumulatedDeficit (90,116,254)us-gaap_RetainedEarningsAccumulatedDeficit
Total shareholders' equity (deficit) (680,498)us-gaap_StockholdersEquity (11,245,680)us-gaap_StockholdersEquity
Total Liabilities and Shareholders' equity $ 28,135,926us-gaap_LiabilitiesAndStockholdersEquity $ 16,400,789us-gaap_LiabilitiesAndStockholdersEquity
XML 24 R6.htm IDEA: XBRL DOCUMENT v2.4.1.9
Basis of Presentation
 3 Months Ended
Mar. 31, 2015
Basis of Presentation  
Basis of Presentation

 

1.Basis of Presentation

 

The accompanying condensed consolidated financial statements include the accounts of AxoGen, Inc. (the “Company” or “AxoGen”) and its wholly owned subsidiary AxoGen Corporation (“AC”) as of March 31, 2015 and December 31, 2014 and for the three month periods ended March 31, 2015 and 2014.  The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2014, which are included in the Annual Report on Form 10-K as of and for the year ended December 31, 2014.  The interim condensed consolidated financial statements are unaudited and in the opinion of management, reflect all adjustments necessary for a fair presentation of results for the periods presented.  Results for interim periods are not necessarily indicative of results for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

 

XML 25 R35.htm IDEA: XBRL DOCUMENT v2.4.1.9
Subsequent Events (Details) (Ja-Cole, Subsequent Events, USD $)
 0 Months Ended
Apr. 21, 2015
Apr. 21, 2015
sqft
Ja-Cole | Subsequent Events
    
Subsequent Events    
Additional leased office space in square feet 2,100axgn_AreaOfRealEstatePropertyAdditional
/ us-gaap_LeaseArrangementTypeAxis
= axgn_JaColeMember
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember		 2,100axgn_AreaOfRealEstatePropertyAdditional
/ us-gaap_LeaseArrangementTypeAxis
= axgn_JaColeMember
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
Leased office space in square feet 5,400us-gaap_AreaOfRealEstateProperty
/ us-gaap_LeaseArrangementTypeAxis
= axgn_JaColeMember
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember		 5,400us-gaap_AreaOfRealEstateProperty
/ us-gaap_LeaseArrangementTypeAxis
= axgn_JaColeMember
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember
Term of agreement 3 years  
Annual lease expense $ 60,000axgn_AnnualLeaseExpense
/ us-gaap_LeaseArrangementTypeAxis
= axgn_JaColeMember
/ us-gaap_SubsequentEventTypeAxis
= us-gaap_SubsequentEventMember		  
XML 26 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Details) (USD $)
 12 Months Ended
Dec. 31, 2013
Mar. 31, 2015
Dec. 31, 2014
Accounts Receivable and Concentration of Credit Risk      
Reserve for accounts deemed uncollectible (as a percent) 100.00%axgn_ReserveForAccountsReceivableDeemedUncollectiblePercentage    
Allowance for doubtful accounts reserve balance   $ 101,000us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent $ 94,000us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent
Minimum      
Accounts Receivable and Concentration of Credit Risk      
Age of doubtful accounts 60 days    
Age 61 to 90 Days      
Accounts Receivable and Concentration of Credit Risk      
Reserve for doubtful accounts (as a percent) 5.00%axgn_AllowanceForDoubtfulAccountsReceivablePercentage
/ axgn_AccountsNotesAndLoansReceivableAgeAxis
= axgn_Age61To90DaysMember		    
Age 61 to 90 Days | Minimum      
Accounts Receivable and Concentration of Credit Risk      
Age of doubtful accounts 61 days    
Age 61 to 90 Days | Maximum      
Accounts Receivable and Concentration of Credit Risk      
Age of doubtful accounts 90 days    
Age Over 90 Days      
Accounts Receivable and Concentration of Credit Risk      
Reserve for doubtful accounts (as a percent) 20.00%axgn_AllowanceForDoubtfulAccountsReceivablePercentage
/ axgn_AccountsNotesAndLoansReceivableAgeAxis
= axgn_AgeOver90DaysMember		    
Age Over 90 Days | Minimum      
Accounts Receivable and Concentration of Credit Risk      
Age of doubtful accounts 90 days    
XML 27 R24.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Details 3)
 3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Summary of Significant Accounting Policies    
Expected term 4 years 4 years
Expected volatility (as a percent) 76.32%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate 81.26%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
Risk free rate (as a percent) 1.28%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate 1.12%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
Expected dividends (as a percent) 0.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate 0.00%us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
XML 28 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 29 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
Organization and Business
 3 Months Ended
Mar. 31, 2015
Organization and Business  
Organization and Business

 

2.Organization and Business

 

Business Summary

 

AxoGen, Inc. is a leading medical technology company dedicated to peripheral nerve repair. The company has created and licensed a unique combination of patented nerve repair technologies to change the standard of care for patients with peripheral nerve injuries. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several European countries and includes Avance® Nerve Graft, an off-the-shelf commercially available processed human nerve allograft for bridging severed nerves without the comorbidities associated with an additional surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments and the AxoTouch™ Two-Point Discriminator, a tool useful for measuring sensation after a nerve injury, following the progression of a repaired nerve, and during the evaluation of a person with a possible nerve injury, such as nerve division or nerve compression.

 

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen.  AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

 

 

 

XML 30 R3.htm IDEA: XBRL DOCUMENT v2.4.1.9
Condensed Consolidated Balance Sheets (Parenthetical) (USD $)
Mar. 31, 2015
Dec. 31, 2014
Condensed Consolidated Balance Sheets    
Accounts receivable, allowance for doubtful accounts $ 101,000us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent $ 94,000us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent
Common stock, Par value $ 0.01us-gaap_CommonStockParOrStatedValuePerShare $ 0.01us-gaap_CommonStockParOrStatedValuePerShare
Common stock, shares authorized 50,000,000us-gaap_CommonStockSharesAuthorized 50,000,000us-gaap_CommonStockSharesAuthorized
Common stock, shares issued 24,926,014us-gaap_CommonStockSharesIssued 19,488,814us-gaap_CommonStockSharesIssued
Common stock, shares outstanding 24,926,014us-gaap_CommonStockSharesOutstanding 19,488,814us-gaap_CommonStockSharesOutstanding
XML 31 R17.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2015
Summary of Significant Accounting Policies  
Schedule of inventories

 

 

 

 

March 31,
2015

 

December 31,
2014

 

 

 

(unaudited)

 

 

 

Finished goods

 

$
2,188,691 

 

$
2,072,235 

 

Work in process

 
272,470 

 
331,891 

 

Raw materials

 
876,737 

 
809,494 

 

 

 

$
3,337,898 

 

$
3,213,620 

 

 

 

Schedule of weighted-average assumptions for options granted

 

 

Three months ended March 31,

 

2015

 

2014

 

Expected term (in years)

 
4.0 

 
4.0 

 

Expected volatility

 
76.32 

%
81.26 

%

Risk free rate

 
1.28 

%
1.12 

%

Expected dividends

 
0.0 

%
0.0 

%

 

 

XML 32 R1.htm IDEA: XBRL DOCUMENT v2.4.1.9
Document and Entity Information
 3 Months Ended
Mar. 31, 2015
May 04, 2015
Document and Entity Information    
Entity Registrant Name AxoGen, Inc.  
Entity Central Index Key 0000805928  
Document Type 10-Q  
Document Period End Date Mar. 31, 2015  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   24,926,014dei_EntityCommonStockSharesOutstanding
Document Fiscal Year Focus 2015  
Document Fiscal Period Focus Q1  
XML 33 R18.htm IDEA: XBRL DOCUMENT v2.4.1.9
Property and Equipment (Tables)
 3 Months Ended
Mar. 31, 2015
Property and Equipment  
Schedule of Property and equipment

 

 

 

 

March 31,
2015

 

December 31,
2014

 

 

 

(unaudited)

 

 

 

Furniture and equipment

 

$
880,114

 

$
873,824

 

Leasehold improvements

 
285,697

 
285,697

 

Processing equipment

 
1,194,712

 
1,194,712

 

Less: accumulated depreciation and amortization

 
(1,777,103

)
(1,735,205

)

Property and equipment

 

$
583,420

 

$
619,028

 

 

 

XML 34 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
Condensed Consolidated Statements of Operations (USD $)
 3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Condensed Consolidated Statements of Operations    
Revenues $ 4,951,316us-gaap_Revenues $ 3,138,256us-gaap_Revenues
Cost of goods sold 982,881us-gaap_CostOfGoodsSold 701,300us-gaap_CostOfGoodsSold
Gross profit 3,968,435us-gaap_GrossProfit 2,436,956us-gaap_GrossProfit
Costs and expenses:    
Sales and marketing 3,932,522us-gaap_SellingAndMarketingExpense 2,720,707us-gaap_SellingAndMarketingExpense
Research and development costs 671,036us-gaap_ResearchAndDevelopmentExpense 812,615us-gaap_ResearchAndDevelopmentExpense
General and administrative 1,908,581us-gaap_GeneralAndAdministrativeExpense 1,894,776us-gaap_GeneralAndAdministrativeExpense
Total costs and expenses 6,512,139us-gaap_CostsAndExpenses 5,428,098us-gaap_CostsAndExpenses
Loss from operations (2,543,704)us-gaap_OperatingIncomeLoss (2,991,142)us-gaap_OperatingIncomeLoss
Other expense:    
Interest expense (994,748)us-gaap_InterestExpense (1,191,317)us-gaap_InterestExpense
Interest expense-deferred financing costs (33,746)us-gaap_AmortizationOfFinancingCostsAndDiscounts (51,216)us-gaap_AmortizationOfFinancingCostsAndDiscounts
Other income (expense) (3,003)us-gaap_OtherNonoperatingIncomeExpense (5,889)us-gaap_OtherNonoperatingIncomeExpense
Total other expense (1,031,497)us-gaap_NonoperatingIncomeExpense (1,248,422)us-gaap_NonoperatingIncomeExpense
Net Loss $ (3,575,201)us-gaap_NetIncomeLoss $ (4,239,564)us-gaap_NetIncomeLoss
Weighted Average Common Shares outstanding - basic and diluted 22,517,361us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted 17,383,786us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted
Loss Per Common share - basic and diluted (in dollars per share) $ (0.16)us-gaap_EarningsPerShareBasicAndDiluted $ (0.24)us-gaap_EarningsPerShareBasicAndDiluted
XML 35 R12.htm IDEA: XBRL DOCUMENT v2.4.1.9
Notes Payable
 3 Months Ended
Mar. 31, 2015
Notes Payable  
Notes Payable

 

7.Notes Payable

 

Notes Payable consists of the following:

 

 

 

March 31,
2015
(unaudited)

 

December 31,
2014

 

 

 

 

 

 

 

Term Loan and Revenue Interest Agreement with Three Peaks Capital S.a.r.l. (“Three Peaks”) for a total term loan amount of $25,000,000 which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of March 31, 2015 and December 31, 2014 resulted in a 10% rate. The Revenue Interest Agreement is for a period of ten years. Royalty payments are base on a royalty rate of 3.75% of revenues up to a maximum of $30 million in revenues in any 12 month period.

 

$
25,269,050 

 

$
25,085,777 

 

Long-term Notes Payable

 

$
25,269,050 

 

$
25,085,777 

 

 

Note Payable

 

On October 5, 2012, AxoGen entered into a Revenue Interests Purchase Agreement (the “Royalty Contract”) with PDL BioPharma, Inc. (“PDL”), pursuant to which the Company sold to PDL the right to receive royalties equal to 9.95% of the Company’s Net Revenues (as defined in the Royalty Contract) generated by the sale, distribution or other use of AxoGen’s products Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector.  The Royalty Contract had a term of eight years. Under the Royalty Contract, PDL received royalty payments based on a royalty rate of 9.95% of the Company’s Net Revenues, subject to certain agreed upon minimum payment requirements, which were anticipated to be approximately $1.3 to $2.5 million per quarter tobegin in the fourth quarter of 2014 through the third quarter of 2020 as provided in the Royalty Contract. The Company recorded interest using its best estimate of the effective interest rate accruing interest using the specified internal rate of return of the Put Option of 20%.  The total consideration PDL paid to the Company was $20,800,000 (the “Funded Amount”), which included $19,050,000 PDL paid to the Company on October 5, 2012, and $1,750,000 PDL paid to the Company on August 14, 2012 pursuant to an Interim Revenue Interest Purchase Agreement between the Company and PDL, dated August 14, 2012 (the “Interim Royalty Contract”). Upon the closing (the “Closing”) of PDL’s purchase of the specified royalties described above, which was concurrent with the execution of the Royalty Contract, the Interim Royalty Contract was terminated. On November 12, 2014, the Company paid PDL $30.3 million to fully extinguish the Royalty Contract.  The Company has no further obligations under the Royalty Contract.

 

On November 12, 2014, the Company sold 643,382 shares of common stock for a total of $1.75 million to PDL (“PDL Equity Sale”) at a price of $2.72 per share pursuant to a Securities Purchase Agreement by and between the Company and PDL.  The Company intends to use the proceeds from the PDL Equity Sale for general corporate purposes.

 

Term Loan Agreement and Revenue Interest Agreement

 

On November 12, 2014, (the “Signing Date”), AxoGen, as borrower, and AC, as guarantor, entered into a term loan agreement (the “Term Loan Agreement”) with the lenders party thereto and Three Peaks Capital S.a.r.l. (“Three Peaks”), an indirect wholly-owned subsidiary of Oberland Capital Healthcare Master Fund LP (“Oberland”), as administrative and collateral agent for the lenders. Under the Term Loan Agreement, Three Peaks has agreed to lend to AxoGen a term loan of $25 million (the “Initial Term Loan”) which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of November 13, 2014 (“the Initial Closing Date”) resulted in a 10% rate. Under certain conditions, AxoGen has the option to draw an additional $7 million (“Subsequent Borrowing” and, together with the Initial Term Loan, the “Term Loan”) during the period of April 1, 2016 through June 29, 2016 (the closing date of each such Subsequent Borrowing, a “Subsequent Closing Date” and, together with the Initial Closing Date, the “Closing Dates”) under similar terms and conditions. AxoGen has to maintain certain covenants including limiting new indebtedness, restriction of the payment of dividends and maintain certain levels of revenue. Three Peaks has a first perfected security interest in the assets of AxoGen.

 

In addition, AxoGen entered into a 10 year Revenue Interest Agreement (“Revenue Interest Agreement”) with Three Peaks. Royalty payments are based on a royalty rate of 3.75% of AxoGen’s revenues up to a maximum of $30 million in revenues in any 12 month period. In the event the Subsequent Borrowing is drawn, the royalty rate increases proportionally up to a maximum of 4.80%. AxoGen has to maintain certain covenants including those covenants under the Term Loan.

 

Under the Term Loan Agreement, AxoGen has the option at any time to prepay the Term Loan, in whole or in part, and the Royalty Interest Agreement, defined below, by making the following payment, and Three Peaks has the right to demand the following payment upon a change of control of AxoGen, sale of the majority of AxoGen’s assets or a material adverse change to AxoGen: (i) on or prior to the first anniversary of the applicable Closing Date, 120% of the outstanding principal amount of the Term Loan or any portion being prepaid; (ii) after the first anniversary but no later than the second anniversary of the applicable Closing Date, 135% of the outstanding principal amount of the Term Loan or any portion being prepaid ; (iii) after the second anniversary but no later than the third anniversary of the applicable Closing Date, 150% of the outstanding principal amount of the Term Loan or any portion being prepaid; or (iv) after the third anniversary of the applicable Closing Date, an amount generating an Internal Rate of Return of 16.25% of the outstanding principal amount of the Term Loan or any portion being prepaid. In all cases, the amount due is reduced by the sum of interest and principal previously paid and all amounts received under the Revenue Interest Agreement. In each such case AxoGen will also owe an additional 3% of the originally advanced Term Loan amount. Upon payment to Three Peaks, AxoGen would have no further obligations to Three Peaks under the Term Loan or the Revenue Interest Agreement.

 

In connection with the Term Loan Agreement, on the Signing Date, the Company and its wholly owned subsidiary, AC entered into a Security Agreement (the “Security Agreement”) with Three Peaks, pursuant to which each of the Company and AC grants to Three Peaks a security interest in certain collateral as specified in the Security Agreement to guarantee the payment in full when due of the Secured Obligations.

 

Also in connection with the above transaction, the Company sold 1,375,969 shares of common stock to Three Peaks for a total of $3.55 million (“Three Peaks Equity Sale”) at a price of $2.58 per share.  Pursuant to the equity purchase provisions in the Three Peaks Term Loan Agreement, in the event that we sell prior to November 12, 2016 our securities at a lower price per share than the $2.58 per share paid by Three Peaks, or where the terms of such subsequent sale are otherwise more favorable, then in such case we have agreed to match the more favorable terms of such subsequent sale with respect to the shares purchased by Three Peaks. A subsequent sale does not include the issuance of securities or options to our employees, officers, directors or consultants pursuant to our approved employee option pool or any other employee stock purchase or option plan existing as of November 12, 2014.

 

The Company records interest using its best estimate of the effective interest rate.  This estimate takes into account both the rate on the Term Loan Agreement and the rate associated with the 10 year Revenue Interest Agreement with Three Peaks.  The effective interest rate is based on actual payments to date, projected future revenues and the projected royalty payments and the quarterly interest payments due on the Term Loan Agreement.  From time to time, AxoGen will reevaluate the expected cash flows and may adjust the effective interest rate.  Determining the effective interest rate requires judgment and is based on significant assumptions related to estimates of the amounts and timing of future revenue streams.  Determination of these assumptions is highly subjective and different assumptions could lead to materially different outcomes.

 

XML 36 R11.htm IDEA: XBRL DOCUMENT v2.4.1.9
Accounts Payable and Accrued Expenses
 3 Months Ended
Mar. 31, 2015
Accounts Payable and Accrued Expenses  
Accounts Payable and Accrued Expenses

 

6.Accounts Payable and Accrued Expenses

 

Accounts payable and accrued expenses consists of the following:

 

 

 

March 31,
2015

 

December 31,
2014

 

Accounts payable

 

$
1,966,422 

 

$
1,160,859 

 

Miscellaneous accruals

 
194,985 

 
105,315 

 

Accrued compensation

 
1,261,865 

 
1,165,020 

 

Accounts Payable and Accrued Expenses 

 

$
3,423,272 

 

$
2,431,194 

 

 

XML 37 R23.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Details 2) (USD $)
Mar. 31, 2015
Dec. 31, 2014
Summary of Significant Accounting Policies    
Finished goods $ 2,188,691us-gaap_InventoryFinishedGoodsNetOfReserves $ 2,072,235us-gaap_InventoryFinishedGoodsNetOfReserves
Work in process 272,470us-gaap_InventoryWorkInProcessNetOfReserves 331,891us-gaap_InventoryWorkInProcessNetOfReserves
Raw materials 876,737us-gaap_InventoryRawMaterialsNetOfReserves 809,494us-gaap_InventoryRawMaterialsNetOfReserves
Inventory, Net 3,337,898us-gaap_InventoryNet 3,213,620us-gaap_InventoryNet
Inventory valuation reserves $ 575,000us-gaap_InventoryValuationReserves $ 404,000us-gaap_InventoryValuationReserves
XML 38 R19.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangible Assets (Tables)
 3 Months Ended
Mar. 31, 2015
Intangible Assets  
Schedule of intangible assets

 

 

 

 

March 31,
2015

 

December 31,
2014

 

 

 

(unaudited)

 

 

 

License agreements

 

$
851,603

 

$
850,859

 

Patents

 
111,303

 
79,996

 

Less: accumulated amortization

 
(365,453

)
(353,681

)

Intangible assets, net

 

$
597,453

 

$
577,174

 

 

 

XML 39 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
Subsequent Events
 3 Months Ended
Mar. 31, 2015
Subsequent Events  
Subsequent Events

 

10.Subsequent Events

 

Commercial Lease

 

On April 21, 2015, AxoGen Corporation, a wholly owned subsidiary of AxoGen, Inc.  (“AxoGen” or the “Company”), entered into a Commercial Lease with Ja-Cole, L.P. (the “New Lease”) for property located in Burleson, Texas. The New Lease supersedes and replaces a current lease with Ja-Cole. Under the terms of the New Lease, AxoGen leased an additional 2,100 square feet of warehouse space that will be combined with its current 5,400 square feet of warehouse/office space in Burleson, Texas.   The New Lease is for a three year term expiring April 21, 2018, renewable thereafter by agreement of the parties, at an annual cost of $60,000 per year.  The expanded Burleson facility will house raw material storage and product distribution and allow expansion space as required for AxoGen operations.

 

Processing Agreement

 

Under an Amended and Restated Nerve Tissue Processing Agreement (the “Agreement”) with LifeNet Health, AxoGen processes and packages Avance® Nerve Graft using its employees and equipment located at LifeNet Health, Virginia Beach, Virginia.  As a result of business requirements of LifeNet Health and their need for additional space on April 16, 2015 they notified AxoGen that it will need to transition out of the Virginia Beach facility on or before February 27, 2016 and therefore is terminating the Agreement effective February 27, 2016.   AxoGen’s planning has included the establishment of manufacturing space under its full control to meet its needs as it continues to expand its revenues. AxoGen is formalizing its plans and has sufficient time to establish new manufacturing space under its control that will meet its future needs.

 

XML 40 R13.htm IDEA: XBRL DOCUMENT v2.4.1.9
Stock Options
 3 Months Ended
Mar. 31, 2015
Stock Options  
Stock Options

 

8.Stock Options

 

The Company granted stock options to purchase 269,500 shares of common stock pursuant to its 2010 Stock Incentive Plan for the three months ended March 31, 2015.  Stock-based compensation expense was $368,249 and $257,542 for the three months ended March 31, 2015 and 2014, respectively. Total future stock compensation expense related to nonvested awards is expected to be approximately $2,275,000 at March 31, 2015.

 

XML 41 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
Public Offering of Common Stock
 3 Months Ended
Mar. 31, 2015
Public Offering of Common Stock  
Public Offering of Common Stock

 

9. Public Offering of Common Stock

 

On February 5, 2015, AxoGen entered into the Underwriting Agreement with the Underwriter, in connection with the offering, issuance and sale (the “Offering”) of 4,728,000 shares of the Company’s common shares, par value $0.01 per share (the “Common Shares”), at a price to the public of $2.75 per share.  The Company also granted to the Underwriter a 30-day option to purchase up to an aggregate of 709,200 additional Common Shares to cover over-allotments, if any.

 

The Offering was made pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-195588) previously filed with the Securities and Exchange Commission, and pursuant to the prospectus supplement and the accompanying prospectus describing the terms of the Offering, dated February 5, 2015.

 

As of February 13, 2015, the Offering was completed with the sale of 5,437,200 Common Shares, which included the exercise of the over-allotment option, at $2.75 per share resulting in gross proceeds to AxoGen from the Offering of approximately $15.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by AxoGen estimated at approximately $1.4 million. The Common Shares were listed on the NASDAQ Capital Market.

 

XML 42 R16.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2015
Summary of Significant Accounting Policies  
Revenue Recognition

 

Revenue Recognition

 

Revenue is recognized when persuasive evidence of an arrangement exists, the price is fixed and determinable, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Revenues for manufactured products and products sold to a customer or under a distribution agreement are recognized when the product is delivered to the customer or distributor, at which time title passes to the customer or distributor, provided, however, that in the case of revenues from consigned sales delivery is determined when the product is utilized in a surgical procedure. Once a product is delivered, the Company has no further performance obligations. Delivery is defined as delivery to a customer location or segregation of product into a contracted distribution location. At such time, this product cannot be sold to any other customer. Fees charged to customers for shipping are recognized as revenues when products are shipped to the customer, distributor or end user. Revenues from research grants are recognized in the period the associated costs are incurred.

 

 

Cash and Cash Equivalents and Concentration

 

Cash and Cash Equivalents and Concentration

 

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. Cash and cash equivalents are maintained at financial institutions and, at times, balances may exceed federally insured limits. The Company has never experienced any losses related to these balances and does not believe it is exposed to any significant credit risk on cash and cash equivalents.

 

 

 

Accounts Receivable and Concentration of Credit Risk

 

Accounts Receivable and Concentration of Credit Risk

 

Accounts receivable are carried at the original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts on a monthly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions. Accounts receivable are written off when deemed uncollectible. Recoveries of accounts receivable previously written off are recorded when received.

 

In 2013, we established a reserve for doubtful accounts as we did have some accounts deemed uncollectible.  We regularly review all accounts that exceed 60 days from the invoice date and based on an assessment of current credit worthiness, estimate the portion, if any, of the balance that will not be collected.  The analysis excludes certain government related receivables due to our past successful experience in collectability.  Specific accounts that are deemed uncollectible are reserved at 100% of their outstanding balance.  The remaining balances outstanding over 60 days have a percentage applied by aging category (5% for balances 61-90 days and 20% for balances over 90 days aged), based on a historical valuation that allows us to calculate the total reserve required.  The reserve balance was determined by applying a percentage to the cumulative balance between 60 and 90 days and a higher percentage to the balance over 90 days.  In the event that we exhaust all collection efforts and deem an account uncollectible, we would subsequently write off the account.  The write off process involves approval by senior management based on the write off amount.  The allowance for doubtful accounts reserve balance was approximately $101,000 and $94,000 at March 31, 2015 and December 31, 2014, respectively.

 

Concentrations of credit risk with respect to accounts receivable are limited because a large number of geographically diverse customers make up the Company’s customer base, thus spreading the trade credit risk. The Company also controls credit risk through credit approvals, credit limits and monitoring procedures.

 

 

Inventories

 

Inventories

 

Inventories are comprised of implantable tissue, nerve grafts, Avance® Nerve Graft, AxoGuard® Nerve Connector, AxoGuard® Nerve Protector, and supplies that are valued at the lower of cost (first-in, first-out) or market and consist of the following:

 

 

 

March 31,
2015

 

December 31,
2014

 

 

 

(unaudited)

 

 

 

Finished goods

 

$
2,188,691 

 

$
2,072,235 

 

Work in process

 
272,470 

 
331,891 

 

Raw materials

 
876,737 

 
809,494 

 

 

 

$
3,337,898 

 

$
3,213,620 

 

 

Inventories were net of reserve of approximately $575,000 and $404,000 at March 31, 2015 and December 31, 2014, respectively.

 

Income Taxes

 

Income Taxes

 

The Company has not recorded current income tax expense due to the generation of net operating losses. Deferred income taxes are accounted for using the balance sheet approach which requires recognition of deferred tax assets and liabilities for the expected future consequences of temporary differences between the financial reporting basis and the tax basis of assets and liabilities. A valuation allowance is provided when it is more likely than not that a deferred tax asset will not be realized. A full valuation allowance has been established on the deferred tax asset as it is more likely than not that future tax benefit will not be realized. In addition, future utilization of the available net operating loss carryforward may be limited under Internal Revenue Code Section 382 as a result of changes in ownership.

 

The Company identifies and evaluates uncertain tax positions, if any, and recognizes the impact of uncertain tax positions for which there is a less than more-likely-than-not probability of the position being upheld when reviewed by the relevant taxing authority. Such positions are deemed to be unrecognized tax benefits and a corresponding liability is established on the balance sheet. The Company has not recognized a liability for uncertain tax positions. If there were an unrecognized tax benefit, the Company would recognize interest accrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company’s remaining open tax years subject to examination by the Internal Revenue Service include the years ended December 31, 2011 through 2014; there currently are no examinations in process.

 

 

Fair Value of Financial Instruments

 

Fair Value of Financial Instruments

 

The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include cash, accounts receivable, accounts payable and accrued expenses. The fair value of the Company’s long-term debt approximates its carrying value based upon current rates available to the Company.

 

 

Share-Based Compensation

 

Share-Based Compensation

 

Stock-based compensation cost related to stock options granted under the AC 2002 Stock Option Plan and AxoGen 2010 Stock Incentive Plan is measured at grant date, based on the fair value of the award, and is recognized as an expense over the employee’s requisite service period. The Company estimates the fair value of each option award issued under the Plan on the date of grant using a Black-Scholes-Merton option-pricing model that uses the assumptions noted in the table below. The Company estimates the volatility of its common stock at the date of grant based on the volatility of comparable peer companies which are publicly traded, for the periods prior to the October 2011 merger of LecTec, Inc. and AxoGen Corporation, and based on the Company’s common stock for periods subsequent to such merger. The Company determines the expected life based on historical experience with similar awards, giving consideration to the contractual terms, vesting schedules and post-vesting forfeitures. The Company uses the risk-free interest rate on the implied yield currently available on U.S. Treasury issues with an equivalent remaining term approximately equal to the expected life of the award. The Company has never paid any cash dividends on its common stock and does not anticipate paying any cash dividends in the foreseeable future. The Company used the following weighted-average assumptions for options granted during the three months ended March 31:

 

Three months ended March 31,

 

2015

 

2014

 

Expected term (in years)

 
4.0 

 
4.0 

 

Expected volatility

 
76.32 

%
81.26 

%

Risk free rate

 
1.28 

%
1.12 

%

Expected dividends

 
0.0 

%
0.0 

%

 

The Company estimates forfeitures when recognizing compensation expense and this estimate of forfeitures is adjusted over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures are recognized through a cumulative catch-up adjustment, which is recognized in the period of change, and also impact the amount of unamortized compensation expense to be recognized in future periods. The Company did not apply a forfeiture allocation to its unvested options outstanding during the three months ended March 31, 2015 and 2014 as they were deemed insignificant.

 

 

Use of Estimates

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

 

Recent Accounting Pronouncements

 

Recent Accounting Pronouncements

 

In April 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”) which changes the presentation of debt issuance costs in financial statements to present such costs as a direct deduction from the related debt liability rather than as an asset. ASU 2015-03 will become effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. We do not expect the adoption of this standard will have a material impact on our consolidated financial statements.

 

In February 2015, the FASB issued Accounting Standards Update No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis” (“ASU 2015-02”) which updates the considerations on whether an entity should consolidate certain legal entities. The update removes the indefinite deferral of specialized guidance for certain investment funds and changes the way that entities evaluate limited partnerships and fees paid to service providers in the consolidation determination. ASU 2015-02 will become effective for public companies during interim and annual reporting periods beginning after December 15, 2015. Early adoption is permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements.

 

In January 2015, the FASB issued guidance, which completely eliminates all references to and guidance concerning the concept of an extraordinary item from GAAP. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

 

In June 2014, the FASB issued updated guidance related to stock compensation. The amendment requires that a performance target that affects vesting and that could be achieved after the requisite period, be treated as a performance condition. The updated guidance is effective for annual reporting periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted but we do not anticipate electing early adoption. We do not expect the adoption of this guidance to have a material impact on our consolidated financial statements.

 

In May 2014, the FASB issued a new standard on revenue recognition which outlines a single comprehensive model to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is designed to create greater comparability for financial statement users across industries and jurisdictions and also requires enhanced disclosures. The guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016; however, in April 2015, the FASB voted to propose a one year deferral of the effective date. The proposed deferral may permit early adoption, but would not allow adoption any earlier than the original effective date of the standard. We are currently evaluating the impact this standard will have on our consolidated financial statements.

 

The Company’s management has reviewed and considered all other recent accounting pronouncements and believe there are none that could potentially have a material impact on the Company’s consolidated financial condition, results of operations, or disclosures.

 

 

XML 43 R34.htm IDEA: XBRL DOCUMENT v2.4.1.9
Public Offering of Common Stock (Details) (USD $)
In Millions, except Share data, unless otherwise specified
 0 Months Ended
Feb. 13, 2015
Feb. 05, 2015
Mar. 31, 2015
Feb. 13, 2015
Feb. 05, 2015
Dec. 31, 2014
Public Offering of Common Stock            
Offering, issuance and sale of common shares under Underwriting Agreement         4,728,000axgn_OfferingIssuanceAndSaleOfCommonSharesUnderUnderwritingAgreement  
Par value of common stock     $ 0.01us-gaap_CommonStockParOrStatedValuePerShare   $ 0.01us-gaap_CommonStockParOrStatedValuePerShare $ 0.01us-gaap_CommonStockParOrStatedValuePerShare
Shares of common stock sold     24,926,014us-gaap_CommonStockSharesIssued 5,437,200us-gaap_CommonStockSharesIssued   19,488,814us-gaap_CommonStockSharesIssued
Public offering price (in dollars per share)       $ 2.75us-gaap_SharePrice $ 2.75us-gaap_SharePrice  
Number of days to underwriter to sell additional common shares   30 days        
Additional Common Shares to cover over-allotments   709,200axgn_AdditionalCommonSharesToCoverOverAllotments        
Gross proceeds from issuance of common stock $ 15.0axgn_ProceedsFromIssuanceOfCommonStockGross          
Underwriting discounts, commissions and other estimated offering expenses $ 1.4us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees          
XML 44 R21.htm IDEA: XBRL DOCUMENT v2.4.1.9
Notes Payable (Tables)
 3 Months Ended
Mar. 31, 2015
Notes Payable  
Schedule of Notes payable

 

 

 

March 31,
2015
(unaudited)

 

December 31,
2014

 

 

 

 

 

 

 

Term Loan and Revenue Interest Agreement with Three Peaks Capital S.a.r.l. (“Three Peaks”) for a total term loan amount of $25,000,000 which has a six year term and requires interest only payments and a final principal payment due at the end of the term. Interest is payable quarterly at 9.00% per annum plus the greater of LIBOR or 1.0% which as of March 31, 2015 and December 31, 2014 resulted in a 10% rate. The Revenue Interest Agreement is for a period of ten years. Royalty payments are base on a royalty rate of 3.75% of revenues up to a maximum of $30 million in revenues in any 12 month period.

 

$
25,269,050 

 

$
25,085,777 

 

Long-term Notes Payable

 

$
25,269,050 

 

$
25,085,777 

 

 

XML 45 R26.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangible Assets (Details) (USD $)
 3 Months Ended 12 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Dec. 31, 2014
Intangible assets consist of:      
Less: accumulated amortization $ (365,453)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization   $ (353,681)us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
Intangible assets, net 597,453us-gaap_FiniteLivedIntangibleAssetsNet   577,174us-gaap_FiniteLivedIntangibleAssetsNet
Amortization of Intangible Assets 11,772us-gaap_AmortizationOfIntangibleAssets 10,955us-gaap_AmortizationOfIntangibleAssets  
Licensing Agreements      
Intangible assets consist of:      
Finite-lived intangible assets, gross 851,603us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember		   850,859us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_LicensingAgreementsMember
Licensing Agreements | Minimum      
Intangible assets consist of:      
Amortization period of intangible assets 17 years    
Licensing Agreements | Maximum      
Intangible assets consist of:      
Amortization period of intangible assets 20 years    
Patents      
Intangible assets consist of:      
Finite-lived intangible assets, gross 111,303us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentsMember		   79,996us-gaap_FiniteLivedIntangibleAssetsGross
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentsMember
Amortization period of intangible assets 3 years    
Non-amortizable pending costs     $ 79,996axgn_NonamortizablePendingPatentCosts
/ us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis
= us-gaap_PatentsMember
XML 46 R5.htm IDEA: XBRL DOCUMENT v2.4.1.9
Condensed Consolidated Statements of Cash Flows (USD $)
 3 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Cash flows from operating activities:    
Net loss $ (3,575,201)us-gaap_NetIncomeLoss $ (4,239,564)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash used for operating activities:    
Depreciation 41,898us-gaap_DepreciationDepletionAndAmortization 33,944us-gaap_DepreciationDepletionAndAmortization
Amortization of intangible assets 11,772us-gaap_AmortizationOfIntangibleAssets 10,955us-gaap_AmortizationOfIntangibleAssets
Amortization of deferred financing costs 33,746us-gaap_AmortizationOfFinancingCosts 51,216us-gaap_AmortizationOfFinancingCosts
Share-based compensation 368,249us-gaap_ShareBasedCompensation 257,542us-gaap_ShareBasedCompensation
Stock grants   60,125us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims
Interest added to note 183,273us-gaap_PaidInKindInterest 891,845us-gaap_PaidInKindInterest
Change in assets and liabilities:    
Accounts receivable (289,280)us-gaap_IncreaseDecreaseInAccountsReceivable (71,458)us-gaap_IncreaseDecreaseInAccountsReceivable
Inventory (124,278)us-gaap_IncreaseDecreaseInInventories (67,661)us-gaap_IncreaseDecreaseInInventories
Prepaid expenses and other (150,579)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets 101,230us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Accounts payable and accrued expenses 992,078us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities (175,196)us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
Deferred revenue (5,396)us-gaap_IncreaseDecreaseInDeferredRevenue (3,571)us-gaap_IncreaseDecreaseInDeferredRevenue
Net cash used for operating activities (2,513,718)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations (3,150,593)us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Cash flows from investing activities:    
Purchase of property and equipment (6,288)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (195,482)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Acquisition of intangible assets (32,051)us-gaap_PaymentsToAcquireIntangibleAssets (8,346)us-gaap_PaymentsToAcquireIntangibleAssets
Net cash used for investing activities (38,339)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations (203,828)us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
Cash flows from financing activities:    
Proceeds from exercise of stock options   92,424us-gaap_ProceedsFromStockOptionsExercised
Proceeds from issuance of common stock 13,772,133us-gaap_ProceedsFromIssuanceOfCommonStock  
Debt issuance costs (180,142)us-gaap_PaymentsOfDebtIssuanceCosts  
Net cash provided by financing activities 13,591,991us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations 92,424us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
Net increase/(decrease) in cash and cash equivalents 11,039,934us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (3,261,997)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents, beginning of year 8,215,791us-gaap_CashAndCashEquivalentsAtCarryingValue 20,069,750us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents, end of period 19,255,725us-gaap_CashAndCashEquivalentsAtCarryingValue 16,807,753us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental disclosures of cash flow activity:    
Cash paid for interest $ 803,607us-gaap_InterestPaid $ 303,919us-gaap_InterestPaid
XML 47 R10.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangible Assets
 3 Months Ended
Mar. 31, 2015
Intangible Assets  
Intangible Assets

 

5.Intangible Assets

 

The Company’s intangible assets consist of the following:

 

 

 

March 31,
2015

 

December 31,
2014

 

 

 

(unaudited)

 

 

 

License agreements

 

$
851,603

 

$
850,859

 

Patents

 
111,303

 
79,996

 

Less: accumulated amortization

 
(365,453

)
(353,681

)

Intangible assets, net

 

$
597,453

 

$
577,174

 

 

License agreements are being amortized over periods ranging from 17-20 years. Patent costs were being amortized over three years. As of December 31, 2014, the patents were fully amortized, and the remaining patents of $79,996 were pending patent costs and were not amortizable. Amortization expense for the three months ended March 31, 2015 and 2014 was approximately $12,000 and $11,000, respectively. As of March 31, 2015, future amortization of license agreements is expected to be $36,000 for the remainder of 2015 and $48,000 for 2016 through 2020.

 

License Agreements

 

The Company has entered into multiple license agreements (the “License Agreements”) with the University of Florida Research Foundation (“UFRF”) and University of Texas at Austin (“UTA”). Under the terms of the License Agreements, the Company acquired exclusive worldwide licenses for underlying technology used in repairing and regenerating nerves. The licensed technologies include the rights to issued patents and patents pending in the United States and international markets. The effective term of the License Agreements extends through the term of the related patents and the agreements may be terminated by the Company with 60 days prior written notice. Additionally, in the event of default, licensors may terminate an agreement if the Company fails to cure a breach after written notice. The License Agreements contain the key terms listed below:

 

·

AxoGen pays royalty fees ranging from 1% to 3% under the License Agreements based on net sales of licensed products. One of the agreements also contains a minimum royalty of $12,500 per quarter, which may include a credit in future quarters in the same calendar year for the amount the minimum royalty exceeds the royalty fees. Also, when AxoGen pays royalties to more than one licensor for sales of the same product, a royalty stack cap applies, capping total royalties at 3.75%;

 

·

If AxoGen sublicenses technologies covered by the License Agreements to third parties, AxoGen would pay a percentage of sublicense fees received from the third party to the licensor. Currently, AxoGen does not sublicense any technologies covered by License Agreements. The Company is not considered a sub-licensee under the License Agreements and does not owe any sublicensee fees for its own use of the technologies;

 

·

AxoGen reimburses the licensors for certain legal expenses incurred for patent prosecution and defense of the technologies covered by the License Agreements; and

 

·

Currently, under one of the License Agreements, AxoGen would owe a $15,000 milestone fee upon receiving a Phase II Small Business Innovation Research or Phase II Small Business Technology Transfer grant involving the licensed technology. The Company has not received either grant and does not owe such a milestone fee. Other milestone fees are due if AxoGen develops certain pharmaceutical or medical device products under the License Agreements. No such products are currently under development.

 

Royalty fees were approximately $96,000 and $61,000 during the three months ended March 31, 2015 and 2014, respectively, and are included in sales and marketing expense on the accompanying condensed consolidated statements of operations.

 

 

XML 48 R27.htm IDEA: XBRL DOCUMENT v2.4.1.9
Intangible Assets (Details 2) (USD $)
Mar. 31, 2015
Future amortization of license and patent agreements  
Remainder of 2015 $ 36,000us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2016 48,000us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2017 48,000us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2018 48,000us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2019 48,000us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
2020 $ 48,000us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.1.9 Html 63 162 1 false 17 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.axogeninc.com/role/DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R4.htm 00200 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations false false R5.htm 00300 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.axogeninc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows false false R6.htm 10101 - Disclosure - Basis of Presentation Sheet http://www.axogeninc.com/role/DisclosureBasisOfPresentation Basis of Presentation false false R7.htm 10201 - Disclosure - Organization and Business Sheet http://www.axogeninc.com/role/DisclosureOrganizationAndBusiness Organization and Business false false R8.htm 10301 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R9.htm 10401 - Disclosure - Property and Equipment Sheet http://www.axogeninc.com/role/DisclosurePropertyAndEquipment Property and Equipment false false R10.htm 10501 - Disclosure - Intangible Assets Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssets Intangible Assets false false R11.htm 10601 - Disclosure - Accounts Payable and Accrued Expenses Sheet http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpenses Accounts Payable and Accrued Expenses false false R12.htm 10701 - Disclosure - Notes Payable Notes http://www.axogeninc.com/role/DisclosureNotesPayable Notes Payable false false R13.htm 10801 - Disclosure - Stock Options Sheet http://www.axogeninc.com/role/DisclosureStockOptions Stock Options false false R14.htm 10901 - Disclosure - Public Offering of Common Stock Sheet http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStock Public Offering of Common Stock false false R15.htm 11001 - Disclosure - Subsequent Events Sheet http://www.axogeninc.com/role/DisclosureSubsequentEvents Subsequent Events false false R16.htm 20302 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) false false R17.htm 30303 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) false false R18.htm 30403 - Disclosure - Property and Equipment (Tables) Sheet http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) false false R19.htm 30503 - Disclosure - Intangible Assets (Tables) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsTables Intangible Assets (Tables) false false R20.htm 30603 - Disclosure - Accounts Payable and Accrued Expenses (Tables) Sheet http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesTables Accounts Payable and Accrued Expenses (Tables) false false R21.htm 30703 - Disclosure - Notes Payable (Tables) Notes http://www.axogeninc.com/role/DisclosureNotesPayableTables Notes Payable (Tables) false false R22.htm 40301 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) false false R23.htm 40302 - Disclosure - Summary of Significant Accounting Policies (Details 2) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2 Summary of Significant Accounting Policies (Details 2) false false R24.htm 40303 - Disclosure - Summary of Significant Accounting Policies (Details 3) Sheet http://www.axogeninc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3 Summary of Significant Accounting Policies (Details 3) false false R25.htm 40401 - Disclosure - Property and Equipment (Details) Sheet http://www.axogeninc.com/role/DisclosurePropertyAndEquipmentDetails Property and Equipment (Details) false false R26.htm 40501 - Disclosure - Intangible Assets (Details) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsDetails Intangible Assets (Details) false false R27.htm 40502 - Disclosure - Intangible Assets (Details 2) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsDetails2 Intangible Assets (Details 2) false false R28.htm 40503 - Disclosure - Intangible Assets (Details 3) Sheet http://www.axogeninc.com/role/DisclosureIntangibleAssetsDetails3 Intangible Assets (Details 3) false false R29.htm 40601 - Disclosure - Accounts Payable and Accrued Expenses (Details) Sheet http://www.axogeninc.com/role/DisclosureAccountsPayableAndAccruedExpensesDetails Accounts Payable and Accrued Expenses (Details) false false R30.htm 40701 - Disclosure - Notes Payable (Details) Notes http://www.axogeninc.com/role/DisclosureNotesPayableDetails Notes Payable (Details) false false R31.htm 40702 - Disclosure - Notes Payable (Details 2) Notes http://www.axogeninc.com/role/DisclosureNotesPayableDetails2 Notes Payable (Details 2) false false R32.htm 40703 - Disclosure - Notes Payable (Details 3) Notes http://www.axogeninc.com/role/DisclosureNotesPayableDetails3 Notes Payable (Details 3) false false R33.htm 40801 - Disclosure - Stock Options (Details) Sheet http://www.axogeninc.com/role/DisclosureStockOptionsDetails Stock Options (Details) false false R34.htm 40901 - Disclosure - Public Offering of Common Stock (Details) Sheet http://www.axogeninc.com/role/DisclosurePublicOfferingOfCommonStockDetails Public Offering of Common Stock (Details) false false R35.htm 41001 - Disclosure - Subsequent Events (Details) Sheet http://www.axogeninc.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) false false All Reports Book All Reports Element us-gaap_CommonStockValue had a mix of decimals attribute values: -4 0. Element us-gaap_DebtInstrumentFaceAmount had a mix of decimals attribute values: -6 0. Process Flow-Through: 00100 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2014' Process Flow-Through: Removing column 'Dec. 31, 2013' Process Flow-Through: 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: Removing column 'Feb. 13, 2015' Process Flow-Through: Removing column 'Feb. 05, 2015' Process Flow-Through: 00200 - Statement - Condensed Consolidated Statements of Operations Process Flow-Through: 00300 - Statement - Condensed Consolidated Statements of Cash Flows axgn-20150331.xml axgn-20150331.xsd axgn-20150331_cal.xml axgn-20150331_def.xml axgn-20150331_lab.xml axgn-20150331_pre.xml true true ZIP 50 0001104659-15-034272-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-15-034272-xbrl.zip M4$L#!!0````(`-6`I4:4E_$(_W<``*1"!0`1`!P`87AG;BTR,#$U,#,S,2YX M;6Q55`D``]$B2571(DE5=7@+``$$)0X```0Y`0``[#UKM'UAO?:X_M;$T^N3"TY$X031JPK?GU>[IY""200$(2DIE4 M)A8TI\^[SSG].OWGQ]@4WA!U,+&^-*26V!"0I1,#6Z,O#<]I:HZ.<>.?9W_[ MZ^G?FTWA@B+-18;P,A&^(4JQ:0H7A-J$:BX`$)K-H.&_OS[<"@;1O3&R7$$/ MOGK'[FOTW5>*C1$2A$Y+DEL*]#S]^JOF0&N`Q\'(+2EZ$_9/K&.ATU;:LBAU MA,&Q-#B6!\+Y-[_=QPLU!:#+"YNSU"Z`5-O^8:_^N\-;28#!H\[=14P!DX*AM'&ZW[;\,FVH? M(RL!5/L@(V1A2V_I9,RI%15%"IMCAZBRU%M$I=\BC@HNP!10@)&FV=$70\UY MX:V#%PPCM2E*S2E.GDLS.QBTX6W8T$`S/'&0WAJ1MS:\2('[X>`T=@-4J?WO M;[>/^BL::\V(`-`#03AE8CAV^*L'-!2X6([=B8V^-!P\MDU&*'_V2M'P2X.Q MOQDRN?7A&`VA[0-BJDO`8&U\:EYYO!\\2_,/@/#^1 M9^59"7X`8<^W:*295Y:+W69?/3]`]ND?:'\Z%9F-7,[^A\0NBSP&7 MGV^)-7(1'5^B%_<)L)]^^8#>D.6A&\"!(L>]]ZC^"EIZ/@*`S/1F`#UHULC_ M.GSR3?O`8V_LM_.Y!D0ACF#P"WYC@ST98D0%SDV4$$4HN(N;7QIG(ORO+W8& M^39PC#YL$^LXP%DP,+3SW1(P[GB&<8TS1O]Q!N=. MVZDP"W4:<.@XC?E![_FX7R8RD0`;9^&CA`27]77:3O+_M)T0]:F-*"9&3%JN M1MU+<+EG3(.918H2P(B>1@V19<2:*6"X#+01:W3:C@$_;0=VL\B(Y&=%9):C M,C-BOR3_5VU'M1WMLQVI34EN*N(R._*;E6!'$C.>R(ZFOVH[JNUHS^U(`AO) M84=^LW7M*#6H"Q7W!K*F,7ITH0-&SRW1^5<)Y7Y$)D2;HW/+^*;1/Y`+?U]] MV,!35&U]#T6[@,:I_)<1>5`ARK,4.58EBD]JE:B22JCY5$)=3R7.G>>[88I; MN*<$`+B3>U.S7&#`U9\>MADI7R?1R!D-JPB<]2LQC9NQ3Z&0ZRC0Y0K M#RB7DEIU,<>J!K5'KII'CA+<'4KX$$UW^RYYEY*L??+>R#G*F_K/DL(D+?.* ME/C<\7]D%J3N+V\9D>[D43-1R<6HJFI&=I$IA1M[56!:*YV3FV*_*2G+TCFY M*8E-L;-VAI_05/BAUII::VK)FLJ:J645'C90U'^"I[=$LV#`.51%W6W=OC"# M]RCMJO6QUL,@U_DZ^:;]3NB%J3E. M(G6\!V>]-^6``@1.$\@$A0NXI0;R&;!M99H\B_';*` M,ZFMNK!3*D6U">_2A#=5_ZMMN(HV7%I(5KF%:555D:HF"A6HLFQ[$9CXK-:5 MZ[H>N%(]D)6DU0U7KK=8#]Q7+:Q&<67O0NU:DSZK)I42WLO!3%IGXV(N9B,R MGZ-9RT96CUP_CB[>(K!S M0G>V0K[CIT]5&P0Z/##?Q!33S@G=V3S+9@LZ=>BX+Z%C>0/$#H]0J!5L'^HM M^Y7]UIIWD)I7SF18!69#ZFWZ5=;0(LAL>YO^+K+WV@\?HI;O7//J*;YZBB^G MPD4S=Y5;JIJY2F31$`_]5'Z(W\W:F76'WCAG#V99;90K*3LO><5L4BEY95H] M"M2CP$;3OV@4B.9+V3!0G3C[S<+*#%:[A(IU.-8:9V34ZJZ=5N:>0:I/[S"97WM11ZM*/>LM2%;8L MK;;LI:1CF+<7O!ZD8FQMI]-.`T4QW6?L9-#:]^+@X0YN>U.`5'E)?'L^=E_, M9Q]*"+7Y[+Q,L6WSV=:U1?7BS>HNWMSQE3_%_'>M@@>O@MRY;=$';O%0@EH' M]T<'MU:"59_EF=H`/YW[G%(6B3`*DDKTO]H%F8M='[T7!_WI0>.KM_@7&>^K MK8")4\I3^!#H0YP19:I@!B]CUYND,7.S]4FU*:]?GYQJ&GBZ6NUJM>Y3K?B8N<<\M@GM]Y0#K";QJK'HYBN@D_[MX0'8B7 MVJ3B)5&N0OEH"_0MA;@-^IIRUT^M)LNN]$0.5I:SQ%57EK-E`B61I)5CIOM> M]-]5?)5SU0RBU?E:&7LU;Y*?6RJ&NJ];)2>KD/095(6V''P]^;S5\M M[`J/2&<*W&SZCSWVC)'+7DK=B$@#OP&"T\Y9N^_>&('ZDX2?'R/-\2@ZPPY1 M9:EW_.OCY6D[?#BU[/3O.=A+9)$QMK(`,Y^!CYU7C2(G"_(\B--VC`*_41K! M4X4-`?,ASZ;$\'0WV5TV%'4.BN?28^?/86X(RAP$GVP;_LP+0\Z`D<:Z;"AS M0#(%&XN%1REK'BCO`QJF MF*+`>N:O?)P%`^EXK)G.EX;8.).D;D>4Q=/VDCY6163J[9;@(7>E?K=3"`_# MP.R-9D*[,;$>N>R>R`6!C)5EK>>F25R^%"^!V.)Q:09-.8[GS??KQEE/',AB MQ+#\.,0QAX?OFJ6C:T(OB??B#CTS##,3D>7=SH$KT&W97F:R2<$KS[8P)FA[U6965T<$719`A`R98ZR M.-D4:7?#!Z295Q#@NRB\K'@Z-J<(N#IDJW,1ABQ-"5]*6XP1;!7*#20YU&/X M?]4<[#S:`,"XLZ[Q!S(>`,"=S3Z3,QSA[E87+3(0SA1P#5+`E`)TELJ=G2W_ MVP?F[&AQ[K99X[_7S*D!?B64DG=LC3*RC.H859PWS2[+9,28C\U/9R9S[GE% M!>OWVH3_I-C2L0U`+"-<$Y_!H[W<&;&(O1UPXYUL]N;@U"?F;6#SVLMV[X<\0(60Q>(N;*)>44SI3GA2A*\$. M+H4',M%,=W(W]%&9BK'R+&#V%[%@,2T)LAT=F:9F(>(YO`X%`,LHM(D=1>I$ M^&1WLCHNN6MM`W70+XC*=Q@"QH2Z^#]^^F$9(!%_-_0%<;(J;!O?8[Z8T-Y@ M,.@&="XC($&K"_KA.P_(PMB@RNKE0-"\YBPF?#O;J6.UNT*HQTGV&*B[(4M9 MG\BOEH'H.P4W2M3'%?I*P77>W_BP>$0+F'0,8E=2:OM`;[.A,D27C=LB"Q73%&3`<@EI; MHQO'\5A]!`9QAO;=,*XF'$:D4G'9I'`H?\U?[%PFVJB?>@S@LIB]D\@\\R$0Q]@+\M,'!#I-D1_-PXC!,_CA`W(]:N6K[U;$9!84 MA`L2&V/3`W(0?6.%Y/D"\B7#QOC5THEILLGF_`7QY267L-ZRZ#/*R8CIV'S(I27%#(,K6_:8Y5X0*C:BA/%2X1VPPG M6`WB;KBD;%B5*>FS>^6W@+X9O&,4L;+I!:*NABW^K3,M6<2Y<4?Q",,SD;%U![+"Q%D8A91"\"(&IH6T`,]SV8I=5J@+`=TB-HS_C^8\ MX-$KI)"7:`P-SH>L>O2*J7%N61"64$>C$Y"=S9;.LVCSPB0L]F!KMO>`[U)7 M[F1Q?HN<6B2P,,$LVO4UIHX;Z_JKYWY%0T+1(P*Y'(+XI):2*;R=<6T3HISK M.\+J4"Q1:I4NR;695K(D[ZP[>D\QH4]D5LGV5VIRB5(KSB!?0NQ8HG.(&PP6 M.UR;VJA`HMTX&P(YZ+0]!V0*.YBAN\:.KIF_(8U>^5N2"G73#+?&+((X[?.2 MZ'Q:W6\23C+I7I$B0N/L7T%_F="R.F0X%>^._7]:AQ&T^>Y\7%9A:'PG52;$ M^0Z9PA?J1Q*;_TKVP$!,`?O6=X%8.=V\`;W^^`5-"O40WWV5"7&NPVG)UI\$ MB9E9BM^(;EM?.O\BJP.Y"_XE@R("G:OAB7>>VW"5T3#*.=OXKG%V@LV,9N9*&$9 MA:PJDC0`15BAWS(1SKO60E%E1>[)6\+W$EP;C$0>A!.`[E<3;*.0X'\RW1,# MO_TT"Q8&QER$\`SNV MJ4V.!6R9V$)^KS]I8_O$>G'L$]:\S=K'D6G;9:$F+D*-<;F)+;95-WJ%B"X%F"^##A4"WA6"YOY--6OE2WH$"QN4AJ2VU+)U,%4@6_^T8_[6` M_RC@/W,C#F8+O,+4F>2Z.?_F]# M>.-FQSIP73)N)/'M#%I*_\>3`+\9@-GL9^QJOOJF*8G=5K?WXVHB65,J28D$ M$G*-8CP0I5:W)![$W!PK;"*Z.E>2!.>@$10&U,IB\YF+Z97Z+5']\210.)?8 MQY+M"A:QD/##Y8#](X0ON99EOO6A\_<.,;$A_."OS(@:!&/5W/<[976_H/XM M&(;Z(?[?-*J_3D6F2$=S:OI"A?::HU[4'8NW-F('/?63V4&WMH,R[>`2Z;S0 MME534#=B"N(>#PG^;YKXO2`R`-5/#PM>-/V/$87XSF!Q":''P@\7%U=7U]=% M.2.$_TH+V13$L$)36CFO*BN,W5B841I/RPW""KO99;3*_3G7FNX<<_O6U/=9 MKK4:;"Y#-?^K?%64NJW>_,A7#?'DY*T4);Z^;^4=G32@FW>JV5\:_G^C5"R6 MJ`U-HKG)*D0[*%M)1X-N]TB5Y:DYK!]/54,3-V_PBEA1C:H-OC;X3(.7NN)1 MOS,HR^#%`QCARXH>#RU&3&QV]6N#?J?,4?Z` MA=7=L;#$SI$BE2:LLO+Z_?'#GRJ+Y_-.>NSHSSJ3/Z")@ZI&D7)7.NIW2QU0 M/J5V[;8<7U7MDKJ=(U$6ZQRESE&VM#ZFZ,"[)]/SU2F6E5L=!WP%@WA,O-N< M>JR+8FN+89<#BW*DRLJ1W"NUVGU89EIN3;LVT]I,BYNI?*0J$`,.U$]?`?%_ MLBAFED?AVPHO%;63L17T^:4A<3`+*A1Q&H7XCV);`E)6]B_<'E#.U3!BOS/( MQ#//+H4R#JOL=E4Y>P/%0BRFYPU]1VX9NT_Z/5D1^_/(I'6T%DJY]Y=(7:G3 M7Q4C;^R9FHN,2V13@,JK;?"WB=@?3`^#$S/9S_#H^7M3LUQXQTZVF3]OL:B. M]92.S.Y\*!NIK9&:6X][O9[$3E38,*73DQDT;-Q8P6[;V&:Y=<35ZW=[G6Z_ M&Z-B:7\EX)>7QP.YUY6Z@]X:Z.6Z?:,$3S)0^?EW*_5;+LJY%5B42D,YIM=W MPVML`1@(97(>)*SD9'%'DJ6XIB[HM"3T9K;3+?'<2D\M'3UP#"Q2\.M%N^!D M'($-H+TI#N=%>_:\N_)X+(F#3B<+V=EN2T.Q$#\E&,/D%5',N,=FSV[FZ:@) M#YA!U`SI\U(H&B1UH=M>/QZ)I[$XJY^\XI7[DM(9R-T\W9217JBJ)(F)T#4. MNEBON6GL0ANI,\?*U$[Y#3'1'6NS9QC4>ZD/>"^U5-&]U+.3-H5G?981SG6> M[?&]I\AA![ME+,#8G%[LJ\KFD=?3*V*K#OV3/`*'8K#Y.WX<("^(LGQ0&/K! MB68*?&#Q3^K%EFYZ!N*[K[5P3A`D%9S6,>4".[9#^`=KQI_]\`$.Z>(D.#]D M^NCR1"`TT<2'%&_QWWRR$4-'[Z_$-"<">;<`/P>&3VQ@C4Z"WH4+0FWB.T3A M'PF8%S/P.,[SNRT%YC5Y;ZD[T-AKE;\>`M*,-I>=*"5`&N>^"OY5WH[`CG`R M%@)G8%HQA8G^8J*98]'@Q"DDHE?M#0DO"/@!";VM46B'+2XL:K!427C'@*TV M'5!L_THB$U1NA"Q$V>&)[#VR7?];1BD;R.`7.V(&^1(?`[VZQ@ER7HEG&M"I MP&XR8Y\`FK][%K]`VN^/*XQGX$RT@RW]`?D1AR=(HP%+LV5R!)J!=2"*HE!# M(\3]:QN#,VP$0`=2Q?$4A"0V?PGT(2[87-UFRA"S#7IX7$AL#'?/"EG$-=XG M@-C88FP$#,$7:'[X>02<'K)#RP60EJ`9OWM.<,NT!>@Z[&@P3HLF##5,F29, M'2D`@I^>"8U#4/B%5 M-SF?6P*D\8(#`Q$>0GOP9AQXX*&F;H;QA!W\XVAKT!M)..;E\*VY"!X;HJ!@.4=4!@-%W2`%,!+H MDPH>15;2COYJ#3G%LY,%R2#G$*A+$-,?>^QPU"E13-`\*.!_Q$3N/R26SD^* M9)_N^4"[RW01PF7!]B"Q'Y8%PC,X2'J*T@9 M0D(3@Y@,\`$O+,H+[TAU6`_\.@`CR$X@U'4]BMV)WV6493DL781,Q1%NYQMV9H9J,P5JXZ;,O27`9L(Z!-Q\./K:P^:4! MS@$U"D:?[1+[61##I'033.7?:_2.\BJ)P<-$"%SXR<"%Z.AFW"!?H+\R$,RZ MF[(BZ&7*9Y/X^<<\GWON*Z%@0:E7J&3*=?Y0Z>`20C$5N=F^UD$JDUF;Q8E= MI;CR/3,I5YJ@4,([I*?#KX;+X5/J2!35W*OV*:)7+ISQ895:@ MRG$?B4MA5;9`LI/I^=*J/N4@FM-?S"*K=$I'-O>Z":YS)?:<>^T$5ZO\'3ON MW?!G0@SGD9A&>86WGB@I27K1%4!GD18=?\W$0UB&M-1^=C-N-0L=N%$F;?!1/HS(9G M682L3NY&[\3,3ZX_DFR>WHU>?+D3IEW$?#">BC_+=/[_K.^;X M5>-2IHM80EFY3-FA[_S_]M[UN6TC61S]?JON_X";3:J<*HI+\$W[G*V293L_ MG^O$NI:S6^>3:T0,2<0@P,4`DKE__>W'#!XD*/$!BJ"$2B4126"FIZ>[I[NG M'R?`";N*'J:22G4BQ`;LV^!D=6%E(J0J;%,5A%2%98ZPSG2XGY[;3I3 M6^Q@;N]DPY?7:_P?U\/_W;1T7,*>2WQ"'6KKA=JM,U_IJEYPW=]I01,9AM+A M?"M)9N$?@3_FA(L_Y$$Y)(-1ISO*L=`CDQT.V]8.@LYHF.U3N"=HFLI*R;>Q M[>$Z//D)]@1BZY"C@V%(4798:8->9]C:"$@ZR?ZP;)]6.QH-"^CD45`>3QDO MS\W4Z8RZ.1@?G[QD<'=R1G7MX6AX$+A)M8W/DZM,)=(O'#-"S$N.]+<8-W,M MEG3-7<%`MZJ$/SS7/+'A2\T3XU(-GQ<E:[/VKT6BU+T94>Q0/2E8Q^!9Y3,4:FP3N8P07BIF7QOGVD^$Q,#L%R M(D4I58_D4A7FJ-#8%[="K=9OUDU$K7NAK)\[_6&CW1U1;-S/[=Z@T>NV]X`@ MR>;"=!RU8*>"MVQ:7P/0;:U)'('TUI@H!"83_^<'_AVH\!@?>"]"1^E(/QB3 M?[^5EE@LPN`''#$13`)P-]J#7@/KCHEH,X[.FQ&.%+)VX-F:/ZC?B]`'D:E, M[!!Z(L=4S,&+(WG(K6-_Q<%UT6JV,RK0(Q.7!^7#BD\!E-E*';M!.5]XP5+* M&QG>N6.9[D%VE_XPK'))G$+,EOT=M^^/(/I?"4".@ZF_:TC4ZIUSFZ(",BLZ M%I`KN&`AH6GR:_`.^]Z[MQ2D_#GDR0&Q@,H_,3#^/G0QNO&#W'2EF@3F8>$*)D=D-(@X*OBV4P1`PDX/[)1,?-?NLQ\!^JT+G_5[W6QZ\C&!S[RDM9/+";#Z_TH1?B#YN/LYHO$O#4X7Y%2U5AX..A!>W/`J@J!.61UI]ZF,G:(Q@CB0S;E M\#7`_(>N@2[H3KD(`N#@5=P')UW#?;#U"GX+`_5P8;[D&5 M)Y3*U1C\!/:IK]`<,U?"ZO$X1"S);2T/)KYQW7G?[=:YD.@G]7Z-XJ(Y(DO6,8V]\[O M`HSA>)[@K-VJD?8XTF">+-+L0=E(^XT+\F&@@#.'5Q05-+F36MLHL?3S<-0= M##+'X2,SEP?F;O6"1J"79&WBW_?WNO,66[#'LG:OEQ,"035\@@B]T]C< MRTGIL^J&I8EUU0P54N_M.T3)A=9BC)98JT^UMR M0=(8CR4:5?OR+?;EDP];C&>Z^FF(!7Y"JBI$%XIFR4 MQ#XD$0JM>]?S=%TE+%CKX=4KSD@528NF11K@.J,*^X:Y@'X' MZROA:@K&%^I1N#1Z"15`*7@B%$/U$>#0_6,:YJTX`C3])R$N*JV;W$JLDQI? M;<`.XT4T%;&ZE5RN"F\X4(!8%$#N4YED=2.IT&HFJF38QL4)7,M6=*^^!ZFZ7]&@H/5@41H>!]0'/"BXK M$RV;UDT,<*2PH5!T4"TWL5"Q'Z:Q'1DV8E0)$%PA7I`&7,K"B)8E156M,W%. MKA;4<-/R7T\G,N.1?"Y&*##O1*/R'O\#.-P$=;YRWCU5TTZ>Y'+(`'5R`9H) M&]N,!P`G>=$<4(@;^$MX)/219Q-)D;]4+;Q"#8W9@J_Q8K%^L\)2[']A+6J` M1_X05(F9"(!W>4VXZ+B97#%Y'NB!BMOI!X#&QB"]()[.*/KNC<:R/IFQ>CE5 MH\X"0ZL%:L7JU+5\VE\^5>+F=I,ELV;OY*K%?O2W:7)98G5>>]"SLQ[F_0`Z M^J)VJSDR:K<&PZ=:4]K#K<3:+7:WM]4"TLE+!G'HW8V3:@,>%?R>\HL M2-T;V`_!NC)SF8#NA-6+7N=ASMP1T(\^MO`"W:5,`=(?]/L/8C,S:UD`[N:- M:W?;#PN#'2"\QFXEKF,0;V(H?.5]UP5-H*OC0'SN&MJI4\UZ+S75+.4"2S-MG6Y6NL,C;VVZ*5 MJR+C:)@$Z*`#"GI]WNC/2,![UXEF@)S6+PD=1ZQ.2L_3_(*2GCZKA1B;S_K] M6W11AQ=CP(Q8*/G:_/&&!X;M:C5A\#5>S"\O"I./_-E!KRAP)4X01<'\ISR\ MO4%S`(-J^%8&W(Q^1-?%C!G/;O6;_<$O^VW)@;N2WQ&]0Y&S&PY:=G-8$@Y* MN@7#6?,+WF*-0#!`5C[F<3V\7GM(Z]4$%P6+U_8BPB1&:?WMW0C_LO?)0_HHVSM_9.B>K@C_3UPR`P-_.LIG&MD>AM:?S_P3$NF M0W7L.'S0KOF@YH/]";/8_7MD5N@>A17L,SX2^'.8^UQK!K5FL)]$+)9I6XO$ MPM]?C$1\E32&_;4^L6OZ/#6JZU,O00&03_&1=RO&WZ=A$/L.6N-!^-KZV]75 M^_I2WKZMHIIV1MV[8;G3).LGJ+CK5%@U%C-.I7PUX['Q'[@JPSJ=1K#!PW M%78LDT>UAL[!*MC/<5N3W\'DU^LT^D/[F-;) M\R._4ULR[:HQ4OYM<*1[2?-*%@_3Z: MTL&Y&H%V?F#F_YT,K075W%)6B%H<_#P)@[EE#R[:+4Y(;UKLO`9#3,$XE,9? M.!#WC-'O7%)ED\(P1MTMANHDL%N/7UU( MKG&PR$**K].O6+K`>'R`F`"X;'EG4Q?@@-8WU%!GI3.-W>:V--A=Q[;Q[]4& M.8RB#6,GA4ZRKBI\WEO?VO4N.3]W^C2[65-HZA7C"`GH/W>'R5/P93]34*#= MJ@L$[,!^^U>K,IQZ61PY4N-]SSPJJEE"`5-46PK88AY[D;OP9!$'O4(F25.O MKHJV)?GUW9M?K7LWHA(QUI\^<'.H=.V7#UX0NHZPOD@ED:^M#^@L8=Y]E1W_ MSP]?/N1'1(;,#_95_D"Q$EF7L8K;UK4:88EF`SGRF2(K:\D7VA% MC*EB%G:4&'NQPAKD]T'H.:`^)*A2NL0+4B[UAXCD>.8'7C!=6K$B!%N45!O2 ML4"%=TSQ+_@"_K@S157TB$XZ!%=A2:N@D.)$#=9KE8?RAT(Q@0CRV`"H'M-18]V&$FNI M"2S:OP;'UV(L8>*ST%!]ETM-?9Y+?=QNI1?(RR6U^;QCS,Y8_@-Y`""Q108;`4'E;\P@9K>8/A%Q0CG5]T,;T- M$I4["L%AB!7ZE/"XH&)R)H`"[<1CE-.?_:234=:&\51@Y`T69IMS[>$$+#0+ M0._&7IQ@U5C_CD4(TJBA*[JA6#0'C;#&<.9AA4+?*-KZ:64DK!)S;,_DP1$@ M0C)K$G4:=/(8*[;!GZL@P"DJI0+2U@*\%?"W@MQ/P'R=&#JGX-M'X<_KY&!T\J?): M(-FIY*\;HC(<1B1O])A^T&/+ MAP\]-`L2B()[!B6%3*\>13N6K`SN?;2IC(#/@EQ+Z%I"UQ+Z!4IH+=9"Z04U#M3R185WIA*<^,SVCT.^J*2XY@+?*-PDA.2604B MYW')_X:&J`53+9AJP?3B!%-&]6(5*$CM]B+'74+!,J2*\/T) M*E38=)@50G(I6]UQSYR^P^7X>"44[U>@:B+U3^`O?N63*ZIM&`]C8A9@(?P.; MRF%.0^L*`WOHED3A3<[R&0L@\J6>C2[>P$^V1Y8,:0]R*B*)P& M!_&@>3,A0^X.>T6M'?[;0=%O]A)SF.WRR_=O]APK71%@"B'\#2%D2S,6H5-% M$*\"WP9U&$0:3-3G5L99S0<'$.9SJF5^QJR0<<@_L69PU`)!SUESJ*A\?,&5HX\A'W>WU^H! MSV_`MAR@4>II])NV,-AHS^R4\(X_-2M!CG4I%\)TA]6 ME_1;@W:CW>F51?KV,R#]LM2)YZ8T_"L(OV,TWR(,QE(=3VLX#RK9UTER4G8' M9N\.6F6><\]XL[JGW:Q.QVX,RU-*:G/N^9IS7\2]A0'>H2N\VII[1M??U=0: MAX-^8]`9U.;265\I5Y2V6J-&=]2M[9'ZCK:^HZT+5C\;%U#_!1>L[C0ZG0'8 M,L.7:WC6;'H>;#I\T6S:MCN-?KLT_]#9NASX8R5RT\\X@XC+K$M*Y0@YUQ#_ M7$E([PUZ:49ZM]7E#]&#>>.4)=Z[*R__OM^QV-NE]%RCR M"_CDBEO7"!UJ?> M_SO&,OX'K!M@:+4&P^)U%\YV,&S;8\CN]$;M?@F@Z0I2!Q%(M]OKV.U"8/3P M>TR_=2F";F?0&;5VF#WPIU]E.'\G;Z.Z&L&3J[99-V8&0PG&+&W&&+MMT&QG M8\+W#`-/U>9!0>VL37'F.\+:S5N*.E5GU%12=QOMMIU)O%.GM\SR*@O M4QU;1W.*C*"&)!CZ_U*1#<<>4+MF^- MI66*&Z?%^+DA[%D[:9.:<-Y,\>]%/%0 M;_9'`A,P+B'V(JZ'+X!\?K%"F(O[1SRP\Z[2FP;@N@&O5/J$2]6T3+G_%&NA MI'Z:6%8_;?R(,^&;U-*1PS%H0F7%"^RA)JRY^$$=*Y$&.M1WP\/N&=3"63^* MXW!H+2TOU9E*H?43K@R>/.QJWX,<;D@ M]?^12_\7Z739X\RH$T0J<3:\G`21XVA]-9_6?%KS:?5UM?/@TQ6-C#_NFLE5 MTGW2(7>750@KW+\=%VIXA0K>V449GC20\[-O?1Y'0ZUA+>(0\T0B=#&S!SW*-$L&>>S@+S@P?D^B#[_0W9.U]QK3 M-N2_8[RP"*Q1<\0.[,Q`Z:2C-[@3D<&!LEX)A7WL`;WD=L>75E?ZJS65/C:2 M3=O98[?:!G8RCT+W-J8NTD%H!=2-.5;D2&?T[[D8OW M=976!!=J46S M,(BG,]VYV@V=_!/M%M[8P;QWKK-9`.0[N(=XI/'3^BH.F\1/+1<1C1_A7UJ% MP:J<3#C;.'V#L"_&XS"F-_,#D8!9R+$[<,-I=BR441SZ9O#K.+(^+U@" MX8I^V4AJ?*5+H?Z.;HM-9+/`-KR`Z:S@O0>L_-QN-89\T;M^&GR(J?/W)5T+ MK\ATWN6DN??/-MF#-,ZF^8*'3C%*^[8;@\?'N(RGL8K2(3#9&\?('3/"YY// MG:]?JA8.69&FEY2PTK/3D6H,YQBV9+P-[F3"IX*R(<*+G M'W(<&XHK%D?X[::UTK@HX%P?L=>T0(7Y`Z;-7XKCQG.V?A;QM.](`#]W6B`? MC%R`79W$'D@-4#D!*[&K9L6,O(DWS/@8B>#C8"$=Y<$M*/C<0-Z*-TK?5ZF6#?`$R%G$!<)$989#\B21TD3 MSP'?43@;:I@X!%59EO#=)`SF?!KDET/X8.45)7^X".@0`<@7@9*J)MQR+-V5 M0*UTVQ\.V:JQ?RRQL79T9=3 MT!>%3]V,5^SH3'3<9K.Y@"P*+&?J@RSQA,%XM#`B*Q,4O8`@.3RJ#U<$8#N@ MBN,!/`O@L+P([M'H!84>%$)7A$L4;Y/Q+.NMD8!=[O0J'BC*J? M]>DZ/[%Y;W5690D';0(PE`6IP-R_V?,PB`Z&%U/$&HJI#`JRIDX!_AHYA%#P M(%L@@"X<`?^O/1_93>+8Q>0T*-#-0'P#2,F,*_OT/$,5"]BHH\,1VXZQP%+)O?IT.G/7:4DN#+B]A M8[T,'@F-_<0$_9_8E^FO[9'^^556SW>TC2<%;)"*X3]%:P.^LC:L?]/6/(:" M['OK6,C^NA(NS&JQ!-0<28#)(R`%.2*P,HVU&G,F# M`5&5MWPX0#!"X1:HRI=*4?6N"'2RK`%B^`@^.BZ:\J@H(11K-Q;M=A21K-LM4^;6C@*AE.2L>5[BO@I5?9E0=,A_3)E_DRO;;K$< M?B`Z.B%RP`+3P4$!Y@#:$V`AL+"%LZ4`N"Y6N]^+H:,96!R97^+U$[XV1_;GE4<4 MIN)3%NU;(*D(`,-]7(02J#L_2`/I#O5%B=H#=O8!S8/UXZPK9)V?&LFMRJWT M@OL&FL!S\=V$@-P/3\01W>@GDHS2Z)GOK9>N;^FQ,*W0:`- MH%K+3DH^4D!!.Z8M+K\&6RW6XE?/H@C%<'::<&)]ICFY.3W MG2Y&0%(Q*P/^^36)SK,W`&D65#&)--VL0W@;8\2"1:HZ/")8T,!A&*`RN\M2 M.KTC+,6BM10OI@#(XM7PG%J=@/'@?-'A=/0R<>9^Y6^:A)="WD^8S) M!`>B&\3*T\Y@,JP\`YI*+\$R_MJ-AS[!ENK:8W+:L:B\=W%03P56<"]7[)!. MBB803BZ?EB`;\$[7R:"%8=+N?".H0"!DI%PBFN^#V'-`YH&)O,$!G7^QZ`"U M@D<77!^QAZBC8[YY1AI/+*C"\U9?WV3=3GEG-I(M7ABR*\9:=<4`65RMZKHW MQ@IY($AC_9F']=JB``SBA_R%L/:'65,JX+E*B:+80$JUP=3;HW(7FXRC]67! M^-KK)F7.OH-7\)X'``6.0>FAP:0Q8,C/*;O4E+X_I5^BV'.+R9UN"*T(-D>) M,9MF:YDT>[UB3T_VK>VO;7K#]-JF\)[E.L,$ M9$SQT,G=*04(*)+"FFJS@!1*`#=OE@%,]ZB6>%ZJ%V[T8/?A^`T-4^&-$JW( M0]>T7E=Z"Y5H,BOKY-,1CM0@@*9[%S`P M#^#C1-P%(6H;M.=DGJ;G)BR/3J_4%PMJLX[GRK_]R,1$:KI$N]D034=F0U87 M!A;IVC!.(/$N-S*!"#2.JZL2T^0I?C%V:Y&'R3L> M[+#\X2I6XC9Y;?7E1RWW]I=[ZU$^&7_^?D$^&ZYU0>M-!HC$=[XW"#`BB!3C MVT!+6_8F^9L4C<0.YW@BI8*Q2Q$IB;C>PD&VYNO:=!.]*8[)S0:8C:,XO=@@ M=G)(^0&&^(N]J9,83`Z9.K;,&M(GUN+7S"/IO4<"0?(,J0,;,56XJ`]T;:Z] M'_C_1D[[AU?OJ%*]U&$O"P8/Q-W,FH`X-CYF5/[_BE6T,R&\DQP'8[PBFS"< MW"[]%3O39..S>%>H:8*<0B$$=!#/M3@+I6="[`S!)55>C M8)]0BGDQ41CP1<87KV1N?H!QYDYGL&,Z<-#<`3HNK)7BBK*/C\D*\J0P!PCY M7>#M]'&P3$&7./_@A7QH:6F-.PJKA!<7$J<?%SH\]N'N&'5U_6=47;_]4JOK?PZGPG?_PTM54) M%'PD)=E:A=HJX[EP[HRUCD;CSS`R^8 M8F<;-OX<^DGKS7C1OIB1_]*GK!ZZUP@Y*62<"1P?4[P57TEX[ECZJ)L+/*?^ M'=.3MQE5&3-??'PZ.V8*"WHE,,5&7S2B"P2O8T1(D484CH=>,QC%)>N'C+@U M2%W_KQC[[#6+L]&",)H$GAMP.(RY*8+W"#6`VC1A#3%W)UR/=`/MV\)S%Q9P M$Z%1T;"NA"\<0:M7<(0C%._C,%A(@9Y$L#2HXQ\9+NR1.8,T.`H;G%S`:B_4 M3'KLQI3AF(V2%",+[LH%V)C%0,L:_?!0,,6!:*]N0]>9(N$1=LS.\]:!4"E#-3N3ERR*[VFA* MT@6+T01(,`R)*0`DG##U7]^0TKO,\O#;JBQ0.DS5]0%78Q8I1O2@*S,*8^WI MG[E$T.2Y)G(-@(`C])QBD&HDQK.\4P8P^C6(Q[/2,-JVV^T24GT+<8W*IUOS-_@ M$:2!.'>?R$DUAFJ?113^G9PR12>F!L(Y%P_K@!:!\".,UYBOU4$=,KX4A!`L3,90+2.!I MK_1$+UO:O�CN2W7G>^K3CG9'0EU.Q:I^J_7?X)3NUN1VU#P/KR9:XXJM\I(%LIS>R1]D6R4^P2FQS3#?< M3[61%^U69]@>/KK(+0%[LD7NM)47G6&G,WK2-7XVI\>3;63'[K5ZH\ZCJ]P2 MLB=;Y6X[V>[9G8'].+WNNTI45N;R$]@@)6Y-M]T9]?IY>9E.M"\,.[)`;]"# MY[:$X?Z28S``68!9'_X<<_6:Z\!SQTO^;]U^N1HFW/ZN]B\2$^VL=+.M_&Z? MN9)VXCCIE4Q8)'\.$]4:@_"RF+_1GFUEO0W0P9WS_'VXO'F;=_V1)\HI'N#/ M!670_A$T\[-?M#J-E8(`\X7G3I;&,W,=2@7[GOAF\(;:^FBB!:\"%>7R7O,P M7M[\:>E9BG+&V8FOS:Z5>3"Q-8U*'.,\%.66(?VWI'')MK/_6: MUGM!6>Z.CH5$)PB&'$54..A?&.5),9X99BD>"%Y*+$UH.QZBF*5U` M!UB3")^/.:@3:\`2RHHVX07;O&4(A@_R-HSQ9K-(-@"G[\G<[3QS7R6[2`'D M7X,%T.K0;OWZVKJ$7702=N+(]>S#E[[PELK=BMG;1-7-V:.J)6:IQ'*EN*H.F;MV>*1 M?)OCCB]1TQ@EMZ*W,@WJBJ`?#*`0*F/N%&JNP3\8ZF=`794I*%^`7KMU@>%C M=17C`$8TGT#@C2<3Z((E(G9PEK!2?P@@4-N&`U4]X)W&Y6D*V[H!9,-%GTR\ MGLTQ>DDS)'/C"3@U+*1+7=26F&SXDPBCE,4T4)@F^F[@8`KM1A!X(JYH'$&V MM;/D2Z"E.4/_\Q-,_+]A%"K3)JED'&5JZEB!+&SAK=TIQ[,X>:O]`I"N MNS!1(/G9!XDF`V\T0SB"?R2_9PJ*'0#72O/V4J]3"36=S4Y3D@9@2OMGXFS& M]OWB5;&73LJHV]HIE=S'MIKL6LUR?ERVG%=DN^Z'T?PCW766IUEH3A,\$Q;>^P>!#M237G@F:XPN:H1C[Y^)FN?:, M42RG;V75BO'8HMQ&N?9ZJEPA'DL64;:7NO1L:@/6?^G) MD0#OVE-4S3CJU-:T$FFLO_SD8"]J?TV?HEIC%$N0?4[D+M:D5G`(`A\EA!\#5;>Z?44A9)9V%G#;W0;TDO,@A) M`LK`H]%[B27N'(51Y2M/HCHVO*ZXZ^N#Z_]'OOFZ!#4.SBNEX66;N@(<&I? MR^54X_PNV;(Q#-5)-#5;0!/)ODM*4VD\OJ)62)RU]4';%FC+DZ7]ES,L@9#/ MLYQR:[;V0=:VR,J4IB6!D^HBN4)Q.[N#O+$/LK9$5J8PM5O@M'&5E&V/JZ3L M!U?;XBI+F);8#-4D,IJ0_K9*V+46/UC;`FO%$N58,>M[AU0\AJ[#`BJ;8?RX MG&&<8P$U/9&XY190;3&#?;9+-L3++5&&,#^+)-6R!?"MHOZYGA,A%T01KH M=2_4S!=^JD*D4/A>K6DJ.I##HXK31X](/!D^Q$G6$ML[Z*'*(ZUC*B%O`. M?!-7--AOB08K@H\GY\Y\3G97*4H(0C(Q?HO)3W,?9,BS1Q##1Y1*`.'*2:1Q MH]82J1O)F+I9^09]$$8H`!F0AVYB>Y9+'5+S8C<)DN;T`+\!'50\V2-6QEA*U@+?D%]<2 M#5JZWTKGR

P+KB6BMD(RD4D&8L^-PM"SKUC

>0[)?$@M`?3%$=?%,?`R MW(JO*YR47U?(OS#(/I&\3YQ]9)!_I2\O+F08PEQ.CB\*CN;42#AU1/[U^63_ MX/3P^&@XU/804#4);J#S!'U(-U2YKS(?;8V6C)M#5#56GCK:DH)1SG,;H++^ MR_$@*VRB)@X/V*7?"PL4)="IH4N9`UO?7S3?5[P#7K4EE;9,7874 MB=N.[;I%$/*DECRW-*3XXD%^`I$D9NL0KIF`UH7ZX#TH-X^:XO M8]17E#1F=//%7ARELB@ZV.V'P/TT12]['H"I?L@/FVHAO_K]!DP=_S(@8V-1 MX3]74<(8-:@*>:4>652<[7GM:\0Z.DJ[6>GRMOEG8[0C*^-UK0BAF.HN,'X" MF&SWO7-G#LF2^#?@^-'S.9%.I2.:3!6C-"G4R\;.MPXV4U6;9,VY`\Z/,$/# M5BFCJ#&JK*V;#?6JX-2NUI:B^U`P)7V8T=7FD7R,XVQ>5=08"M1?-97A&17" MM=EKK@-Y=6'C="BM";$2>[CD4F?#&^0$Y.Q[#UY`$--L'X!H(;J+L?OL%/R* M.#.V:B/&DT!^D6X'NW9Z='$TO1%XA3-*KPOH4#\YZL_R*@@[-5PV.F$U6R_H M`"E:F3BKQ691PYG`UV?U,` M;=&:*!J#)NR[&YV;C)M'V4JH"IM&-M4^+-4Y M)1BH;H[.-DY(#0";JOW\T"<^$ENG30E@1B7(V-(5G@$Z55]495%Q%-J/*SR- MVI&5L>P5GNDS8\OW/)HU)]1#G3N=[E3804CFQ#XG&O8BF*]UJ,L M'J.6NJTG5.SEHB>'R:CT30TR)QJ@(KZ@&8HQ^5!@1.9$4Q3+Z5M9M6(\MBBW M6>;$?BI7B,>2U?*=WG(R%5_CEM.X[!!YDHM"2HQ;$&6FJTHS'J^"X.2Y\@BIDA-JSBEG"A%DPK)_S`+H+]4YE1E*^^&6/+H.]B+5(3O-=R8 MK`--P#V0_CG>.+B";\"CZ,9)SP^JMBD*U==E=-17AK0"N],T5IFPDFSTD(WR_=VAV'@PKF3O9672$`\[4@T8@E76@3? M:7(LY>M:UO50"NH17;[1/(`Q#)^S\R+-#%CA^BA9RR8ZU$2;Z?^+T=>#XRI"B`0J5 M5HM8HQR$VAU>.@E3,U!]'!UL[)PE@)FJM>V&EA[W6\T.E%Y!3,K.K&_ M#&D%=J?1B9I<^O1&)_:74.UA[S0ZL:V`LW68XZR/(\^#Z4]G"&/T"H/IYB%7 ML;8E[&@#=2\"$3O,W]-S[:L#[33R\+@EA7^?H^`_'?G/`>3I^C1W0!9J3`.!CC.]JS1W0%<1B-@H!, MDSAT\&(\&G<1R%IZZ*\V]78$YLH:I`$.XW`;&NR:T->HPGIXZ:D MSN+H#$P0!@_`1:2,MO'03N\^QLC6I-IM]*IQ`Z!4!2*J"K3-H;+%_E@].'3+,1\.W=RU=#8<5H?IXCEKC.$4DM_Y MBY'W0D,NO5QZX]=5M"&7UW4:7A>L`:_KMDG0U@22,\VJ!U>SPWZUW:.ZD"5L M40"7:]Z0JY5V-'^.9C,4/$3(_?'P3&0JG"NLU5 MMGNU3HM_.#YS2M@L9B\1V/!R!C2]`#&,`0GS[S!T6;I?%;!,ZP)@N;Z[N=A8 M:KO3W!8)I=,;G3!+1;&SIAAF:HLOP_W-U!9)8X.LM65J"],36RP1C"=DF-/\ M:DZ:,<>GGEWG*(S"A`BT@UZ6BS%D)'>QEBOZ-%*3GOC1/Z6\8A2S_X`Z^9,R,TPZ-2K//%J1EB:MZM;B4F/CN MR,3C@[X0OW;X<#F;^V@!P`/`+V0%KQ;`+0I>0$A$F@R<\!%%CE_\.Y7T+8K^ M3>^[730-X!_,$U%GW[.8E=N564ONMF5B=[I#NXN??.B.)Z2',)@FDL^/(FH; MMM/RABUM>Y`W/D"30=I\MI7KR18NZ>PS\HEZPS1`G299$R2)%55J)^(\DVR> M,F\4>#1V?JG%Q*B09'=._O5*MOZD]#+]2)6%MV&3QLPF:LI;!:UW`-^2'5!A M9KAS\!BGH2F)O8+L`1/)B*TWK)H]YDU3E"UMB-;-.A\F7B.((&O6;3=&Y\., MU[6*Y4QWQKTB>AO3B/+QY,)9D(WN<@4#^!$]`+_@6P;= M08!,*_RHAO"(SA&98,;D?R/?1U%R[JIBA4+UOG.A*=0.@EG:23U6F8B[L*)5 M&6`5:O9=[PU0=A"GHL7PE;X1DUEE'A$Y\4<8/L44#=GT)J86>B0*O.()Z0J4 M%I+F#:Z+V8`W0]4W$BV#[R`T9ANWA/%3"'[&I)W4ATK)\+0_K+@I7#8X2%OL MC:EI0Q(B(Q.C>,*-X3H\/CH]//0TTYNSI=H,O8W/_?\XYXB44+OZ]%RKDZ&!CWRZ$IEUGW2RX_-F94=HXW3>8 MG%4@=IVBO56UGJ52/6GPW;3SANG%M%+%%I]+8.IW@ MV\I..0J"V/&3@VUV#U`YH9=*6:5-27B=IAL]XEYS_+*7ZB2[%R"_^7]02P,$ M%`````@`U8"E1D?@4I;H"P``WG<``!$`'`!A>&=N+3(P,34P,S,Q+GAS9%54 M"0`#T2))5=$B255U>`L``00E#@``!#D!``#M7=USXC@2?[^J^Q]\/.T]$$*8 MS%ZHR6X1,MG-5A*HA*F:MRUA"U"-D%A)3L+^]=>2/["Q+=M`9D*M7Q+'[FZI M^R>UNO653[^^+JGSC(4DG%VVNB>G+0KQSO&XZR\Q4XX;7EY.4&O M?(X98>Z)RY=&TFFOUVTY2"E!IK["-UPLK_$,^52!T=A?/J*F=+`EQ=H"*8+$ M9S`^DWVH1JJ\E]X)%W,HZ+3;^7I_]V1J&!-/!24I!C7'>L"J5>=`2G4',<4Z/7.:N$6T`N\*Q0^,<.?-W`0\KA:6_;_35CP)"O M>W%QT3%?8S7+\4ECXV&2MI_$[LF$$:,)('T*[LF)Y<%S+-))RG1"H4X@]5-G6]1V*3Y(&+%?S/-*8`G"C?5T MCPFY0Q(;IXNHZ],=&#'N[P:O%.T9^`V\&WFLB7P%.?LOPW@%L#'@H/C4^L!\S[_Y9.5[C"AZ;;1M9': MH?QPVMV&,A+F(.8YL;@8M@8T&VBWH"J;DRG%`RDA)"D`K(C,#M9Y%JR-(">0 MU.!4":?0,L(N`J\]F1_)A%,I+LA*)-]PN%.Y'T M!ET;NN$$2/1;>T,8>]3Z%I(AL30ZA'A6H;0'.Z<7.MB)!"0?C=LTTIR$N`:O M?1+,,1)`M\`*P@I:.]M,EGN>[I)[.3ZE"FNYI<[Y72!+(*\8)K;?];!Z) M#;@N`)=QJ4:(#DF38AID+,B,Q!PQ\K>I-3C%*U\2AF5F%"PBLR-TED4H*<@X MSDA4@]+>J>!N*6`)AKTLAM53OP;4FNE>E3RO!+#*"5X#3HVTKBR?*P&E2B+7 MX+%/^E8[;RM!;->$K4'1@N(#5SA"9!NPU#<[-C]GL3'<$3`-!K980G'WVVB5 M6/@I^&;'X'\Y<8'F=D+V!@/;T.]/(4`:S6980+@TF@WY$_T^+\CVB&O#>L>8-W;!^N@C`;INHEQ M/JX62CN*'[(H%JV"-HC5SY;ST2J@LB-UGD4J9PFT`>D`*70^:E79[#!^S,)8 M7IV/8@Z%';"?LX"EF&A71E6%4)4YM^ M53N<*1@;\TCL")4M&C2#W*[89/Q=+DT9.AE?EX].X^=JXY/Q<;DT9?B4I0.- M;ZN]_%84]^>0V-$I6XQK?-N^RW)%YS#*.>S(U5^D:[#<:;FN,,?.)[.B5FGQ M[A^%D_ZACZL_XIECSE[W];GJRY8DRY7>ZA&\6Y@SX?H<>3LZ+?XGJ'ORNJ01 MB99O.>EN0-ZV4%AP)`()-R,E@Y(+#8HJD6*C0J2XVEI.NWO6[G[HTD_S;22I6(&+0 M)9^GRBPLSWHUAZUCY#)V,%4R>I/I)N:FCRH7SR0,%=YG8VI^V8I6R$RF-6#> M'4=,/F(7DV>S%#?'@U<2AC3:I_U9E2%PC>:JF[Y4.LJ\57BIQW6P`@0RBBA? MV^`WP?U50.BIOD>@;OHB(TW<2JRY82/C`R0JDN)?H[$`^>CG!O8@KT M?!&>_=E#Y6N^1(354CIB"=0.;NSI>^9EJ=ZD3PZE;:3IIN9S_+$[X1>GUV@M M[_%RBD4KLD/NIZTR#ZF/K?YU6W*>HJ-G+`H4S?ET)(KFM%]*^8MVAS=<7'-_ MJF8^C1IHJDV.9MG7R4:]GYQD!X_4V\%B,T3EP7IV)8W&6+@ZMI_7-T:2-6PP MT%I6P=NW5#X8`96E^4.[1?0.0Z`7[FN(6W_>E]S&'Q2[Y`R22K&NK(ZUM9MO MT^!8*WS`4Z(.T-FO\53=@DF$.1T]-D43=XS6YD\8;%RR0A0<]2U3&%(Y%1EC M%\;CLE6V5]@.I`_"IICH"=7(=QC>WW*8N_$%9(!Z*Q'S1K,9<7&\O2X]%E0A M/-J1X0\TA%PFTB,V3OKU#XY0LK6^)Q0Z&O2DL!L.N=DK`$]?5IP9Y[M2H]EO M`K%D.ZW'ME>OK>BP,UUW-VLPLO27CWR-J%J/9G?01,%G#^8"X\WQS=`"9:1' MH_4#A]^03Y&_@V&6Z=M+QY"1:URE2B8@Y:1'I+4"R()1".*."19+P@Q3%LRT M"6KQO<-([<'7SDC?Q<`]WU7R"_.PN,;/F/+55BLO)TWJ1V#AXQ]%:R'/F((*P0.XDB&Z",XJ-'L$4/HP9)91&C4VFSY,! M$IXZ':A6IC[::#7LUC<8RPUHQKO;QKY:7._,.T2.+.'V'K`*D6ZES5)(]!Y[ M?D93'9*,9HE(--`M^]J27-<.5=YT?E%774_[IGMIYNV1],:,>B.H/D2T'@S# M1"'Z.X8VN!@B@=/ZEI,=JP'&UW=Z)D"MGQ#=4CK_T[$JFIX",]>9/:T$1MZ( MW9!7[)F0PP0C9_FS9F4L;^B@WLP,0>T1'7@>"9ZNN!#\!2)2F6^%$HX?-&GH M0NQXD!E6/881VK_8[D(YDO MU(1?@VP&CF0DQE`[,>$W1$@U8(SH?VEC3BL-5BM*7&V;(>60'\^OP=\4MJWO M5?I1-,9#6& MHD;'B6'>!$]=Z^V+VO>MPU'@=$^DBZ&B#'-?FHL"(/L?^D(DDM@2FK>-_#:J MOE'@%]Z.,.1+O5?`Q`A;^ELICES[Z$3$K92^%CU@GD[ZXE,7"TAU@Q4(\^-% M$+WFF)GGV%^,Q8[2<+^+[A*MS>B-51,>ZP)N@3]!%]F$^4F]6UMK0'69CV;* M*%^#"1]R<)9Z1YK>=*3"JRFE.O+A:"`PTI$9 MHI^E_N\1\65DL9N('4<5RL(0#'P%>A<#"E3;Q=B3-X(OH\$S=>01ZB-C;UF9 M^HBV\`5'<8)S`O#G_P%02P$"'@,4````"`#5@*5&E)?Q"/]W``"D0@4`$0`8 M```````!````I($`````87AG;BTR,#$U,#,S,2YX;6Q55`4``]$B255U>`L` M`00E#@``!#D!``!02P$"'@,4````"`#5@*5&[C)UY1T*``#5B@``%0`8```` M```!````I(%*>```87AG;BTR,#$U,#,S,5]C86PN>&UL550%``/1(DE5=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`U8"E1G%MM?QY#P``$P,!`!4`&``` M`````0```*2!MH(``&%X9VXM,C`Q-3`S,S%?9&5F+GAM;%54!0`#T2))575X M"P`!!"4.```$.0$``%!+`0(>`Q0````(`-6`I4;`M*V9,3T``._;`P`5`!@` M``````$```"D@7Z2``!A>&=N+3(P,34P,S,Q7VQA8BYX;6Q55`4``]$B255U M>`L``00E#@``!#D!``!02P$"'@,4````"`#5@*5&8FXX<1,E```$N0(`%0`8 M```````!````I('^SP``87AG;BTR,#$U,#,S,5]P&UL550%``/1(DE5 M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`U8"E1D?@4I;H"P``WG<``!$` M&````````0```*2!8/4``&%X9VXM,C`Q-3`S,S$N>'-D550%``/1(DE5=7@+ B``$$)0X```0Y`0``4$L%!@`````&``8`&@(``),!`0`````` ` end XML 51 R20.htm IDEA: XBRL DOCUMENT v2.4.1.9
Accounts Payable and Accrued Expenses (Tables)
 3 Months Ended
Mar. 31, 2015
Accounts Payable and Accrued Expenses  
Schedule of accounts payable and accrued expenses

 

 

 

March 31,
2015

 

December 31,
2014

 

Accounts payable

 

$
1,966,422 

 

$
1,160,859 

 

Miscellaneous accruals

 
194,985 

 
105,315 

 

Accrued compensation

 
1,261,865 

 
1,165,020 

 

Accounts Payable and Accrued Expenses 

 

$
3,423,272 

 

$
2,431,194 

 

 

$Y!*W^9D:JTIBYSK MG'\O*),9&5'-*.0M0WB97/4IT!X]1W=X>-_(PP-3S8,[/0M&(@"INO`U_"'# MD*/H*=%">+`%CC6-8604,,B[9GB7E'Z*)IS$)F$^*ZON*1E41`D(5A(/2>GY M>,L@PLB7H9JY"WY_(C%,6U=G4S*\HVAU5E'#)'I^G,.YDPTCS$J@]CE(('3I MZ1)I6(!,>_CUL6*DR^01T52+GR<1/_\C_&VDCV$74P@/BGR/A/=I M%"),4:ECOJU'FDM8#2OGR3`)[:6/"R(%"N>/0A&$#@P5+BU@I3F?V+]=7EYG M&3TS'H:,YSA@(W7S%3NS@?D.KYB(^3`+7[^Y+S>X*,"*^(%R;.^30SDM\0EH M0\!A!IGCIFV/\`0)@.3Z`#\I!^6+V"1%^K+LLT:ZF2!TSG)!AC(7K4SNPIS+ M::P['3UT1PK4/N?MAT5+G4XEB!F4I3U7^CH:?N`8^:R`_, M_(TCG(W+G/E3SP08S#"\!F/#`D=ZI@HE%J5)575D`3.P"%U*F*)CC6IQB+&) M4QO'(`;FJ`]2L%B,81`2X\'F8-$:9:H0Q/1D3BO+@/X+XX7+"YU:/$Z>,B%Z MF`W)!032^A]F=%Z.:\3-JEZN)_]/^@(5(@&#@OF"$F$G7&0-U-RYB[?STP!Y M.`B-`LRA?,FBJ9*/J8%`TX(:X9$P6[,:\G7Q-6S,ETK7S:8O/;Z3EC]TQ"!7 MU$/)L@8,8R4A!I?J_[I3GP4T!S$FM>-(OPZ-UP!'+>!@)`7A*+>PRPMEW67ML7Q^EY,T]M6O.>G# MF%#&`GQ%-C=8FA-ADC3'6*14-&,D>:+G$-< MUR_V4*-">@B97*BC44;M6@08ULSAL9O5@F@3V!O()U'$&KK").4P!LEE%B6V M9^7'R]4HSC7\8\>+MY5K.WC>7'ORU=[['VA@R!*O,NUV=]AMMS,@;YJT#-AV MN^*T6QV[.QKL#-OG_#,E7_ZV1R/;[F8P5C#=8?#L>H/>[0Q:W5W@04'W%,35 M&PXS41H/3UL:B#M>H[=:G?U`O!:N\]'_?T$O3*H/E(:YX<@>=GLI7.MS'03+ M;G%3PTY[T-D%%BY=\'F"MXWFLI'N&LL$JI7CP0(RX=P)EYUVJV>7!^@U)D>%T?+:$WYTZ3M8T&A!*EMI MF+5'O>ZP8/2B_?G2GL:#JA]8+=&G7Y& M=&\Q71GP;5\.8#3J#@\"CUN,8*D4(RP^3ZZHF-=-M&,$U&-AIX-!V^YD!>AC MDV\#:[8@1C&PPV]V!P%L([3PHFQK2L)PZ".YWQQ!3^Z+[7@AV$'F56 M*U:N2B*!DC3BU^>-ZHS(XT;P=JOU2T*X$5>2DIZG&02E.7U6"S$VG_7[M]A4 M-;R@:L$+)5^;/][PP+`U+6QTM,9\^>6E;=WUYT<:U_<&S7[_Q(WK#]B5_([H M'I?-1_4?%`Y/E@/*7@"5N@>A17:W?-E M!?X3B,4R;6N16/C[BY&(KV)?Q`XFB_Q:TV=-GZ=&=7WJ)2@` M\BD^\F[%^/LT#&+?06L\"%];?[NZ>O_^PX==,6.9?^T'T:0]:]:%O;>G9EMA MM>*L^1"'ODOE[G/>FJ,)JM(P6ZZ:43H7=2JSUC*HY.?RZ<$>-#O=AW"TY0+3 M4@(&(\KYI$Y4W'+8:MMVMR;TF]Q=! M[H-.8]@^D-S;#R[O/,B]+/WAN6D)G[`[]@P;V[ESZNNU7B&F:M9,=6V74W)Z M>]AK]$>#>HN>^1:59<2=C\A].2;;-==`IL3EVEX[EH.IDHJ:W;!'W<;`;M<; M6V]LK8._,!U8G1K/8U/0;A%BA:ND<9688]$-[F15*^?G%@IP2OGSRFX, M!H.&W>H<3B#GX.'9[R:N)J:MB:G3:[1;O<-/L^='3+7!LX?!4Q!07)L\9?CL M2[M'!W@M)X@QW'E;&54-1%?\PJ":&W3*XZ4W[#2Z[5;-Z#6CUXS^G!F];X\: MK?:P=HFLJ(S\$3.+5C%F?JUPOE2503/HY&%+J^RT2_KMEHF[OX6KA8%6JS8D M:=0;QWB[S&=5)Z%@6!2!6N@ECVZ54#T<=(8K2EU$MJILS+.\/KD MV26AU>GI-1_4?%"GIU>$%7:\!*TU@UHBUNF_=7IZ39_5IL\Z/;T._:G3T\\E M)*`2:ZWXK7PE+\;K]/2:W%\2N=?IZ>7J#\]-2ZC3TTNT74[)Z75Z^LO8HCH] M_?F:;'5Z>IW%7&]LO;&U#O["=/`Z/?U9AP*<4O[4Z>DU,=7IZ4]"3+7!LX?! M4Z>GUUFK%98`==9JG9Y>,WK-Z#6CU^GI=7IZ<*:I7$^>GKXA*?V+5!*S2>#1 M=_).>@$]_/['0OI*EM?R>FBW^W8O!?/!:Q'ZP.#J,O6;O9,3=^P>E(UZ,6K9=K_=ZV9A>VS"$@#<%G$7HTY_9'=[O4/@ MHQ;P7^0XF,(,L(77<"2-EW62ZC$D6VL7T!X(.D_/8:"'@/?D-9Q[,DP7I7?6 MRFSMF,@OX.1T8RG+L^'O<-^.3!<.'2F@EE M!<#"8:B?@]=#>E4`'$(%]((EE`+.U!-C/K$86>"%LG14T]*+ M@?F#T`)4Q1,QQN!@!Y]QXG&D:*[D@\*0H"B`.<>Q`O5+AA:\2/0&WP'ZHM"] MC?E^8AI*7K``.%=1Q8NG47$->IF2!L??LL,GPP9APQ(1#.".9U8$FPS_B6#1 M"U@UK.&Q5S&0"7;%:5BSX!X6'N(>P'@N@S,6BK`6)C@)@SDW69^"'-6X2S:$ MH.:MVK`HP(-'*X8)A`7[,G7'PF/L.X#DIO49-TH4(H+IXRJ8+X3/N^\'UB0. M<=N1T&##YKS/MZ`/$]_#?K[+03=7 M@!%"(`V\A,INLAFA:5T"$\5Z6Q!V5R5CC(7O!Y%U*U/R@24%M!(#2]/Z(`&[ MXQEP-%.!^85I4\WTR\DV[>'?7LCOWXQ,%2>-%R=^,EJ6/S MT1\#D]Y$P$5X?'S2(B97Z^9&>D`84[`+?A?A=QG!WWK&K0K>].U6*U/*)0_S MWNO)H_,IUS/J[[H>H\44K\=&R\CL4.:3(]UOG^"4\-[[ZW\4/=Q[/'\?311^XA_UCZ[C28.R!*S`A6RFNTDIC-:ZVY),7AJB;\0RT M/T]^GH!%'L2@5ER+)>KNP/SP31A+YY,K;D%UC%RION(OM0F^Z9@__V),HV9G M6)=$@W-):6^M7P#516@.*+GP7(HQ#T65&C?K_1;;=3=CAA[T[X,H@5)D:&L?#4\33%\Z"6?=U/)V7[4;V6679]><[QZYFBBVI)_/A<' M5=4BVWV[,>R7>J"\2.HZK3N^JM1E]WN-5KM5VRBUC;)+6'[>L:VC/"B>VIR3 M.D)KO;#BK@?OF5S/5\=95JYW?(\,S-HI5KY3;(]M..7!@EGMG49[4*JW^WFQ M:;D^[9I-:S;=HSYKH]NAYV'?^[:5///OZWWSG]J7W`KI1F8+3.-]AK=T=+O]EJUW&/)9C9E8K_+7." M8[>0J_FMYKIFEO>4S1@T_IL?TJP[GU*1#!:_'?M)-UU<;I6$Y8O$I9R?UA+*4*>%5<; M8G%O6":6&>+E!KZWQ!P@\GMQCPMKXOI4-LGUQ^X"_^*?+0?P)"*JNX,%?'2) M*QR\F>+/35.*_AV+$+Z%">"M$3ISL'0/3.+'!WR+"*M'3:Q/']]^ M_H+U@8`+?]%+P3)<$VO=WK30)B2`"W5C_+F+]81B+S(5H6P8-(2YFK"K\J&= M=Y7>-%UI"%+[DZ5_&"ZT+- MN>@!T4"G90'U>QB_!;`FCR+<_A*$A#6'W9YI@)I'T[C./4QBZWNN]>OH:@3> MU/=?K^UNLU]'W17J5%AA5%'VX*5_S@^FXD/[EWTOGH1\*? MNAC^J)2,ZOJEC^QE=4$[^]#*WH!Z\K[TT,KABPKU&M)ZZU"O@VWV2H56EL(' M[9H/:CZH0QZ!%>PS/A+*\+;6FD&M&9Q]G-KI)>*QDQ3J$_OET.<3>&5?T*E7 M4&Z%C[R74XKLDSNFAEU)&\KU(BMEG:'G?H&]];5&92[KJWKG,&AV'\31*2\$ MACV[T6]U#C^2JT$"-;G7Y/XPN5-=Z<-5AFJ0P.E5A^>F(%R+Z*A:P7E0Q[YV MRBE9V[;M1J>,DZS>HF-MT6#4&(WZU;#7SD?$OB#K3"KU&DOXQ_/8HW;I8AZ$ MD?L?B@BH+;7GWP5:??:W1[1[6&SL$JV,]Q6Y/?P>37ZS3Z0_N8ULGS M([]36S+MJARFCV59I$%XEJ`HO(;ERZBV=+9W^]3!VY7P++W4X.W>:%".=E*S M9LV:-6N6RIJ#0<,>=%^H:X,_GFL%Z`J#9M#)PQXAIV/K'(U-21X?_3O0;X-P M>16'(?Q59W:<*[$]A\R.?K^.WQR4A(,SCH^K(]KKS(Z7%R=ZVMHTSXX/GE-F MQQFSPH[NW1(U@Q=7S+HLS:&B\O$%Q]$?0SZND6`]X#,<\%RR>2HJI`>3GF[U&[8PV&C/[++*MI5)^S4I)\C_6%U2;\U:#?:G5Y9I&\_`](O2YUX M;DK#OX+P.S:C6(3!6*KC:0WG027[.DE.RN[`[-U!:45DG[]U>Q$Z-Q&\ M\GF!237JG\*+*;WF4JEXSM_5R3CG2H?GGXS3:[9/V\OV">7Z,<(KO\Y"*5.: MH<;J*OTLP:)UTH];)&V4$JWW#'*+'G-Z]<^?;"L5)WRD!)_VLTATJXGQR8GQ M&"DV[7WZ-%>&&`^_SBP\[)\RTOGEW*2^_[&08RR-2/VR7[F^M90B5+\>[;P_ M]\N)`T1M-2CXE!Z7;K,D7TO[65W0U[1T8EJJ3$SOZ4_=9WO`W06>B%S/C9:5 MMF6K)75.R>"#?K/3+O.X.+-_>_Q$U]:?8#?ZPCO##I MP6JGE[[SNPB_RPC^QH,.&QH_%-O5S<9V=7^R8M_E!_^$/^R?+$>.W;GP%$8- M_:,]:+<&K4%F01LG+06XE<"SAX'KC#KM7KN]!W#)7EP%<_R=8"@1:[U!KYN% MJW"^@V':#5G]8;L[*@.FRS`4_I3Z9;]=%I/U!^&&2,XR0\I&"7NG=;`O8-T? M@/).=GV=G_Z!86NMQY97(NA5PM3#A%!!3-T^/MWM+M-]E>'WA^J-(:_6_P8*0^ M^M*4?Y9GBW00B_#5KW1Q^C%-T[>>T) M7UT'GCM>UGDF)5K!K5U`>R`"-O7K`$4%O">O8]^18;HHVNL+VFPKN]MG;N@_ M*?977#]D[5^0)@5LD;/R5&2%DKM<1P&,B1E:`7.E-46VA!]H@ZQH)JW+*ZO= M:K4M&M!B_K.0Z2SA.];EC^`WZ<,3=DL_D3`F/^0J:RZ%BD/LJ1WQ^)8#DSN_.T'@#1Z@^_].W:5"T>%DN&=.Y;6@B1.T_H*[R"Q"7]I@4AVL4J0*H!% MBO%,XX=A`G!4G,,1K50O!->&K_%*8^7Z4TM8;ST!VW$SG@6>5!>_RS""QWG0 MBT7H8NJ4-0\L']0TM)0YD0)C?"0V$^ MA[EYVV&J=9AS^Y(?`"E)A#3U0L+BZ;/OPF3W,Q?0!&QL+>);$,;>THI"X4C8 MP4G`6&+$*PO6B]\$].7G<13D>EW`OME`,N$4AH<9/\GQ5SENI+\#?36SI'<5 MA`LM5IA88QC::Y\ M/'B)T)7"&=>]&,TNY(`!$R.2D&M843%@@`#B^%)BRO!B# M(#S30C&.8A@'IX7'[W"/X7FE/7Z*UKT`QKXP/\&J)M*-@.U4'O:$LD)022XH M]L'52@D%01C$N\ELH7B% MR*#`>,!$B,Q0SH7K(UP4.RX6BS#X050*(\)SN+2@`)=929!?Q@R$@"^1]1?" M!9$`7XV%FJ6W;@C>.KD#FIQ`$BO!APCX;H%K7H@EL>GZ*)K;`)U224GKGL2( MUC6L.OI!#S@2!^/34#H7`J`4TSPK(]&MBEPG#@E#R-R8@F=QYIU%"7?66I[= MZ_,^'.L\TTKD2)TP(ZK.,ZU.CL"YD6W54OOJ/-.:&"M#C'6>Z;&"U2J96?5L M(^CJ/-,Z-_"L<@-K6JIIZ=F%EI_^U'VV!UR=9WIFX<1UGFGYA%J!;:WS3'?: MUM*LJ1=CTM1YIG6>Z1F;$]4^.:I*"76>:94.F^=VI-1YIF>J;-9YIL_0@JCS M3.L\TZ>/\2P.^\N$?EGW,^DGH9,<8I8)!34AE!@6%`GX?P5 M*SQODGC+39&5^0`\8#0=3J)&HQGH3U,`P1K'\QA=;W?2&HMH/+N(%WJ! M&*;>T*#FHTYU))A>(\9"TO0<2M7)N(0,Q.6N!)\Z#H9L$`A1>,D^!!C'Z+?0P(Q-W0P69!'*D( M($9:V#'@K(%1OCU:+EXR8Q@NO+JT[B5,[4@Y)]@5"#=WXHZ%'S7WY)^2;HBK MQ>SGFE2^>Q9&01K'=8CB(9N=<:F^?9Y\L^UO=INSFASI?OLDI\)[#^-%R\L? MKOHF?DS];]?O/KT'01,M;X0G?Y?S6QFN9JOTU[-5FH/5K">"H638*(3M6HKO MZDHLW$AXV\/76TTUVA6^]K=>8>I.(3)Z!T]F=\J=+143E^,Q"DL0140_KE1U MXY@G5S>RUFP&0PG&+*V2FAO90;-MT+:5YO)`;A`-TFFNBZGLAP-@[>:/E)S^ MOJO&]2!<>RW\)IX#_)1$)*V4*RW!%@2`_W^/J3!+3OL@[Z\(H%0ZCBQ=.HN`:]3+:7*&$H,WPR;`!& ME(BT80.V$JC\;H197+!J3`AZY%68#W?%:5BSX![3;AJ%6'?H>R;S[A1HA`1C6SF M%V<*!6!2A;CM2&BP87/>YULX$8CO83_?Y:";$&@B`W1^ZQ)#"S"E).S75!AB M24#R^96`\[?(59O99#-"T[J,V+3%;6FP(6[&@+,`;3TP$!/R@24%M!(#2]/Z M(`&[8(Z&4Z8"\PO3IIJYBP6E-^6)2:ATOY@'$[J%!^FM=:)J9.D"%P_&(F8_ MA5F&P,W'?"FT(#F]:"]N$I^$M"B'@UGA..P8S@)!`WQRG:,*I!0>6SNS->8`` M'!#82ONF:/(TFQ,];X8J5G\BIL5/9!V+H@O1$6-XK9$05OTXF$ M0D]A+KB'(EG!RTLXYO&,M282KY\[=2&W*!$VS;#DAU`OH;,OD MN@/JE$SGRJ6#WH*@AV$LEPX3&"M0,I&X&:^6-09(X"',GT4GYW@3+O:562^2 M(?:74-I24JBC2\`]J7*KL@DI_(KW#6-QZIW96U0EZ`XSZ`Y12(2ARQR/`BH` MVQL8'YG^+D!%77O$2:R(U&$/_.Y0>C5U`X\FL6<),T-RCX!J^IT+ZT&+`.1< MUHG-XRI^C,07R`MXTP4Q\;OPA;8<5E+VT5-^3SK@AJF7,.4T]D2(">IW7"T3 M9G-]NF['&XQ$%4P1P1+%R&0N_&`>RU<@2(4B/.VX7+Q`"Q:N&[#DL3COW@+J M]X.Y.TX?A^5MVHI[D.F11)J?L&*GG?.Q;ZP:>+))-NT="DPZQ`K MP$%V3*/*A8[1WOF=_=6TFK&B-Q^IBDJG8=U+Y`[8`%?-D*%(E0[O-I$J''_P M!MX*S<0=V@E@VR4_%NY\!B?)7_^2&8+7W(:LEHQ$YIX^F/LMRQ%+K>A3L0C- MY%1')%>#`PUX/(55HLEHBM;$?A^`689L"3I`(A/(,L!+,^0*%[T`RX91B_3A MS?#[&#-I,,45&QIL@(_IQ+5;"VD.5J M)Z9KNB#&:A.*K#50'Q1N0Z:RA^L;&,0M!?47`G*SD&/4)%8P*]([M-QF:68C M`B#ABF42-"[<,"<)-68V+C\MPI$H0-G7Z5[7["R1DD#S#,]0JEZQX'H@(!G% ME&Z2`4U3E%.O>K\0:2:C]NV+D1Z'+PM7?J>9DB?`9OVUD97UF;HI=Z9,L482 M2FT%YB89N<(;XR4NDTL41/"\X12ZF@X?(`7SH*&F>Y%S2>`B\7J517@&"XDU MG-P?FQ%N970O010"!G'1600(4LS9][`RD'D[BY)"H#_JV_0[NDPGVL>;\IF` MXX48->.PDA-`M[;0D*:("9G:\L1%LN8^B#TG4_E&"WM)HI[.2GYU(R[3I\D] MHQ2)`^\.CT,L]`*;B`A5TG?94V;.Y%R<0#H*G^B;N?B1H[MH:_,%9WZV6W8# M<]0003^/NOQW]."-]SL0!_-!,V+$`E"#MZQ/P/U/P)S&3DI)UM0B MFU6CFLRR#=H/V8C(PW(,S(%2S$/'F.7'N']4Y4H&TU`L9BAB/`RH`.93,N,U MFXOOTHH7#Q20,KH?DC!:Y""2%&A+PDD"*K#V51;^O-%*\2+D&0P\E5NF"5+1 MWQD.4HEZR#8P$26HNRZ*2I@S\8S69N?3F)T??13%`:K/-<(/4'H3++(5"?P! M;"`IP`I+D`F?2T%%5%RL8?DDVX%])W@/='F'(G[W2UF"HM_L)=>ZS-V7[_>X MX%U9$6`*(?P-(6Q0C;I8A$X5001QZX,LQ>N=*H-Y'0:1!A-EGHI)$!6%U@S[Y^H MP-J@V3]U]L$!NY+?D?TS,)Y#$2@@&"`K6&3[IT=#^8>MNB#43K'XCQ2$VJ)P MWFUH_?W`@*9C%T.SF\/V"^.#;LT'9?)!H05_;%8X1BDVS"P]7U;@SUOGL)35J!Z=O)Q=WNM'O#\!GP5^R)VT$'Z:Z6UM(K*G'6= M[(QE#F<^/QVFGTJMJ9P24U"4@C68EU,!Z8/K;G\NG!'C2[#]+#E@L\2K6(=L,>#AO]D5U.S0@^=:M!#C7I5X+T*UL6J]UH M#=J-=J=7%NG;SX#TRU(GGIO2\*\@_(YA=3JNJ':2[.4D.2F[`[-W!R751GH) MUN4I-ZO3L1O#\I22VIQ[ON;<%W&/V6,R=(576W//Z/J[FEKC<-!O##J#VEPZ MZROEBM)6:]3HCKJU/5+?T=9WM&7Y9TJ[(P%X*D,P)8IJ1;_.1J>-9N>!YN6VD?M[-BT;7<:_79I_J&S=3GPQ[H&]F$91%2) MV)<1ER+C-%`L;9#/_NP->FGV9[=5B?3/ND[5`\%+VZ7CC;'PP5?QH\['.X"; MU@HK!5%:ZL.4;G`9UY'XD10QUQ42,']J*GV9%MTA;ES0%_Y45V3"6GL32=48 MTZ%T`J#.ZN5"[E:L3#ZMR>96,REU5JP8SW0]0YWNGU25-),[9AH$%5U[';/"*"%^K$MRR?D":"]@556L!Z$[KF)('!WZ!4*H2G:5UFJAZDN>Y<$Y!J,'+)%2Y3-0\HX_D["K9H M)GS:,,Z,*UA]KEY&*`656,09)['G%4Z+-'"+"\Q6)-$9^P7CP]./P:712Z@` M2IFXFZ#Z"'`XIC2.?HO+0HIL64YQ)UR/DMG628V*$BUAA^]%Z%!EL=LT/YPK M;WY$88MUBDQMTJO`D=8-5U+(2/MA&Q='M5AB+TK+_U/W@>`>2!X+)M:YU^6( M'BP`&[D35U=4T@68)/8S,"5;D(`6@>):2&F5&'P\*3/)M9YT6P;JQ5#X-LD` M71DUK0S+!?"0=I&8+YB8+_"+"Z15X,9;7>?%D*(9$*@,*3!>S*27%$C"BCI< M681[9WBP*"SE(7Y0D9$XF@58BJ]IW6`IT!2V3&$8KL87^]F6%BD;F5HC(*Q1 M(PFXJHL1+536M(")EO^F9&AF/)+/Q0@%YIUH5))*!CCQ!*J\#Y6.!F/PYBJ\B2U_#;C`]%@VY2]=CT+^$%AZF`F`=WE-N-SH1BEP[&$!(GJ(!^*>&\4Y M2LD'@,9."D2@\OE&8UF?S-@/!#7@'#`J$T%1RZT_HEIZ2@:/B1Z MP<>T&&>]$0<=%*G-Q6<\LN:=0;B128%_H<7;!:N-^5*DIBQJQCQT=%FM"6X@ MC:>RJJT"&1U=8)4HRQ>DD+#D5S([(,D1)3?,9E@?JX4VBHK89+YK9: MKCR)7*%F*A?4C04GL)1R5<,I;N:65PG3)G/KL$BT MQQD_#)-%)7NR.**5&NM1MYGCE;*A+ZRWGH#MN!G/`E"_+WX'08Z6'@UZ@0T? M\*DY6&@>&Y.Q,O5<8:JYWAO06=,"\USGY%:"0?O04NX"+.=GE'D2B<%\#G/S MMNO:,GF8<_N2'P`I281<0U5BJ7Z:E%R4W`0/F[O%H(J/T3[&4F&P@\83H;N^ M88,+_(8%[>=Q%.040](%YS*<E=!N-!BI9$OT;FY MRED6!0B=@2PM%DB<@08+0[+2J2Y?&)3GA>LE.C"_)3I M%IB'/:$L+,IV0:W;$YLB)#+PC7%)93&7+MIZ&3T\.2GAP3^;-S!Z2/R]9+90 MN@:[GZD8GC$SZ*S.^ZWA.5Q:4(#+K"385!Q](5RNBDYERI.FP0C>.KEGZZ(# MJ0/?+7#-H(\0FZZ/HKD-T`F:CZ1UL\MF#:M.OLB2Q:>A="X$0$F%1C.LC$2W M*G)W[%I85W$R[Y^HBA.WWS[S2B9;4L,Q\O*IQV!*,TSMZ6+;I*7WF9%NI`A-'J@Q57AOTFAA?%#$>HS93>>W;SZ`V4T$>3.%A_Y0E M,EY."L[[I$TZV@JO0`.GFX1?CW;>GWM4^P&BMAH4?,I0O6ZSI""]]K/*[*II MZ<2T5)EB$*<_=9_M`9?Z5BMMRU9+ZIR2P0?]9J==YG%Q;KD"OY1/J!78UJ'= M;/?+E-S/>UM+LZ9>C$F#K3DMNFO!*Y;:D"E#^:RD!@B"I*34O"J9$]4^.:I* M"79YFD)EC('S/6R>VY&2&!')775M0YR%LMDJU^'TO+G_)6[J2[,?^&.=(GQ8 M9E$:]I<)_4J:F%/H)(>894)!LSDDT8SS:+A1=3#)#8-Y0\Y?L<+S)HFWW!19 MF0_``T;3X70Z0I`CV;*C<]YA`[O78?Q@$@(&[YB?J"$WQ>,EZVQ:5VFBFOG6 MR0UL^KF;7!J=8"*R;8['(AK/+N*%7B#&LC8Y,EQS"&U/=7Y M6!2Q1JU^.34+_@XC&J(0^9S\E)](9P7JL,25X$/7X?`U[.,,:TD73.F-XR1X M$*/?8A\#`G$W=+!9MC'VC@%GF:QQO&3&,%QX=6&"D+F>18WMF^%TN,A'=?_J4OGL3D12'B2[G$L.' MTRSP3(MQX&]JYIR*?1)#F1!33I8&\:E%$N=N8_C\G)-P-J9JH'0N M$`8APT)PYDWOY"/)\WGC&429E/$B<$+.)M2YL3H?*"NFTOQS$\1_R<<)9R]C MM"_F6?*IP8=&-`M4!DUU0L^32*`O$B4W[$["`M=AX`>85EMG"1Y:%\:Z!'GB MY3(F>IQNG&9D9C!_@^<]YAE8;P/,7GF5)D-?,V_?SNS:\FN:5P@#\7 MQ-]_!,W\[!>M3L/*#GM#Z0.3I6'<:PR?]Z-$AK[#;+V/,!/E:%\%*E)9*/(P M7M[\:>E9\J"RFF;J%40LJG/S4%:@:^;!U"<2U862"42J?ITU37Z:BB,X('Y! MC():%%/]!"-:9))(11.E.>3`%3-2DS%-BM*52&R"O$K7PN4A;B45"I$DJ%$A MI7P42J')9-=H&4B9&NZ<9;WOQ[F2'":)Y58"35*RA9C`XP6YUT@N"$33>B]" M/(DSM(F:/"4AE,J/2="E*^`%SE_@. MLX]@><"(:D8:08;PDBQJ3TXQ-0N?`E MH'U,TW:YI(LUC6%D%##(NV9XETPO4M8F,:8244OVC*RZ%TM6T@P(23F0I)0+ MJ)V1KL#"[T^D5)SQA/EIQNSF^CEADJTTSN'<9*O1IZP$:I^#!!*Y*A`:0^98 M22N@/"R::O'S).+G?X2_C?0Q[&+\+$ADGN1<0*1\G^T9#TDK*4@%](XTE[`: M["5PFF\H@3XNB!0H-S@*11`Z,!3F)<+N\HG]V^7E=9;1,^.A]RO'`1NIFQ*2 M-1N8[]#@(^8+R)U&;^[+#2X*L")^L&[CR+I/#N5,_J+T$'`L^9+CIFV/\`0) M@.3Z`#\I!\6^S+%/=YU]UDAW+9D_ZV=DBUX^V'1,LIZ M#E22:\QV._S`)O8M5K2;N6"P.YJL\RYA)OX&/A>%DL`C33H[W1A+.:4PUBQ9 MLV0%6?)WL7R,(X7EP_19;4-[LG)U&_FP"^+(H\H!PL+2$)CE#-P:RADP+-*Y M+@(18$HYZG,9+R*R@!E8A"Y5EJ!CS90(T+GWXQC$P!SU0>0+%0.U*NF@_Q!+ M?R2%;PI`3$]FKN;#&I\#XX7+"])X)Z`4FJ>8;<=8$3%Q#^.G_0OT M^C/`^0-LH6L?*'Q32#Z)(M9(+E*`?G4A2:I""D(A*S]>KD9Q;-!,"`P/"W/^]T\V M#6-M#K')ALQ8V0__]?=874R%6+R^26_E4]_?-9#"&,Z1K\#[;STP'/[Q?_]? MEO5?R3MH2\P"#SU+[^$T@0,*%0UX^(N<_/=/E^K;Y\DWN_VM8W]#M>@G*P8M M@G["FTS[)Y"X8W<.IQ'6:OG'A6VWN[W^L)4!:FV"/0#HZ/E[C\T/4W='PT-F M_P.8[UW"!0G6^D04;-`B[,?C@`V&[^$,Y%&1X, M^#5[K*!5Q6Z9.+/K6;+1@V;?UN?WY`> MO9D#HF&Q3RITQTDE5GT3`:#\W&X.>NG`F6NJ7(`S)::P$5.MR0]:HT8;>ZGHLOV@,N760(8=Q47B?R[0 M;J"+GZ1\^PM6F$K1P1/!=2]0]W:0*D*D\VBE7F^>1%.;3,VDA_%%4Q=,9[;\ M4_,:/GP(PGF*DIN+CO7J2_;AW*5HI].YL$>]WG#X*T8,W+E!K$`?G[CH)4A8 M\D:"K9?&4[TWK@.D'I%SEZDK`+J`2T#&6HUPL/(;1A$VA`4$KU2:$>=21 M:ARZMTD\)Q:*-.S[.1$.K/AOE%$UF>Y/II>$[G74VATC_Z-50C;W7AFB(8$- MX_0:W1ED&5\&R!95P2H-O;8R0<2$[U+ M5$]?.B32](&5Q+IDU8>5UE-`.RT+D.RQ&T5BO4P3+H,=([)''!J2'/+'UK)A M!_[,YG(:SVU.MC0>T!0/OUTF1VKRM(C6(&MV#6!)''5&JMJ4J;TNU M2[:E[%9SG?+.P99*:==BXJVMIRB.=/$O3V&NN'V*RK%S#VBL6: MK[`.*DB`[F?L#>90Q737<3',!C,6Z(658NT97"1_Y4/^Z*U<2*"N&+]B->8U M?+(7<]:TL%8)@S6K_Q$75P$V(/G4O&ZNVZ.(62:CG$%,87`A>L&CI46)57P) M^#8./:D0%W!L"7V9EHR1O6_EGEVP!6.Z[S4WK]X:9$TV4-=5]V389#/H98=, MU-0:;3=L--K_':-6-Y'<*/0>/LP"O$;&FMGZ&D%'_*':!<:"43VI4+J&#E3/ M!\;Z.^AC:)SSD`78*-KM]*\\JEPNA"YT^AG=Z5'11]#U7%+ZBDESB/<4OKSG MABUX6<(WCJ`1BL1_8GJ7B1!M,/8L^"80A)I@H$NAWR)_!^K$.'TA^%^Y+KV@ MM#BS7FLBQGQKRY=TA.A0W*?W,5C]G^J^HY$7!J@+H^X;@9D6ZPM%1]\QTNB* MK%+"JU#F`I?;1>J]3V]DSET=/9-SYIJ[B^4<_T<*+YHE\E,WC#,],\3X MN\"`[,L[=)KJ82[?O]'0_!:"9-%-7%!(FAXS.D4-6'1!D)GC`83,ZKS_=!'1 MKK#>8B.9]'.AJ+G,M^*\Q9FQ7:.6!GQ5C%U1KNO4WHIC=%CHNDB:G4OE2,Q]%M:.-$QN:7F$I&?"HTWH""W(0! MAX,8\$-^$(.%3,"Z=F>E))"Z]#:/]\@9M*INH*<02)=#5_`V/^]=,:TES:$" M7!%/,(N=#BC&+7<"0@*AAK,4CQ50%-<<#U#\P2>O"O>1Y6S*F!W'?++0,R;_ ML6GV@`_(.:89&`I$2)GZ$%05XW'L4D:H.R>?>0(P!:4]#&T":*(:)/#J%'0" M^]Q/FV,Y/S9Y,?+.CJ_8!NG2=SXCB>O;=_4E:8M'M_#+VO%QIBJ"V5`KW5'B MSJN`^J"E:>-7H,P![V,IP#-GIY.ZV=?[2G)Z]\%:*_H<%#J M?2Q2CS%?)N%YZ03Q;032.VU2F90Q$3J^B_S>&-&5J:&19*_C8U0_`TQC:H7> MM'Y/@\16.H:E?<@W3+W$NZK8H_#$3*"@ZU.U+[)@=+QK!A$J%W[&?>?,8_GC MKC#T:\P$RFW+ECR6M@F!^OU@3OE@^G$\HS9L!?KY([16)A.N/Z-K@\0^-F;" MT_L6+5[@%[RIH2)BWC^1WIG/LY=>)(=R".3@.S&;+M MM$D=)5VXF%2%HOP'U^%X1(6IA,F/A3M?I)/]2V8(7G,;LEHR$B=*_L"[*:O? MLARQ5.G%E&%RBKS-M0#4B==*&>W-4+0F]OL@Q$!F>*"1R@1R&V"&"7*%Z;^N M55W35CS5F#!2F!PJM$(DP@TN!*%S7W$9J%^J)%5TBHS@Z_0P#J)_/%B"A\PNRL#FV%M>$92DZ4!;ARN5;3R.\V4/#&5SJ^-K*S/M&W4@C?0QA!);076(,5["&^, M-:287*(@XBHDQ"G&=_,`+OA!0TUX&YP<$;Q(K.[$(CR#!=,2,BU?94:XE=&] M!%$(&,1%9Q&`2YKBI>KZ0.;M+$H*@?ZHBWG=29-3@6+BQTS$BO!B2(\*6TT` MW?IV%VF*F)"I+4]<)&LXW#YMO*F%/84T)1$/,1:3VH#+]&EMVI,X\#!]FZZ" M81,1H4KZV'4T$[B=*U.6CL(G^F8N?N3H+MK:U2OIEDU.1T30SZ,N_QT]6'!K M/9="_]QM9%J&>W6@T0$G8$YC)Z5$'Q+8*95]2AK5%".V0?LQJ?NWUG.[P_N"3`(3%7;"2+2-H7=&][NEFX%HAK%" MH"T))XG_09LS"W]S/41.&_\JMTQ3(T]_9SA()>HAK8^9&]1=%T4E1R*-I5/G M!IRC&V,K_T3>I?&GDI\G27FYZO@NZBRF`[T9=>7`NG)@73FPKASX+`ZV_"F5 M/\'^I;NS7W)S]C](._L\H:C0SZE9^E8H=PQGXSO7BR.JX+OYI.MF3[JU=+CV M2CZ:/>@,.X-A/P5W/Y".OJR5`_R19;7;/5A9WRYG6?_/Q<6'((C\(*)X>@3K MX@)^^J^__[@-/?CC_P=02P,$%`````@`U8"E1NXR=>4="@``U8H``!4`'`!A M>&=N+3(P,34P,S,Q7V-A;"YX;6Q55`D``]$B2571(DE5=7@+``$$)0X```0Y M`0``[5U;<^*X$G[?JO,?M.S+[@/AGIFDDK-%R,Q4:I,A%?;V-J78`E1C)%8R M"3F__K2,#>8B6S)A$20O.UG3W=+77ZMUMR]^G8X"]$2$I)Q=EFHGU1(BS.,^ M98/+TD26L?0H+?WZW__\:3B>WLO-E"[;NYW!T@Z-,\P8"R[^?J/X]0()I*>BZ] M(1GA6^Y%>"Y+PS`"[3.N)/H.U@./P?\>1?@ M4[;_1>S75'H!EQ-!>I/1"(N7;K]'!PPRDX=9V/8\/F$A9-I[J+)'B;PF(::! MK!L[H'@!>_'"O>`0A.%+F_F?_IG0L2(GKE(!R)G6]H+OAD$B'=#'@+2EA#13 M')O6TEYPQ8$D[_$+5E5B/CP1$^)_FHY5L]L"J+EI:^0>#KQ)$*6\6_@M1JO* M?]V>).58,@T):/CSIS14I4'_7(7A#9K;A;_GIE':-HJ-(^M^*L(,J`/N+54I M4&,9+I;)CLU%IOI8/D;V8+0WP'BLADK-"@E"F3Q18=$L5VOQX.6G^/&W66@F ME@/\2(++4O*PLK<*=29"@(]7ZK51YMMIHW5Z6F_66A];]5,5^?54S5,!U!;+ M(+#P$OOPYUI,+7,42U2DRM'*6IE"&"3Z?<%'"[?%A7";"G/A$P&#]Q*:2*@' M'ZLR<%!"SX0.AF'TRS[H4)TN-&CUCTK03SA0G7$[[&`A7J!7^A,'$Z*AR4C7 M'?K,R5HGN#A45XE/DOH#\0C@@;S^E80YS3)#Y3AHMD88LUMWC=T;]@15YN(% MZJ]A,RUR'.SE(HK9:KC&UKT@8TR3X13DF6XX),*DIS30/`YNBP*-*6^Z1_EL M8G0?J$E@:G:D;[!9*NZ0K!\D6=??U>3ZF3+`?4N?B+\Z!]2SEZUT"/P50.!J MPKTF?0(YPP=(:B;7X1(P<.;-$HF>Q%R]0^"Q&`A7$^DMQ8\TH"$E$G)*+^3> M]R$/H*Y2Y9?P987)?/$]@]!$7DIBF9[&'F/,U/?IZ,L#XNI\*57O["'9NJ`[ MA)F2D$E;%BI7V=,N81K3:F'!:;ZSZJB?$!=%[6H\)'W@`X$IXX1D4[]9^(A8 MM@#HZIC\EK/![T2,OO*0)-&J2]`;1)TFTS1%F^)RE<.5,%R,24>4_^&=?"8ACA(8=*-Q%9>50RVY/NFB/#Z98T!YYJ9L>>5F4 M@G@?%3JFN(<6\96$-PS\2&ZYU"VL+OTX\=Z]>S#V7[:"PH%Y`CHJR]#SZ_"*C^O>!];1).2;C'GRD7 MZRSFP7)U!!5/NW2M+OG9/:KR'+ZI1\S`XBH_:M>JV__"N2][,`K0SD^6I(Z! M+1-(N2/4\AY94W/HY.!P!FUI,?=X*YX0C;`Y2V"/!&!S`/6_P^([41Z(@>C6 M=;0*[I%J1,V&I1X[B*YFU`>"' M)'^I*WC1\0O=:KVA^O&QOA5R9T?7T9EVV\R=K71\U!?`>Q"+]^GK[R9K]XUB M:_>J&&1[S=Z9BXGW!+I='Q@7!.IU36;_KK0,.]6]C,Y(J&IW+_@3!6ZO7OZ0 MZE#]?%6A[<&X$F4MD0\48_( MKN@$F(YTR<'*QAL-E>U]%$?0J6L1-#LC^QME?K+DJ@F3=<$W&@N&CH@)_^`: MX:MS[1NV_GH<[:Y#ONH;#8K"KHG#Y*-SJ];KB)(7\>BOLV?JO$>&H4_BD#@[ M@)"(W]^3W&K;^!X?XU@Q,?8>1-LZ*UD2JQY`>)G<4[?NJ[*,O8?7MLY*PLNY M)==UC"MW<8T#:47O/68L_)*$AW-+K1J?J;Y:OO;>G:%1=P)K1WMWV_C!U25[ M2)C1IOSOO.V!JQ;O2E][/YYVGFUJP)WXV"'/F^;?6SG(V5-C:[@,]WMR]=[C MQ,(OSIXBT_ALOG/QFAV4H5%W`FM''=0V?G!U^Q`P>H3X\C,X+EK,[D8UDY^F M1'A4$MVENUP]=Z)AAZQN2#.%_.+JP90TFL6F1_X;1G+UWJ/#PB\'<5,AZ5^[ M_6OR&";@LHXA9&B\U?"P]$ANIU+>'!FO?@!ZB\]?IA,[[GL/S37C\VH=X0+H?$CVZG0W6Z M?75U4CQEK+WF:BY']^D>V_LF#C9^?L(2C*L]_!S/7UQ\5_L(T$%).UKUF@=( MJR485]>=YG@>\/,=#F'F@P,[5K6*!TBJ'98]7B0R_::B2:?9K-96.\W$*,+, M1W.S\P[2\>[1XFLJV:).?0HF>CF,?AJ5H>1.0S1AQN@C,7I9Z_3=F3?)\:SW/+PRBF<5#2?%6'UW*$W;LJU%9 MB3Y/S9WF:\:0X1>E#B_=9X!))2J#>WOVAHXT!FS0NI&N+;Z4;9*_3]?S=U(" MBHN(QNMQ(2@IY5!R^K_Z51XG/CQDA6;C=UCVV;JWX"WCHT)9,'?\F--3=0;(D`8SP"9_(J,8XT.20 M7/DE6!_.#IP^:Z0FBUV&.T@7E9GCX[X&GOP?4$L#!!0````(`-6`I49Q;;7\ M>0\``!,#`0`5`!P`87AG;BTR,#$U,#,S,5]D968N>&UL550)``/1(DE5T2)) M575X"P`!!"4.```$.0$``.U=6W.C.!9^WZK]#VSF9??!<>PD/9-49[>4S2E#'A=@=#IAPS\O'X>&14U_AAW/,,->;\1[6?>[9,2:8L,X M/>SU#X_YE3>]+Y'+6W-Y@9C^86_]R^KZU#DW3KO'W?Y1[]0X.^^=G9^<&H/[ M=;M[CF!"TAK:Q/E^+OZ,^06-=Y>J=G9UU M@U\/N*$-XS.C-G[$$R/X[MQ;S/'%@4MFITY'D'5TO#35 M+]?$-6WJ^@P_^;,98HO1Y(E,'4ZOB1QO8)K4=SP^7!^H34R"W6OL(6*[!X:X MY-?'NXAZZ)U.L4,<\]"DLZYHTN>GR`I,ZY`=<3,%;[PX[8V M:PG$\;H6F77#-EUDVP>I!DE09;6&BRW&:6"G0%H!6O'/V!$;PXY%9X@X!:H8 M%UV$OH&HS@S/QI@5J6Q4;@&:OG"EF.F/<6=MB`+UE4HO=CS@"?)MKYP!L9(= M:LS_)PX1V_$AEQM*%_J4M[';`H7?/>Q8V%I_2SQQY9.CXZ.>T3$VU^#_A)XXD,?/NOA'WV9/.42\\GOP2?OU-G"@LW\:C20C"#1:!(46.R_>,M\3A MIP$.[!&;F+R*A>%9_%FI8J,QMH-CY'[2NIF@QQ<.\QEWF)V,X_(D2[RDM]K6,K[I2WE M$GQ0V)#."6F+FA?JQ#$4,S"T`:]KXNB:TX.QV&8UNQ0$`";NN?%F_DS)Q4Z; M.I=7Q0#:-OR.QA#LC-[3[1QM4^):TTNIW+XF= MP$6J'OM9(6X3EGO1WJ%VZ24[-ZGCX7?OQL8B0'=QX.*I^+#YW:8NMBX./.87 MY2UYQ"YFK_B6LA6"C:[7F.MA?75,:MO8]$0DZH%O:[A&:+KK^]E7&(39F65:(EVHL\FHE/'3XM?MC'#3 M&?_/!%H&^+0OI1:?2NMC8EMH+@!,C) M",3YD@@ES3^KT[$^SZP^++E/-FUC6;T3MF2Z?V?4S4QUV`GT35))>!HR-!W:;5_IS`; M0!L\B:I^P4D#0MT%@O.VX'D?X*K19Y=?4Z; MB?^39>*W^=\5V;G-_ZY['YP66]#K6E]T(0LT>7PA?45H:H1!@4P58TCO!F$2 MYB4^'1TT9[%"XRT/^;8G/#NQB8(@1`]*H#H1;X/(3XX5I'6"$"TH@53-B`$8 M`A^QL)R`0T,9[VGA/&^]I MXSUZ=KYS^/$)/WG\Y!WDWX8O2%'X45M9@D?1)@0)@]`G;MMB#.]8]8M^Q>`#\S?N/P(O(S:W%+VC-F,.*$'>GDX MQINCL3RDDDD`A#UESOA*)IREA[\>Z0+9WN(68W?S:*VO#L>M15NF[DU,1,B. MLG3*PD-AJ%1\V,AX2N_3Q(0"36BE,[(9%*/)%9K/Q8-&`W4(=ODDO^?[,S*W M<:CB`UH$0^69+E6E3#JU"A#:Q(R!HK!7,`UM['K4P>'EKVCPRB'^Z>N<.L'# MZ^;>:/([0TE3,DO_QB849(-9?KJ'+Y`&CZ2P?--S@[OX-7[%-I75\FOV:6*Z M@"8T:.D>X9P/CS))[O2=1I7R\UNQYX%=+#6F;\C?&;IEQ,3,C5_CM?2!,".4 MUI0Z^FL\]NXH+V9I1M^,G M&/[5C!:68BACGS/B*Y*-'(OOGHF'[#\P7T->KA"3NT+UNM3I!DT:*^N=3*KV M95CYF?^*'S#Z[H:73;9N8M/:W^JF.536EDY$`F!W.*3.U,-L)E:2E,TY;A4K"79A4`(8:J'X&9]R8X.P/R*WJYC)WKEZ7`( M(5Z9`F![#DF7IJ:66(M1*8;EA3_=;E>%.3$I6NA^+A[-[B"=F*2("T69TWTE0K2C4& ML#MJ9D".IN1MN:RS;&LNVQK(,.['U$KE$U$7<3";8],@K%E]F)C=!"H0BDD(83L!7 M>LE!5*-`BZGCM<9^5 MRH!09%+(1)2BJW@:+BMPB1E6)3TPXIADCNR!8ZU439^,6D(@U)[DFY):\,HO MKEQ>_9G>O(O",9^X+^&66922,61*B=+I52DS9_LQHX.G="I&8YM,@V+UH$Y, M@X:T'M7ZAX[VXR`-#+0U:C5)U;5RL5;576@LL/MO^31\SU=A*WTOE$0'`/ZM.3#R.T^?3`J(FQY=YR*]RYKH\< MD^N];86$^:73$8(O,?M\TT$&*R]7]T']O\8?U)^0EPO](?UMP7>->;=MSE8C M<[8:DV64-5>K^"RCCUJ]G35_JZW>;JNWFUE1TE9OMQ4E'Z^0H9@*WI7JY3_% M]&/5Y^Q71M*@HNDV/;I22[?IT3]SVF[.].@V;3>3[3]DVN[/%E+9/]Q5;BRE M312M-MVWR8FB34G1+CJYMYDIVFTJ;YO*VZ;R`IF,;2IO$U)Y1Z'P@661Y:=+ MRAA](\Y4^F*-++V;F[RKQE75>X6:6=&W9ZYN915]";87+]:XPLSCR&[X-3UW M];Z4T63D>ZZ''(LLXQEO,')&[$$H^DQO"7.] M@>/P6I3[3C-[XD$8*KJ1^;FM+*]>QXQ,B7\.WLQL%Y%EK2U0CEZ MVV0?*X=8/L'5CI7\'M`B,4-SSX2G*?G1,:E1M<3M[^K_43`4"F)__(#MQFL2;5T?QEU%N!!I+B4UY(>6. M)50%2O*FM2078Y&/R)C(/`K2(U)RO1.;PZED4O$0R3%.Q`+@UB533IWXK>@` M)(4P;:RED0/I%5[%T;/]OJMC?B:#]2JO0BB30BSC$/MO=$55=6[1WR&D?*8/ MI/6A,JH\@$FP>Z-5+QV)K>%4"NFN'(E08)*BO#$IV@-9-E*&60HQ@!:-PJ@! MO60405?Q"T8I#"KK"Q+:0EAT4@>B@B2XZT_LM*PF9`BA_B`-@FJV`'MP^(!A M),(@R+YQ15[V`Z-\`?86&]>W;$>FTPM"O8$.4=J`H/G)DG1.F$C)S2%4%F29 M4LE(2H^WB4C/:+*N!)7-C5@3"$4`VA,AIGWI)ATXCH_LX$0E?\YB8BL(V?CZ M=Q@)@%P.X,_=I7%"GRG_YO]02P,$%`````@`U8"E1L"TK9DQ/0``[]L#`!4` M'`!A>&=N+3(P,34P,S,Q7VQA8BYX;6Q55`D``]$B2571(DE5=7@+``$$)0X` M``0Y`0``[7WI<^,XDN_W%_'^!VS/1DQWA%Q''_.F>F=V0V67>[WK*CM<[MV= MJ-B8@$A(YC1%JGG8UOSU#PGP`"6"!"F22+KGP_2X)"`O9?Z0N!)_^K?GK4\> M611[8?#GK]Z^>O,588$3NEZP^?-7:7Q&8\?SOOJW?_V__^=/_W1V1LXC1A/F MDM6>?&11Y/D^.0^C71C1A!,@9V=9P_]Y?W=-W-!)MRQ(B)/U>O*2AZ+?^\AS M-XR0'UZ]_?;5=YQSV?L]C7EK3D^0^?;5V^*;G'\8_$A^>/W=ZV_?O/V!O/OQ M[;L?O_^!+#\6[3YR#=9>6T/?"W[Y$?ZSX@S)<^S]&#L/;$NO0T?H\^>O'I)D M]^/KUT]/3Z^>5Y'_*HPVG-2;[UX7O;0MX%]G>;,S^.CL[;=G7-'GV/V*<+,' ML>!MP"1OSB6LM'[Z+F_[]O7_?+S^+(0_\X(XH8%3]N(TO08N1^V/I,KXO'WW M[MUK\>U7W'J$_"D*?7;'UD1\]F.RW[$_?Q5[VYT/M,1G#Q%;U[/VH^@U]'\= ML`W\I&"A=V"AMW\`"_TN^_B:KIC_%8&6/]]=:;5X5Z&5=1+J&)GWM=1'^@-T MON9_5=1BSPD+7.;FB@&[!M)"FM)20#MT*@1]\+$PJAJ*/F^",W#5-]])1_D= M?/+7BRR0EH'[(4B\9'\5K,-H*WQTN8J3B#I)3DB(+RF9]NMH)E`&F"RCJD8T MT7QB,5A M&CFLDV^H^G;]S0K9>4_`:1:<_?RY@S+_FC,A-'")9$,4/G^2XG5RW8RKX+BF M\4JPY0/(AM(=H._WKYF?Q/DGX.3?G[UYF^'A[[*/__HYX?$+DMW358DBF7VT MC9`Z<+-2X*WU+1"Z9HN@??VP($>^"(+_B\#S./2S*_YGW&8"M>%-KEWG2&_D?AT[(/_JKA.$[MO$`Y(/D M$]T>`F!#,Z0.V*88N)^N#4+G:Q6UK^ME8W!)E0#9:5WOG'M^1/TKGN8^_R?; M:U4_;H?>^32J5;WOH!%J]]/)>J+_962)H$LXX:D\,$]([SG9&J4/OD;L;W6* MY&ZF?H?4NVI%/'F6`=2F]J1;%GDAGT*Y%WQ0;]#TL-T,?*M6M4,GJS1"[FWU MLI[L=I(LG]^Z!`A/Y8%+SMP%`2Y]NJG1^O![Q!Y7JTKN:94OD7I8O8Q]/:N@ M1H#<5/YTGD81:.#%#O7_PFBD![6&IHB]K$W!W.%T[9#Z7JNX?=TP(TPD90*D M)P>Y+`V5DMRQ71@E7K"!&71ZN'!BT!RQC"/J&V+U$F-1#YU5I'Y:T&> M2/K3^NJEY[/HG(?()HSTD]O#5N@]LU:MJD-6FJ#VPWI)3W0_093D5"<&R'"[ M#8//2>C\\OF!2Z2"'/F2$SPZ/C&(0@F+8G8] MM5:V@RA;1S&*I>.VLP@IC8K'D770$'V`Z>0]S2,7Q=H:CH`;6LM<.RJH_V@O M`,]I_+`,7/B_#[^FWB/UN5CQ,CFG4;3G<_#_HGZJ.ZYJVA=Y@'8R@1JP1AT1 M!W`W^7N[.BT`T_=HP2U)59LXP4!^`2WQY[1R`[P6[:#Q9S,<<*42W#'',:E6?GL$TNR M`4LW2#9W03X`F"A<2=0:VB.&>R.Q>Z=M&7$2%=07)&`)Q##U_?!)S-G7843< M,%TEZ]0G-.\"37:[*'SVMGR&[^_)/__P_>+-FS\3P M4"MF7V\NB"T()VX_,O0H2KI.W\ID$9CU2M79"CE5F M2JMHU=P#,5X9"M[7G27Y,T&?E`R*--X:9(VLMZ)J?:8Q#51-K64M*D\'5A=L MS7AZY\H3;>P\C+F>/-QESJ?'*Y-^R"'+6'45M5H[(08N<]E[']C-.)",!1$\ M.&857"SBUX3JK^7YT&!#'.!B>_FA<;*(/U"K2ARO-"`.N0,!ASVQ..62PD!K M";:/7EY[=.7Y7N*QF$]#Q"6LA]!W.73`E"39MYS&[-`=>4QU-80:=:9]$<=E M9Q7ZNKW"J%A[X%-5VP<\K>DO+CQFK'Z?6^-K/G!ZCI=\@P(8S`YF-W:83_`; M'-'6MYY'@`]]C%DAC>?$]HCZYBKZ)0N+9[?S(T.W=`_'A3AZ\4^BE+G'%M`E M-)TH(`_E'N:H.]5GT!UQL/?1XN0C:QDS,:IE[$@=--@]MC>I27:*26AFDGPS MWM+D!8MG?-"88?J5OCOVR(*4-6.DMC%R.&Q6LFXAK]H2, ML-4X2CVR:!5:4`N(%4GV63Z4PUD)QM5(R"U7Y(&W),M-Q)C=PT`'^4SI9F;Y M3Z4]1A`/6@6./HX:NZ!/*X,U*V4 M2M$W1QQW)E+WKVY7T);5453JEBI>3*BNTZ3NE`4L.QY[F?-!EVY'6V9YF&7$ MXQLJZ>*XQC))(F^5)F+^E81\*H9B"WQ,,U1.K;#LU(J;G5JQ66+3L MN!GRL-4I=CB^JFT0AZA6U%.&EK*,O*"Y(%=QG+)QZF@9C:-C:!A+#?_YU9NW M9$V%&/(Z"-_[Q$7!@@`/X@4DX[*H MO+-AZ0C.I`:`RA=GW`".Y&(OSN]80KV`N1]H!/4,XZ7CI-O4AS+FV3%?C;V, M.B*/GQ:<)\`OU59;-)!Z;5`^/Y M&/[XU2O7O$J`.#X;A)U@5<#.IJ6+<4K[:U MT&C388XK>',E6?3(R$H^;H9B%X5GK3>1>.G-%8NHMRP2XT'[RFU#3^1XVD%] MS?:+KAMB[.PB_3";-)P-X7$@&'I9N0#5]TQ M:@2=JT#5<,9LRC?(.)ZPXA7[EC/?^M;(`[=%S>HC9;5-$8=KF\3]O39PH3Z- MN)+!1QK/%8L4!2,Q'-WL6$3AN)'%NPO954'=]2+E:^1N>JA(]3R0_`ZQ(QZ) MV/]LCR1DZ_#.R&I,F:'%RMD,>)1JUJZE5I@CAJ=)+V MA^U8O)4J*)+/-3.$J3*J-)>5K MQ'%4)V5?7Q.TB"1FYYS+\-KL:K69=BR",SMYU<.6N49#<^31U*;HX3!5UQ9Q MG+6*?`K`9P?,\L:D;2YSQ(P[ M^@-7](+/+/U0O&G8'*EM?9`'JY'*U562A@Z(0]9,[OX+$9*Z\&2%?AZXMM99 M)M/9572V_/K63RQ@$?6AZKB[]0(/$HK$>V3-<=S>"WDD&ZI=F78V=T$D^FJ':B[%LDS'8R*W.ZS#6A5E]2^21UJ">&FPUS1#'6Y.T?3VSH$DD4?(U MD!WICG];W(VA(!`AX!PD1+"O_BD,PJJ2&<:T+-V:]$,>DL:JJP':V@EQN)K+ MWM>W50Y%_&9,OK&^TCN^_C?)`XORP=3B:F]>$K]YPGG<"GG$:M2J'NVJ-$$< MC3I)^_I>\0S"*-/#=U*A@&W@@%A3E(VF%[,Y[9U:JPD+#6S#*/'^+A*1F_5E M_H)]/N6X\&)Y;5=CF`[=D:-+5T-4*@L8]D6,1YU5Z'T]7&$$AWT*5J2<;A?< M;*'89-8X!(*SXJFZ=6$7R\O9(JO1)D^ZJ5-;)^1H8*9T9>[>V`-QY!L*?EI2 MW#@UL#.F3Z*WEZG*-*HBF.IWG2[A#]Y.<3O'D!W/:RW$:=LJW'C*RF7P4)VU M6XQ/EK2N?1^VP1Z'=2I58D]M@#G>:N7L'6,L(4#(TC+8X+KXH^G2"@V3_"[3 M8.=QOV*=VN6'2S%M=5E=NJ[VGL.6(:XJ>)MB9$;V+(4>4T M(ZGPTX\28IPZ4:&^@9.S)1E?(AG#[#ZK:J`P7Q#!/IOG"P'L`"$68^77Y8_N MC),SLBI,Y=:;:CILR@N=Y^6RS$"HO1=RM#%46X65EBZ(\<-4\KZ^7Q3R+PK@ MH4&#L547^_Z@=EXI`IC413CYV@N(&_H^C6+"YSVRI<6%@Z(:P,WZG,8/EW[X MU':SJZ4+\I`W4;CZ+H"^/>)@-Q)[U,H2P)8(OE:GW2#&;10^>BYSW^]_YD)? M!<71GZ63>(^B2KA\)#3EGY45,=J.R0Q%''G$#&O$@Q6"`2@CCL*!%3QE[BO" M,1>$K/;D:Y"%>,$WI!"'E/(L2"F14B3&_CD?'!85UEP#N%6.^\'-ND(`BV>$ MEN[?TE@^4GP?WC$(K*SIA#RRS936GZ(\[($XF@T%'^K$ M9,F`2`Z6TH)IM?9*K6FMUCC.3!L9ZZC+K&*Y7F'3\]"SB6.-V$/YL^E!7QO! MC$3U"?00UO2^A91Q$R>VQ+,S ML$:0,M0T!Q2SWW*OA/+W#SZV(:X]0V1![R M>N74N#YNA3AX&X3MZXA`\LP+SH`HR:G:B<`1M"MN05(7MD1@Y3Y,+-[%N`J< MB'')+IC\?V4KXYSNO(3Z[<_HF!-`'J#=C7'PV(YA;\0!W4.)_J$@69"OTR?D#[\?`#'+E3V0GOD=7GF][`^_8"LMC)H6Y_9 MA7B-RLVQK72855#7R3UP-"LL\$3QL'I+6GM,07L;L1V?QUQD.Q%Y);C`%64; M&C?F>Q.;79AW,5)S_)M0FA4P=%)H8,3(>.>5WD0V+*N-C'$P75#^V2H["V9NUQM8\[C<[ M7-&HW@PA!YUFA18ZV0<&AIP-R?A@`8"AU2_TC.KUG,MU58T!3R:*'!"&,=IP MUU(10\E`BMF_AFJM()5M\[7?=T*'7K!"%(]UV;X[\7FB64\C&J!:1\KS0[>^ M"HZ$X4)45SSY!/1[/KLTODU]2+&[<6-D.QON;X)O.S% M/Q5O5VK/W'0@@!R_NANC>A#,M#=B'.JA1/^#8_OBDG3&C.3<%D3P6\@G[G*6 MMI:/IS0*%_\!IK/AFNPR+O(A/)T1+&*%X7U1DWYS0P:36Z.MG>:$`X/?HJP+ M_Y'OCYX0\<-?(@6ZL8?P#NEIB=,HV1A^@!C&:,-->1!#RT"*V9_BH%K(F=)\ MU86J5R5E;)\08 M8RY[_Y-KDH-T=7G7-&-""BZ6+OE-K#S+Z,(L+1:&"'>6WT9735#>.I;EVX5) M#$RGZS>C6&]471?KM9UF$NO-L@_C[NJ%^_S]#V!C/]BGT-Y3M'>RYQ#JM)]^ MT?5F?<%626Z#IH)>S3VPQW>[NG5+K#7-,<>T@=0G+ZMR#P;J94"?#U_#J_N" MZA@J"S6+R+5G-QDX@]6BF*Q=FFZ MV_GB42WJYP]Y707K,-H*.&U[JLVX-W(`Z6B&2KE3LZZ(8:.K!KWKX2E\RN?; MB,+*^D:&%5.X7NSX89R*%US7$AQ@%R//-?962Q3)XFI0MTUCLX,FR".]3J'J M5;[R>\0Q6ROFR17T@)JM:W@#ZB.P15SKEX3A=$-]&&!ED)\_)%2_EB MR2T7#6"@4CN=^N5;ERU#\%"TD8?MH"94XWT0PHB!8EC]^D8D/(@L!C>5I;V` M%.+73OD@:)5377ZHT:('5@OZ\G.6-(D7^[9IP8=?=X$$$H_O/DN"R3XI`(M'$W>I[$7L%@W8!EV01I>712&2#-ICS#H M.HG=UR]5^F(Y).=@<4N()GSZ=;-NW^:I:XC49]N5JVS''+5"Z)\&PO9>MQ,D M`2[5@Y76AX41-$48?^6H=\L35,?@6>BF#LCCL5W9RG-HVM:(X]-`Z/Y+9]LM MC?;BM1%O$WAKSZ%!HN9R.4N+J^JE8,>6`$@1B*);@S3MC-S-NQFALJ1NU!.Q M^W=4H'OZ3_'2&A2X]2@R$J35&.#E!P1#(Q6 M[((%+'X*0_?)\_VE>`6L4K2A5+]E6.Q*`SE<]#*)BA>=""`&C'YZG+#SW5S- M9-*3%AIMVP9.LY[(`Z"#^@?'-=JZ(7;V+M(/YN*X!D(K)K!Z5PSJO<=Y67GJ MMZUT-O=`'M4&ZA[<%=,U1QS%)E*?_%!`W>L)'ZP_%&#R6(+Y0-:?&O(P.-%, M-=L!74DA#I]3-1HEM!3>N,9+E-:R#T1PP=1X[JAMC!Q&FI544:*^)6(0:!&X M]Z9^F+#"9>UYYW48;.Y9M`4MVP9!75ODOMFHHNJ:M0T1>V:SO'T=$ZB><;#? MR@H`]L>5<=1$$G\ELHC*)#!8B=,O=\R'J@BBQL'G!QHQD-K-"R&TC2*G$D4> MT<,8K3(JG401,48,I%CO[6^U^-<,HNR]:H6V\?!TJB\ESIK-UBO0ZDF^A$AK MT:QW(9MR+BBK;Q42D$P$6<1G08049R+@25'QQ_XX;]N`2+!*B/$0^BZW%^R( M)GM(5=JNN[=U0HXT9DI73N(U]D",$X:"]W\#9.5[#KE9KUD$Q\M:*O'9]FOS M)=@N_6?I[8;+K,:=9Q<#8RP.JIQ^3R0O`LQPK9U.9Q"\^)"N8O9KRL?T#X\& M<]R&YMBCOT71:@F7^K:88[M-Y/Y'J7/"1%+&XZNM8U=#^YEY:_/8I&L\(W\= M\NS_@<-B&&BFT]9>>&;OH]\Q)]P$XI4L<-" M)Q.HN$3$N=)._;Q@(+L+E!1]2G#XK.>%#B&E,4V.*8VP0"TX1<[V$W'FQ MQ?4F>/,RX+3W9EE#0W/D@-"F:/722GU;Q&'?*G+_NQD987SQ/+K.5NL17`5. MN&7W]-DT,K7-T4=FLZ+5R*QOBSHR6T3N[Z5`F'#*&$-S=*5MQN8E]:+_HG[* ME*JL5T&<1.FVG'1H3&/:%WG4=C*!&L)&'1''DL>IQ)5YF`-XCPSJ2C3C1#]*R%'C!/-4=MBZDT&,**=H MTWN?2CG]J')=9$?_Q)2UX"SJM<13X\TCBU9ART:>-=.]/S*=/=#Y.>:(^R%. MO"U-F*XR[E$CY%!1KY2*`M46B`-<(VA?!_Q9OJ1=$,27"(RLL,VG29^4.HE1 M&/`_':9D-V:3]1YDD$=K7\-4'QSM1@-QQ/=6I?=%/O94*:=988D/(":W#RS& M'U0JC.O#MR".EJB,J$P+`O8LCH MK$+O_#5C!$.JLKJ?,2-?!#O[$&'%'AZ&E?]2\Z.+7LLG&KGBB'IV0PO60>1# M('&<;N5G'7%C(":S09EU[@)>S:>V1'Q8H[)DE=*"%' MAA/,4Y_N&)-!C!VG:#-$#$FN9X(M.2X)C`59;)O)*RU#+5<*+DUA4O*Q(]ST M(CD;W.EOL'H`ZDYO%DAT@EI#Q)IQ_55\X&399FE,4(U*SP))^&@V9F"QD8"V( MX"X&V8*_>OM*HLX1U)@$'KRW#N'TPYOOLF`2+[!7=.=J"P%*CLL-6SY[AP>Q MNO5$&B0]U(>`Z-#-LO.[H2.&`K&BWO\7'."BPSJ,MG*'8K4GL-#.73_>,0=> M3R6@8`R?)/(F9IYQ0A`$8KB)"I%>C3+(UJ'$E`8JIB=R=`7%)0XHD<]YD2_` M;=K@OPBWU.OI/$7?>0-`U00=($!VG#\('.C1_]S2CBL@DF=/080(JL'",)>$ M+PL:!C+;`3@LM>`@^4T\#;%J"SU0:FQQ"E1NV!_>WH?OWES0??R1;5W@'[OWA"7 M"SLUD(U@*$&3`%$"5,D72=<*-HVC7OF3`=UA<>;FD44&.%/3##G.Z!13<>:P MS0QP1BLR%ISA/4(NHSV`&=Q"$(&2*`:`&4V]4_!EF(76.ZY`W0I0W?=(T4>K M2J5B9OXEX@7+8QE[`PQ0.F$Y84#?JAWBZEO,P;^.![::K['[V%##F/0R*]`\ MHCXGS"V'B9N/7N!MTVUCY!RV01X[M2JIT5-I@#A^ZN7LZW$9-'ST$;[.%3IU(E?-0&F,.G5L[>KB:IV0Z?,72R%SXMB[W77L"N$K;531@Z M=$<>=%T-H<:C:5_$H=I9A5,7_8W/2`!K(GA;BOC)33-V@5[-6N4=BUGTR"[# MFA+$%XQMF?MSX(2^SYP$SKG?L@BDHIO#PR@W$(#/Z0"15;L5W`4DY?QK<7RYJ=ZA*K^RL=MF MUVK2%&YNKMR?)H?IYE2Z!XWY@W%#XMR5P,N`W/'2Y,>BX`RMP$B)I3RY27F2 MG#S0A-"(B9N"3L*3G20D*X8UEY[2L++]6-*(-"L4W0!M!C/]W&/UR%=Q&H<.'JDXQWMAS+C'>KGYM MC.N[S2'&#:0?(,:!"_$"DO'!%N0C&B'7?">)(XCR._KTD7+;>-3O%N1-'><2 MXZW*UX:XMM<<(KQ=^`$"G#,A!1=LX3V>!4#M;4X:06P7U45-8[JNPUQB6:ML M;0P?M9Y#[.J%/CEFE9JZ2,)T3&7+]9Q(H^S$KXZM#I]!6D81'+Z%5;'W^[*) M6D>X>+%-J1W\(5MVNF?1]JW&PJ,R1(X6XQO[Z*FS4;@A1JL)E.Y=B$;S"+M,>-R*3(!F2U"-/(?H[#88VDQ M+/M/@]H/S@9?1HQ=!?QW8W$R%7QK^/Z6P+O)]*-!=QW3WPIP-^J.$+9!7@(" MDUSBEX+:H_P2PEQK,%?$R;U,N,['I0OOT7-9X$Z=;1_P_2W!=9/I1\^T5::_ M%;ANU!TA7!9;-8>42K_?O]/>?=4"?*K"?R*.B@OM%+A&4WQ+[?1?I1 MW'Y!@(_U:E7ZR.><:\MD=^LY5]\_5M_L%!5K9OUVG-8P51?>=6D$])8[J9T<7VJM0?V^U+F M"O2>PQ01"ZY;/.S(G3H.`^K#`5<9Y$ZXW8:!OR#6. M-1I/6GPXW:8^A3UHJ$GC>&+1A__M,[&O';C+;1@EWM_%YUHC:8PZ('GD$#&T M(0^*&P]"&S'L#*[B"16`V3N59"O/R_CF"6QV0D5 M`P+((:V[,>I/J;3U1@Q+/93H?7Q.><5>,CL3W$C)CDA^]H^M-!CC_?XC_5L8 MG?LTCAN.KW2C@#Q0>IA#C90.W1&'2A\M3JEEU1`?JST1#(G@:/V@2X-E2KM\ MHMOF0R_=J'+PMS\TRX M%>TY+(#-@.4F8B8;T0WMD0-'JZJ536A=8\1@T"YS[XE83IF4I&UO/T^JK,6% MS&4$OT1)ZNFJ^_:G-%V=,S&0(-DVDYHDX1AJ-!3L%\PKH$,D>73(S MJJDJ!M@)HG!TX"C;&?!Z[Z!+NKX^PH0(@T2XL4\)AP_=>7UX"3D'"%0UG('5#-' MD%.$B2\1CV[[*@.2<2"2!1$\+-P?GD+M,U7OS).DSZ%,U"Y3<9]:\6GRM2/)_8[(8)XA`L MYYE(#JKY:/-<-_5-JPG'=I1IOLLB."6',JJ13@,9H/2B,*:BD`6(`?YS09A! M;,4C_X^S`AC>=C@+2F(O#V`4(YT(,+SMRP(852$;`,/[S`9@AK`5C_QW,;KAOWWS[QAX, M705.N&6?$YJ(_;5KX`15H/156II[((<1`W55F&AHCA@&3*3N?T,*:).".,FI M6Z^HHM&ZL7Y*6Y]Y>K.^-DICA_EY]$"5/1I\VFJ%$VQ:3UARC_D^')$.W(\T M^H4E_.]L[&TLE6#0#7E$FRI>*:K7T@=Q7!N+WKN`GF0@GL@$@\1PF;S!((#D9BVKK;"RU,J!*7H10!K"_8VA MW!/HT!O_I8$^RO0_S@W<\CLOZS`B2TR?61"Q#VG+``;H'L:F^+G0"+=^&>^LG^DK'X5CZQ33?L9SC_902* MW;ICAL0>AB@`L4-?['#81Y7>1PTE+[+FS/('WCDWDHKCA]:1T(8I@!FY/30% M"A"TYAD1IY%;(GE@-8XQ(!Y^]`)OFVXS`8[AO#XEX@-YZ3!$[Q`ZG8-^( MNN\\#;[,F*S\BIE\W'>;^8^@44QU`C>Q>%;NHD M"[)+HSB%Q[_@RCX4`=@=(+*XIU^;I$P,U?9_@=N*U3,92"&$L'8N1@'XN2!@ MX$(4"XAOWWRY1>*$.K^`JPF#187YA,=R*VW#B$&EB4`D$'[&7S2.Q%__;P+@SOF,&^7W*Q_XA&B29X[]<<\3O0QA9)4FW?& MCOZ]=!F@*`NX.96E4[C3;W,I>*@(,8B;,N+59]C\`R[5(VQ$D`W(E67H2E(N M/HY)O&..M_:RDBQU4#]Y4CZAM0MF.5*3DAU).3^2,02K"996TG4K%EDS)DT@ M?4ED!N3V@;F1_6O7EIV@N9LL-S4JI M)VBJ+1"?E]$(>NI,2',H9)IC,"/I)'8XU")_<7$:9ENS`AS4LR-9=PZT<)>>B>8)Z#M[*[DD$,`J=H MT[NP;,:39$SE<]>2+5'XHHFDS`!F)BP;SRL>#I1L3FPH<;X*:Q-6:P M:5>S@!I]4^Q`8R#Y4+L362[J**PF!ID1E;WD%II$KOZED@!R$`]=2Y1TPSQ1*))VMXWJ?*2WG!L+@PV9W"VD``G M4K**R1?![>1[DS%S7FW"Q]9KA![8)&7O.RM`CTB"`UVQ-W4OR;3V_GS-UX@=JTZ1W*O4[Y"Z5*V( M??TI]R0K%]NGUN:$6HOH!MV01HC710N)B4M M[;'/3$S%'V!ZX@7K,-H6;[(EV6-U24AR(4@F!9%B./"RU?6KVXGG+V.;1*,M M`1:6KN+;U#O_E0<$+5'9]Y;17^*,E1ZL]$TQ@U2+@@4X:=IA!Z4VL4<%(\&< M".Z%IWY^M7QU]^KZU8+0@-#UVO,]FHA9$"[H&LMP=3:QB%03J&EOK07FU3"M MAEGU/6?64().TQ0IRR+(@0-AZA;E#31M+RVD; MS\Q+]<7DZEO.R%,'FH3F9.5ZH/14JW7C1M3S.":'GWI#%9CKD`;+P+UCCRQ( MV57`V;(XN>6F@E/_Q?7@AORV!Q&DD7F:4?6>)]ADG M*+L^),L?@.`NX4+2LE0"I/#J"]D@A"LOV&RSZ_(9D:G/:4S_DP)'`BQ%B4"# M7\IJ_H_?/%CV:J^]@%TE;*N;0NA;(QT%#-74[]L631%G:&T2]W7C\XBY7D+6 MU(%SRGOB>K'CAW$:'9]8GB9%&TO13V'"\J.N0Q:SZYV'O8CDJV?&]3+2K,ER MJW\D269)$IX?Q&8NA,<*(TQ]V^>UL\#->G6.9J3SP$&-M*/.)8N9I*5YV."S M"`23IZ%U&K*(W,7UAU]3/FI!Y78]!M0WPPP$#8J5I=N.VV"'A":11\4%SIA( MS@183UT!;02U;\D%J>AD$RI&4?#B>OCJXFHQM4\LR9*5VG2II0-F]#!2]K!F M>'UK[(AB)OQ`=V;RN0Z%VES54HX!2_@L27"U4QQ\+`ODU1`KVG(&^=JFO?K? M(VNL_KZ!^OMB6;&]I`Y;BAIS1FMFE>9(T]#.%OF_KN27Z&IFG MA<"L\,C$&'J$:NH]&\PR4F(P%"O6$H'=0K[`Z"HI"09H&]4BA0$TY4KL0-XT M*LN-!?F3?ZUFWM]@!,?W-/:@+/>']9HYB??(X,/.UM11F2U,-IK%#"MK2-))"P3[L2*X=L!EYNJ MZ@GFGP7OF^`2.(-.-X+MMW4SW&[=D:)"7T,4"U,=^F)?INJC2N^%TW+A8A=Z ML'9%72CI"=MC#RSS?/X/J!B2)DP^_21F4V*H#64M>9A9$:\0>>)%K2GM=0"< M&5!*=N0F((*A@$HB69)O+2QZ36D1`[`\,@&&Y*L8,DZ8G-;30`JQ)YG$+.VJ M(3#+I*M)CW%2+D*3_#GA#\'12[FVTZPQ[%$FEEYE]G;ZM,THS9+&]ISLK8W; MR`L<;T?]9>#FFK[/'O5V@4[)';0 MH'^5!"8.D9,P3=9^^"2PCA7LY*M4^9D*2\@V@1GR<+T/2&8R9V/CU-9T MNB>A\L,?_>:#EB'SO8UP>O$2D0%\M?;`#%UFZBHUR)J:8X/C"%`J^E4EK_W$"`US((7U)&XS\I3O-]_ MI$D:0;74YN>-6CLAA;5N2A^65]'W0+QH92AX7\_^F-V^HT&0\NG2KC)[L'2= M%Y7*ULJC.X$6@W>WJ20!IFIQBD7+?HUA_[C*"O.J=-$;)5 M62_CE6V;K_DWP"[?0(>+][Q5]@K\U_)E3;'F$>R)RSC17U,8E/+EWF_(TX/G M/-1?RG_R?)^L%.9\0BTNY>=/O\/5!+'<3,F6BQ-YL##J/@($Y-]%).0M(TAH M74\DNDP`27IP:WT0:]A#+J+UTY`%'_?1A%X1,?Z`[+CG7OC31T>YI! MLQ??U!5[LM9#DP'N[>["!'(H/J2M4SZ4,3@,F3$DJX(C#'#LV8M%SG5P]#$F MWIHXLIP`3YYX,D7%H4I."Q:+X6/F6MV0']66ASOQ.3-2.E%<;(,`@^F!33:WZR7NYWO.>)A93^,.:V+X]LJ M=B7!C.IV?YYBA+`C!O;1QK)5!JHX42TR$9:"JV?&*D?-RM)1\*]SN6%)'JBD MEYW>3D+>7RP?P.$I^,(7!A#M*(G`"-#(%68HUL_A_`;O+4^L\?\6-PJX;6"M M/3=.+@LM3$0R&Q$PDBP*2(GS`!4)H;'88PO]!8FI?#-2/(1-_Q;"KD#^[_-B M\Y7&,>,&XA+4K'9D5#/9LDX3#\\S=3X0FV1R$RDXR24G-VNBR*[XF12?-6D>5XU(W8A4[F4G@9A^WGDDAF-" M$L:,\<@'"N^X?_`BVQGC$-+])C+&P7[&X3/&DT7[S62,PUGJ-Y`QUJ#O`3XG M8+1_9(POTU-'RAAKDD(E913*_08R1B0_[]PRQN$A:X`7U='&3)'G%:> M666%%GXJ?1XXH3"SR_QLV&:@7$][B%P"E"VD+='U'^GO+]ICCY MWC^?FUO&-KM?L"Y'>W%0,F8:5AX/5)\1N>'">_PS?[]T'^&8M9O_\#=/S#5R MI9Z$9Y48G6(\?8;3A^KL4I63E!PHYU!.K5;G=2+("U%@T!6R*+"0W:!NC_H) ML@#+H[Z57[)N^%;.82NE?V'P+G_*Y?%/"?)@&'OMV;%N$#TY-DA88]?IKL=E M95'J'[;3-D(Z^C0KI5YQJ[9`?)U-(^BICY59>8QM9)VRY]8@#LF>T4'U^ MH!&[C3Q'%U"5!LB#Z5@9-9#*;Q$'48V0?9U-D"*"EIW@&5"7VW3%IU%\L%KS M=$G.\AP&E0>(&_H^C6(12C$PM/AVCE#X/1?8A6R/!;%(GI=1!#F=J&V_+YMD M]0.73S1RY>6K^*>(BAF[K+3Z4Q3&AW='Q^4TA_`>Q[Q'.#$L&^R`,Y*VI]U% MY&FK(`Z/8_%`%\$='T7WA%"&S$J?D]#Y)5NYBLDF,Y6L\,;UU/X7!(XNY3L*0L7@54_W^/(R33V'R M%W@?UPDW@??WHW6L*?@A!\W13:U"YVC,$`/H^#KW+NDD7C[*[G/'`@P.649N)\I',[A=MB&@;!; M+$K*BO\\11X4@5CFE;#JUK!.)XD4#X MR`C6X_-5=T<(E24W61Z4*G)9*P%GVXPY_[+^$Y>`@`BPE"Z%(%**K":V*@B^_`S\Y7J,*J-ZHS;EQ!F MA#_).`6N]Z*"'#;/B\-,C//*6E2/!1S(52-ZVR*`L? MLS,77N")XE?4]\/$`JS;L:?D"L`-?.%XDL(9_@F\U8W3"KY;@'"K9LK]C+M3 MBW=5H'Q`M*[7[SX\!S^^X?];YNY;B]'=NF-&YAZ&*/"X0U_L*-Q'E>$/QU03 M%T!0)Y^O'L2)(_`6_G-6`&T\,=).:3,=<@*T"GX$&)*2HP5(16$/G6\,62._ MMCILIC,LOM1MD77KB1DQNZE?%L(WZH8=)SMJ<4K9^PU0DL_Y>8%\S0^J)1]" M)MUYB8#.((F\59H?&!8EZD4I^ZDKRT]CH:*$]&6EA+2RU##O;9VN5-^`RUB3NW(G1>4.QZ<+_F)-KK+N!B)8VKNR M9[**!5PO=L2!]H7`)HY5XI@`6$J^E<+BQ-L*TQ:GJK+=*XNOB'U.5S$3C\>( M$]3W<'%&=R2COBERT&E2L'((J:8=8J!H%+?W`9>"J+P/0+X(NO]K\;E*Q@53 M3OW<C8T1^ZF;8I6'J?4M$7LKJTB]W5909@HE!<$:),O0!V9XUZ$ M\,9#!PL5'6;HO%5EV]Q7MIZ9`Q\(/9@+9QXLR1_Y\#19U93Z+IH5/F$]ZS_H M.=?V(X.MB;JY[,'W2,-,JTJQ`J5^B7V=J5;6OK[T'_3,X=06V272.`ZC_(+= MX;N'OX_)$XW80YC&\DP!S\+A3D.\H_R_^7J\%Y#W:<0IA0$\I_I,IUYZ']@\ M!*B1+Y+>Q%@RRL\-U/!,EYK347UKI$ACJ&;3O`E_+MHF\6"S)Q2):(VVC7EH M4_OY>:T^"]4VGI?G#I23:7S7:@J*15MKL5J;M[:UG5>,'N>SC0WG$YL#)3S' M*W)6,KEIE<2S''[M!>PJ85O#!$]M/J\X/%*T(12+MO.)QF.1APM(H$T$<1Q! M.9ZN@Y[2C!B%ZGC4_Q`G?.9]&X4[%B7[\O13W632J!?2R.NH=GD4L[4+]A6? M#AH,?_"2.X,.R\\&J'US-_S6%JBUKQGI=&1HF[=!90H/X#CQ*DF#8&*>S?KQ@O:QTV0QEB30D4VJ><.M]K+U,%2)C"XIE!+DNMH\S+Q6#K1$2[Y M+H,@I;X`G^Q$86W*4M<*,Q[HU2HG&$=-L*-"@\2G`$-9OUSDBDIMD5]3#R"" M"K[^/KMX+NJ0,\RUGV&=N M+3(P,34P,S,Q7W!R92YX;6Q55`D``]$B2571(DE5=7@+``$$)0X```0Y`0`` M[5U9<^,XDG[?B/T/6L_+S(/+\EGEBNZ=D*\>[[@LA^V:XZF#)B$94Q2A`DG; MZE^_``^)$HF+AP#"CH[I]M@`B"_SPY7(3/SRU[>9/W@!.(0H^'5G_]-P9P`" M%WDPF/ZZ$X>[3NA"N//7__WO__KE?W9W!^<8.!'P!D^+P3>`,?3]P3G"B(?'+R%\&OH/H.9DJ:& MAWO+6LP2]/_MYL5VZ:]V]P]V"="WT-L9$+$'8?)MB8_DQ4D/UTJ_'N9E]_?^ M]>WF(>G\+@S"R`G<52W2)N1\I52^U*OL._NGIZ=[R5]WB/0&@U\P\L$]F`R2 MWWV-%G/PZTX(9W.?MI7\[AF#R:\[SMLTV*4:&!ZF^/]TD5$C_^\H\"Z#"$:+ MZV""\"R1_LZ`MO_]_GJM+\X;FH(`!NXG%\WV:(D]N<82<%+"WFN*[B$B)*4] M.4>!!P)"9O)#B'SH4?*>.3X5]\,S`%$H#5*I33.QWCF8E'L&$70=OPO@&Q\P M1@K+OX;CR7@.TLFR+=6S&C<2_;D3/E_YZ+4+\(6VMXC]`H:NC\(8`[)J0=*- M.PQ"TB'%*8S?BA8\8SQU`OA'T@4RI9[%(0Q`**\YB9:TX'J(9S,'+\:3!S@- MR"[!=&LZGKF@OB)S$7CR01@,C&1E1/-9BA(.E9G M2N"UIFF&?PK!SYA,39J#K&S%%#QU1EYU,Z8@JC/BJIO1;M=IL)^K:L4T*T^#!5NB42-L/DUV MY(R6E''-"Y.:(_T.X?[0[W,S>./Y%?_9Y^_!Y,(?UF$-TZ M,[#17U:QWT\.CT].#H[VC[\<'^Y3L1P4>EQDSPBO]][!;OX-\F.)4.OJRDKL MS9/K\5WW&?I+EDPPFBD)-.L%4D2%L`?PKSO[.X,X)'U%R01)+^FWI:!S@@P[ M_C49(F]_!PNFAC;*K8/9[ZV*9&!E.CK0H*,1M7+VJ$8,*]/1D08=C4@//=K+*]^95NAF[>_]UXD83J:+ M8PVZ.(\Q!7Q%=H^._V_@8/:0817MOX:4D&7*.M&W$TA[>P_F"%/#*O4ABT/V MAJ"R>/^5IHPN4]QG;8J[@C[`YX174X39&[BU4K:H20PJT\X7?<-J90EX>"9R M",=Q1!W+:2@!>W!Q*MFB.V6,F2I/-6[_5E/Y%?E-U>3(*-E_I:D`RT^U0^VJ M2C>L6J!&S(&O?TA->@MVR4_+YL>%-L> M9(T/E,-":I-WXH1/27MQN#MUG'G*8.!'8?Z;32IGO_Y]"6<\N8(!Z38DVD0A MY)@!Y:K4'XGUP:2WAXQN5Q=:I^N!OI&HH@@Z"!7@,(V`!-X$D(VH=Y.*B-G] MI.\1P"%(2NK4;K9SEE+R1EEC=*V@.Y;"9:!9HG<:8$26)OH?ZJSRXOCT>F@4 MG3L8+\AF[A^.'V\>_)7J&LH+&167Z5$?L25TR5TL[H$+"/PG']R"*),E:[;@ M5+&*',I`F7<3]3DQ)UM%3#:9B2U*!T&N`WJ_3`[T!#N#$,4B5A%`"(QY!]*O M2>`.@[D#`UR3'4+U$3:L841F:O`;PJAI)`>>@K(NQ@-Z"##.1\#2-P`U^`M^EY MS*8#OY(=A*B!T9+]PD76V=3T`LY12""CP$UG1C8KA/76A7;84V+4@VG5%H&[ M-[!#RQPLEFP#;J#S!'T801"2]2ZY&WQ&/H$6TK4O6@BLBK+5C:%#7:-R(Z"6 M[!(*,I"S.;,K&,.'5O3+I8L,.&`DYK5QOI5<8^]:O-`(W/GKHWI2B8/@(\V\BQ5:G\ MBJ(6JE\694L'S!>`GY!)B\#J:"VW#JS*VT<&-:AMG5/-60W$RX!].A>!8\8R M]&OBIQ[*,$K2Z%*/#93DFP&!R]8ZIX;)+&CCC*D*W9)]H;*-J@=6J8X84L], MU?>;BT*8`]<1;J.8<61H98(0(K3$:##R/)CV_,Z!WG5P[LPA6TC1DW,EBP@]S2-2@"\2P<'9,4,1ZX;SV*?!BJ0K35T(6LA$5>TCRHU,5NR ME)3%)[W'L(\*DAC;NN/6;8,2;,5J7H@:1XON+K[D\7=&&;U1=)NO`!64R0FI M.ZX34C?X\]K'_K+S$6*WM9VG[Z-7JHHKA"]0_!1-8K\<52"X]E1I8WT('?7/ MEZ(Y6DL.+84--QF^8YP(U$O.:G<`)S'ZXL,KJV;O:5(7HR7'E%*VAE$?6SQ3,=S5ESA,'LBDZ5E\9H,F@UON=6B)7B1#!LN^,PP.SE![S8W)MS[K0 MS/]LS(@5B'C=6,CINS5[]I#,7;\AY(4/R&>OQ&NE^JA,&0B6;+5_PR@,[S": M,$W_A1)]U*6H^Y;X#2916#1L,WLZ1.`8P"K>1PTK8;%DC_P`?-+FE*#^YN`? M@+J_9/!9MS3,"L:HO)8^*^YJU)!:LC;?$S41$=-L/Q=D*^*C)':;SPEN'=MH MH0[6EA4>!.1`X].0&F\&@^21B`B^`#XW!+5L8T<=N-;8V=8E)[ECL(T!4O@L MN>#/3!S!--UEW9`=,D/K%25M4[PL1$NBWF]1@-81Y]F>^"<&83UC>*%P=*@' MRI*XDNN`]`"$@DWB1BECM-Q,A64JR.!L>E8X314?@"FU.^MT&9[1ER;^2/2T MO(T(IOE,2M_A2UP26#X;DM6M)4LC`30]5QC#HB0Y(%.DK!T%MY*UC*D!VY+S MA2I!WA\W:M&B[V>06Q`)3Q]K98Q1O\K^4@C`DNC5?P(X?2:KT>B%\'@*;N/9 M$\#C2>*O4'!7.'-"Z"8+I!]'3%^>>HWUD1\M(F6^#-:OU2(/MLG='.48(ZC5 M1VK4@<1\?ZS7CC_T]8(K'[W*^OTTO2R2QO[>#'R_A.':3J11W0/7!2X,'D-907_ M$4G*7?0650>?>M\LW9I$+?$'N`"DORY,9$U^]D%"C,`KVC09Y)6I:AP9M\:/ M,C5KR\N6>77-3+[YBH#4Y<)FI0]Z-9*4)7,8[_ZEQIW5!ZD:R,F2:XKRK5HK&LK)DLU660KE)#C21"M7-8YB#;4N0R-) M*5CCPEB60/Z<,3MC-K?.>R2-"+XUKHIEZ-E3Q_F+`I5/'DO32*:Q]\BOVG)I MNLX93#R9IZZ4USY>8^^1>+7E8DE\>%DB&T^G2#-LH]Y[)).,""PQ'C0["W7B MEV,09&.1F25'[L\8 M8D!D1000+>Y\)XAH-#+Y;9)B@FE]E6W`&!9M@1U5=MA& M![W4Q6.-7:29K#M9/-\W'SN0G249[AB267JH=+'?4VS<&.JVM-]K`[XE-U9$ M-"X`7GA%Y)LX&(P3(.'E&\`N#)F1:<)ZQG!F"URH6'YKB<<2]]@B^)7[BOC= M/F&]#TZIB\>R<^EX<@&>HAP^SS&64^.=\TA1,-;<6363SB)-\%F2P2@/%Z`!!$POFU418U3=A@JKO&D$ M4#NSY720LXCF]?11&*?9F,C!\*[0ULZ:06U'+-X>GTDJCSSV1=D%B):T=L>J#Z^=8SQW^JIPJ!2/[ MJ#RR\]:2Y;78GL&CF.GRR!C,$N4UW7=7=VNE(-'(5FG"F/$MK;Z-6^QF2/LY MV%E>K8*!?EP>Z*N6!LNF#![C]+7A5^C3)^@V9;""Q1COBG4U6<48_1(->8F: MZ_S_K&^DUU+BAKFL%MA^#G9FE.;F6X2"T7]2'OUYTX.L[62YSUH?%)HW>$;( M>A[F8G%\UN:=6U)+?CZ)\%OY&:!F:\;,"A**7,O`UR+!S M>0I(6AFLFC%XJ%,',^$JSRJD8X#?H&#Z"/",]DDT?"O+&C,X^:(OCDMY'/T< M=47_:\E1]Z7"A!, M/:<5IKVDT4'>:O*H3]+N(&_8X,DHZ>(S\HDV0VKKB19T_R)R)Q)4TF*YK^R3 M_&Y?NKXQ$X6:"M=L^8VP]G/H/\1/(?@9DW8N:?(YR:W&_K#JDBYO:;!LRN01 MO@%]N>93:C&;:))BA]DGXM1*-<6,^8T:YVQUX/ER5AR8Q8(2E" M2-7M*2GJ8[,DMO@1.]XJ>6LIWW0J"08QI.KVE!CUL5F2'"-/([V0FR18Q7NJ M?B4X]N2713/PZ+S):KRZ>&\UK@#'DLRP5P[$281?(0+@.B`RBF>K99"A?JFZ M/>5"?6R6/!U3_=)7>@&4^,&X1`[P!5!'-CY-:K344]*TA;2ED$G]3Z=]#\GX MN0PC.',B9OK[]4(]5;T$B$RK7WH^,=R"UX)H,`K(CRXHS(IR>P?59GK*BU9@ M9LPYM='B^)CX4$G9&P^'Y)\F]L;T6Q_6QHYV#.XS\&(?T#>+LZ/3>8SI,$KD M+KQ:D*R^/D*^]&4B:`3/$A/D2@8E=XC1JX.]HJL2W7RG6@S#>);^3I%';7RD M]VSK3`B=63^W'G6FM`0=E9>@ZMBSGBPWM@>AU0X],V\*:#?@3-.*L]4P,Z61 M?5P>V:5@LYX,:LNCSE:KVQ4,8`1NX`LH=59QLR#=DC'30>.HM+;`]W.N$$:I M*4T>)^7)0RI6K2<3BGS0FD2-A$3#DZ.3HX.CH].C+Y^/CG3/(S+!68H3BGJ3 MQLPL=77(FV):$D<_YYIBY)O2M/*Y/*VLQ;_U9/KH72#42O4-$:!7:AFI?BF$M&MY`LT;R01M*JP\`&`& MO.^!BWP?N!&]8;X#F$9$.---6UJSQHQC4B-=;^SMVY6*]O6'=:KS??1*W^4E M."]0_!1-8K^,EYYS)N5?5Y[_FC1H-:':EXSV=:\1J?B3DFH;']21G(+Z'BPO M)XO,Y9^U55)IPU9FM2>,EH+RJ\(HS;F!7LE.=`7=*%53]K7!P<5*D[SIF M06@K_1**'-\$;2Y#,F5'=:E"WS4M!ZBS)$SF[.\/I??WC5(CY/O[PX_]?8?Y ME)XVG4@"=5>9J(JA&?3Z"$W`AY]MV2?Y8?:V0=[.K=L M62"6'$*J9R1HD8\DAJE7QW